[
  {
    "text": "# 中国临床肿瘤学会（CSCO）宫颈癌诊疗指南2023 GUIDELINES OF CHINESE SOCIETY OF CLINICAL ONCOLOGY (CSCO) # 版权所有，侵权必究！# 图书在版编目（CIP）数据 中国临床肿瘤学会（CSCO）宫颈癌诊疗指南2023 中国临床肿瘤学会指南工作委员会组织编写.一北京： 人民卫生出版社，2023.8ISBN 978-7-117-35114-0 I.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "$\\textcircled{1}$ 中…·Ⅱ.$\\textcircled{1}$ 中..：Ⅲ.$\\textcircled{1}$ 子宫颈疾病－癌－诊疗 -指南IⅣ.$\\textcircled{1}$ R737.33-62 中国国家版本馆CIP数据核字（2023）第140372号人卫智网 www.ipmph.com医学教育、学术、考试、健康，购书智慧智能综合服务平台人卫官网 www.pmph.com人卫官方资讯发布平台 中国临床肿瘤学会（CSCO）宫颈癌诊疗指南2023 Zhongguo Linchuang Zhongliu Xuehui ( CSCO) Gongjing Ai Zhenliao Zhinan 2023 组织编写：中国临床肿瘤学会指南工作委员会 出版发行：人民卫生出版社（中继线010-59780011） 地址：北京市朝阳区潘家园南里19号 邮 编：100021 E - mail: pmph @ pmph.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "com 购书热线：010-59787592 010-59787584 010-65264830 印刷：三河市宏达印刷有限公司打击盗版举报电话：010-59787491 E-mail: WQ $@$ pmph.com质量问题联系电话：010-59787234 E-mail : zhiliang $@$ pmph.com数字融合服务电话：4001118166 E-mail : zengzhi $@$ pmph.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "com经开字版印坛 ：新华 1/32 印张：3数：80千字次：2023年8月第1版次：2023年8月第1次印刷标准书号：4N978-7-117-3511-0 # 中国临床肿瘤学会指南工作委员会 # 组长 徐瑞华 李进 副组长 （以姓氏汉语拼音为序） 程颖 樊嘉 郭军 江泽飞 梁军 梁后杰 马军 秦叔逵 王洁 吴令英 吴一龙 殷咏梅 于金明 朱军 # 中国临床肿瘤学会（CSCO）宫颈癌诊疗指南 组长吴令英李力 # 副组长（以姓氏汉语拼音为序） 黄曼妮 李贵玲 娄阁 吴小华 张师前 周琦 # 专家组成员（以姓氏汉语拼音为序）（ $\\mathbf { \\widetilde { \\Gamma } } ^ { 1 }$ 为执笔人） 安菊生 中国医学科学院肿瘤医院妇瘤科陈建国 广东省人民医院妇产科范江涛 广西医科大学第一附属医院妇产科高琨 广西医科大学附属肿瘤医院妇科哈春芳 宁夏医科大学总医院妇科胡爱民 江西省肿瘤医院妇瘤科黄曼妮 中国医学科学院肿瘤医院妇瘤科黄向华 河北医科大学第二医院妇科 江萍 北京大学第三医院放疗科 居杏珠 复旦大学附属肿瘤医院妇瘤科 李力 广西医科大学附属肿瘤医院妇科 李莉 新疆医科大学附属肿瘤医院妇外一科 李东红 陕西省肿瘤医院妇瘤科 李贵玲 华中科技大学同济医学院附属协和医院肿瘤中心 李魁秀 河北医科大学第四医院妇瘤科 李艳芳 中山大学肿瘤防治中心妇科 林安 福建省肿瘤医院妇科 刘开江 上海交通大学医学院附属仁济医院妇瘤科 刘乃富 山东第一医科大学附属肿瘤医院妇科 娄阁 哈尔滨医科大学附属肿瘤医院妇科 宋艳中国医学科学院肿瘤医院病理科 孙志华 江苏省肿瘤医院妇瘤科 王珂 天津医科大学肿瘤医院妇瘤科 王建东 中华医学会北京分会 王永军 北京大学第四临床医学院妇产科 吴强 江苏省肿瘤医院妇瘤科 吴令英 中国医学科学院肿瘤医院妇瘤科 吴小华 复旦大学附属肿瘤医院妇科 邢艳霞 青海省第五人民医院（青海省肿瘤医院）妇科 熊慧华 华中科技大学同济医学院附属同济医院肿瘤科 阳志军 广西医科大学附属肿瘤医院妇科 杨兴升 山东大学齐鲁医院妇产科 袁光文 中国医学科学院肿瘤医院妇瘤科 袁建林 新疆医科大学附属肿瘤医院妇外三科 张红平 云南省肿瘤医院妇科 张师前 山东大学齐鲁医院妇产科 张云艳 哈尔滨医科大学附属肿瘤医院放疗科 郑爱文 浙江省肿瘤医院妇瘤科 周琦 重庆大学附属肿瘤医院妇瘤科 朱红 中南大学湘雅医院肿瘤科 朱根海 海南省人民医院妇产科 朱宽青 浙江省肿瘤医院妇瘤科 邹文 中南大学湘雅二医院肿瘤中心 邹冬玲 重庆大学附属肿瘤医院妇瘤科 # 协助编写（以姓氏汉语拼音为序） 李晓琦 复旦大学附属肿瘤医院妇科于浩 山东第一医科大学附属肿瘤医院妇科赵羽西 中国医学科学院肿瘤医院妇瘤科 基于循证医学证据、兼顾诊疗产品的可及性、吸收精准医学新进展，制定中国常见肿瘤的诊断和治疗指南，是中国临床肿瘤学会（CSCO）的基本任务之一。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "近年来，临床诊疗指南的制定出现新的趋向，即基于诊疗资源的可及性，这尤其适合于发展中国家，以及地区差异性显著的国家和地区。中国是幅员辽阔、地区经济和学术发展不平衡的发展中国家，CSCO指南需要兼顾地区发展差异、药物和诊疗手段的可及性及肿瘤治疗的社会价值三个方面。因此，CSCO指南的制定，要求每一个临床问题的诊疗意见根据循证医学证据和专家共识度形成证据类别，同时结合产品的可及性和效价比形成推荐等级。证据类别高、可及性好的方案，作为一级推荐；证据类别较高、专家共识度稍低，或可及性较差的方案，作为I级推荐；临床实用，但证据类别不高的，作为Ⅲ级推荐。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "CSCO指南主要基于国内外临床研究成果和CSCO专家意见，确定推荐等级，以便于大家在临床实践中参考使用。CSCO指南工作委员会相信，基于证据、兼顾可及、结合意见的指南，更适合我国的临床实际。我们期待得到大家宝贵的反馈意见，并将在指南更新时认真考虑、积极采纳合理建议，保持CSCO指南的科学性、公正性和时效性。# 中国临床肿瘤学会指南工作委员会 # CSCO诊疗指南证据类别 。# CSCO诊疗指南推荐等级 2 1宫颈癌概述3 # 2宫颈癌诊断及检查 5 2.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "1 宫颈癌诊断基本原则6 2.2 宫颈癌病理学诊断9 # 3宫颈癌临床病理分期 15 4 宫颈癌病理分类·21 5 宫颈癌治疗原则 27 # 6早期宫颈癌治疗（无保留生育要求） 29 # 7宫颈癌保留生育功能手术 37 7.1 适应证38 7.2 诊断及术前评估40 7.3 治疗42 # 8中晚期宫颈癌的放（化）疗·47 9早期宫颈癌根治术后辅助治疗·55 # 10意外发现宫颈癌的处理 59 # 目录 # 11复发宫颈癌的治疗 63 11.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "1 局部或区域复发宫颈癌的治疗64 11.2 远处转移宫颈癌的治疗·68 11.3 复发或转移性宫颈癌的系统治疗7011.3.1复发或转移性宫颈癌的系统治疗选择 7011.3.2常用晚期、复发转移宫颈癌化疗方案 74 # 12 宫颈癌随访 79 CSCO诊疗指南证据类别 <html><body><table><tr><td colspan=\"3\">证据特征</td><td rowspan=\"2\">CSCO专家共识度</td></tr><tr><td>类别</td><td>水平</td><td>来源</td></tr><tr><td>1A</td><td>高</td><td>严谨的meta分析、大型随机对照研究</td><td>一致共识 （支持意见≥80%）</td></tr><tr><td>1B</td><td>高</td><td>严谨的meta分析、大型随机对照研究</td><td>基本一致共识 （支持意见60%~<80%）</td></tr><tr><td>2A</td><td>稍低</td><td>一般质量的meta分析、小型随机对照研究 设计良好的大型回顾性研究、病例-对照研究</td><td>一致共识 （支持意见≥80%）</td></tr><tr><td>2B</td><td>稍低</td><td>一般质量的meta分析、小型随机对照研究、 设计良好的大型回顾性研究、病例-对照研究</td><td>基本一致共识 （支持意见60%~<80%）</td></tr><tr><td></td><td>低</td><td>非对照的单臂临床研究、病例报告、专家观点</td><td>无共识，且争议大 （支持意见<60%）</td></tr></table></body></html> CSCO诊疗指南推荐等级 <html><body><table><tr><td>推荐等级</td><td>标准</td></tr><tr><td>|级推荐</td><td>1A类证据和部分2A类证据 CSCO指南将1A类证据，以及部分专家共识度高且在中国可及性好的2A类 证据，作为1级推荐。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "具体为：适应证明确、可及性好、肿瘤治疗价值稳定 纳入《国家基本医疗保险、工伤保险和生育保险药品目录》的诊治措施</td></tr><tr><td>级推荐</td><td>1B类证据和部分2A类证据 CSCO指南将1B类证据，以及部分在中国可及性欠佳，但专家共识度较高的 2A类证据，作为I级推荐。具体为：国内外随机对照研究，提供高级别证据， 但可及性差或者效价比不高；对于临床获益明显但价格较贵的措施，考虑患者可 能获益，也可作为级推荐</td></tr><tr><td>级推荐</td><td>2B类证据和3类证据 对于某些临床上习惯使用，或有探索价值的诊治措施，虽然循证医学证据相对 不足，但专家组意见认为可以接受的，作为Ⅲ级推荐</td></tr></table></body></html> # 1 宫颈癌概述 宫颈癌发病率居妇科三大恶性肿瘤之首，是导致女性癌症死亡的第四大原因。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "2020 年全世界约有 60.4万例宫颈癌新发病例和34.2万例死亡病例，其中我国新发病例10.97万例，死亡病例5.9万例。因此，规范宫颈癌的预防、诊断和治疗是提高我国女性身体健康水平的关键。人乳头瘤病毒（HPV)是宫颈癌的主要致病因素，规范化宫颈癌筛查至关重要。病理是诊断宫颈癌的“金标准”，盆腔磁共振成像（MRI）可用于评估局部病灶，复发转移宫颈癌推荐进行分子病理诊断。对于初治宫颈癌，以手术和放疗为主，辅以化疗、靶向治疗、免疫治疗等。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "随着“早期低危”宫颈癌的概念出现及相关研究进展，在保留生育的患者中可考虑采用保守性手术治疗。早期宫颈癌术后辅助放疗根据病理类型不同，放疗标准不一。放疗适用于各期宫颈癌，特别是局部晚期宫颈癌。复发转移宫颈癌以局部治疗、系统性治疗和免疫治疗为主。近年来，免疫检查点抑制剂在宫颈癌治疗中效果显著并且应用前移。宫颈癌治疗后的随诊和规范化的检查也是必不可少的。本指南参考美国国家综合癌症网络（National Comprehensive Cancer Network，NCCN）指南、国际妇产科联盟（Intermational Federation ofGynecology and Obstetrics，FIGO）指南、欧洲肿瘤内科学会（European Society for Medical Oncology，ESMO）指南，依据最新国内外临床研究结果及国内诊治共识，结合我国国情，为临床实践提供有价值的参考。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "# 2 宫颈癌诊断及检查 # 2.1 宫颈癌诊断基本原则 <html><body><table><tr><td></td><td>|级推荐</td><td>Ⅱ级推荐</td><td>Ⅲ级推荐</td></tr><tr><td>临床诊断</td><td>体格检查 妇科检查</td><td></td><td></td></tr><tr><td>病理诊断</td><td>子宫颈活检 宫颈细胞学b</td><td>宫颈锥切</td><td>穿刺细胞学d</td></tr><tr><td>实验室诊断</td><td>SCC、CEA、CA125、CA19-9 和NSE等肿瘤标志物e HPV检测</td><td></td><td></td></tr><tr><td rowspan=\"2\">影像诊断</td><td>宫颈肿瘤 盆腔MRIf</td><td></td><td>盆腔CT</td></tr><tr><td>转移病灶 颈胸腹盆腔CT，必要时 PET/CTg</td><td>颈胸CT+盆腹腔MRI</td><td>其他相关检查</td></tr></table></body></html> # 【注释】 a包括双合诊与三合诊检查，推荐2名及以上高年资医师进行妇科检查；必要时在麻醉状态下检查;分期判断有分歧时，推荐较早分期。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "b需注意子宫颈腺癌存在细胞学假阴性可能「。c子宫颈活检无法判断有无浸润、微小浸润癌，需明确浸润深度时，推荐诊断性宫颈锥切。如宫颈及阴道细胞学检查（TCT）结果与阴道镜下活检病理不符，如多次结果为高级别鳞状上皮内病变（high-grade squamous intraepithelial lesion，HSIL），而阴道镜活检病理学检查未予支持时,也推荐诊断性宫颈锥切。d腹股沟或颈部淋巴结可疑转移时，推荐活检或细针穿刺细胞学明确。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "e子宫颈鳞癌推荐检测 SCC[2，子宫颈腺癌推荐检测 $C \\mathrm { A } 1 2 5 ^ { [ 3 ] }$ ，子宫颈胃型腺癌推荐检测 CEA、CA19-9[4]，子宫颈小细胞神经内分泌癌推荐检测 NSE[5}。f推荐盆腔 MRI 作为评估子宫颈局部肿瘤首选方法。MRI存在禁忌证时选择盆腔 CT[6-7]。g建议 I BI 期以上有条件者行 PET/CT 检查[8]。h可疑有骨转移时，推荐骨扫描检查；可疑有膀胱和/或直肠受累时，推荐膀胱镜和/或肠镜检查。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[1ASIENSTANNAUICKngadaamaftCa093 [2]CHARAKORNCTHADANIPONKCHAIJINDARATANAStalTheassciationbeweensrum squamoucellcarcinomaantigenandrecurrenceandsurvivalofpatientswitcervicalsquamouscelcacinomaAsytmatirevwand meta-analysis.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "Gynecol Oncol,2018,150 (1):190-200.[3]GADDUCCTANtlseumassayfumarnpgstivluonmentmonitoringandfolw-upofpatinswitcervicalcancerAreviewoftheliteratureCritRevOnclHmatol2008.66(1):10-20.4NISMMOKUNAGAalsisfgai-tucaaftiaggressivetumorwitapoorprognosi:Amult-nstiutional studyGyneclncol01953（1）:19 [5]COHENGAPPHIalllarmaftrviTnndsuivmpatients.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "AmJ Obstet Gynecol,2010,203(4）:347.[6]MNGAKHMHRWltnndualusingMRIUpatdguidelinesoftheEuropeanSocietyofUrogenitalRadiologyaferrevisedFIGOstaging2018.Eur Radiol,2021,31(10):7802-7816.[7]ALCKALLGEEMANladdainntstratofwithgyecologicmalignancies:What theradiologistneeds toknow.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "Radiology013266(3）:717740 8]TRIMHNGDEHDSTFaliltyfPETCTvurpriteallyhdetasadvancedcervicalcancer:ResultsofACRIN6671/GOG0233trial.GynecolOncol.2016,142(3）:413419.# 2.2 宫颈癌病理学诊断 <html><body><table><tr><td></td><td colspan=\"2\">|级推荐</td><td>级推荐</td><td>Ⅲ级推荐</td></tr><tr><td>标本类型</td><td>大体检查</td><td>镜下检查</td><td>免疫组化</td><td>生物标志物</td></tr><tr><td>活检标本</td><td>标本部位 标本数目 标本大小 标本性状</td><td>组织学分型 组织学分级 淋巴脉管间隙浸润</td><td>鉴别诊断免疫组织 化学相关指标</td><td>PD-L1h MMR或MSrh TMBh NTRKh</td></tr><tr><td>锥切标本</td><td>标本描述 标本完整性 标本数目 标本大小 标本性状</td><td>组织学分级 淋巴脉管间隙浸润 切缘情况 伴发病变 组织学分型b 浸润深度d，e</td><td>鉴别诊断免疫组织 化学相关指标</td><td></td></tr></table></body></html> 宫颈癌病理学诊断（续） <html><body><table><tr><td></td><td>1级推荐</td><td></td><td>Ⅱ级推荐</td><td>级推荐</td></tr><tr><td rowspan=\"7\">手术标本</td><td>宫颈肿瘤</td><td>组织学分型b</td><td>鉴别诊断免疫组织</td><td></td></tr><tr><td>部位</td><td>组织学分级</td><td>化学相关指标</td><td></td></tr><tr><td>大小</td><td>浸润深度de</td><td></td><td></td></tr><tr><td>性状</td><td>淋巴脉管间隙浸润</td><td></td><td></td></tr><tr><td>区域淋巴结</td><td>宫旁侵犯</td><td></td><td></td></tr><tr><td>部位</td><td>阴道侵犯</td><td></td><td></td></tr><tr><td>数目</td><td>淋巴结侵犯</td><td></td><td></td></tr><tr><td></td><td>其他器官：宫旁、 阴道、宫体、附件、 网膜和腹膜等</td><td>其他器官</td><td></td><td></td></tr></table></body></html> # 【注释】 a标本离体后应尽快（1h内）以 $3 .",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "7 \\%$ 甲醛溶液固定，固定液体积应为送检样本体积的4\\~10倍。不同标本需遵循相应取材规范。活检标本：描述标本数目、大小、性状，分别取材、全部包理，如果标本最大径超过 $5 \\mathrm { m m }$ ，应垂直于黏膜面对部、立埋。锥切标本：测量记录长度（锥高）宫颈外口（锥底）切缘最大径以及宫颈管内口直径。以锥顶为中心，垂直于管腔黏膜面间隔约 $3 \\mathrm { m m }$ 、纵向连续切取管壁全层组织，确保每片组织均含有从宫颈内口至外口的全部黏膜。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "手术标本：记录病变部位、外观、切面、浸润间质深度、是否累及阴道壁，测量距阴道壁切缘的最短距离。肿瘤区域以 $3 \\mathrm { m m }$ 间隔连续全层切开宫颈，测量肿瘤浸润的最大深度以及该部位宫颈管壁的厚度。垂直于宫颈管壁纵向切取两侧宫旁组织（含切缘）及附着的部分宫颈管壁组织各1\\~2块。淋巴结应全部取材并标注。b组织学分型参考2020版WHO女性生殖系统肿瘤分类[21（见病理学部分）。c组织学分级见病理学部分。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "d早期浸润癌（IA期）应注明肿瘤间质浸润深度，测量值以mm计；IB期及以上浸润癌，应描述肿瘤浸润深度占宫颈管壁厚度的三分比，如浸润深度达管壁内1/3层、中1/3层或者外1/3层[] 早期子宫颈腺癌深度判断存在争议。Silva分型以组织形态学为基础，采用“浸润方式”取代“传统的浸润深度”对宫颈腺癌进行分类{35）（见病理学部分）。伴发病变包括炎症性疾病、囊肿、良性肿瘤和子宫内膜异位症等。需警惕同时存在鳞状上皮和腺上皮病变的可能。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "g生物学标志只具有辅助诊断意义。子宫颈上皮内瘤变分级常用指标pl6和Ki67。子宫颈鳞癌和腺癌分为HPV相关型和非HPV相关型。p16基本可代替PCR检测、HPVDNA原位杂交、HPVmRNA原位杂交等技术。其他常用免疫组织化学标志物如CK7、CK20、CEA、ER、PR、 MUC6、CD56 和 CgA等[1 h复发、转移或持续性宫颈癌基于生物标志物为指导的全身治疗[6。宫颈癌免疫检查点抑制剂应用相关指标包括 PD-L1、MMR 或 $\\mathbf { M S I } ^ { [ 7 ] }$ 和 TMB8]子宫颈肉瘤建议 NTRK 基因融合检测[9]。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "# 参考文献 [1]中华医学会病理学分会女性生殖系统疾病学组.宫颈癌及癌前病变病理诊断规范。中华病理学杂 志，2019, 48 (4): 265-269.[2］ HOHN AK, BRAMBS CE, HILLER G, et al.2020 WHO Claification of female genital tumors.Geburtshilfe Frauenheilkd, 2021, 81 (10): 1145-1153.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[3］ DIAZ DE VIVAR A, ROMA AA, PARK KJ,et al.Invasive endocervical adenocarcinoma: Proposal for a new pattern-based classification system with signifcant clinical implications: A multi-institutional study Int J Gynecol Pathol, 2013, 32 (6): 592-601.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[4］ ROMA AA, MISTRETTA TA, DIAZ DE VIVAR A, et al.New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome.Gynecol Oncol, 2016, 141 (1): 36-42.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[5］ SPAANS VM, SCHEUNHAGE DA, BARZAGHI B, et al.Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma: Pattern a predicts excellent survival.Gynecol Oncol, 2018, 151 (2): 196-201.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[6］ National Comprehensive Cancer Network.Cervical Cancer (Version I.2022).(2021-12-13)[2023-07-12] https:// www.nccn.org/professionals/physician_gls/pdf/cervical.pdf.[7]MINIONLETEWARIKS.Cervical cancer-Stateof the science：Fromangiogenesis blockadetocheckpointinib tion.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "GynecolOncol,2018,148(3):609-621.[8]MERINODMMCSHANELMFABRIZIODtal.Establishingguidelinestohamonizetmormutationalur den（MB）insiliassmentfvaiationMBquantifcationacrossdiagnostilatfomspasefteFrinds ofCancerResearchTMBHarmonization Project.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "JImmunother Cancer,2020,8（I):e000147.[9]RABBAJDEVINEANGOIRaTRKfsvilamorftreassi morpholgalandmhistochmicaldistintionfomthreriesarcmaludingadenosarcomaHisp thology,2020,77(1):100-111.# 3 宫颈癌临床病理分期 宫颈癌分期系统包括国际抗癌联盟和美国癌症联合委员会（UICC/AJCC）的肿瘤、淋巴结、转移（TNM）系统（2021年第9版）I和国际妇产科学联盟（FIGO）系统（2018年更新版）【23 <html><body><table><tr><td>TNM分期</td><td>FIGO分期</td><td>分期标准</td></tr><tr><td>T</td><td></td><td>原发肿瘤无法评估</td></tr><tr><td>T</td><td></td><td>无原发性肿瘤证据</td></tr><tr><td>T</td><td>I</td><td>肿瘤局限于子宫颈（忽略向子宫体的侵犯）</td></tr><tr><td>Ta</td><td>IA</td><td>显微镜下诊断的浸润癌，最大间质浸润深度≤5mm</td></tr><tr><td>Tiai</td><td>TAI</td><td>间质浸润深度≤3mm</td></tr><tr><td>Tia2</td><td>IA2</td><td>间质浸润深度>3mm，≤5mm</td></tr><tr><td>Tih.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "</td><td>IB</td><td>镜下最大间质浸润深度>5mm：肿瘤局限于子宫颈，测量肿瘤最大径</td></tr><tr><td>Ti</td><td>IBI</td><td>间质浸润深度>5mm，最大径≤2cm</td></tr><tr><td>Tin</td><td>1B2</td><td>最大径>2cm，≤4cm</td></tr><tr><td>Tiba</td><td>IB3</td><td>最大径>4cm</td></tr></table></body></html> 宫颈癌临床病理分期（续） <html><body><table><tr><td>TNM分期</td><td>FIGO分期</td><td>分期标准</td></tr><tr><td>T</td><td>Ⅱ</td><td>肿瘤侵犯超出子宫，但未达阴道下1/3或盆壁</td></tr><tr><td>Ta</td><td>IIA</td><td>累及阴道上2/3，无宫旁浸润</td></tr><tr><td>Tai</td><td>IIA1</td><td>最大径≤4cm</td></tr><tr><td>T2</td><td>IA2</td><td>最大径>4cm</td></tr><tr><td>T2b</td><td>IIB</td><td>有宫旁浸润，但未达骨盆壁</td></tr><tr><td>T</td><td></td><td>肿瘤累及阴道下1/3，和/或扩散至盆壁，和/或导致肾积水或肾 无功能</td></tr><tr><td>T</td><td>IIA</td><td>肿瘤累及阴道下1/3，未扩散至盆壁</td></tr><tr><td>T36</td><td>IB</td><td>肿瘤扩散至盆壁，和/或导致肾孟积水或肾无功能（除外其他原因 所致）</td></tr><tr><td>T</td><td>IVA</td><td>肿瘤侵犯膀胱黏膜或直肠黏膜（活检证实）疱样水肿不属于IVA期</td></tr><tr><td>Nx</td><td></td><td>区域淋巴结无法评估</td></tr></table></body></html> 宫颈癌临床病理分期（续） <html><body><table><tr><td>TNM分期</td><td>FIGO分期</td><td>分期标准</td></tr><tr><td>No</td><td></td><td>无区域淋巴结转移</td></tr><tr><td>Noti)</td><td></td><td>区域淋巴结的孤立肿瘤细胞（ITC）</td></tr><tr><td>N</td><td>IICI</td><td>区域淋巴结转移：局限于盆腔淋巴结</td></tr><tr><td>Niai</td><td>IIC1</td><td>盆腔区域淋巴结转移，最大径>0.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "2mm，≤2mm</td></tr><tr><td>Na</td><td>IIC1</td><td>盆腔区域淋巴结转移，最大径>2mm</td></tr><tr><td>N2 Nzmi</td><td>IIC2 IIC2</td><td>区域淋巴结转移：腹主动脉旁淋巴结转移 腹主动脉旁淋巴结转移，最大径>0.2mm，≤2mm</td></tr><tr><td>N2 Ma</td><td>IIC2</td><td>腹主动脉旁淋巴结转移，最大径>2mm 无远处转移</td></tr><tr><td>cM,</td><td>IVB</td><td>临床诊断的远处转移（包括转移至腹股沟淋巴结、腹膜、肺、肝、</td></tr><tr><td>pM,</td><td>IVB</td><td>骨等，不包括盆腔和腹主动脉旁淋巴结、阴道的转移） 病理确诊的远处转移（包括转移至腹股沟淋巴结、腹膜、肺、肝、 骨等，不包括盆腔和腹主动脉旁淋巴结、阴道的转移）</td></tr></table></body></html> # 【注释】 a在获取所有影像学及病理学资料后确定最终分期，此后不再更改，例如肿瘤治疗或复发后分期不变。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "规定所有影像学检查手段（包括超声、CT、MRI、PET/CT等）均可用于分期，病理学检查对肿瘤大小的测量较妇科检查和影像学检查准确。细针抽吸、粗针穿刺、组织活检、组织切除检查、手术标本等病理学方法均可用于 $\\mathbf { N }$ 、M分期。b淋巴脉管间隙浸润（LVSI）不改变肿瘤分期，镜下浸润宽度不再作为分期标准。c病理学对淋巴结转移的评估包括以下3个层面。$\\textcircled{1}$ 孤立肿瘤细胞（ITC)：淋巴结内肿瘤病灶直径 $< 0 .",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "2 \\mathrm { m m }$ ，或单个淋巴结内的单个肿瘤细胞，或 $\\leqslant 2 0 0$ 个成簇细胞。$\\textcircled{2}$ 微转移：淋巴结内肿瘤病灶最大径为 $0 .2 { \\sim } 2 \\mathrm { m m }$ 。$\\textcircled{3}$ 宏转移：淋巴结内肿瘤病灶最大径 $> 2 \\mathsf { m m }$ 。ITC 不影响分期，在TNM 分期中可记录为 $\\Nu _ { 0 } { \\bf \\Gamma } _ { ( \\mathrm { i + } ) }$ ，采用FIGO 分期时也应记录其存在。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "微转移（ $\\Nu _ { \\mathrm { { m i } } }$ ）和宏转移（ $\\mathbf { N } _ { \\mathrm { a } }$ ）被认为淋巴结受累，TNM分期中盆腔淋巴结受累为 ${ \\bf N } _ { 1 }$ ，腹主动脉旁淋巴结受累为 ${ \\bf N } _ { 2 }$ ；FIGO分期中则分别为ⅢC1和ⅢC2。对用于诊断FIGO ⅢC期的证据，需注明所采用的方法是 $\\mathbf { r }$ （影像学）还是p（病理学)。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "例如，若影像学显示盆腔淋巴结转移，分期为ⅢClr；若经病理学证实，分期为ⅢClp。需记录所采用的影像学方法及病理学技术类型。若分期存在争议，应归于更早的期别。d TNM 分期系统中的前缀，c是临床分期，p是病理分期，如 cN 为临床诊断的淋巴结转移，pN为病理确诊的淋巴结转移，cM 为临床诊断的远处转移，pM 为病理确诊的远处转移。对确诊所用的病理学技术方法进行标注，如N（f）是指淋巴结转移通过细针抽吸或粗针穿刺确诊，N（sn）是指淋巴结转移是通过前哨淋巴结活检确诊。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "# 参考文献 [1OLAWAIYEBAKERTPWASHINGTONMKtal.ThewVrsion9）AmericanJointCommittonCane tumor,nodemetastasisstagingforcervical cancer.CACancerJClin,2021,71（4）:287-298.[2]BHATLAEREKJSCUELLOFREDESMalevieFIGOstgingforcrimafthrviri Gynaecol Obstet,2019,145(1):129-135.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[3]Coigendum toRevisedFIGOstaging forcarcinomaofthecervixuter[IntJGynecolObstet145(2019）129-135].Int JGynaecolObstet,2019,147(2):279-280.# 4 宫颈癌病理分类 2020版WHO肿瘤病理分类将宫颈鳞状细胞癌分为与HPV相关型与HPV不相关型两类（表4-1）。两者无法单独根据形态学标准区分，必须进行p16免疫染色或HPV检测。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "在没有条件区分HPV是否感染的情况下，可以不进行区分。目前尚未发现明确的HPV不相关型癌前病变，所以癌前病变鳞状上皮内病变（squamous intraepithelial lesion，SIL）被归为HPV相关的类别，仍分为HSIL（CIN3及CIN2）及LSIL（CIN1），需要强调的是，p16的染色不代表任何病变级别，仅在CIN2形态学鉴别困难时作为参考指征 WHO分类中宫颈腺癌及癌前病变也相应分为HPV相关性腺癌及原位癌、HPV非相关性腺癌及原位癌。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "HPV相关性腺癌主要包括普通型腺癌、大部分黏液腺癌[非特异黏液腺癌、肠型黏液腺癌、印戒细胞癌、宫颈浸润性复层产黏液的癌（iSMC）]，宫颈HPV相关型腺癌，最常见的亚型为普通型；根据形态学及镜下特点，HPV相关型普通型腺癌可进行Silva分类。SilvaA型：边界清楚，预后相对较好；SilvaB型：边界清楚，小灶浸润型生长；SilvaC型：弥漫浸润型生长，预后相对较差。HPV非相关性腺癌包括胃型黏液腺癌、透明细胞癌和中肾管腺癌等。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "对于宫颈腺癌，HPV非相关型相对预后较差。但在宫颈鳞癌中，HPV对于预后的意义，有待进一步研究。需要强调的是无论宫颈腺癌或鳞癌，分期仍是最重要的临床预后因素[2-5]。宫颈神经内分泌肿瘤，分为神经内分泌瘤（NET：NET1/2）及神经内分泌癌（大细胞神经内分泌癌及小细胞神经内分泌癌）。宫颈中神经内分泌瘤非常罕见，宫颈常见的神经内分泌肿瘤多为神经内分泌癌。无论大细胞神经内分泌癌还是小细胞神经内分泌癌，均具有高度侵袭性，就诊时远处转移很常见。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "即使在早期诊断的患者中，死亡率也很高。在宫颈、子宫内膜和卵巢中，神经内分泌癌经常与其他肿瘤一起发生。![](images/14e5c3312022776b7772a98a4d539a1c0082739563a2cd17a055ac3a220ce125.jpg) 表4-1WH0宫颈癌及癌前病变分类（第5版，2020年） # WH0宫颈癌及癌前病变分类（第5版，2020年）（续） ![](images/aab7603c90973a0791c16782f097aff18ce8d0aef7a72cd7d7acb6b8361b1696.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "jpg) # 参考文献 [1]WHOClassificationofTumoursEditorialBoardWHOClassficationofTumours:Femalegenital tmouth ed.Lyon(France):International Agency for Research on Cancer,2020.[2]OMAAADIDEIVARAPARKJtalvasivnocericaladenocrcmawatt-basdla sificationsystemwithimortantlinical significance.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "AmJSurgPathol01539（5）:667-62.[3]STOLNICUSBARSANIHOANGLtal.Itenational EndocervicalAdenocarcnoma CriteriaandClas sification（IECC）Anewpathogeneticclassificationforinvasiveadenocarcinomasoftheendocervix.mJSurg Pathol,2018,42(2):214-226.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[4]STICUANGHUDlnialumfVcidandciadvia nocarcinomascategorizedbytheInternationalEndocervicalAdenocarcinomaCriteriaandClassification（IECC）.Am JSurgPathol,2019,43(4):466-474.[5]PJicamgatfatpfanlgnlc ersinto classification.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "Histopathology,2020,76(1）:112-127.# 5 宫颈癌治疗原则 宫颈癌的治疗手段包括手术、放疗、系统性治疗（包括化疗、免疫治疗和靶向治疗）。早期宫颈癌患者（ $\\mathrm { ~ I ~ A ~ } { \\sim } \\mathrm { ~ I ~ B ~ } 2 \\ \\mathrm { ~ I ~ }$ 期以及ⅡA1期）可选择根治性手术治疗，然后根据术后病理是否存在危险因素来决定术后的辅助治疗；也可以选择直接行根治性放疗或个体化选择同步放化疗。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "早期宫颈癌的手术与根治性放疗两者的疗效相当，5年生存率、死亡率、并发症发生率相似。由于放疗可能导致相关并发症，对于未绝经患者，特别是年龄小于45岁且无手术禁忌证的患者可选择手术治疗。另外对于符合条件，有保留生育功能要求的患者采用保留生育功能的手术方式。对于局部晚期宫颈癌（IB3 期和ⅡA2期）首选同步放化疗，在放疗资源匮乏地区也可选择手术治疗。对于ⅡB期～IVA 期宫颈癌，治疗方式首选同步放化疗。对于IⅣB 期宫颈癌一般以系统性治疗为主，部分患者可联合个体化放疗。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "6 早期宫颈癌治疗（无保留生育要求） <html><body><table><tr><td>分层</td><td>级推荐</td><td>Ⅱ级推荐</td><td>Ⅲ级推荐</td></tr><tr><td>IA1期ab 且不伴淋巴脉宫颈锥切术 管间隙浸润</td><td>A型子宫切除12）</td><td></td><td></td></tr><tr><td>IAI期伴淋巴B型子宫切除+ 脉管间隙浸润</td><td colspan=\"3\">盆腔淋巴结切除术 根治性放疗（体外放疗+ 阴道近距离放疗）</td></tr><tr><td>IA2期</td><td>B型子宫切除h+ 根治性放疗（体外放疗+ 阴道近距离放疗） 盆腔淋巴结切除术[22]</td><td>B型子宫切除ch+ 前哨淋巴结显影技 术5-16]</td><td></td></tr><tr><td>IB1期、 IB2期 IIA1期</td><td>根治性放疗（体外放疗+ 阴道近距离放疗）± 铂类为基础的同步化疗[21] C型子宫切除，h+ 盆腔淋巴结切除术（1类）d，e</td><td>C型子宫切除c，h+C型子宫切除h+ 盆腔淋巴结切除术+前哨淋巴结显影技术d 腹主动脉旁淋巴结 切除术d，ef</td><td></td></tr></table></body></html> 早期宫颈癌治疗（无保留生育要求）（续） <html><body><table><tr><td>分层</td><td>I级推荐</td><td>Ⅱ级推荐</td><td>Ⅲ级推荐</td></tr><tr><td>IB3期、 IIA2期名</td><td>根治性放疗（体外放疗+ 阴道近距离放疗）± 铂类为基础的同步化疗</td><td>C型子宫切除+ 盆腔淋巴结切除术+ 腹主动脉旁淋巴结铂类为基础的同步化疗+ （1类）切除术d，e，f</td><td>根治性放疗（体外放疗+ 阴道近距离放疗） 全子宫切除腹主动脉旁± 根治性放疗（体外放疗+ 阴道近距离放疗） 铂类为基础的同步化疗 盆腔淋巴结分期手术（17-19）</td></tr></table></body></html> # 【注释】 a分期按照FIGO2018版分期标准。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "bIA期需经宫颈锥切组织的病理方能确诊，不能单纯由宫颈活检组织病理来确诊。c子宫切除范围参照Q-M手术分型（表6-1）。d 对于C型子宫切除的手术方式首选为剖腹手术[34.20]。e盆腔淋巴结切除范围包括骼总淋巴结、骼外淋巴结、骼内淋巴结以及闭孔淋巴结。f腹主动脉旁淋巴结切除范围一般达肠系膜下动脉水平即可，但也可结合影像学以及术中冰冻病 理结果个体化扩大切除范围。g对于IB3期、ⅡIA2期宫颈癌采用新辅助化疗加手术的治疗模式还存在争议，一般仅建议用于放 疗不可及区域或者临床研究。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "h近年有两项前瞻性、随机分组的Ⅲ期临床研究结果显示，对于早期低危宫颈癌（即满足所有以下 条件的患者：FIGO分期IA2\\~IB1期（基于锥切病理分期）、无脉管瘤栓、锥切切缘阴性、鳞 状细胞癌（任何组织分级）或普通型腺癌（组分学分级1级或2级）、肿瘤最大径 $\\leq 2 0 m$ 浸润 深度 $\\leqslant 1 0 \\mathrm { m m }$ 以及影像学检查未发现远处转移），采用单纯子宫切除与采用根治性子宫切除，生 存结果相当。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "这一结论尚有待更长时间的随访结果来验证[23-25]。[1QUEREUDMORRWCPClassifcationfradicalhysterctomyancetncol00893）:973 [2]CIBULAD,ABU-RUSTUMNR,BENEDETTI-PANICIP,tal.Newclassification systemof radical hysterectomy:Ephassonathre-dmensonalanatmictmplatfrparametrialresectionGyecolOncol1 122(2):264-268.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[3RAMIRETFRUMOVITZAREJARalMinallyvasiveerusabdominalradcalhytertmo cervicalcancer.N EnglJMed,2018,379 (20):1895-1904.[4]MEMDMRGUDJHENlivlallsiditmflst cervical cancer.NEngl JMed,2018,379(20):1905-1914.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[5]ALGSECTEANDTADTltilidnyftl cept in cervical cancer:AGO Study Group.JClin Oncol,2008,26(18):2943-2951.[6]BATSTHETUENEDleidequtsxdna waysandallownodalulrastaginginearlycervicalcancer:IsightsfromthemulticenterprospectiveENTICOL study.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "Ann Surg Oncol,2013,20 (2):413-422.[7]EIRKSSONLRCOVENSA.entinellymphnodemappingincrvical cancer:Thefuture？BJOG012, 119(2):129-133.[8]CORMIEIAJHstblisingieanglgritt early cervical cancer.Gynecol Oncol,2011,122(2):275-280.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[9]CIUADBUUTUMUEKLlsticifaflsnl di ease in early-stage cervical cancer.Gynecol Oncol,2012,124(3):496-501.[10]UUMTVETQUEREUilaraiviuraty lymphndmtastasisarycericlcaneultsftENTICLudlnl19136 1691.[11]ATSUNERDUEREUDaliaostiafraprtivexainonfntil nodeinearlcervicalcancer:Arospectiveulticentr study.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "GycolOncol01113（2）:23035.[12]CIBULADBU-USTUMNRDUEKLtalBiatralulastaingfentilymhnodnv calcancerLowering the false-negativerate andimproving the detection ofmicrometastasis.Gynecol Oncol,2012,127(3):462-466.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "13]ADEDWADTlnlbyeystvialctlt intraoperative versuspostoperativeassessmentGynecol Oncol,2008,111(1):1317.14]AMUNDRUEKLalHigfalsetivratffoestnxintnfn nodes in patients with cervical cancer.Gynecol Oncol,2013,129(2):384-388.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[15]FRUMVIANTEPteafedfrefodetinfnl womenwiicnrit Oncol,2018,19（10):1394-1403.[16]ATSRATIATHETtalonrutonfyositigraphyttraprivseillh node detectioninearly cervical cancer:Analysisof theprospectivemulticenterSENTICOLcohort.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "Gynecol Oncol,2015,137(2):264-269.[17]GOLDATIANCWHTNEYCWtlSurgcaversusradographicdemnationfpara-aorilyh nodemetastasesbeforechemoradiationforlocallyadvancedcervical carcinoma:AGynecologicOncologyGroup Study.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "Cancer,2008,112(9):1954-1963.[18]GOUMICEARDUCalrstiveltyvungsuvivalfpn locallyadvancedcervicalcancerundergoinglaparosopicparaaorticlymphadenectomybeforechemoradiotherapy in theeraof positronemission tomographyimagingJClinOncol201331(24）:30263033.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[19]FRUMOVITZMQUERLEUD,GIL-MORENOAetalLymhadenectmyilocallyadvancedcervicalcan study（LiLACS）haseIllinical trialcomparing surgicalwithradiologistaginginpatientswithstageIIA cervical cancer.JMinim Invasive Gynecol,2014,21(1):3-8.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[20]MARGUJANGEAGLLalumeandcstfotindlaparospiradicalt ectomy forstageIB1 cervical cancer.JClin Oncol,2018,36（15_suppl):5502.[21]BAALBERGENAEENSTRATALERSLt alPrmary surgeryersusprimaryradiation apywithorwithoutchemotherapyforearlyadenocarcinomaof theuterinecervix.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "CochraneDatabaseSyst Rev,2010(1):CD006248.[22]OKKAFANTCKBANKElugialteaentfstageviclcaerCchraDat base Syst Rev,2014(5):CD010870.[23]CHMELERMAREJROPEZLANCOAalCoCevposetivetrilfconsevativeurfo low-risearl-stagevialaneJGyolCanr0110）:17-5.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[24]PANTEWFEGUtalntationaramzedphastialcmarngadicalst tomyandplviodedissetionssmlehyerectmyandpelvinodedissetioninpatietswithlwiskerly stage cervical cancer.JClin Oncol,2023,41(suppl:abstrLBA5511.[25]NationalComprehensiveCancerNetwork.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "CervicalCancer(Version1.2022）(2021-12-13）[2023-07-12]htps:/ www.nccn.org/professionals/physician_gls/pdf/cervical.pdf.表6-1 宫颈癌子宫切除的Q-M分型 <html><body><table><tr><td>分型</td><td>对应术式</td><td>输尿管 处理</td><td>子宫动脉 处理</td><td>侧方宫旁组织 切除</td><td>腹侧宫旁 组织切除</td><td>背侧宫旁组织 切除</td><td>阴道切除</td></tr><tr><td>A</td><td>介于筋膜外子 宫切除术和改 良根治术之间</td><td>识别但不 游离</td><td>于输尿管 内侧切断</td><td>输尿管与宫颈最小切除 之间</td><td></td><td>最小切除</td><td><lem</td></tr><tr><td></td><td>B1改良根治术</td><td>隧道”输尿管正输尿管水平 顶部打开上方切断 与侧推</td><td></td><td></td><td>韧带</td><td>部分切除子宫骶韧带在切除1cm 膀胱宫颈子宫直肠腹膜 反折处切除</td><td></td></tr></table></body></html> 宫颈癌子宫切除的 $\\mathbf { Q - M }$ 分型（续） <html><body><table><tr><td>分型</td><td>对应术式</td><td>输尿管 处理</td><td>子宫动脉 处理</td><td>侧方宫旁组织 切除</td><td>腹侧宫旁 组织切除</td><td>背侧宫旁组织 切除</td><td>阴道切除</td></tr><tr><td>B2</td><td>B1+宫旁淋巴同B1 结切除</td><td></td><td>同B1</td><td>同B1，再切同B1 除宫旁淋巴结</td><td></td><td>同B1</td><td>同B1</td></tr><tr><td>CI</td><td>NSRH</td><td>完全游离</td><td>骼内动脉</td><td>骼血管内侧水 平（保留盆腔（保留神经留腹下神经） 内脏神经）</td><td>膀胱支）</td><td>膀胱水平直肠水平（保切除2cm</td><td>（或根据实 际需要）</td></tr><tr><td>C2</td><td>经典的宫颈癌同CI 根治术</td><td></td><td>同C1</td><td>骼血管内侧水 平（不保留盆 腔内脏神经）</td><td>膀胱水平 （不保留膀 胱支）</td><td>骶骨水平（不保同C1 留腹下神经）</td><td></td></tr><tr><td>D1</td><td>侧盆扩大根完全游离 治术</td><td></td><td>血管切除</td><td>连同骼内盆壁血管切除膀胱水平</td><td></td><td>骶骨水平</td><td>根据需要</td></tr><tr><td>D2</td><td>侧盆廓清术</td><td>同D1</td><td>同D1</td><td>盆壁肌肉筋膜根据情况 切除</td><td></td><td>根据情况</td><td>根据需要</td></tr></table></body></html> 注：NSRH.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "C1型广泛性子宫切除术，又称保留神经的广泛性子宫切除术（nerve-sparingradical hysterectomy， 7 宫颈癌保留生育功能手术 # 7.1 适应证 [1-4 ] <html><body><table><tr><td>项目</td><td>|级推荐</td><td>Ⅱ级推荐</td></tr><tr><td>FIGO分期</td><td>IA1~IB2期</td><td></td></tr><tr><td>病理类型</td><td>宫颈鳞癌、腺癌和腺鳞癌，排除神经内 分泌癌、胃型腺癌</td><td>透明细胞癌[56]，腺肉瘤，胚胎横纹肌 肉瘤a[7]</td></tr><tr><td>影像评估</td><td>肿瘤局限于宫颈，病灶未侵犯宫颈内口， 无淋巴结转移及远处转移</td><td></td></tr><tr><td>生育力评估</td><td>年龄≤45岁 有强烈的生育愿望，无明确生育功能 障碍</td><td></td></tr></table></body></html> # 【注释】 a复旦大学附属肿瘤医院于 2006—2019 年共对15 例宫颈腺肉瘤或胚胎横纹肌肉瘤的患者实施了腹式根治性宫颈切除术或宫颈锥切术，患者年龄中位数为19（11\\~36）岁，肿瘤大小中位数为5（1.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "5\\~20）cm。所有患者肿瘤均局限于宫颈，截至2023年5月，随访时间中位数为141（47\\~201）个月，仅1例复发且死亡。[1]Jalogilreultsandurnrkfacrfollwingabdnlraicala tomy:Anupdated series of333patients.BJOG,2019,126(9):1169-1174.[2]lacaamalalmyfrvcaligcallogil tility outcomes in62patients.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "GynecolOncol,2011,121(3):565-570.[3]MARTHANDONIMAHNERtalCvicalcanESMOClncalPrtiGuielinrd sis,treatment and follow-up.Ann Oncol,2017,28(suppl_4）:iv72-iv83.[4]PREJENDONJUEdiatradiclratmyruseaduatr followedbyconservativesureryforpatientswithstageIIcrvicalcancerwithtmorsmorlarerAliteratur reviewand analysisofoncologicalandobstetricaloutcomesGynecolOncol2015137(3）574580.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[5]BU-UTUMUEVINEAaridialamlaltmyrrvil cinoma:Anovel surgical approach.Gynecol Oncol,2005,97(1):296-300.[6]LESTERCFARMERDLABBANJTtaladicaltrahletmyforclercellcamaftcrvx 6-yearlartvinrnftgilqiau018） 7]W.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "7Fetiltyspigryrdiic/dlsentpatntwihmavlvinr vix.Int J Gynecol Cancer,2019,29(Suppl4):A389.# 7.2 诊断及术前评估 <html><body><table><tr><td>目的</td><td>级推荐</td><td>Ⅱ级推荐</td></tr><tr><td>诊断</td><td>妇科检查+宫颈活检</td><td></td></tr><tr><td>分期诊断</td><td>胸部CT+腹部增强CT+盆腔增强MRI2或PET/CT[34]</td><td>胸部、腹部、盆腔CT</td></tr><tr><td>生育能力评估</td><td>抗米勒管激素（AMH）或窦卵泡计数（AFC）a</td><td>年龄≤45岁 性激素检查b</td></tr></table></body></html> # 【注释】 a为了更好地评估患者术前卵巢储备功能，建议在月经周期任意时期进行血抗米勒管激素（AMH）检查，或月经第1\\~3天通过超声检查双侧卵巢窦卵泡计数（AFC）。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "b性激素检查包括卵泡刺激素、黄体生成素、雌二醇、孕酮、睾酮以及泌乳素，可于月经期第1-3天（卵泡期）抽血检查。[1]AKMANKINKtaltcviclcanlfrativMRmagngofpatients forfertility-sparingradical trachelectomy.Radiology,2013,269(1):149-158.[2UANaEalyvlmniltineas a toolinpatient selectionandafollow-upmodality.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "adiographics,2014,34（4）:1099-119 [3]ADAMJA.VANDIEPENPR,MOMCH,et $\\mathrm { a l .} [ { } ^ { 1 8 } \\mathrm { F } ]$ FDG-PETorPET/CTin theevaluation of pelvic andpara-aorticlymphodenpatientswithlocallyadvancedcervicalcancerAsystematicreviwftheliteratureGyecolOncol,2020,159(2):588-596.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[4]GUENWANCHstfDGTRlwivilnancy:a systematicreview of the literature.Front Oncol,2020,10:519440.# 7.3 治疗 [1] <html><body><table><tr><td>分期</td><td>|级推荐</td><td>Ⅱ级推荐</td><td>川级推荐</td></tr><tr><td>IAI,LVSI（-) IA1,LVSI（+)</td><td colspan=\"3\">宫颈锥切或LEEP刀 根治性宫颈切除术b，e</td></tr><tr><td>IA2</td><td colspan=\"3\">盆腔淋巴结切除术 （前哨淋巴结活检术）， 或宫颈锥切术 盆腔淋巴结切除术 （前哨淋巴结活检术[6-10]）</td></tr><tr><td>IB1</td><td>腹式或阴式根治性宫颈切除 术b盆腔淋巴结切除术 （前哨淋巴结活检术）</td><td>腹腔镜或机器人根治 盆腔淋巴结切除术（前 新辅助化疗+根治性 性宫颈切除术b，d 哨淋巴结活检术）1-12</td><td>宫颈锥切术+盆腔淋 巴结切除术（前哨淋巴 结活检术）h（13-15]</td></tr><tr><td>IB2</td><td colspan=\"3\">腹式根治性宫颈切除术， 盆腔淋巴结切除术</td></tr></table></body></html> 注：LVSI.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "淋巴脉管间隙浸润（lymphovascularspaceinvasion）。# 【注释】 a至少保证 $3 \\mathrm { m m }$ 阴性宫颈切缘。b至少保证 $5 { \\sim } 8 \\mathrm { m m }$ 阴性宫颈切缘。c至少保证 $8 { \\sim } 1 0 \\mathrm { m m }$ 阴性宫颈切缘。d 经过锥切且切缘阴性需要补充手术的患者，实施腹腔镜或机器人根治性宫颈切除术更为安全[\"]。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "e 相当于Q-M B 型根治术的切除范围。f 相当于Q-M B 型或 C1 型根治术的切除范围。g 相当于 Q-M C1-C2 型根治术的切除范围。适用于部分早期低危宫颈癌，如肿瘤直径 $\\leqslant 2 \\mathrm { c m }$ ，肌层浸润深度 $\\leqslant 1 0 \\mathrm { m m }$ 或 $< 5 0 \\%$ ，伴随/不伴随 LVSI。i盆腔淋巴结切除可在新辅助化疗前或新辅助化疗后实施，需确保盆腔淋巴结病理阴性才可实旅保留生育功能治疗。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "# 参考文献 [1］ SERT BM, KRISTENSEN GB, KLEPPE A, et al.Long-term oncological outcomes and recurrence pattems in early stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "Gynecol Oncol, 2021, 162 (2): 284-291.[2] SUPRASERT P, KHUNAMORNPONG S, PHUSONG A, et al.Accuracy of intra-operative frozen sections in the diagnosis of ovarian masses.Asian PacJ Cancer Prev,2008,9(4):737-740.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[3]NationalComprehensiveCancerNetwork.CervicalCancer(Version1.202）2021-12-13）[2023-07-17]https:// www.nccn.org/professionals/physician_gls/pdf/cervical.pdf.[4]BENTIVEGNAMAULRDAPAUTIERtalFrtilityresultsndpenanyoomsaconsrtv treatmentfcervicalcancer:Asystematicreviewof theliterature.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "FertilStril2016106（5）1195-1211.[5]FRUMUNCHMEERMalPralmrdiayrmy women with early-stage cervical cancer.Obstet Gynecol,2009,114(1):93-99.[6]WCKntvilcpnt transperitonealradicalhysterectomy:Astudyof100caseIntJGynecolCancer200616(2）:649-654 7]DOSTALEKIKANMFISCHERVADtalLNbiopsyncrvialcnepatintwittmorslarghn 2cm and4cm.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "GynecolOncol,2018,148 (3):456-460.[8]KADKHDAYAANADEEGLIGlnbpydlstgngf cervixcaytmatireiwand-analyisftnliaugcol5（0 [9]ROBOBHALASKAMCre statfnldappinitanan vical cancer.Expert RevAnticancer Ther,2013,13(7):861-870.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[10]ALVGMIEZPTEVENBACKCFtalsitivityandgivepditivvafsnl nodebiopsy inwomen withearly-stage cervical cancer.Gynecol Oncol,2017,145(1):96-101.[1]MUAJlallasiraayry cervical cancer.NEnglJMed,2018,379(20):1895-1904.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[12]ALVGAMIEEAMtlnallyvaivradiclrayelysa cervicalcanerIntrationalRaicalTrachlctomyAssessmenttudy.mJObsttGyecol2022226（1）:97.[13]CHMELERMAREJAOPEZLANCOAtalConCervAprsectiveriafcnserativsrgry low-risk early-stage cervical cancer.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "Int J Gynecol Cancer,2021,31(10):1317-1325.[14]NTEFGUntnaranmizeaItalmandia tomyandpelvicdedissectionssmlehysterecomyandplvodedissctionpatientswithlowriskerly stage cervical cancer.J Clin Oncol,2023,41（suppl:abstrLBA5511.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[15]XXIACHallecnizatnndvilhadetmyely-stecervicalcn spective analysis andreview oftheliterature.Gynecol Oncol.2020,158(2）:231-235.[16]Ualaduahtraywbadatsun radicaltraclmyforatntitFIG018stage2cervicalcanerGyecolncol316910112.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "8 中晚期宫颈癌的放（化）疗 <html><body><table><tr><td>临床 分期</td><td>分期</td><td>分层</td><td>|级推荐</td><td>I级推荐</td><td>Ⅲ级推荐</td></tr><tr><td>IIB期 ⅢA期 IB期</td><td></td><td></td><td>盆腔EBRTd+ 近距离放疗 同步含铂化疗！（1类）</td><td>盆腔EBRTd+ 近距离放疗</td><td></td></tr><tr><td rowspan=\"2\">IIC期</td><td>IC1期影像学</td><td>检查</td><td>盆腔腹主动脉旁 EBRTd+ 近距离放疗+ 同步含铂化疗！",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "</td><td>盆腔腹主动脉旁 EBRTd+ 近距离放疗e</td><td>新辅助化疗h 盆腔 腹主动脉旁EBRT+ 近距离放疗d+ 同步含铂化疗</td></tr><tr><td></td><td>病理细 胞学</td><td>盆腔EBRTd+ 近距离放疗+ 同步含铂化疗</td><td>盆腔EBRTd+ 近距离放疗</td><td>新辅助化疗h 盆腔± 腹主动脉旁EBRT+ 近距离放疗 同步含铂化疗</td></tr></table></body></html> 中晚期宫颈癌的放（化）疗（续） <html><body><table><tr><td>临床 分期</td><td>分期</td><td>分层</td><td>|级推荐</td><td>I级推荐</td><td>I级推荐</td></tr><tr><td>IC期</td><td>IC2期</td><td>影像学 检查b 或病理 细胞学</td><td>盆腔+ 腹主动脉旁EBRT+ 近距离放疗+ 同步含铂化疗！",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "</td><td>盆腔+ 腹主动脉旁EBRT+ 近距离放疗</td><td>新辅助化疗h 盆腔 腹主动脉旁EBRT+ 近距离放疗 同步含铂化疗</td></tr><tr><td rowspan=\"2\"></td><td>IVA期无淋巴 结肿大</td><td></td><td>盆腔EBRT+ 近距离放疗+ 同步含铂化疗</td><td>盆腔EBRTd+ 近距离放疗</td><td>新辅助化疗 盆腔 腹主动脉旁EBRT+ 近距离放疗d+ 同步含铂化疗</td></tr><tr><td>淋巴结影像学 肿大</td><td>检查 或病理 细胞学</td><td>盆腔 腹主动脉旁EBRTd+ 近距离放疗 同步含铂化疗</td><td>盆腔 近距离放疗 腹主动脉旁EBRTd+</td><td>新辅助化疗h 盆腔士 腹主动脉旁EBRT+ 近距离放疗 同步含铂化疗</td></tr></table></body></html> $\\mathbb { N B }$ 期系统性治疗 $\\pm$ 针对肿瘤局部放疗或同步放化疗 # 【注释】 a临床分期：2018年FIGO分期。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "b影像检查（r）：推荐MR、CT或PET/CT。c病理细胞学（p）：对可疑的影像学结果，可以考虑对异常病灶行穿刺活检，或选择手术分期（即腹膜外或腹腔镜淋巴结切除术）（3类）[1-2）]。由于穿刺活检或手术带来的损伤，专家组反对意见较多。更多一手肿瘤指南、专家共识、医学资料等，请关注”放瘤班”微信公众号！d体外放射治疗（EBRT）：推荐以影像引导（CT或MR）为基础的适形调强放疗技术。放疗范围包括已知及可疑的肿瘤侵犯部位，EBRT靶区为盆腔 $\\pm$ 腹主动脉旁区域。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "剂量45（40\\~50）Gy。不可切除的淋巴结可以通过高度适形的放疗技术，给予同步加量或后程推量10\\~15Gy。对于图像引导的EBRT，高剂量区域必须注意避开正常组织或严格限制正常组织的照射剂量。e：近距离放疗：近距离放疗是所有不适合手术的初治宫颈癌根治性放疗的关键部分。通常采用宫腔管和阴道施源器。对于局部肿瘤巨大而且不对称的患者或者肿瘤退缩不足的患者，组织间插植可以提高靶区剂量并且最大限度减小正常组织剂量。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "推荐近距离放疗前或放疗中行MRI检查，有助于勾画残留肿瘤。A点或高危CTV（HR-CTV） $D _ { 9 0 }$ 的处方剂量为（5\\~7） $\\mathrm { G y } \\times ( 4 - 6 )$ 次，总量20\\~35Gy。联合EBRT，A点或高危CTV（HR-CTV） $D _ { 9 0 }$ 的 $\\mathrm { E D Q } _ { 2 }$ 需达80\\~85Gy；对于肿瘤体积大或退缩不佳的病灶，A点或高危CTV（HR-CTV） $D _ { 9 0 }$ 的 $\\mathrm { E D Q } _ { 2 } \\geqslant 8 7 \\mathrm { G y }$ 。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "正常组织的限定剂量：直肠 $D _ { 2 \\mathrm { c c } } \\leqslant 6 5 \\sim 7 5 \\mathrm { G y }$ 乙状结肠 $D _ { 2 \\mathrm { c c } } \\leqslant 7 0 { \\sim } 7 5 \\mathrm { G y }$ ：膀胱 $D _ { 2 \\mathrm { e } } \\leqslant 8 0 { - } 9 0 \\mathrm { G y }$ 如果达不到这些参数要求，应该考虑使用组织间插植技术作为补充 $[ 7 .",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "1 0$ 0 f同步化疗：同步放化疗可降低宫颈癌患者复发风险和死亡风险。通过充分评估无远处转移者，推荐盆腔 $\\pm$ 腹主动脉旁EBRT联合同步含顺铂化疗和近距离放疗（1类）【1-7]。同步放化疗，通常在盆腔EBRT时进行化疗。g同步化疗方案推荐：顺铂周疗（ $\\mathrm { D D P } 4 0 \\mathrm { m g / m } ^ { 2 }$ ，每周一次，46次）；如果不能耐受顺铂者，选择卡铂（AUC=2，每周一次，4\\~6次）或含铂双药增敏化疗。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "h放疗前新辅助化疗在既往的研究中不获益，近期有少量文献报道，淋巴结转移者放疗前化疗可以获益。专家组意见不一，建议根据各个医院和患者具体情况慎重选择，推荐放疗前化疗方案紫杉醇 $^ +$ 顺铂或紫杉醇 $^ +$ 卡铂，少于2周期[18] i参见复发转移性宫颈癌治疗。# 参考文献 [1]GFFAMUTZGPALlatfgalstgingmnwicallyaadcervia cer.Gynecol Oncol,1999,74(3):436-442.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[2]riddafnf ingforpatientswithlocallyadvancedcervicalcancerResultsfaprosectiverandomizedtrialmJObsteGyecol,2015,213(4):503.[3]IMMALLJRRTELANCEtlonsnusguidelnesrelietionflincaltargel forintensity-modulatedpelvicradioterapyforthedefnitiveteatmentofcervixcancentJRadiatOncolBiol Phys,2011,79(2):348-355.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[4]LOISELLECKOHWJ.Themerginguse ofIMRTortreatmentofervical cancerNatComprCan Netw,2010,8(12）:1425-1434.[5]CHENFSENGCENGCCllniclstystretmyicapinttat concurrentCisplatinandintensitymodulatedpelvicraditherapyComparisonwithconventionaraditherapy Radiat Oncol BiolPhys,2007,67(5):1438-1444.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "6]Mlnitft modulatdadatonrafrecoloicmalignaniIRaiatniolPhy00654）:11701176 [7]HAIE-MEDERC,POTTERRVANLIMBERGENE,etal.Recommendations fromGynaecological（GYN）GEC ESTROWorkingGroup（I）:Conceptsandtermsin3Dmagebased3Dteatmentlanningincervixcancerbrachy therapywithemphasisonMRIassessment of GTVandCTV.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "RadiotherOncol2005,743）:235-245.[8POTTERGEOGIMPUOJCalnialmftclbasedmaMidda tivebrachytherapycombinedwith3Dconformalradiotherapywithrwithoutchmotherapyinpatientswithlocally advancedcervical cancer.Radiother Oncol,2011,100(1):116-123.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[9]POTTERRHAIE-MEDERCVANLIMBERGENE,etalRecommendations fromgynaecological（GYN）GEC ESTROworkinggroup（I）:Conceptsandterms3Dimage-basedtreatmentplanningncervixcancerbrachytherapy3DlntfDbasdanyatnidilgi Oncol,2006,78(1):67-77.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[10]VISWANATHANANERICKSONBAThredimensionalmagingngynecologicbrachytherapy:Asurveyoft AmericanBrachytherapy Society.Int J Radiat Oncol Biol Phys,2010,76(1):104-109.[11]GAFFNEYDKERICKSONWTTMANNBAHINGRANAtalCRAppropriateessCritriaonAva CervicalCancerExpertPanelnradiationncologgyeclogynadiatncolBilPhy01l13）:09 614.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[12]MNKTEWARIOHWJMtdaltyterayflcallyadvancedeviclcanmaStft and future directions.JClin Oncol,2007,25(20):2952-2965.[13]OIIFELUlPviradiatnwiretchtraymaedwitvinda aortic radiation forhigh-riskcervical cancer.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "NEngl J Med,1999,340（15):1137-1143.[14]NWUEUDNtlamizdcmparisonfrouracillat sushydroxyureaasanadjuncttoradiationtherapyinstageB-IAcarcinomaof thecervixwithnegativeaa aorticlymphnodes:AGynecologicOncologyGroupandSouthwestOncologyGroup studyJClinOncol1999 17(5):1339-1348.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[15]EGDTIBlrisnbasdaditrantrll advanced cervical cancer.NEnglJMed,1999,340（15):1144-1153.[16]THOMASGM.Improved treatmentforcervicalcancer:Concurrent chemotherapyandradiotherapy.NEng Med,1999,340(15):1198-1200.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[17]ROSEPG.Combination therapy:New treatment paradigm forlocaly advanced cervical cancer?NatRevClin Oncol,2011,8（7):388-390.[18]GREENHMCOUNSELLNWARDAet alNeoaduvantchmotherapynlocallyadvanced cervical caci noma:Arolepatietswithpara-aortilymphodenvolvement？",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "A10-yearinstittionalexperienceClinOncolR CollRadiol),2022,34（7):e281-e290.9 早期宫颈癌根治术后辅助治疗 <html><body><table><tr><td>术后病理</td><td>分层</td><td>|级推荐</td><td>级推荐</td><td>川级推荐</td></tr><tr><td rowspan=\"2\">腹主动脉淋 巴结阴性</td><td>高危 因素</td><td>盆腔体外放疗含铂同步化疗 近距离放疗d</td><td>序贯放化疗</td><td></td></tr><tr><td>中危 因素b</td><td>盆腔体外放疗 近距离放疗</td><td></td><td>盆腔体外放疗+ 含铂同步化疗近距离放疗</td></tr><tr><td rowspan=\"2\">腹主动脉淋 巴结阳性</td><td>无远处 转移</td><td>影像学或活检提示阴性者行延 伸野放疗+含铂同步化疗±</td><td></td><td></td></tr><tr><td>有远处 转移</td><td>近距离放疗 影像学或活检提示阳性者进行 系统治疗加个体化外放疗</td><td></td><td></td></tr></table></body></html> # 【注释】 a早期宫颈癌接受根治手术者术后辅助治疗取决于手术发现及病理分期。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "“高危因素”包括淋巴结阳性、切缘阳性和宫旁浸润。具备任何一个“高危因素”均推荐进一步影像学检查，以了解其他部位转移情况，如无腹主动脉旁淋巴结和其他部位转移，需补充盆腔体外放疗+含铂同期化疗（证据等级I）±阴道近距离放疗。同步放化疗一般采用顺铂单药，顺铂不良反应不耐受可用卡铂替换。b病理类型为鳞癌的患者中危因素（肿瘤大小、间质浸润、淋巴脉管间隙浸润）可参考“Sedis标准”[1（表9-1）。其他可能影响预后的因素还有病理类型（如腺癌和腺鳞癌），但目前仅有回顾 性研究结果，尚无前瞻性研究支持将其纳入术后辅助治疗的危险因素中[24。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "浸润深度是鳞癌复发的重要危险因素。肿瘤大小是腺癌复发的重要危险因素，并且这种风险随着 LVSI 的存在而增加［。表 9-1 Sedlis 标准 <html><body><table><tr><td>LVSI</td><td>间质浸润</td><td>肿瘤大小（cm</td></tr><tr><td>+</td><td>外 1/3 </td><td>任何大小</td></tr><tr><td>+</td><td>中 1/3 </td><td>≥2</td></tr><tr><td>+</td><td>内 1/3 </td><td>=5</td></tr><tr><td></td><td>中或外 1/3</td><td>W4</td></tr></table></body></html> c推荐调强放疗等放疗技术，放射野至少需包括阴道断端及上段阴道、宫旁组织和直接的淋巴结引流区（如骼内、骼外淋巴结区、闭孔和骶前）。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "如确定有淋巴结转移时，放射野的上界还需要相应延伸。通常建议常规分割的剂量 $4 5 { \\sim } 5 0 \\mathrm { G y }$ ，对于未切除的大淋巴结应该用高度适形的体外放疗推量 $1 0 { \\sim } 2 0 \\mathrm { G y }$ 。建议在术后 4\\~6 周内开始放疗。d 某些患者特别是阴道切缘阳性或近切缘者，应增加后装近距离治疗作为剂量加量，降低阴道残端复发风险。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "推荐柱状施源器阴道黏膜下 0.5cm，5.5Gyx 2 次或阴道黏膜面 $6 .0 \\mathrm { G y } \\times 3$ 次。é我国一项Ⅲ期研究一STARS研究，将 $\\mathrm { ~ I ~ B 1 { \\sim } ~ I I ~ A 2 }$ 期宫颈癌根治术后存在病理高危因素的患者随机分为3组：单纯放射治疗组、同步放化疗组和序贯放化疗组。结果显示前两组3\\~4级不良反应发生率相似，而序贯放化疗组有较高的3 年无病生存（disease-free survival，DFS）率并能降低死亡风险，可用于放疗资源紧张的地区[6-7]。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "1]EDUDMrizdfviaitauf apyinselectedpatientswithstaeIBcarcinomaofthecervixaferradicalhysterectomyandpelviclymphadenec tomy:A GynecologicOncology Group study.Gynecol Oncol,1999,73(2):177-183.[2]ARKMtalmarinflniaumfacamandnqou nomainuterinecervicalcaceratientsrecivingsugicarectionfollowedbyradiotherapymultnterre spective study (KR0G13-10).",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "GynecolOncol,2014,132(3):618-623.[3]ii ectomy:AKorean GynecologicOncologyGroup study.BrJ Cancer,2014,110(2）:278-285.[4]OYAMAQUINGAtalPdirfrsdlcmaasiayrm followingcervical conization with positivemargins.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "GynecolOncol,2014,132（1）:7680.[]EVIEAVILUalyndsisislgsmgrmdin vical cancerrecurrencerisk:AnNRG/GOG ancillaryanalysis.GynecolOncol2021,162(3）:532-538.[6]HUNGENGWNtlfftivnsfquelhmradtnornmradat radiationaloneinaduvanteamentafterhysterectomyforcervicalcancerTheTARSphase3randomizedclinical trial.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "JAMA Oncol,2021,7(3):361-369.[7]TRIITTIMWSHMCCLUHWALTERNPsertivhradiatnri riskcericaavaluaingtndingfglogclogyoupt9nlroulao-ad cohort.Int JRadiat Oncol Biol Phys,2015,93(5):1032-1044.# 10 意外发现宫颈癌的处理 <html><body><table><tr><td>分期</td><td>分层</td><td>级推荐</td><td>级推荐</td><td>川级推荐</td></tr><tr><td rowspan=\"2\">TAI</td><td>无淋巴脉管间隙随访观察 浸润</td><td></td><td></td><td></td></tr><tr><td>浸润</td><td>伴淋巴脉管间隙宫旁广泛切除加阴道上段切除+ 盆腔淋巴结切除b 盆腔体外放疗+近距离放疗 含铂同期化疗</td><td></td><td></td></tr><tr><td>或以上</td><td>查均阴性者</td><td>IA2、IB1切缘及影像学检宫旁广泛切除加阴道上段切除+ 盆腔淋巴结切除 或 盆腔体外放疗+近距离放疗± 含铂同期化疗 切缘为阳性，存盆腔体外放疗（若骼总和/或腹 在肉眼残留病灶、主动脉旁淋巴结阳性加腹主动</td><td></td><td>宫旁广泛切除加阴 道上段切除+ 盆腔淋巴结切除+ 主动脉旁淋巴结取样</td></tr></table></body></html> # 【注释】 a意外发现宫颈癌是指因良性疾病进行单纯子宫切除术后病理学检查证实的子宫颈浸润癌（仅包括鳞癌、腺癌、腺鳞癌和子宫颈神经内分泌癌。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "对这一类患者首先需明确病理学诊断，确定分期、是否有LVSI阳性、切缘阳性等。其次，需进行全面检查评估，包括手术范围、查体、血生化检查和影像学检查。根据病理学、影像学检查结果，结合当地技术条件及患者具体情况选择最佳的治疗方案[-2]。b二次手术治疗的选择需考虑手术后病理学检查结果、患者对再次手术的耐受能力和当地医疗水平。二次手术适于部分早期年轻患者[9-14，手术后无须辅助放疗，可保留卵巢功能和阴道功能。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "对评估术后放疗概率大的病例，不推荐手术和放疗方式的叠加，建议选择盆腔放疗 $^ +$ 同期化疗[3-8]。# 参考文献 [1] LU HW, LIJ, LIU YY, et al.Can radical parametrectomy be omitted in occult cervical cancer afer extrafascial hysteectomy?.Chin J Cancer, 2015, 34 (9): 413-419.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[2]KOH HK, JEON W, KIM HJ, et al.Outcome analysis of salvage radiotherapy for occult cervical cancer found afer simple hysterectomy.Jpn J Clin Oncol, 2013, 43 (12): 1226-1232.[3］ CRANE CH, SCHNEIDER BF.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "OCcult carcinoma discovered after simple hysterectomy treated with postoperative radiotherapy.Int J Radiat Oncol Biol Phys, 1999, 43 (5): 1049-1053.[4] CHEN SW, LIANG JA, YANG SN, et al.Postoperative radiotherapy for patients with invasive cervical cancer following treatment with simple hysterectomy.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "Jpn J Clin Oncol, 2003, 33 (9): 477-481.[5]MDNGGlqfryu carcinoma oftheuterine cervix.Gynecol Oncol,2004,94(2):515-520.6Gnivi inadverenthystrectmyllwedbyalvageradiothrapyaditcolBilPhy004592）:27.7]AIIUMARPTDGHSHlutfaaitrayfaqutu invasivervicalcanmapatnt:AspctiveanalsisJaditcolBilPhy2005633）28833.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[8MTHBMUUGlsrtvraitrvietllyied simpleyrtmyrtnindinrvasivalomll3）9 [9]GORRRTCHESGASTANNtalaicalpamttmyfocculvicalcmadt posthysterectomy.JLow GenitTract Dis,2004,8(2):102-105.[10]EATHCATRAUGHNMHOLAMalholfrailpramctmye occultcervicalcarcinoma aferextrafascial hysterectomy.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "GynecolOncol,2004,92（1）:215-219.[11YHTEGENUVENtaladcalrrtionforvasivvialnoueh ectomy.J Surg Oncol,2006,94(1):28-34.12]Mfcaiviauf tomy.Ann Oncol,2010,21(5):994-1000.[13]RUENGKHACHORNIPHITHAKWATCHARANVIRIYAPAKB,tal.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "Comparisnofncologicoucomef unanticipatedcericalcarcinomainwomenundergonginadverentsmlehysterectomyandthoseundergoingurgical treatment afterpreoperative diagnosis.Gynecol Oncol,2019,153(2):248-254.[14]RDUEESlulvaiicauafe hysterectomyIsthidealmanagementSystematicparametrectomywithorwithoutradiotherapyrradiotherapy only？",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": ".Ann Surg Oncol,2015,22(4）:1349-1352.# 11 复发宫颈癌的治疗 11.1 局部或区域复发宫颈癌的治疗 <html><body><table><tr><td>局部或区域复发 （分层因素）</td><td>|级推荐</td><td>Ⅱ级推荐</td><td>Ⅲ级推荐</td></tr><tr><td>既往未接受过放 疗或在既往放疗 野之外复发</td><td>手术切除（充分评估可手术切除）至 术后个体化EBRT近距离放疗 系统治疗b 或 个体化EBRT±近距离放疗 系统治疗</td><td>系统治疗营养 与支持治疗、姑息 性治疗</td><td></td></tr><tr><td colspan=\"4\">既往接受过放疗或者复发于放疗野内</td></tr><tr><td rowspan=\"2\">中心性复发</td><td>手术治疗（盆腔廓清术）</td><td>系统治疗 营养与支持治疗、 姑息性治疗</td><td>术中放疗（1ORT）</td></tr><tr><td>病灶直径<2.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "0cm并经仔细评估者： 根治性子宫切除术 近距离放疗</td><td>系统治疗 营养与支持、姑息息性治疗 性治疗</td><td>营养与支持治疗、姑</td></tr><tr><td>非中心性复发</td><td>系统治疗营养与支持治疗、姑息系统治疗 性治疗</td><td>个体化EBRTa （可考虑SBRTf）</td><td>手术切除IORTd</td></tr></table></body></html> # 【注释】 a放疗原则可参见“中晚期宫颈癌的放（化）疗中放疗”部分。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "放疗后复发而再次放疗时，放疗方式及放疗剂量需谨慎设计。如首次放疗后2年以上者，可以根据具体情况酌情给以全量放疗。但对首次放疗后短时间内复发者，再次常规放疗治愈肿瘤可能小，且有严重的放疗并发症，应防止盲目高剂量放疗。b不适合手术或放疗者，可首选系统性治疗，具体参见复发转移宫颈癌的系统治疗。c 放疗后盆腔中心复发或未控制的患者，盆腔廓清术是一种治疗的选择。需要术前评估，明确是否存在远处转移（术前PET/CT或胸腹盆 MRI或CT检查）。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "如果复发限于盆腔，可进行手术探查。术中肿瘤未侵犯盆壁及淋巴结者可行盆腔脏器切除。根据肿瘤的位置，选择前、后或全盆腔廓清术。若肿瘤部位可以保证足够的手术切缘，可保留盆底和肛门括约肌（表11-1）。建议在具有较高廓清术水平的医疗中心进行。需要指出的是，这类手术（之前没有盆腔放疗）很少用于初始治疗，仅用于不适合盆腔放疗或既往接受过盆腔放疗后局部进展且不适合进一步放疗的患者。d术中放疗（IORT）是指在剖腹手术时对有肿瘤残留风险的瘤床或无法切除的孤立残留病灶进行单次大剂量放疗。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "尤其适合放疗后复发的病例。IORT时，可将高危区域内的正常组织移开（如肠道或其他内脏）。通常使用电子线、近距离放疗或微型X射线源，可选择不同大小的施源器（与手术定义的高危区域匹配）来限制放疗的面积和深度，避免周围正常组织接受。e 难治性复发肿瘤患者需要根据个体情况，采取综合的治疗方法，包括临终关怀、疼痛咨询、情绪和精神支持。f立体定向放疗（SBRT）是一种允许实施少分次、高剂量分割的聚焦式EBRT的放疗方式，可用于某些孤立的转移灶，也可以考虑用于治疗再放疗区域内的局限性病变。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "表11-1 无远处转移的局部复发宫颈癌切除术分类] <html><body><table><tr><td colspan=\"4\">肛提肌下型盆腔廓清除术类型比较</td><td colspan=\"2\">肛提肌上型盆腔廓清除术类型比较</td></tr><tr><td></td><td>前盆腔</td><td>后盆腔</td><td>全盆腔</td><td>后盆腔</td><td>全盆腔</td></tr><tr><td>适应证</td><td colspan=\"5\">盆腔中心复发 适用于部分经过筛选的不适合初始行放疗的FIGOIVA期患者</td></tr><tr><td>目的</td><td colspan=\"5\">根治</td></tr><tr><td>子宫、输卵 管、卵巢</td><td>切除</td><td>在则切除</td><td>则切除</td><td>则切除</td><td>如果仍然存在则如果仍然存如果仍然存在如果仍然存在如果仍然存在则切 除</td></tr><tr><td>阴道</td><td>切除</td><td>切除</td><td>切除</td><td>切除</td><td>切除</td></tr><tr><td>膀胱和尿道</td><td>切除</td><td>切除</td><td>切除</td><td>切除</td><td>切除</td></tr><tr><td>直肠</td><td>切除</td><td>切除</td><td>切除</td><td>切除</td><td>切除</td></tr><tr><td>肛门括约肌</td><td>切除</td><td>切除</td><td>切除</td><td>保留，如果可 以，与结肠吻合</td><td>保留，如果可以， 与结肠吻合</td></tr></table></body></html> 无远处转移的局部复发宫颈癌切除术分类（续） <html><body><table><tr><td colspan=\"4\">肛提肌下型盆腔廊清除术类型比较</td><td colspan=\"2\">肛提肌上型盆腔廊清除术类型比较</td></tr><tr><td></td><td>前盆腔</td><td>后盆腔</td><td>全盆腔</td><td>后盆腔</td><td>全盆腔</td></tr><tr><td>泌尿系统重 建方案</td><td>回肠代膀胱术 或可控性尿流 改道术</td><td>不适用</td><td>结肠双腔湿性 造口术[23] 回肠膀胱术或 可控性尿流改 道术</td><td>不适用</td><td>结肠双腔湿性造口 术[2-3、回肠膀胱 术或可控性尿流改 道术</td></tr><tr><td>胃肠系统重不适用 建方案</td><td></td><td>瘘术</td><td>结肠末端造结肠双腔湿性结肠末端造瘘结肠双腔湿性造口 肠末端造瘘术</td><td>联合暂时性回造瘘术，或吻合术 肠造口术</td><td>造口术2或结术或吻合术，术[23]、结肠末端 联合暂时性回肠造 口术</td></tr><tr><td colspan=\"8\">阴道重建方案 肌皮瓣（腹直肌、股薄肌），或带网膜J-形瓣的中厚皮片移植</td></tr></table></body></html> # 11.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "2 远处转移宫颈癌的治疗 <html><body><table><tr><td>远处转移（分层 因素）</td><td>|级推荐</td><td>Ⅱ级推荐</td><td>川级推荐</td></tr><tr><td>可考虑局部治疗</td><td></td><td></td><td rowspan=\"3\">系统治疗 营养与支持治 疗、姑息性治 疗e</td></tr><tr><td>评估局部可手术 切除</td><td>局部手术切除±EBRT+ 系统治疗d</td><td>局部个体化EBRT67 近距离放疗+系统治疗</td></tr><tr><td>不可局部切除</td><td>局部个体化EBRT 近距离放疗系统治疗</td><td></td></tr><tr><td>不适宜局部治疗</td><td>系统治疗b.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "d±营养与支 持治疗、姑息性治疗</td><td>系统治疗（二线治疗）b，或 参加临床研究营养与支持治 疗、姑息性治疗</td><td>营养与支持治 疗、姑息性治 疗e</td></tr></table></body></html> # 【注释】 a无论患者是初治还是复发时出现远处转移，都很难治愈。对于经过高度选择的、具有可局部治疗的孤立性远处转移的患者，采用局部方案的放疗或消融治疗，可能改善生存，例如淋巴结、肺、肝或骨寡转移可能受益于局部治疗。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "在局部治疗后，可以考虑联合系统治疗。b对于出现盆腔外复发或转移的患者，不适宜放疗或廓清术，推荐化疗或最佳支持治疗。对化疗有效的患者，其疼痛和其他症状可明显缓解。但是，对化疗的反应通常持续时间短，生存很少得到改善。更多一手肿瘤指南、专家共识、医学资料等，请关注”放瘤班”微信公众号！放疗原则可参见“中晚期宫颈癌的放（化）疗”及“局部或区域复发中放疗”相关注释。d见复发转移宫颈癌的系统治疗。e难治性转移性肿瘤患者需要根据个体情况，采取综合的治疗方法，包括临终关怀、疼痛咨询、情绪和精神支持。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "f经过一线系统治疗后失败的患者，无论手术或放疗，预后均不佳。这些患者可以接受系统治疗或最佳支持治疗，鼓励参与临床试验。# 11.3 复发或转移性宫颈癌的系统治疗 11.3.1 复发或转移性宫颈癌的系统治疗选择 <html><body><table><tr><td>系统治疗</td><td>级推荐</td><td>I级推荐</td><td>Ⅲ级推荐</td></tr><tr><td>一线</td><td>颜铂+紫杉醇+ 贝伐珠单抗a9 或 卡铂+紫杉醇+ 贝伐珠单抗 或 顺铂+紫杉醇 或 卡铂+紫杉醇 （先前用过顺铂）b</td><td>帕博利珠单抗+顺铂+紫杉醇± 贝伐珠单抗（适用于PD-L1阳性卡铂 肿瘤） 帕博利珠单抗+卡铂+紫杉醇± 贝伐珠单抗（适用于PD-LI阳性 肿瘤） 拓扑替康（托泊替康）+紫杉醇+ 贝伐珠单抗 拓扑替康+紫杉醇 顺铂+拓扑替康</td><td>顺铂 紫杉醇</td></tr></table></body></html> 复发或转移性宫颈癌的系统治疗选择（续） <html><body><table><tr><td>系统治疗 二线</td><td>|级推荐</td><td>I级推荐</td><td>Ⅲ级推荐</td></tr><tr><td></td><td></td><td>白蛋白结合型紫杉醇d 多西他赛 培美曲塞 拓扑替康 帕博利珠单抗（适用于PD-L1阳 性或TMB-H或MSI-H/dMMR的 卡度尼利单抗（含铂化疗治 疗失败的复发或转移性宫颈癌） 赛帕利单抗 参加临床研究 吉西他滨d 肿瘤）k.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "m，a45.8.18-19]</td><td>异环磷酰胺d 伊立替康d 斯鲁利单抗（MSI-H实体瘤） 替雷利珠单抗g（MSHH或dMMR 实体瘤） 恩沃利单抗h（MSI-H或dMMR 实体瘤） 普特利单抗（MSI-H或dMMR 实体瘤） 纳武利尤单抗（适用于PD-L1阳 性的肿瘤）！丝裂霉素d 氟尿嘧啶d 长春瑞滨d Tisotumab vedotin-ttyp20)</td></tr><tr><td>其他</td><td></td><td></td><td>塞尔帕替尼（selpercatinib）用于 治疗转移性RET融合阳性肿瘤 Larotrectinib或Entrectinib（适用 于NTRK基因融合的肿瘤）</td></tr></table></body></html> # 【注释】 a顺铂 $^ +$ 紫杉醇及卡铂 $^ +$ 紫杉醇是转移性或复发性宫颈癌应用较广泛的化疗方案。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "GOG-240研究比较了贝伐珠单抗联合两种化疗方案（顺铂 $^ +$ 紫杉醇 $^ +$ 贝伐珠单抗或拓扑替康 $^ +$ 紫杉醇 $^ +$ 贝伐珠单抗），结果显示接受贝伐珠单抗的患者总生存期有改善。根据此研究结果，2015年美国食品药品监督管理局（FDA）批准贝伐珠单抗作为紫杉醇和顺铂或拓扑替康联合紫杉醇用于治疗持续性、复发性或转移性宫颈癌。对于不能使用紫杉醇的患者，可采用顺铂 $^ +$ 拓扑替康替代。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "无铂方案拓扑替康联合紫杉醇可作为无法耐受铂类化疗的患者的选择。不耐受联合化疗者也可考虑单药化疗。b基于GOG240和JGOG0505研究的结果，卡铂 $^ +$ 紫杉醇 $^ +$ 贝伐珠单抗作为复发和转移性宫颈癌的另一治疗推荐方案。卡铂 $^ +$ 紫杉醇作为接受过顺铂治疗的患者首选，而既往未使用过顺铂的患者推荐顺铂联合紫杉醇。c2021年Keynote-826（NCT03635567）的结果发现在一线治疗的PD-L1阳性宫颈癌患者中，与化疗 $\\pm$ 贝伐珠单抗相比，帕博利珠单抗联合化疗 $\\pm$ 贝伐珠单抗将患者死亡风险降低了 $3 6 \\%$ +显著延长总生存期（OS）和PFS。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "基于此，美国FDA批准了帕博利珠单抗 $^ +$ 化疗贝伐珠单抗在PD-L1阳性（ $\\mathrm { C P S } \\geqslant 1$ ）的复发或转移性宫颈癌的一线治疗。d单药治疗有一定缓解率或可以延长PFS、可以用作二线治疗的药物。国家药品监督管理局（NMPA）批准用于含铂化疗治疗失败的复发或转移性宫颈癌患者。fNMPA批准用于既往经治局部晚期不可切除或转移性高度微卫星不稳定型（MSI-H）或错配修 复缺陷型（dMMR）实体瘤成人患者。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "gNMPA批准用于经标准治疗失败后、不可切除、转移性高度微卫星不稳定型（MSI-H）实体瘤患者。hNMPA批准用于标准治疗失败的MSI-H或dMMR晚期结直肠癌、胃癌及其他实体瘤。经过一线系统治疗后失败的患者，再次系统治疗缓解率低。这些患者可以接受系统治疗或最佳支持治疗，还可参与临床试验。鼓励癌症患者参加正规临床试验。j赛帕利单抗在Ⅱ期临床研究第一阶段中，41例复发转移宫颈癌患者的ORR达到 $2 6 .",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "8 3 \\%$ 结果公布于2020年ASCO及IGCS会议，2023年NMPA批准用于既往接受含铂化疗治疗失败的复发或转移性且PD-L1表达阳性（ $\\mathrm { C P S } \\geqslant 1$ ）的宫颈癌。k基于研究Keynote-158宫颈癌队列结果，PD-L1阳性患者ORR为 $1 4 .6 \\%$ 2018年美国FDA批准了帕博利珠单抗在PD-L1阳性（ $\\mathrm { C P S } \\geqslant 1$ ）的复发或转移性宫颈癌的治疗。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "1Checkmate-358研究中，纳武利尤单抗单药在PD-L1阳性（ $\\mathrm { C P S } \\geqslant 1$ ）的20例复发或转移性宫颈癌患者中取得 $2 0 \\%$ 的ORR。m适用于患有不可切除或转移性、高肿瘤突变负荷（TMB-H，≥10mut/Mb）（采用一种经验证的和/或美国FDA批准的方法检测）的肿瘤，既往治疗后疾病进展且无其他合适的治疗选择的患者。n复发或转移性宫颈肉瘤可考虑进行NTRK基因融合检测。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "0目前国内针对宫颈癌靶向药物及免疫检查点抑制剂有多项临床研究探索中，缺乏相关高级别研究数据，仍在不断探索。临床实际应用时，须结合患者的一般状况及耐受情况，对化疗及靶向、免疫治疗药物剂量进行适当调整。选择合适的治疗方案时应慎重考虑费用和不良反应。p基于一项关键的复发转移宫颈癌ⅡI期临床试验，tisotumabvedotin获得了 $2 4 \\%$ 的客观缓解率（ORR），缓解持续时间（DOR）中位数为8.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "3个月，且安全可控。美国FDA已加速批准tisotumabvedotin-ttv用于治疗在化疗中或化疗后疾病进展的复发性或转移性宫颈癌成人患者。目前在全球开展宫颈癌二线治疗的Ⅲ期临床研究，中国有多家医院参加。q2020年5月获得美国FDA批准，2022年11月获NMPA批准，用于治疗晚期 $R E T$ 基因融合阳性甲状腺癌和非小细胞肺癌（NSCLC）成年患者。2022年7月22日，普特利单抗注射液正式获NMPA批准上市，适应证：用于既往接受一线及以上系统治疗失败的高度微卫星不稳定型（MSI-H）或错配修复缺陷型（dMMR）的晚期实体瘤患者的治疗。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "# 17.3.2 常用晚期、复发转移宫颈癌化疗方案 DDP+紫杉醇【1-137]紫杉醇 $1 7 5 \\mathrm { m g / m ^ { 2 } }$ ，静脉滴注 $3 \\mathrm { h }$ 第1天DDP $5 0 \\mathrm { m g / m } ^ { 2 }$ ，静脉滴注，第1天每3周重复 拓扑替康+紫杉醇[10]紫杉醇 $1 7 5 m g / m ^ { 2 }$ 静脉滴注 $3 \\mathrm { h }$ 第1天拓扑替康 $0 .",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "7 5 \\mathrm { m g } / \\mathrm { m } ^ { 2 }$ ，静脉滴注，第1\\~3天每3周重复 # 常用晚期、复发转移宫颈癌化疗方案（续） 卡铂 $^ +$ 紫杉醇【 12-13、15-16 ]紫杉醇 $1 7 5 \\mathrm { m g / m } ^ { 2 }$ ，静脉滴注 $3 \\mathrm { h }$ ，第1天卡铂 ${ \\mathrm { A U C } } = 5 { \\sim } 6$ ，静脉滴注 1\\~3h，第 1 天每3周重复 顺铂 $^ +$ 拓扑替康{10.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "14]DDP $5 0 \\mathrm { m g } / \\mathrm { m } ^ { 2 }$ ，静脉滴注，第1天拓扑替康 $0 .7 5 \\mathrm { m g } / \\mathrm { m } ^ { 2 }$ ，静脉滴注，第1\\~3 天每3周重复 注：常用的联合化疗方案如上，NCCN 推荐的一线系统治疗还包括化疗联合靶向治疗，GOG240 研究中贝伐珠单抗联合化疗时采用的是 $1 5 \\mathrm { m g / k g }$ ，每3周一次，静脉给药。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "值得注意的是，目前尚无国内数据。临床实际应用时，须结合患者的一般状况及耐受情况，对化疗及靶向药物剂量进行适当调整。# 参考文献 [1] CIBULA D, ABU-RUSTUM NR, BENEDETTI-PANICI P, et al.New classification system of radical hysterectomy: Emphasis on a three-dimensional anatomic template for parametrial resection.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "Gynecol Oncol,2011,122(2）:264-268.[2]BACKESFJIEREJEISENHAUEELlComlitionafdoublearledlostmycm toseparateurinaryandfecaldiversionduringpelvicexenteratonTmetochangeback？GyecolOncol013 128(1):60-64.[3]MCMdifdoulebaldwlostmyaftalvxertonatSur094）5 548.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[4]RNEEUElfyandfliuba deathligand1-positive cervical cancerResultsfrom the phaseIbKEYNOTE-028trial.JClinOncol2017 35(36):4035-4041.5CGaydluousda cal cancer:Results fromthephaseIIKEYNOTE-158study.JClinOncol2019,37（17):1470-1478.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[6]PEIEElrtnflvaonfstI cal cancer:A novel treatment strategy.Gynecol Oncol,2020,156（1):100-110.7]ALMALARltttiblivaiayustandardfpll treatmentpatientswtligomastaticanersSABRCOMET）:randomisease2pn-labtrialan cet,2019,393（10185):2051-2058.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[8]MDlstrtvi cer.NEngl JMed,2021,385(20):1856-1867.[9]TEWARISLLWONG3rdalmrovedsurvivalwithevacizumabiadvancedcvialcan EnglJMed,2014,370 (8):734-743.[10]MONKJSILMWMCMEEKINDStalPhaseIItialf fourcislatin-contaningdoubletcomn tionsin stageBecurrentrpersistentcervicalcarcinoma:A GyecologicOncology GroupstudyJClin Oncol,2009,27(28):4649-4655.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[1MREHSSGCQUELNhastrwioli stageecrntrrsistentquamousllcarnmaftcervigyclogicnclogygoupst ClinOncol,2004,22（15):3113-3119.[12]GEWlmarisnfcislapalaxlndcbp/alitxlst IVB,recurrent or persistentcervical cancer Gynecol Oncol,2007,105(2):299-303.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[13]KITAGAWARATSUMATANHIBATATtalPlitaxllucaboplatinersuspalitaxel s platininmetastaticorrecurrent cervicalcancer:Theopen-labelrandomizedphaseItrialJCOG0505.J Clin Oncol,2015,33（19):2129-2135.14]NGDGENDClazehaIalatiwtrwtt incarinmaftrincrvixAGyecologicncologyroupStudyJlnncol00532）:462633 [15]ISGRENNIGNVhasIlfcalaifrnrtatiq carcinomaoftheuterinecervix:SouthwestOncologyGroup study.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "GynecolOncol1990393）33-336.16]THGWEEDlaaindplixfvdr carcinoma:The British Columbia CancerAgencyexperience.Gynecol Oncol,2005,98(1):5458.[17]CGUIEEIGEDallitaadratativitnquica GynecologicOncology Group study.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "J Clin Oncol,1996,14(3):792-795.[18]MARABELLEDTCIERTOPAtlffcayfmbliuabipatintswithnolorecth microsatelltinstabilty/mismathrepair-deficentcancerResultsfrmthephaseIKEYNOTE8studyCin Oncol,2020,38（1）:1-10.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[19]MERINODMCSHANEMABIZIDtl.Establisingilinestohanizeturuttonur den（TMB）InsilicoassesmentofvariationinMBquantificationacrossdianosticplatforms:PhaseIof t FriendsofCancerResearchTMBHarmonizationProject.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "JImmunotherCancer,2020.8（1):000147.[20]COLEMANRLLORUSSODGENNIGENSCtalEfficacyand saftyf tisotumabvedotininpreviousl treatedrecurrent ormetastaticcervical cancerinnovaTV204GOG-3023/ENGOT-cx6）:Amulticentreopen labelsinmhasstdLol025）099 # 12 宫颈癌随访 <html><body><table><tr><td rowspan=\"2\" colspan=\"2\">期别</td><td colspan=\"2\">|级推荐</td><td>级推荐</td><td>Ⅲ级</td></tr><tr><td>频次</td><td>随访内容</td><td>随访内容及频次</td><td></td></tr><tr><td></td><td>保留生育功能 后2年内 每3-6个 月一次， 3-5年每 6~12个 不保留生育功能 月一次， 5年后每 年一次。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "</td><td>健康宣教 选择其他影像学检查 健康宣教</td><td>2.在手术后6个月进行一次盆腔MRI检次 查，然后每年一次盆腔MRI检查持续2~32.既往高危HPV阳性 年；根据复发转移的相关临床症状及体征者复诊时行HPV检测 1.病史询问、体格检查、血液学检测、 2.根据复发转移相关的临床症状及体征选</td><td>检查（TCT）：每年 3.宫颈和/或阴道细 胞学异常，或HPV16 （+）和/或HPV18（+） 者行阴道镜检查+活检 4.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "治疗前SCC-Ag、细</td><td></td></tr></table></body></html> 宫颈癌随访（续） <html><body><table><tr><td rowspan=\"2\">期别</td><td colspan=\"2\">级推荐</td><td>川级推荐</td><td>川级 推荐</td></tr><tr><td>频次</td><td>随访内容</td><td>随访内容及频次</td><td></td></tr><tr><td>FIGOII~IVA (TNaMo)</td><td></td><td>1.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "病史询问、体格检查、血液学检测 健康宣教 2.治疗结束后3~6个月内进行一次胸、腹 盆腔CT/必要时PET/CT±盆腔MRI 3.根据复发转移的相关临床症状及体征选6.复查结果异常者可 择其他影像学检查</td><td rowspan=\"2\">5.超声检查：双下肢 肿胀者可行双下肢静 脉超声检查排除静脉 血栓 增加复查频次</td></tr><tr><td>FIGO IVB （TNaM）或 复发患者</td><td></td><td>健康宣教 2.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "根据病情可选择CT/MR/必要时PET/ CT评估治疗疗效或决定进一步治疗方案： 3.可疑复发或转移：PET/CT+盆腔MRI 1.病史询问、体格检查、血液学检测b</td></tr><tr><td>小细胞神经内 分泌癌</td><td></td><td>健康宣教 2.胸、腹、盆腔CT检查±头颅MRI， 或PET/CT±头颅MRI 1.病史询问、体格检查、血液学检测b</td><td></td></tr></table></body></html> # 【注释】【1-9] a随访的频率基于患者的复发风险及个人意愿，治疗结束后2年内：高风险患者每3个月一次，低风险患者每6个月一次。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "风险因素包括淋巴结阳性、切缘阳性、宫旁阳性及LSVI、肿瘤大小、宫颈间质浸润深度达到建议盆腔体外放疗的 Sedlis 标准。b血液学检查：全血细胞学检测、肝肾功能等。c健康宣教 疾病可能复发的症状体征（异常阴道出血，消瘦，食欲下降，盆腔、臀部、腰、背、腿痛，持续咳嗽等症状，盆腔、腹部新增包块，异常增大淋巴结等体征），定期自我检查，健康生活方式，减肥，戒烟，营养咨询，体育锻炼，治疗后潜在远期并发症，性健康（阴道扩张器使用，阴道润滑剂，激素替代治疗)。",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "d有条件者建议行增强 MRI、CT 检查。# 参考文献 NatlComprCanc Netw,2006,4(5):463-469.[4]LAKHMANKINARKJtaltaervialcnerlefppativeMmagntn of patients forfertility-sparingradical trachelectomy.Radiology,2013,269(1):149-158.[5]ELITREADECJRecommendationsforfollow-upcare forgynecologiccancer survivorObstet Gye col,2015,126（6):1207-1214.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "[6]SALAECKALLGFREEMANladdrlMangentstratatonf withgynecologicmalignancie:What theradiologistneedstoknow.Radiology201366(3）:717740.[7]MANGANRAKMAHRWAltnrandfllwuuivi cerusingMRIUpdatedGuidelinesof theEuropeanSocietyofUrogenitalRadiologyaferrevisedFIGOstaging 2018.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "EurRadiol,2021,31（10):7802-7816.[8]AICGrystifviatan whole-bodyforodeoxygucosepositronemissontomography/cmputedtmographyinthepretreatmentaessment ofpatients with cervical cancer.Int JGynecol Cancer,2015,25(8):1461-1467.[9]BHATLAEREKJSUELLOFREDESMlvidFIGOstaigrmaftvixri Gynaecol Obstet,2019,145(1):129-135.",
    "source": "CSCO宫颈癌诊疗指南（2023)",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CSCO宫颈癌诊疗指南（2023)/CSCO宫颈癌诊疗指南（2023).md"
  },
  {
    "text": "# 宫颈癌诊断发展与展望 # HPV与宫颈癌 人乳头瘤病毒（Human papilloma viruses，HPV）与宫颈癌关系的揭示，使宫颈癌成为了目前所有恶性肿瘤中唯一病因明确、唯一可以有效早期预防和治疗且唯一可以彻底根除的癌症。# 1.HPV发现与研究历程 宫颈癌（cervical cancer），又称子宫颈癌，是常发生在子宫颈鳞状上皮细胞及宫颈管内膜柱状上皮细胞交界处的恶性肿瘤。早期常无任何症状，或仅在阴道检查时可见表浅糜烂或一般慢性炎症如少量白带等。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "中期常有白带增多、腥臭、阴道不规则出血、骶尾，臀部及大腿部持续性疼痛、且在膀胱和直肠浸润时可出现排尿和排便障碍等临床表现（见右图）。![](images/ea0c3a6dbb05ed7dc037174f449b35e6a95c85e9b2bfb4fe20229857b549e710.jpg) ·宫颈癌是全球第三大女性恶性肿瘤，是中国女性第二大最常见恶性肿瘤。·根据世界卫生组织（WHO）估计，全球每年新增宫颈癌病例超过47万例，而中国占到了 $2 8 \\% ^ { [ 1 ] }$ 。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "·近年来，我国每年新增宫颈癌病人13万多，每年约有5万人死于宫颈癌，且发病年龄明显趋于年轻化。![](images/e4b50b488f89079fca812562300581e20f85dc96c948dc2a3bbb1616699aed17.jpg) 宫颈癌发病率—亚洲 ![](images/6faa6b89ff0013df02bf749be0881c0e274d97bcc3cebfe78f94a23264922226.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "jpg) 宫颈癌死亡率—亚洲 19世纪40年代，意大利医生Regoni Stern分析死亡登记资料发现，宫颈癌患者大多为已婚女性，未婚者很少，而修女几乎不患宫颈癌。据此，他最早提出了性行为与宫颈癌的发生可能有关。虽然科学家们很早就怀疑宫颈癌与某些感染因子有关，但长期以来各国科学家的大量研究工作都未能明确宫颈癌的直接病因。直到20世纪六七十年代，人们将主要的目光投向单纯疱疹病毒II型（HSV-2），但流行病学调查却不支持HSV与宫颈癌相关；而其他的因子如巨细胞病毒、EB病毒、衣原体等，至今未能发现其与宫颈癌相关的有力证据。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "认知HPV始于19世纪前半叶欧洲医师对喉部乳头瘤的认识。·20世纪初，滤过性实验证明乳头瘤的病原为病毒。·20世纪30年代,首次分离了乳头瘤病毒（棉尾兔）。·20世纪50年代，乳头瘤病毒在动物中的致癌性被证实。·1977年，美国科学家Lavertry在电镜中观察到宫颈癌活检组织中存在人乳头瘤病毒(HPV)颗粒，德国病毒学家Harald zur Hausen[2]等据此提出了HPV与宫颈癌发病可能有关的假设并在2008年10月6日获得诺贝尔生理医学奖。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "![](images/58ee6172bae6cc54f1807eff74ee74a00507a8f34d6d96e1cea86dd427b7ad74.jpg) 诺贝尔奖评审委员会发布的新闻公告中这样写道，“Zur Hausen敢于摒弃教条，他所做出的探索性工作，让人类了解了HPV与宫颈癌的关系，促进了针对HPV的疫苗开发”。目前HPV疫苗人类唯一能预防癌症的疫苗。1989年左右，Johns Hopkins大学教授Keerti Shah和他的同事经过多年的大规模流行病研究发现， $9 9 .",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "7 \\%$ 的宫颈癌与HPV感染有关，证实了宫颈癌与HPV感染有直接关系。经过科学家们的几十年不懈努力，大量流行病学资料和实验室研究证据都强有力地支持HPV感染与宫颈癌之间的因果关系，其相对危险度或危险度比值高达250。HPV与宫颈癌高度相关，HPV感染是宫颈癌的主要流行因素且是宫颈癌发生的必要条件，已被全球科学界和医疗界普遍认同。# 2.HPV致癌机理研究 病例-对照研究是检验病因假说的一种流行病学方法。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "在拉丁美洲采用FISH，PCR和HC-II等多项检测技术进行的大规模流行病学研究均显示HPV感染与宫颈癌有明显的相关性，尤其是HPV16型和18型。在哥伦比亚和西班牙（宫颈癌发病率前者比后者高8倍）进行病例-对照研究中，436例组织学确诊病例和随机抽取的387例相同地区的对照人群同时采用三种HPV DNA检测技术（ViraPap、SH和PCR）进行分析。这一研究避免了人群和地区的选择性偏移，同时又考虑到检测技术间的差异并排除了一些混杂因素干扰，三种检测方法都得出相同的结论：在上述两个国家中HPV16、18、31、33和35型与宫颈癌均呈强相关性，提示HPV与宫颈癌具有病因关系。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "另外，队列研究是用来验证疾病病因假说的另一种主要流行病学方法，能够直接体现HPV感染与宫颈癌发生的时序性，更有力地验证病因假说。Campion等对100 例轻度宫颈上皮内病变（Cervical IntraepithelialNeoplasia 1，CIN1）患者进行了两年多随访分析， $56 \\%$ 的HPV16和18阳性受试者发展为重度宫颈上皮内病变（CIN3），而HPV6阳性受试者仅20%发生进展。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "Murthy通过原位杂交方法研究显示，63例宫颈不典型增生发展为原位癌，对组织标本检测HPV16/18发现阳性率为 $6 8 .3 \\%$ ，而44例非进展性不典型增生的阳性率仅为 $2 7 .3 \\%$ ，相对危险度为5.9（ $9 5 \\% C I$ ：2.5-14.1）, 具有显著统计学意义。此外，细胞学和分子生物学研究也获得了人乳头状瘤病毒致癌的有力证据。1995年WHO及其下属的国际癌症研究署（IARC）将HPV确定为宫颈癌的病因。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "# 常见HPV生殖道感染型别 生殖道感染HPV最常见的型别即16，18，6和11型。HPV6和11型常感染外阴、肛门和阴道等部位，属于低危型，在湿疣或宫颈上皮内低度病变妇女中多常见，与宫颈浸润癌无明显关联；而HPV 16和18型则属于高危型，对各国宫颈癌组织标本研究发现，HPV16和18型感染率最高，在检出的所有型别中，HPV16占 $50 \\%$ ， $\\mathsf { \\Pi } _ { \\mathsf { H P V 1 8 } }$ 占 $1 4 \\%$ ，HPV45占 $8 \\%$ ，HPV31占 $5 \\%$ ，其它型HPV占 $2 3 \\%$ 。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "中国医学科学院肿瘤医院陈汶等[3]2009年发表了一项对国内7个不同区域的630例宫颈鳞癌和569例CIN2/3宫颈组织HPV DNA感染情况的数据分析，其结果表明HPV16占 $7 6 .7 \\%$ ，HPV18占 $7 .8 \\%$ ，两者的感染率占宫颈鳞癌的 $8 4 .5 \\%$ ；其次是HPV31（ $3 .2 \\%$ ）、HPV52（ $2 .2 \\%$ ）和HPV58（ $2 .2 \\%$ ）。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "HPV的型别与宫颈癌的病理类型有关。在宫颈鳞状上皮细胞癌中HPV16占主要地位（51%的鳞状上皮细胞癌标本） 而在宫颈腺状上皮细胞癌（56%腺状上皮细胞癌标本）和宫颈腺鳞细胞癌（39%腺鳞细胞癌标本）中HPV18占主要地位。HPV16和18型感染很普遍，没有明显的地区差异，有些HPV型别有地理位置差异。我国HPV感染型别中，52和58型检出率较高。在台湾进行的一项研究也发现52和58型较常见。HPV45型在非洲西部宫颈癌组织中很常见，而HPV39和59型仅在美洲中部和南部宫颈癌患者组织中出现。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "# HPV感染致癌过程和协同因素 HPV感染通常分为潜伏感染期、亚临床感染期、临床症状期和HPV相关肿瘤期。宫颈癌发生有一系列的癌前病变，能发展到浸润癌的宫颈病变称为宫颈不典型增生，在细胞学上称为鳞状上皮内病变（Squamous Intraepithelial Lesion ，SIL），而病理上称为宫颈上皮内瘤变（CIN）。![](images/8610e6cf2d51c9c3217dc484197192406d6dd58cf89369257d2c089f53c5e642.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "jpg) 并不是所有的HPV感染者和CIN患者都会发展为宫颈癌，这主要取决于三方面因素：病毒因素、宿主因素和环境协同因素。病毒因素主要在于HPV的型别。在宫颈低度病变女性中，高危型HPV感染者的宫颈癌病变危险性远大于低危型HPV感染或HPV阴性患者。除病毒型别外，体内HPV DNA含量水平与宫颈病变进展亦呈正相关。此外，HPV首次感染时间也很重要，因为细胞核不典型增生的程度随病毒持续感染而加重。与宫颈病变进展相关的最重要宿主因素是免疫功能，其次还有产次、激素和营养状况等。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "影响宫颈病变进展的环境协同因子与宫颈癌的危险因素基本一致，同时感染其它性传播病原体如衣原体等也可影响病变进展。![](images/233d1c61c481025f1c98c784fa805432830031de3329b5e7848f9898afc6cd3a.jpg) HPV一过性感染 HPV持续性感染 # HPV 疫苗：宫颈癌 一级防御 2006年由Merck公司研制的首个宫颈癌预防性疫苗，Gardasil®（HPV6、11、16、18 四价疫苗），在经历长达十多年临床研究后，终获美国FDA批准上市，并获得了世界卫生组织（WHO）的认可。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "HPV疫苗的问世及其在宫颈癌预防中的应用，曾被视为人类在与癌症斗争中的里程碑式胜利。在人类与肿瘤的斗争中，HPV疫苗是第一个以预防癌症为目的的疫苗，已证明其能预防宫颈癌。2007年9月24日，欧盟委员会批准葛兰素史克公司的HPV16、18型二价疫苗（Cervarix®）上市。截止目前已有一百多个国家引进了宫颈癌疫苗，其中超过六十多个国家推行了疫苗接种项目。该疫苗在相当一部分国家中被称为“宫颈癌疫苗”，尽管不够严谨，但国际上普遍认定，HPV疫苗在9至45岁女性中对宫颈癌有预防效果。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "如果在首次性行为之前注射HPV疫苗，会降低 $8 0 \\% - 9 0 \\%$ 的宫颈癌及癌前病变发生。2014年12月10日，默克（Merck）宫颈癌九价疫苗（Gardasil® 9）获FDA批准上市。该疫苗被批准适用于9至26岁女性和9至15岁的男性，以预防HPV16、18、31、33、45、52和58型引起的宫颈癌、外阴癌、阴道癌和肛门癌，以及HPV 6和11型引起的生殖器疣。相较于第一代Gardasil® 4价疫苗，该疫苗的预防对象增加了31、33、45、52和58 五种病毒亚型，这5种病毒亚型引起了约 $2 0 \\%$ 宫颈癌，这是此前其他获批的HPV疫苗所不能预防的。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "2016年7月18日，葛兰素史克（GSK）宫颈癌疫苗“希瑞适®”（人乳头状瘤病毒疫苗[16型和18型]）获得中国国家食药监总局（CFDA）上市许可而获准在中国上市，成为在中国首个获批用于预防宫颈癌的HPV疫苗。这就意味着，从2006年全球首次上市HPV疫苗到今天，经过10年之后中国女性终于可以通过注射疫苗的方式远离宫颈癌,这一目前侵扰女性最致命和最凶险的癌症。# HPV认识的误区 误区一：“感染了HPV而已，又不是得癌了，怕什么！",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "” 这部分人对HPV感染重视不够。哲学家培根曾有一句名言：“时间可以治愈一切”，救命的是时间，致命的也是时间，关键看你怎样来把握。如果捉住时机对HPV感染早发现、早诊断、早处理，宫颈癌是完全可以预防、可以治疗的。因为正常宫颈一定会在高危型HPV感染后才会发生病变，很多人通过自身免疫可以把它清除掉，如果消除不掉就称为持续性感染，病变就会发生，首先发生宫颈癌前病变，从癌前病变到宫颈癌需经过差不多10年时间，而10年的时间足够我们进行治疗 预防HPV感染就可以预防宫颈癌没有HPV感染就可以不患宫颈癌 误区二：“感染HPV，怎么办？",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "这回我逃不掉了！”认为得了HPV感染就是得了宫颈癌。其实不然，真正HPV感染到宫颈癌时间很长，你可以在这段时间进行治疗。据统计，HPV感染者中只有 $2 \\% - 3 \\%$ 会发展成宫颈癌。![](images/32ee4202cd75c63caf508bf8a00900def9385139aaf5178aba7fb496541d0465.jpg) 误区三：“接种HPV宫颈癌疫苗后就不需要定期检查!",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "” 宫颈癌疫苗是预防性疫苗，它不是治疗性疫苗。目前上市的“宫颈癌疫苗”均达不到覆盖所有的致癌亚型（既：高危HPV）的效力。即使接种了覆盖面最广的宫颈癌九价疫苗（Gardasil® 9），亦不能$100 \\%$ 预防宫颈癌。因此，定期筛查仍然是预防宫颈癌的最有效方法，且筛查建议和HPV疫苗的接种状态无关。# 宫颈癌检测： # 宫颈癌筛查：二级防御 # 美国宫颈癌筛查方案推荐 2015年1月12日，美国癌症学会（ACS）发布了《2015年美国癌症筛查指南》，并在线发表于《CA:临床医生癌症杂志》[4]。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "文章指出对于宫颈癌筛查应结合年龄、筛查史和其他危险因素选择合适的筛查方式，并推荐：1）21-29岁女性，应单独进行宫颈细胞学检查，每3年1次；2）30-65岁女性，优先推荐细胞学和HPV联合筛查，每5年1次,也可每3年1次细胞学筛查；3）对于前10年内细胞学检测连续3次阴性或细胞学和HPV联合筛查连续2次阴性且最后一次筛查在5年内的女性，65岁后应停止任何方式的筛查；4）任何年龄段都不需要通过任何方式每年筛查。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "2016年1月，美国妇产科医师学会（ACOG, American College ofObstetricians and Gynecologists）发布了宫颈癌筛查和预防实践指南（ACOG Practice Bulletin No.157，ObstetGynecol.2016；127:185-7.)，以替代2012年11月发布的第131号实践指南。ACOG实践指南新版本强调了宫颈癌筛查和预防推荐中的最新改变，包括单一使用HPV测试筛查、HPV疫苗药效更新以及HIV阳性妇女的癌症筛查指南修改。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "# 一、新版本主要更新 1、HPV检测：2014年4月美国食品和药品管理局（FDA）批准罗氏HPV检测可用于25岁及以上女性宫颈癌初筛。超过65岁的女性如果既往筛查结果为阴性，可以停止筛查。2、HPV疫苗：新版指南更新了疫苗使用，包括了九价HPV疫苗的使用指导，这样就覆盖了另外五种高风险的病毒株筛查。3、HIV感染女性的宫颈癌筛查策略：新指南指出，建议依据年龄行宫颈癌筛查，筛查应在有起始性生活开始，无论HIV病毒的传播方式，应不迟于21岁。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "HIV感染女性的宫颈癌筛查应持续终生，而不是到65岁就停止。小于30岁的HIV感染者，应在初次诊断HIV时进行宫颈细胞学检查。如果初始细胞学检查结果是正常的，下一次细胞学检查应该在12个月内。如果连续三年的宫颈细胞学检查结果是正常的，应该每3年随访宫颈细胞学检查。不推荐年龄小于30岁的HIV感染女性行联合筛查。30岁以上的HIV感染女性可行单独细胞学检查或联合筛查。单独细胞学检查的女性，如果连续3年每年的检查结果是正常的，可以每3年随访复查。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "HIV感染女性联合筛查结果正常（正常的细胞学和HPV阴性）可以3年内行下一次宫颈癌筛查。HIV感染女性，联合筛查细胞学结果阴性而HPV阳性，则按普通人群处理。HIV感染女性，细胞学结果为LSIL或更高级别病变时建议行阴道镜检查。细胞学结果为ASCUS的HIV感染女性，如果HPV阳性则建议行阴道镜检查。如果HPV检测结果无效，建议在6-12个月重复宫颈细胞学检查，如结果仍是ASCUS或更高级别病变，建议行阴道镜检查。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "# 二、筛查起止年龄、频率和方法 筛查的起止年龄和频率遵循《2015年美国癌症筛查指南》。对于已行全子宫切除且既往没有CIN2或更高级别病变的女性，应停止常规的细胞学检查和HPV检测且无需重新开始检查。对有下列高危因素的女性，可进行比常规筛查指南推荐更频繁的筛查： 1）HIV感染女性 2）免疫缺陷女性（例如接受实体器官移植者） 3）子宫内乙烯雌酚暴露女性 4）既往因CIN2，CIN3或宫颈癌治疗女性。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "联合检查中细胞学ASCUS和HPV阴性女性，CIN3风险很低，但其风险仍略微高于联合筛查阴性女性，推荐3年内行联合筛查，该建议也是对2011年ACS、ASCCP和ASCP宫颈细胞学筛查指南的修订，对这些女性推荐常规筛查（见下图）。![](images/da525e9fe05d0e587f81fea7c02a63bb41e4f3db9f9b8e1c505ece6799e50329.jpg) 另外，宫颈癌疫苗是预防性疫苗，不是治疗性疫苗。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "即使接种了疫苗，定期筛查仍然很重要的。# 我国宫颈癌筛查方案推荐 我国癌症筛查方案实施过程中根据不同地区经济水平推荐不同初筛方案。经济条件较好地区推荐医生取材HPV检测结合液基细胞学检测；中等发达地区推荐医生取材HPV检测结合细胞学检测；卫生资源缺乏地区可用肉眼观察法。# 1.最佳筛查方案 （ $x \\neq x \\neq x \\neq$ ） 对于经济条件允许的人群，推荐采用高危型HPV检测联合宫颈液基细胞学检查（Liquid-Based Cytology，LBC or TCT），其灵敏度高，几乎没有漏诊病例，准确性高。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "对HPV阴性同时宫颈细胞学检查正常者，其发病风险很低，随访间隔可以延至5年；对HPV阳性但宫颈细胞学阴性者推荐12个月重复细胞学和HPV检测或者做HPV16或HPV18分型检测；对细胞学ASC-US和HPV阴性者推荐12个月重复细胞学检测；对HPV阳性和细胞学ASC-US或者细胞学阳性女性，应进行阴道镜检查，并在阴道镜指引下取一些组织做病理切片检查确诊（见下图）。![](images/1f91e295d7929c4e16a86bab49b9d83420cd7c5a91e0f0f217244ee471957dcd.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "jpg) # 2.理想筛查方案 （★★★★） 对经济条件欠佳者，可采用HPV检测联合传统宫颈巴氏细胞学检查；与常规的单纯传统宫颈巴氏细胞学检查相比，漏诊率可明显降低（见下图）。![](images/562e2af2c345e5fd899162ad80d0f605282a0a88c9297c57d7c5c5b73bc139e7.jpg) # 3.经济筛查方案（★★★） 如果采用单项检测方法，则应先进行HPV基因分型检测。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "对于高危型感染者，建议增加液基细胞学检测（TCT或LBC）。如果细胞学检测结果为阴性，说明宫颈上皮细胞尚未病变，应注意个人卫生和身体锻炼，一年后复查HPV和细胞学检查；如果细胞学检测结果仍是阳性，则需立即进行病理学检查，如阴道镜检查、活检和ECC（宫颈活刮术）。如果病理学结果为阴性，则六个月后复查HPV和细胞学检查，必要时进行阴道镜检查。若病理学结果为阳性，则需进行相应治疗，如激光治疗、冷冻、LEEP（高频电刀）、放疗和子宫切除等。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "![](images/651307496f449f531cb70dc4ad4e9bf2d989d5cbf2403b141e138865911d080c.jpg) # 中美筛查方案异同 # 目前常用筛查方法 我国目前采用的宫颈癌筛查指南与美国最新推荐指南存在如下主要异同： ![](images/2caad7a5d87f13f2101dfa6371ec3701113cdd43f95d5fa8fee31cfddc480961.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "jpg) # 目前临床常用的宫颈癌筛查方法 # 临床宫颈癌诊断“三阶梯” ·细胞学检查·阴道镜检查·组织学检查 我国卫生部于2011年7月发布的中华人民共和国卫生行业标准（WS334-2011）关于《子宫颈癌诊断Diagnosis criteria for cervicalcancer》[5]指出，对宫颈癌的早期诊断应采用“三阶梯”程序，即：子宫颈细胞学检测（巴氏涂片或液基细胞学）、阴道镜检查、组织病理学检查（见下图）。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "细胞学检测为“三阶梯”的第一步，是宫颈癌预防和筛查的关键环节。另外，宫颈病变程度的精准诊断是实现精准治疗的必要前提条件。![](images/af68f87bdc329a0151cb5c5a38fc12cc52fc8ed6dea11e3a84d178b7d30c22e8.jpg) 宫颈癌诊断“三阶梯” # 细胞学检测常用方法 # 传统的巴氏细胞学检测 目前我国多数医院仍采用分级诊断，临床常用巴氏分级分类法分为：Ⅰ级：正常：未见异常细胞。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "Ⅱ级：炎症：发现异常细胞，但均为良性。Ⅲ级：可疑：发现可疑恶性细胞。（1）性质不明细胞。（2）细胞形态明显异常，难于确定其良性或恶性，需要近期复查核实。（3）未分化或退化的可疑恶性细胞与恶性裸核。Ⅳ级：高度：发现待证实的癌细胞（高度可疑的恶性细胞），具有恶性特征但不够典型；或更典型但数目太少，需要复核，例如高度可疑的未分化或退化癌细胞，或少数低分化癌细胞。Ⅴ级：恶性：发现癌细胞，其恶性特征明显或数目较多，可作互相比较以确定为恶性者，例如高分化的鳞癌或腺癌细胞；成群未分化或低分化癌细胞。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "优点：不需要特殊设备及试剂，易普及，费用经济。缺点：假阴性率（误诊率）高，主要原因如下: 1）普通刮板取样，不易取到宫颈癌好发部位宫颈管的有效诊断细胞；2）涂片上存在大量的血液粘液等干扰成份，影响诊断；3）我国细胞病理医生不足，在短时间内须阅读大量筛查涂片，造成细胞病理医生的诊断质量下降。传统巴氏染色及分类法应用半个多世纪以来，为早期诊断宫颈癌及降低死亡率做出了重要贡献。但由于较高的假阴性率（文献报告为20％-50％）或假阳性率，该技术目前在多数发达国家已停止使用，取而代之的是更先进的液基细胞学新技术。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "# 液基薄层细胞涂片 液基细胞学检测，例如新柏氏的TCT（Thinprep cytologic test）是基于液基细胞学的一种薄层细胞检测技术的简称。该方法采用了液基细胞固定技术，并结合薄层细胞制片技术，使得检测样本在切片上可以单层细胞呈现，染色后便于在显微镜下观察和检验。使用该检测系统时，对宫颈细胞分析采用TBS（The BethesdaSystem for Reporting Cervical Cytology，简称 TBS）细胞学分类诊断标准，包括以下几个部分： 1）未见上皮内病变/恶性（细胞）[Negative for Intraepithelial lesion NILM] 2）微生物（Organisms） 3）其他非肿瘤性所见 4）子宫内膜细胞 $\\geqslant 4 0$ 岁（如果无鳞状上皮内病变则需说明） 5）上皮细胞异常（Epithelial cell abnormalities）a) 非典型鳞状上皮细胞（Atypical squamous cell，ASC） I) 无明确诊断意义的非典型鳞状上皮细胞(Atypical Squamouscells of Undetermined Significance，ASC-US)I I ) 非典型鳞状上皮细胞，不除外高度鳞状上皮内病变（Atypical Squamous cells-Cannot exclude HSIL，ASC-H）b）低度鳞状上皮内病变（Low-grade squamous Intraepitheliallesion，LSIL）c）高度鳞状上皮内病变（High-grade squamous Intraepitheliallesion，HSIL）d） 鳞状细胞癌（Squamous cell Carcinoma）e） 非典型腺上皮细胞（Atypical Glandular cells，AGC）f） 腺原位癌（Adenocarcinoma in Situ，AIS）g） 宫颈腺癌（Endocervical adenocarcinoma）h） 宫内膜腺癌（Endometrial adenocarcinoma）i） 宫外腺癌（Extrauterine adenocarcinoma）j） 癌细胞（不分类） 6）恶性肿瘤细胞 液基薄层细胞涂片是目前国际上最先进的一种宫颈癌细胞学检查技术。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "常规巴氏涂片由于血液、粘液、炎症等因素影响，常使样本模糊导致检测误差，与宫颈刮片巴氏涂片检查相比，TCT检查明显提高了标本的满意度及宫颈异常细胞检出率，并相应减少巴氏测试的重复次数，从而降低了患者因重做测试而引起的心里压力。检测误差的显著降低势必将宫颈癌检测工作提高到一个新阶段，使那早期癌变患者得到及时有效治疗。尽管如此，液基细胞学技术仍需通过显微镜肉眼读片判断。而计算机辅助细胞检测系统（CCT）则具有先进、准确、迅速和经济等诸多优点。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "以上两种技术是分别对制片和阅片方式的改良，若将两者结合起来则能达到更高水平的诊断效果。# HPV DNA 目前用于临床样本检测 HPV病毒基因的产品技术主要基于多聚合酶链式反应（PCR）法和杂交捕获技术，可以检测和宫颈癌密切相关的HPV高危型，方法简便快速准确。# 优点 1）筛查人群中通常 $8 0 { - } 9 0 \\%$ 为HPV阴性者，对这大部份的健康人群可延长筛查间隔至每3-5年1次，可节省大量人力物力2）筛查人群中 $1 0 \\%$ 为HPV检测阳性者，是宫颈癌高危人群，可针对性地进行液基细胞学检查或其他医学检查。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "目前，共有3种用于宫颈癌初筛的HPV DNA检测技术已通过美国FDA认证，即HC2、Cervista和Cobas HPV，分别于2003年、2009年和2011年获得美国FDA认证。而我国有国家药监局注册证的类似HPV分子检测产品约有六十余种之多。# 宫颈癌检测新探索与技术发展 $\\cdot \\cdot$ HPV mRNA相关检测·替代性生物标志物检测·其他 # HPV mRNA相关检测 2011年美国FDA首次批准基于HPV E6/67mRNA的检测产品Aptima HPVAssay，用以检测14种高危HPV亚型的E6和E7mRNA片段（HPV16、18、31、33、35、39、45、51、52、56、58、59、66和68）。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "研究表明该方法有着与HC2等同的检测灵敏度，但对CIN2及CIN2+病例的检测显示出更高的特异性[6,7]。宫颈癌发生风险与HPV亚型种类有关，因此该检测产品仍面临着应用问题。对高致癌性HPV16，HPV18和HPV45三种高危亚型mRNA产品Aptima HPV 16 18/45 GenotypeAssay进行的研究表明，在宫颈癌筛查中HPV16 18/45mRNA检测将有较好的应用价值[8]。# 替代性生物标志物检测 2012年7月，美国病理学家协会（CAP）和美国阴道镜和宫颈病理学会（ASCCP）指南推荐CINtec PLUS（p16/Ki-67 细胞学双染检测）用于改善宫颈癌筛查分流管理。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "抗p16（E6H4）/Ki-67（274-11AC3）单克隆抗体试剂盒（免疫细胞化学法）产品以p16 INK4a作为宫颈病变检测的替代性标志物（surrogate marker），采用细胞免疫化学染色法实现对p16INK4a与Ki-67的联合检测。p16 INK4a信号为棕色, Ki-67信号为红色，以同一细胞内同时出现胞浆的棕染和胞核的红染作为阳性结果的判断依据[9]。# 下一代测序技术的应用 在子宫颈和阴道细胞学相关的宫颈癌进行预防和筛查中，目前普遍使用的HPV DNA检测多采用多重PCR技术，可以检测不同分组(致癌风险)HPV基因型的累积感染，但不能明确HPV基因型。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "而下一代测序技术(NGS)出现，可以对每个独立样品使用特殊标记的引物，以空前的速度对DNA进行测序。NGS一方面可以鉴定HPV累积感染，另一方面也可以明确微生物组信息。虽然有研究指出NGS具有很好的HPV检测和基因分型性能，但其实用性和成本仍是其广泛应用于临床实践的障碍[10]。# 表观遗传学与甲基化 DNA是决定生命遗传的核心物质，但近些年来的研究显示表观遗传机制亦是非常重要，而DNA甲基化是表观遗传领域的重要一环。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "据文献报道基因甲基化与癌症发生有密切关联性，许多癌症抑制基因的表达是由基因甲基化来调控。目前一些甲基化基因已被推荐应用于宫颈癌的检测中，而与传统筛查方法联合应用，可能会提高癌症检测的灵敏度和特异性[11]。# 肿瘤特异性DNA突变检测 肿瘤内存在的基因变异可以作为癌症生物标志物的想法在二十多年前就已经提出了。基因变异比传统生物标志物如癌胚抗原或前列腺特异性抗原更具有优势，其原因在于赘生细胞中基因的改变非常特殊。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "将遗传变异用作这一目的一项挑战是体液内的突变模板浓度通常很低。但在过去的几年中，技术的进步使检测这种突变成为可能，同时也使得在血浆、粪便、子宫颈抹片以及尿液内进行变异DNA序列的检测变得便利。Yuxuan Wang等人对93例头颈鳞状细胞癌(HNSCC)病例进行研究，评估肿瘤特异性DNA作为HNSCC生物标志物的潜力， 结果发现唾液和血浆两种体液的结合检测，可以使癌症的检测率达到96%。其中早期癌症病例的检出率达到100%（22名处于疾病早期）[12]。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "# 目前常用筛查方法总结 宫颈癌筛查中，细胞学筛查仍是目前应用最广的筛查手段，但由于依赖主观的形态学判读，因此在筛查效率和准确性上都存在一定的问题。而HPV DNA分子检测虽可以有效的检测HPV病毒，却无法区分一过性感染和其他高度病变，因此特异性不高，且往往造成过多的阴道镜转诊（见下图）。目前，在宫颈癌临床诊断中迫切需要更优的检测靶标和手段。![](images/9ccfbae3acbf360e104dbe9b3a4445e2d07042cf055c05b9fd8ff03eb9d3d77c.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "jpg) # 宫颈癌诊断革新技术 # --宫颈癌特异性肿瘤标志物HPV E7蛋白 # E7蛋白致癌机理 宫颈癌特异性肿瘤蛋白标志物与癌症的发生和发展直接相关。早期宫颈鳞状细胞癌变的关键，在于细胞内高危型人乳头状瘤病毒（High risk human papillomavirus，HR-HPV）致癌基因E6，E7的转录，使得E6，E7致癌蛋白的表达水平不断增加[13]。高表达的E7蛋白与Rb结合使Rb-E2F复合物解离，E2F从pRb蛋白中释放，Rb通路失控，反馈刺激p16INK4a、Ki67、细胞周期蛋白A（CyclinA）和细胞周期蛋白E（CyclinE）等在内的众多细胞增殖相关基因的表达，使宫颈上皮细胞的细胞周期发生紊乱（见下图）。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "因此，E7蛋白能够通过对细胞周期调节机制的破坏而促进细胞转化，引起宫颈上皮内瘤变（CIN）、原位腺癌（AIS）和浸润性宫颈癌的发生，形态学上转化的细胞表现为细胞核/细胞质比例增大，细胞核异形，以及核深染。![](images/79f8cd08bd73e18e0d80054bcacb55edbc6905a7de1c28db463c9caa38aeff43.jpg) 高危HPV E7高表达激活增殖信号通路，刺激增殖基因表达，促进细胞癌变转化。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "Middleton Kate等[14]关于肿瘤演变过程中分子靶点诊断标志物选择的研究中表明，HPV E7蛋白在高级别病变时大量表达，并与癌变程度呈正相关（见下图）。因此，研究数据表明E7蛋白可作为高度宫颈病变和宫颈癌检测的一个特异性肿瘤分子标志物，E7的细胞表达水平与细胞癌变发展程度之间存在线性的因果关系。![](images/61c9b0bf6381aea8d105d8d3deb3dc2bda84c0a894c44f48465f568fb75ba697.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "jpg) E7蛋白表达与癌变程度呈正相关 # E7 检测技术开发及临床应用 基于E7癌蛋白的致癌机理及其高度特异性，艾托金生物医药（苏州）有限公司研制出一种E7-ICC免疫化学染色技术。该技术是针对宫颈上皮脱落细胞中HPV E7癌蛋白表达的临床检测新方法，通过使用E7单克隆抗体，能够特异性识别表达HPV E7蛋白的癌变细胞（见下图）。![](images/ca88d7076cf17f6d9dc7f5ace0adbbf01a634d128b6c68f0671bdaa2158aeb86.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "jpg) # 技术导航 抗体与细胞中E7抗原靶点相结合形成的免疫复合物，再结合HRP酶联二抗，通过催化底物显色，E7蛋白表达定位于胞质中。检测结果在细胞样本中出现明显的棕色胞质染色，即可认为该细胞为E7-ICC阳性染色（见右图）。如果在细胞中检测到了E7蛋白的表达，提示细胞已经开始发生癌变。![](images/e2092818c190617ebf81d22787fd8d5f86f761b933be5172c6ce1b341fec68a1.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "jpg) # 结束语： 宫颈癌是最常见的妇科恶性肿瘤，近几十年来筛查技术的普遍应用使得发达国家宫颈癌的发病率和死亡率明显下降。虽然如此，我国每年新发的宫颈癌患者数目，死亡病例以及近年来的年轻化趋势提示宫颈癌早期筛查和诊断仍是我国未来宫颈癌防治中的重要策略。得益于科学研究和诊断技术的不断发展，提高临床检测特异性和灵敏度的新型诊断技术，如HPV E7蛋白标记物的临床应用研究，将有望为宫颈癌防治之战注入新的生力军。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "# E7-ICC与传统细胞形态学比较： E7-ICC与传统细胞形态学比较，E7免疫细胞学检测技术与传统细胞形态学相比，容易判读，结果更为客观（见下图，红色箭头为E7-ICC阳性结果），大大降低了工作量。![](images/724eaf0fc53a259f1a0f7f366321ce98490abeeab8e5d4ea6e1fc5d9658bd08b.jpg) 同时，可以对同一例宫颈脱落细胞样本分别进行巴氏染色和E7-ICC检测。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "左下图为巴氏染色后的结果，右下图为E7-ICC检测结果，E7表达阳性细胞如红色箭头所示为胞质棕色。![](images/db5481a3c94ea271fa112c09869ffca18c70d27197906777022e398f4c6e3b2a.jpg) # E7检测技术在组织学上的应用 艾托金生物医药（苏州）有限公司研发的E7检测技术的另一应用方向是针对宫颈组织切片细胞中HPV E7癌蛋白表达的检测，即E7-IHC。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "该技术通过E7单克隆抗体，特异性识别宫颈组织细胞中表达HPV E7蛋白的癌变细胞，为宫颈癌早期诊断提供辅助检测手段。其检测原理与E7-ICC相同，经抗体特异性结合E7抗原靶点，并在酶联二抗的催化作用下使底物显色，宫颈组织癌变细胞中出现明显的棕色颗粒状胞质染色（如下图），即可认为该细胞为E7-IHC阳性染色。与临床病理“金标准”组织细胞形态学方法相比较：该检测技术更为客观，一方面可以对宫颈癌前病变做到早期预警，另一方面也可以大大提高判读的一致性。",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "![](images/3f74f8ccc568611150b0b4f698387da590f88222a2f81c3d96eabe86d9888888.jpg) 病理诊断：宫颈慢性炎 病理诊断：宫颈癌 # 参考文献: [1]中华人民共和国国家卫生和计划生育委员会.《宫颈癌及癌前病变规范 化诊疗指南（试行）》.2013.[2] Zur Hausen H.Papillomaviruses in the causation of human cancers-a brief historical account.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "Virology, 2009,384(2):260-5。[3] Wen Chen, Xun Zhang,et.al.Human papillomavirus type-distribution in cervical cancer in China:the importance of HPV 16 and 18.Cancer Causes Control,2009.[4] Smith RA1, Manassaram-Baptiste D, Brooks D, Doroshenk M, Fedewa S, Saslow D, Brawley OW, Wender R.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening.CA Cancer J Clin,2015 JanFeb,65(1):30-54.[5] 中华人民共和国卫生部.《中华人民共和国卫生行业标准-子宫颈癌诊 断》2011-07-01.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "[6] Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, HoL,Terry G, Liddle S, Young M, Stoler M, McCarthy J, Wright C, Bergeron C, Soutter WP, Lyons D, Cuzick J.Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "J Clin Microbiol,2012,50:1867-1873.[7] Iftner T, Becker S, Neis KJ, Castanon A, Iftner A, Holz B, Staebler A, Henes M, Rall K, Haedicke J, von Weyhern CH, Clad A,Brucker S, Sasieni Head-to-head comparison of the RNA-based aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "J Clin Microbiol,2015,53:2509-2516.[8] Partha Basu,Dipanwita Banerjee,Srabani Mittal,Sankhadeep Dutta, Ishita Ghosh,Nilarun Chowdhury,Priya Abraham,Puneet Chandna,and Sam Ratnam.Sensitivity of APTIMA HPV E6/E7 mRNA Test in Comparison With Hybrid Capture 2 HPV DNA Test for Detection of High Risk Oncogenic Human Papillomavirus in 396 Biopsy Confirmed Cervical Cancers.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "Journal of Medical Virology,2016,88:1271-1278.[9] Ordi J, Sagasta A, Munmany M, Rodríguez-Carunchio L, Torné A, del Pino M.Usefulness of p16 INK4a/Ki67 immunostaining in the triage of women referred to colposcopy.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "Cancer Cytopathol,2014 Mar,122(3):227-35.[10] Allex Jardim da Fonseca, et.al., Comparison of Three Human Papilloma DNA Detection Methods: Next Generation Sequencing, Multiplex Nested-PCR Followed by Sanger Based Sequencing.",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "Journal 16,88:888-894.[11 Yung-Kai Huang, Yu-Ping Liao, Chang, Ya-Wen Lin, MuHsie Methylomics analysis identi and implies an activation of cer.International Journal of Cance somatic mutations and $\\mathsf { H P V }$ in the lasm ients with head and neck squamous cell carcinomas ,2015,7(293):1- [13] Stephen .",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "Smith，et.al.,Identification of host transcriptional networks showing concentration-dependent regulation by HPV16 E6 an E7 proteins in basal cervical squamous epithelial cells.Scientific Reports, 2016.[14] Middleton K, Peh W, Southern S, Griffin H, Sotlar K,et al.Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers.J Virol,2003,77(19): 10186-201.病理诊断：CIN2 常小迦、施丽君、韩凤丽、时成龙、胡济梁 供稿",
    "source": "G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016/G-Ref-Atto2. 临床实验室综述 (宫颈癌诊断发展与展望)2016.md"
  },
  {
    "text": "# Guidelines for Cervical Cancer Prevention and Screening published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College of Hong Kong Academy of Medicine # 1 INTRODUCTION The Guidelines for Cervical Cancer Prevention and Screening was last updated in 2016.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Since then, there have been several important new developments including Human Papillomavirus (HPV) vaccines, the expanded role of HPV testing in screening, new technologies in HPV testing as well as new World Health Organization (WHO) nomenclature for histological classification of cervical cancer and glandular lesion.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "This current revision has incorporated these changes.In this revision, the main changes include new information on: i) Guidance on primary cervical cancer prevention by HPV vaccination ii) Guidance on the use of HPV testing as a stand-alone test or as part of co-testing with cytology for primary screening iii) WHO 2020 nomenclature vi) Details of different available HPV tests # 2 PRIMARY PREVENTION PROPHYLACTIC VACCINE Primary cervical cancer prevention is best achieved through vaccination of girls with prophylactic HPV vaccine before they become sexually active and exposed to HPV infection.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "All HPV vaccines contain virus-like particles (VLPs) against high-risk HPV types 16 and 18 that accounts for about $70 \\%$ of cases of cervical cancer globally (1).The nonavalent vaccine contains additional VLPs against high-risk HPV types 31, 33, 45, 52 and 58.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "These 7 HPV types account for approximately $90 \\%$ of the squamous cell carcinomas that are positive for HPV DNA (2).The quadrivalent and nonavalent vaccines also contain VLPs to protect against anogenital warts causally related to HPV types 6 and 11.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "HPV vaccines given intramuscularly are highly immunogenic with much stronger serological response (1–4 logs higher) than that after natural infection.There are vast amount of real-world data demonstrating the effectiveness of vaccines in reducing HPV infections, anogenital wart, and cervical intraepithelial neoplasia (CIN) grade 2 or worse $( \\mathrm { C I N } 2 + )$ among women who are naive to high-risk HPV, as well as herd effects among boys and older women (3, 4).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "In Swedish database involving over 1 million females aged 10-30 years, after adjustment for age at follow-up, the risk of cervical cancer among participants who had received their first quadrivalent (Gardasil) vaccination before the age of 17 years was $8 8 \\%$ lower than among unvaccinated participants $[ 9 5 \\%$ confidence interval (CI) $6 6 \\mathrm { - } 1 0 0 \\% ]$ (5).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "In an observational study using population-based cancer registry data for women up to age 30, the introduction of a national bivalent (Cervarix) HPV immunisation programme resulted in near elimination of cervical cancer among women vaccinated at age 12-13 years (6).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Despite the high efficacy of vaccines, cervical cancer screening is still relevant to vaccinees as current vaccines cannot offer full protection.The vaccines offer no effect on viral clearance in women with pre-existing infection (7).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Several meta-analysis had suggested that adjuvant HPV vaccine might reduce the risk of developing subsequent disease irrespective of causal HPV type after an excisional procedure for CIN (8, 9, 10, 11, 12) but better quality studies are recommended.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "All HPV vaccines are indicated for use in females aged 9 years or older with high efficacy and excellent safety profiles.HPV vaccines were first licensed and marketed using a 3-dose vaccination schedule.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "WHO recommends girls aged 9-14 years as primary target population for HPV vaccination in 2-dose schedule at least 6 months apart, ideally to be completed within 12 months and be included in all national immunisation programmes to achieve $90 \\%$ vaccination of all girls by age 15 by 2030 (13).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Catchup vaccination of girls aged between 9 and 18 years is cost-effective due to direct and herd protection resulting in faster and greater population impact.Achieving over $80 \\%$ coverage in girls also reduces the risk of HPV infection for boys.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "From a public health perspective, a single-dose schedule can be used in girls and boys aged 9–20 years as an off-label option with comparable efficacy and duration of protection as a 2-dose schedule and may offer programme advantages, be more efficient and affordable, and contribute to improved coverage especially in low resources setting.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "However, immunocompromised individuals should receive three doses where possible.HPV vaccine is not recommended in pregnant women.There is no evidence to support the need for booster dose.The nonavalent HPV vaccine has been incorporated to the Hong Kong Childhood Immunisation Programme since the 2019/20 school year in a 2-dose schedule with first dose in Primary Five and the second dose in Primary Six by outreach immunisation team to schools achieving a coverage of ${ > } 8 0 \\%$ (14).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "A three-dose schedule would be offered to those who are immunocompromised.Catch-up HPV vaccination for secondary school female students or older age girls up to 18 years in a 2-dose schedule as an offlabel use is recommended based on local costsaving study (15).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Strategies to reduce the risk of HPV acquisition, like practicing safer sex (reducing the number of sexual partners and the use of condom) and avoidance of smoking, would also help to prevent cervical cancer.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Cigarette smoking including ecigarettes, either active or passive, is associated with an increased risk for cervical cancer in a dose-response manner (16, 17, 18).Quitting smoking was associated with a 2-fold reduced risk of CIN3 and cervical cancer (19).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# 3 SECONDARY PREVENTION SCREENING (HSIL) histologically.Women over 65 years who have never had cervical cancer screening and have a history of being sexually active, should be screened (Table 1).Taking a cervical sample during pregnancy may induce bleeding and cause anxiety to the woman and hence this is not the best time to perform cervical cancer screening.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Nevertheless, this may be an opportunity to perform a screening test in pregnant women who have never been screened.Particular emphasis should be given to recruit those women at greatest risk of developing cervical cancer - those who have never had cervical cancer screening, and those who do not screen regularly or have not had one within the routine screening period.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Women who have hysterectomy with removal of cervix for benign diseases and without a prior history of cervical dysplasia can discontinue screening.# 3.2 Screening Interval # 3.2.1 Screening Interval – Cervical Cytology Screening at 3-yearly intervals, after 2 consecutive normal annual cytology tests, is recommended.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The percentage reduction in the cumulative incidence of cervical cancer is $93 \\%$ with an annual or biennial screening interval, $91 \\%$ if performed every 3 years, $84 \\%$ if performed every 5 years and $64 \\%$ if performed every 10 years.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Screening at 3-yearly intervals is less costly and does not significantly reduce the efficacy of preventing invasive cervical cancer compared to that achieved with annual screening (21).(See section 7 for management of special categories).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# 3.1 Target population The target population encompasses all women from age 25 or the time of commencing sexual activity (whichever is later) until the age of 64.In view of the rarity of cervical carcinoma in women below 25 years of age in the local population (20) and the relatively high proportion of HPV infection and cytological abnormalities that spontaneously regress, screening before this age is less cost-effective and could result in unnecessary interventions.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Nevertheless, women aged below 25 years with high-risk profile may be screened after assessment by doctor.Screening may be discontinued in women aged 65 or more if all routine screens within the last 10 years were normal and they were not previously diagnosed to have high-grade squamous intraepithelial lesion # 3.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "2.2 Screening Interval – HPV testing Screening at 5-yearly intervals with HPV-based testing (either HPV co-test with cytology or HPV stand-alone) is recommended.Women who tested negative for high-risk HPV are at very low risk of $\\mathrm { C I N } 3 +$ for at least 5 years, supporting extension of screening interval to 5 years (22, 23, 24).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "(See section 7 for management of special categories).# 3.3 Methods of screening # 3.3.1 Methods of screening – Cervical Cytology With the current options of cervical cancer screening, cervical cytology may be used as a screening test [either cytology alone (if HPV testing is not available) or as part of a co-test with HPV] or a triage test (for high-risk HPV-positive cases in stand-alone primary HPV screening) (25).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "While both conventional smear and liquid based cytology (LBC) are acceptable methods for screening, LBC is being used by most laboratories with the advantages of lower unsatisfactory rate and allowing HPV tests and application of biomarkers to be performed (26, 27, 28).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "It should be noted that different LBC preparations should be collected according to their respective manufacturer’s instructions.Relevant clinical information should be provided on the cytology request form.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The sample should also be properly labelled with attention to ensure correct identity.Cervical cytology service should be provided by an accredited laboratory with appropriate quality assurance procedures.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Cytology reports should be issued by a qualified anatomical pathologist or (for negative results associated with absence of clinical findings) by a qualified cytotechnologist.The use of oestrogen in postmenopausal women and the treatment of a pre-existing infection may improve the quality of the cytology sample.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# 3.3.1.1 The 2014 Bethesda system and 2020 WHO classification Reporting of cervical cytology should be based on the 2014 Bethesda System for Reporting Cervical Cytology (29).The report elements and diagnostic terminology used in cytology reports should adhere to the specifications of the 2014 Bethesda System.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "It may be noted that occasional cases of low-grade squamous intraepithelial lesion (LSIL) have atypical cells which are morphologically equivocal for HSIL and a variety of diagnostic terms have been used for such cases.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "While the 2014 Bethesda System recommended the concurrent use of LSIL and atypical squamous cells, cannot exclude HSIL (ASC-H) in the diagnosis for these cases, alternative reporting options (such as adopting the intermediate category of LSIL, cannot exclude HSIL, or LSILH) have been advocated by some authors (30, 31).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The histopathological classification of cervical cancer and precursor lesions has been updated in the 2020 WHO classification (32).The diagnosis of cervical squamous intraepithelial lesions is essentially unchanged from the previous 2014 WHO classification.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Squamous intraepithelial lesions are HPV-associated lesions that can be classified into low-grade (LSIL) and high-grade (HSIL).Alternatively, the traditional cervical intraepithelial neoplasia (CIN) terminology may be used, classifying cervical squamous lesions into CIN1, CIN2 or CIN3 respectively, with CIN1 equivalent to LSIL and CIN2/3 equivalent to HSIL.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "HPV-independent precancerous squamous intraepithelial lesion has not been recognized as a diagnostic entity by WHO 2020.Invasive squamous cell carcinomas should be classified into HPV-associated and HPV-independent based on p16 immunohistochemistry or HPV testing.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "There are substantial changes in the approach to classifying cervical glandular lesions by WHO 2020.As with squamous cell carcinomas, cervical adenocarcinomas are designated as HPVassociated or HPV-independent (gastric, clear cell or mesonephric type).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Adenocarcinoma in-situ (AIS) of the cervix is also classified into HPVassociated and HPV-independent.Accurate typing of cervical adenocarcinoma and AIS can be challenging as this involves integration of morphological assessment with p16 interpretation and HPV testing for difficult cases, given that a subset of HPV-independent cervical glandular lesions are p16 positive (33).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "It is worth noting that the cytology diagnosis of endocervical adenocarcinoma and AIS are largely based on HPV-associated adenocarcinoma/AIS.Although there is some published data on the cytologic findings in HPV-independent (mostly gastric type) adenocarcinoma and AIS (34, 35), there is currently no systematic guidance on how these cases should be recognised or reported using the Bethesda system.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# 3.3.1.2 Computer-assisted screening of cervical cytology Computer-assisted screening increases a laboratory’s productivity by replacing the labourintensive job of screening and also reduces the likelihood of human errors with manual screening.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Computer-assisted cervical cancer screening devices may be broadly divided into two types: location-guided screening and risk-stratification devices.Currently, commonly used computerassisted devices in Hong Kong include the ThinPrep™ Imaging System and FocalPoint™ GS Imaging System which are both approved by FDA for use in primary screening.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The laboratories which use these devices should have established quality control for rescreening methods.Irrespective of the type of device being used, cases with abnormal cells found and cases with significant clinical concerns have to be referred to pathologists for evaluation and reporting.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If a case is examined by a computer-assisted device, the 2014 Bethesda System for Reporting Cervical Cytology recommendation is to specify the device together with the findings in the cytology report.# 3.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "3.2 Methods of screening – HPV testing HPV tests are nucleic acid tests designed to detect specific DNA or RNA sequences of HPV.Currently HPV tests can be used as a screening test (either stand-alone in primary HPV screening or as part of a co-test with cytology), as a triage test (in cytology-based screening for cases reported as ASCUS, often described as reflex testing), or as a test of cure (for cases after treatment of HPV-associated lesions).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The major advantage of HPV testing is its high sensitivity in detecting HPV-associated malignant and precursor lesions.Various studies (including recent prospective local data) have shown that HPV-based screening has greater sensitivity than cytology in detecting HSIL or worse lesions (25, 36).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Being a more objective test than cytology, HPV testing has a higher reproducibility, less reliance on screener competency, and the test can be more automated.However, the lower specificity of a positive HPV test result signifies that a triage test is generally necessary (usually with cytology or genotyping), in particular among young women where HPV infection is usually transient.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "As with other laboratory tests, HPV testing also has its limitations with potential for false negative results due to various reasons which may include biological and technical factors (37).It should be emphasised that a negative HPV test should not be considered as definitively excluding cervical pathology, because there exists a variety of HPV-independent cervical neoplasms and the possibility of false negatives.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "HPV testing should only target at the high-risk types of HPV (i.e.16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59; with 66 and 68 acceptable to be included) (38).Testing for low-risk HPV types has no clinical role in cervical cancer screening or management of abnormal cytology.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "There is a wide variety of commercially available HPV testing devices which differ in their technologies and detection targets (39, 40).Although there is no local regulatory body governing which HPV testing devices are suitable for screening or non-screening purposes, one may take into account the overseas regulatory approval status (such as US FDA clearance or EU CE marked) when selecting between various HPV tests.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The HPV tests should have been analytically and clinically validated and the reports issued by an accredited laboratory with participation in quality assurance programs (41).(See Appendix 1 for examples of commercially available HPV tests.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": ") The use of self-collected specimens for HPV tests (also known as self-sampling) have been emerging as an alternative strategy to improve the coverage and compliance of cervical cancer screening.Selfcollected vaginal samples have been suggested by WHO as a method of screening (42) and has been introduced in some countries as an option for cervical cancer screening.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Considerations specifically related to self-collected samples would include the validation of sampling devices for selfcollected vaginal specimens, as well as the performance and regulatory approval of HPV tests for self-collected specimens (43).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Other selfcollected specimens such as urine and menstrual blood for HPV tests have been explored.Currently, these approaches are not recognized or recommended as a standard method for primary screening, although this may be subject to change when data from more definitive studies are available.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# 3.3.3 Methods of screening – Biomarkers Apart from cytology and HPV testing, several cellular or molecular biomarkers have been evaluated for their potential applications in cervical cancer screening.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Some of these biomarkers have been found to improve the detection and triage of women with positive screening tests, which may be used as adjuncts to screening (44).However, currently most biomarkers have not been specifically approved for clinical application in primary screening.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Caution is needed when handling the laboratory test reports for these biomarkers as most of them do not yet have a clearly established clinical role in cervical cancer screening.The p16/Ki-67 dual stain is an immunocytochemistry-based technique to identify cells that co-express p16 and Ki-67 on a cytology slide.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The coexistence of both markers is a relatively specific finding mostly encountered in HPV-associated dysplastic lesions, so this biomarker may be used as an adjunctive or triage test to improve the detection of HSIL, in the triage of ASCUS and LSIL cytology (45) or high-risk HPV positive women (46).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "It is recently approved by US FDA for triage of patients positive for highrisk HPV.Potential biomarkers currently under research include TOP2A, MCM2, HPV viral load, viral E4 protein, viral DNA methylation, host DNA methylation, 3q chromosomal gain, microRNAs, etc (44).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# 3.4 Utilisation of HPV testing in screening # 3.4.1 HPV testing as a triage for ASCUS smears Patients with ASCUS who are positive for highrisk HPV are more likely to carry high-grade lesions (CIN2/3).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "High-risk HPV can be found in around $50 \\%$ of ASCUS (47).Reflex HPV testing in triaging patients with ASCUS is an alternative to repeat cytology at 6 months in decision for colposcopy referral (48), except in women aged 20 years or younger.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Colposcopy is indicated for women with ASCUS cytology and HPV-positive.Women with ASCUS cytology and HPV-negative can be followed up with co-testing or cytology alone at 3 years (49).Reflex HPV testing has limited role in triaging women with LSIL for colposcopy because over $80 \\%$ of LSIL has high-risk HPV (50).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Even in older age groups, reflex HPV testing for LSIL to triage for colposcopy is not recommended since HPV positivity among women with LSIL decreased only slightly with age (30-34 years vs 60-64 years, $8 8 \\%$ vs $72 \\%$ ) (51).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# 3.4.2 HPV testing as primary screening # Application of HPV testing in primary screening includes co-testing with cytology or HPV as a stand-alone test.Incorporating HPV testing into screening strategies has the potential to increase disease detection and increase the length of screening interval.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "However, the improved sensitivity must be balanced against the potential risks of unnecessary testing, procedures, and treatment.HPV infection is highly prevalent below the age of 30 and most of them are transient.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Detection of these transient infections can be harmful since this may cause anxiety, stigmatization, discomfort and bleeding during diagnostic and treatment procedures, and pregnancy complications such as preterm delivery due to unnecessary treatment.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Taking into account of the high prevalence of HPV in young women and the median age of cervical cancer patients in Hong Kong, HPV testing is not preferred before the age of 30 for primary screening, either as a co-test or standalone test.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "In women who had previously received HPV vaccination, primary HPV screening can be considered in those younger than 30 years.In a population where high vaccine uptake was reported in women aged 25 to 33, primary HPV screening was associated with significantly increased detection of $\\mathrm { C I N } 2 +$ compared to cytology, with no significant difference in colposcopy referral rate (52).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# 3.4.2.1 HPV testing as a co-test with cytology for primary screening HPV and cytology co-testing can be considered as an alternative to cytology alone for cervical cancer screening.In many studies, addition of HPV testing to cytology resulted in increased sensitivity for detecting CIN3 at the first round of screening and a decrease in CIN3 or cancer detected in subsequent rounds of screening (25, 49, 53).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# HPV-Negative, Cytology-Negative Co-test (Fig.1) Women who are co-tested negative have a low chance of having concurrent $\\mathrm { C I N } 3 +$ (54) and cervical cancer (3.2/100,000 women per year over 5 years) (22).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "These women should continue with routine screening.A 5-year screening interval is recommended after a negative co-test.The 5- year risk of $\\mathrm { C I N } 3 +$ is less following a negative cotest $( 0 .",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "1 2 \\% )$ compared to following a negative cytology alone (ranged from $0 .3 3 \\%$ to $0 .5 2 \\% )$ (49).HPV-Positive, Cytology-Negative Co-test (Fig.1) Immediate colposcopy for HPV-positive, cytology-negative women is discouraged since the immediate risk of $\\mathrm { C I N } 3 +$ in these women is low $( 2 .",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "1 \\% )$ .However, the 5-year risk of $\\mathrm { C I N } 3 +$ is increased to about $4 .8 \\%$ (54).# Either repeat co-testing in 12 months or immediate HPV genotyping for HPV 16/18 is acceptable.Since most transient HPV infections (about $67 \\%$ ) are cleared by 12 months (55), repeat co-testing at 12 months is one of the options.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If co-testing is repeated at 12 months, colposcopy is indicated if HPV positive or ASCUS or above.Women can return to 3 yearly co-testing or 3 yearly cytology if HPV test and cytology are both negative.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If immediate HPV genotyping is performed, colposcopy is indicated if HPV 16 or HPV 18 is positive.The risk of developing CIN3 or cancer is found to be highly genotype dependent.HPV 16 and HPV 18 account for two-thirds of all invasive cervical cancer.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The short term (within 12 weeks) risk of $\\mathrm { C I N } 3 +$ in these women is about $10 \\%$ (56).The 10-year cumulative incidence rate of $\\mathrm { C I N } 3 +$ were $17 \\%$ among HPV 16-positive women, $14 \\%$ among HPV18-positive women, but only $3 \\%$ for those with other high-risk HPV infection (57).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If HPV 16 or HPV 18 is negative, co-testing or cytology is repeated at 12 months.Although the short term (within 12 weeks) risk of $\\mathrm { C I N } 3 +$ for oncogenic HPV genotypes other than HPV 16/18 $( 2 .",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "4 \\% )$ (56) do not warrant immediate colposcopy, they should be followed up at 12 months since the risk is higher than those co-tested negative.Colposcopy is indicated if HPV positive, cytology negative persists at 24 months.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If HPV testing is not available, cytology should be repeated 6-monthly for 3 times before returning to routine screening.If the repeat cytology is abnormal, then it should be managed according to the abnormality (eg.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "if cytology in 6 months is ASCUS, then the management for ASCUS should be followed, i.e.repeat cytology in 6 and 12 months and refer to colposcopy if there are two ASCUS smears).HPV-Negative, Cytology ASCUS Co-tests (Fig.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "2) Women with negative HPV and ASCUS cytology will need repeat co-testing or cytology in 3 years.HPV-Negative, Cytology LSIL Co-tests (Fig.3) Women with HPV-negative and LSIL cytology will need repeat co-testing or cytology in 12 months.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The immediate risk of ${ \\mathrm { C I N } } 3 +$ for these women is low $( 1 .1 \\% )$ and do not warrant immediate colposcopy, but the 5-year risk of $\\mathrm { C I N } 3 +$ is higher than those co-tested negative $2 \\%$ vs $0 .",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "1 2 \\%$ ) (54).If co-testing is repeated at 12 months and both tests are negative, women can have co-test or cytology in 3 years before returning to routine screening.Otherwise, colposcopy is indicated for either HPV-positive or ASCUS or above.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "HPV-Positive, Cytology-Positive Co-tests Women with HPV-positive and ASCUS or above should be referred for colposcopy.(See also section 3.4.1).# 3.4.2.2 HPV testing as a stand-alone test for primary screening (Fig.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "4) HPV and cytology co-testing can improve the sensitivity for detection of high-grade lesions (CIN2/3), but it means each woman will need 2 tests instead of 1, with significant resources and cost implications.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "HPV testing as a stand-alone test can be considered as an alternative to cytology alone for cervical cancer screening.In several studies, primary HPV screening resulted in a significant increased detection of $\\mathrm { C I N } 3 +$ in the initial screening round compared to cytology (58).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "However, due to the lower specificity with the stand-alone HPV screening, a second triage test (with cytology or partial HPV genotyping) should be performed in HPV-positive women to identify those who have a higher risk in developing precancerous and cancerous lesions, and thus require referral for colposcopy.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# Negative Stand-alone HPV test A negative HPV test has a high negative predictive value.The estimated 5-year $\\mathrm { C I N } 3 +$ risk following a negative stand-alone HPV test $( 0 .1 4 \\% )$ is similar to that of negative co-test $( 0 .",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "1 2 \\% )$ (49) (See also section 3.4.2.1 on co-testing).A 5-year screening interval is recommended after a negative standalone HPV test.Positive Stand-alone HPV test Immediate referral of HPV-positive women to colposcopy without further triage tests is NOT recommended.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Due to the lower specificity of HPV stand-alone test, it is not appropriate to refer women with a positive HPV test directly to colposcopy because this will increase the colposcopy rate significantly (from $2 .",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "3 \\%$ to $1 3 .1 \\%$ with HPV testing vs $1 .9 \\%$ to $4 .7 \\%$ with cytology in $< 3 0 .3 5$ years; from $0 .9 \\%$ to $5 .8 \\%$ with HPV testing vs $1 .0 \\%$ to $2 .5 \\%$ with cytology in $> 3 0 – 3 5$ years) (58) and possible over-treatment of nonprogressive lesions leading to unnecessary complications.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "A second triage test should be done to better predict which of these women would be at high risk of developing CIN2 or above lesion and hence need referral for colposcopy.It is still uncertain what the best triage test is.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Literatures suggested a variety of different triage strategies, including the use of cytology, HPV 16/18 genotyping, and biomarkers (See section 3.3.3 on Methods of Screening – Biomarkers) Triage with cytology.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Reflex cytology is recommended for all women with positive stand-alone HPV test, regardless of HPV genotype (including HPV 16/18 positive).This will allow decision for colposcopy referral and subsequent management (see section 5 on colposcopy and treatment for CIN).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The subsequent management would be the same as for cotest with HPV and cytology.Those with positive cytology (ASCUS or above) should be referred to colposcopy.Those with negative cytology should have co-testing at 12 months or repeat cytology 6-monthly for 3 times before returning to routine screening (See also section 3.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "4.2.1 on cotesting) (Fig.1).Triage with genotyping for HPV 16/18.Women who are HPV 16/18 positive should be referred to colposcopy, regardless of cytology result (if reflex cytology is done) (see section 3.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "4.2.1 on co-testing with immediate HPV 16/18 genotyping).Those who are positive for other (non-16/18) high-risk HPV types should have a reflex cytology.Referral to colposcopy should be considered at the level of ASCUS or above.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Adding a further cytology triage test to those with HPV types not 16/18 could increase the sensitivity of the test by $14 \\%$ at the expense of increasing the number of colposcopies performed (59).Triage with p16/Ki-67 dual stain.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Dual stain cytology may be considered in women who are HPV-positive, particularly those who are positive for other (non-16/18) highrisk HPV.For detection of $\\mathrm { C I N } 3 +$ , the sensitivity of dual stain cytology is significantly higher compared to cytology $( 7 4 .",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "9 \\%$ vs $5 1 .9 \\%$ ), with comparable specificity.With referral of all HPV 16/18 positive woman to colposcopy, triaging women who are positive for other (non16/18) high-risk HPV with dual stain cytology resulted in higher sensitivity for $\\mathrm { C I N } 3 +$ compared to triage with cytology $8 6 .",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "8 \\%$ vs $7 8 .2 \\%$ , with similar number of colposcopies required (60).# MANAGEMENT OF NORMAL AND ABNORMAL SMEARS Please refer to Fig.1-3 for summary of management of normal and abnormal low-grade cytology.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Patients with high-grade cytology should be referred to colposcopy.Review of cytology slides is recommended if no high-grade lesion can be found.Suggested actions for other cervical cytology results are shown in Table 2.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "1, 2.2 and 2.3.# 5 COLPOSCOPY AND TREATMENT FOR CIN The colposcopist’s role is to examine the transformation zone, define the extent of the lesion, and biopsy the most abnormal area for tissue diagnosis.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "In addition to the cervix, the vagina should also be examined.Histological confirmation of the colposcopic diagnosis is advisable before treatment.In patients with a colposcopic diagnosis of high-grade lesion, a “see and treat” approach, i.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "e.perform loop excision without a biopsy, is adopted by some colposcopists.In women aged 25 years and above with HSIL cytology, immediate treatment is an option if the women are never or rarely screened before, especially if HPV 16 is positive.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The immediate risk of $\\mathrm { C I N } 3 +$ with HSIL cytology if the women is never or rarely screened ranges from $3 5 \\%$ to $60 \\%$ , being $60 \\%$ if HPV 16 is positive (61).Although this practice decreases the need for another visit, it carries the risk of over-treating patients with low-grade lesions.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The rate of over-treatment depends on the expertise of the colposcopist.Majority of low-grade lesions will regress spontaneously over 2 years and immediate treatment may not be necessary (62, 63).About $1 5 \\%$ of patients may progress to high-grade lesions and require treatment later.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If a low-grade lesion is confirmed by colposcopy and biopsy, the patient can be followed up with HPV testing or co-testing at 12 months, irrespective of age.If the result is HSIL or ASC-H or HPV 16/18 positive, colposcopy should be repeated.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "In case of other HPV-positive (untyped, not HPV 16/18), colposcopy can be repeated if there is a preceding high-grade cytology.If the preceding cytology is low-grade and repeat cytology shows LSIL or less, a repeat HPV testing or co-testing 12 months later can be performed.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If there is no cytology, colposcopy can be repeated.A 3 year follow up is adequate if HPV testing or co-testing is negative.A colposcopy with biopsies of histological CIN1 or less is associated with a lower 5-year $\\mathrm { C I N } 3 +$ risk of $2 .",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "9 \\%$ and a HPVpositive ASCUS at first 12 months follow up is associated with an immediate CIN3 risk of $3 .1 \\%$ (54).Patients can resume routine screening after having a normal HPV testing or co-testing result if there is no preceding high-grade cytology.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "A prospective cohort study showed the crude rate of CIN3 was $0 .7 \\%$ following a single follow up negative cytology, $0 .2 \\%$ following a single negative follow up HPV testing and $0 .1 \\%$ following a negative follow up co-testing in women with HPV-positive ASCUS or any LSIL and less than CIN2 on colposcopy or biopsy over a maximum of 7 years follow up (64).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Since a negative cytology result does not reduce the subsequent risk of CIN3 as much as HPV testing or co-testing, cytology alone is less preferred for follow up after colposcopy.Cytology is acceptable if HPV testing is not available.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Patient can be followed up with cytology every 6 months for 3 times, then yearly for 3 years before returning to routine screening.If ASCUS or LSIL persists for more than 1 year, colposcopy can be repeated (Fig.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "5).In non-pregnant women with CIN3, treatment is recommended.In non-pregnant women with CIN2, treatment is recommended, and observation can be considered if the women have concerns on the effect of treatment on future pregnancies and the squamocolumnar junction is fully visualised.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Treatment should be performed if CIN2 persisted for more than 24 months.The reason for treating HSIL (CIN2/3) is that these lesions could progress to invasive cancer if left untreated.The time of progression to cancer is variable and can take from months to years.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The risk of CIN3 progressing to an invasive lesion is about $12 \\%$ over a period of 10 years (63).The current recommended method is – Loop Electrosurgical Excision Procedure (LEEP).This has the advantage of providing a tissue specimen that is generally of sufficient quality for histological exclusion of occult invasion.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Complications include intraoperative and postoperative bleeding $( 1 - 8 \\% )$ , infection, cervical stenosis $( 1 \\% )$ , cervical deformity and cervical incompetence and rarely injury to vagina, bladder and ureter.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Reports showed an association with preterm delivery, low birth weight and premature rupture of membranes but there was no significant increase in neonatal morbidity (65).Treatment for CIN can be carried out under local anaesthesia on an outpatient basis in $90 \\%$ of patients.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Ablative methods including electrocoagulation diathermy, cryosurgery, cold coagulation and laser vaporization, are undesirable because they do not provide a specimen for histological examination.Hysterectomy is not recommended for the treatment of HSIL unless there are concomitant gynaecological problems that warrant a hysterectomy.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Hysterectomy should not be performed for cytological abnormality without proper colposcopy examination and biopsy.For those who had a high-grade cytology but colposcopic directed biopsy only showed a lowgrade lesion, review of material is recommended.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If confirmed to be low-grade, HPV testing or cotesting in 12 months and 24 months should be done before returning to 3-yearly HPV testing or co-testing and subsequent routine screening.When $\\mathrm { C I N } 2 +$ is not identified, HSIL cytology should be treated more aggressively than ASC-H cytology.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "In women with HSIL cytology, but biopsy shows histologic LSIL (CIN1) or less, an immediate diagnostic excisional procedure is acceptable.Alternatively, observation with HPV testing or cotesting and colposcopy at 1 year is an option, on condition that the squamocolumnar junction and the upper limit of any lesion is fully visualised at the initial colposcopic examination, and that the endocervical sampling, if collected, is less than CIN2.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If HPV test is positive or high-grade cytology is found during the 24 months period, colposcopy is recommended (Fig 5).A diagnostic excisional procedure is recommended for cytologic HSIL at either 1- or 2-year visit or ASC$\\mathrm { ~ H ~ }$ persisting at 2-year visit since with a preceding HSIL cytology, the 1 year risk of $\\mathrm { C I N } 3 +$ is $3 .",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "9 \\%$ even with a biopsy of low-grade lesion (54).The 1-year risk of $\\mathrm { C I N } 3 +$ with histologic LSIL and preceding ASC-H smear is lower at $1 .4 \\%$ (54).In patients with LSIL involving more than 2 quadrants of the cervix or if the patient is unable or unwilling to return for follow-up, then treatment should be considered.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If the lesion persists for more than 2 years, treatment is acceptable.If the final histology from treatment confirms low-grade lesions, the patient should be followed up similar to other patients with low-grade lesions on cervical biopsies.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "When treatment margins are positive for CIN2/3, there will be a higher incidence of recurrence, but not high enough to justify routine repeat excision (66).No statistically significant difference in residual CIN at 6 months post-treatment was found between completely and incompletely excised groups (67).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "HPV testing or co-testing is preferred than cytology in the follow up management after histologic HSIL treatment, as it provides the most accurate predictor of treatment outcome.Using HPV testing or co-testing, $91 \\%$ ( $9 5 \\%$ CI 82- $9 6 \\%$ ) of residual or recurrent $\\mathrm { C I N } 2 +$ was predicted, regardless of margins status (68).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "HPV testing or co-testing should be performed at 6 months, then annually until 2 consecutive normal results.After that, 3-yearly HPV testing or cotesting for 25 years, then return to routine screening until the age of 65, whichever is later.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The 5-year cumulative risk of $\\mathrm { C I N } 2 +$ was $1 .0 \\%$ ( $9 5 \\%$ CI 0.2-4.6) and CIN3 was $0 \\%$ ( $9 5 \\%$ CI 0- 2.9) following a negative co-test at 6 and 24 months (69).Another study found that the 5-year $\\mathrm { C I N } 3 +$ risk after treatment for CIN2/3 for 1, 2 and 3 negative HPV testing or co-testing were $2 .",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "0 \\% / 1 .7 \\%$ , $0 .9 1 \\% / 0 .6 8 \\%$ and $0 .4 4 \\% / 0 .3 5 \\%$ respectively (54).The 5-year risk of $\\mathrm { C I N } 3 +$ remains above $0 .1 5 \\%$ (54) and the 2-fold increase in cervical cancer risk persists for at least 25 years (70).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "In view of the lower sensitivity of cytology alone in predicting recurrent $\\mathrm { C I N } 2 +$ , cytology only is less preferred for surveillance after treatment of histologic HSIL.Cytology is acceptable if HPV testing is not available.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Patients should be followed up by cervical cytology for 3 times at 6- months intervals and then annually for 10 years, then return to 3 yearly cytology screening.Exit from routine screening may be considered after 15 years if all routine cytology screening is negative and the woman has reached the age of 65 (Fig.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "6).If patient has ASCUS/LSIL on cervical cytology within 12 months, continue follow up with cervical cytology is acceptable.If the low-grade cytological abnormalities persist for more than one year, colposcopy should be repeated.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Colposcopy should be repeated any time when HSIL is found on cervical cytology.For patients who had hysterectomy for CIN with clear margin, vaginal smear for HPV testing or cotesting should be performed annually for 2 consecutive years.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If both results are normal, no further vaginal smear is necessary.If HPV testing is not available, vaginal smear for cytology should be performed at 6, 12, and 24 months.No further vaginal smear is necessary after 3 consecutive normal cytology.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If excision was incomplete or clearance of margin is uncertain on hysterectomy, or if the patients had VAIN, vaginal smear for HPV testing or co-testing should be performed at 12 and 24 months.If both are negative, vaginal smear for HPV testing or co-testing should be done 3-yearly for 25 years or until age 65, whichever is later.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If HPV testing is not available, vaginal smear for cytology should be done at 6 and 12 months, then yearly for 10 years, then 3 yearly for 15 years or until age 65, whichever is later.# 6 MANAGEMENT OF GLANDULAR LESION For cytology results showing adenocarcinoma insitu (AIS) and all subcategories of atypical glandular cells (AGC), except where “atypical endometrial cells” is specified, colposcopy is recommended regardless of HPV test results.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Reflex HPV testing is not recommended.Endocervical and endometrial sampling is recommended at initial colposcopy except in pregnancy.For AGC-favour neoplastic (AGC-FN) and AIS, if there is no significant pathology explaining the source of abnormal cells, a diagnostic excisional procedure is recommended.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Cold knife conization is the preferred excision approach.Ablative procedure is not recommended.Management of glandular lesion is summarised in Table 2.2.and Fig.8.# 6.1 Management of adenocarcinoma in-situ (AIS) A diagnostic excisional procedure is recommended for all patients with a diagnosis of AIS on cervical biopsy or cytology to rule out invasive adenocarcinoma, even when a definitive hysterectomy is planned.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Excisional procedures should optimally remove an intact specimen to facilitate an accurate interpretation of margin status.The length of the excision specimen should have at least $1 0 \\mathrm { m m }$ where feasible.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Endocervical sampling above the excisional bed to evaluate for residual disease is advised.A “top hat” endocervical excision to achieve the desired specimen length is not recommended.When concomitant AIS and CIN are diagnosed, management should proceed as per the recommendation of AIS.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Hysterectomy is the preferred management for all patients who have a histologically diagnosed AIS.For women with confirmed AIS with negative margins on excision specimen, simple hysterectomy is preferred.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "For patients with confirmed AIS with a positive margin on the excision specimen, re-excision to achieve a negative margin is preferred to rule out malignancy, even if hysterectomy is planned.If there is a positive margin on the re-excision specimen, or further excisional procedure is not feasible, a simple or modified radical hysterectomy is acceptable.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Fertility-sparing management is not recommended in these patients.Fertility-sparing treatment with excisional procedure alone may be considered in selected women who have a negative margin achieved on the excisional specimen and are willing to adhere to surveillance recommendation.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# MANAGEMENT OF SPECIAL CATEGORIES # 7.1 Young women including adolescents # 7.1.1 Adolescents (age 20 or less) In view of the low prevalence of high-grade cytological abnormalities in adolescents less than 21 years of age $( 0 .",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "2 \\mathrm { - } 2 .6 \\% )$ with cervical cancer being extremely rare (71, 72, 73), cervical cancer screening is not recommended.Inadvertent screening could lead to unnecessary procedures and overtreatment which could compromise the psychological well-being and reproductive future of these young women (74).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# 7.1.2 Women younger than 25 years High prevalence of HPV infections is found in young women and adolescents.The cytological abnormalities are usually of minor-grade (ASCUS/LSIL) and the prevalence of cervical cancer is very low in this population.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Because most HPV infections clear spontaneously within 2 years, immediate colposcopy for minor cytological abnormalities in adolescents is discouraged, as there could be potential harm due to over-investigation and over-treatment.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "For ASCUS/LSIL, repeat cervical cytology 12- monthly and return to routine screening after 2 consecutive negative cytology results.If there is a high-grade cytology (ASC-H, HSIL, AGC, AIS) or persistent abnormal cytology for 2 years, colposcopy should be performed.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If CIN3 is confirmed on biopsy, LEEP is indicated.If CIN2 is confirmed on biopsy, observation with cytology and colposcopy 6-monthly is suggested in view of the high regression rate of CIN2 in this age group $( 7 1 .",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "5 \\ – 8 8 \\% )$ (75, 76, 77, 78).However, treatment is recommended if CIN2 persists for 2 years.If no high-grade lesion is found on a satisfactory colposcopic examination, cytology should be repeated 6-monthly.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If HSIL persists at 1 year, colposcopy should be repeated.If HSIL persists for 2 years, LEEP should be considered (49).For pathologists using the 2-tier system for histological diagnosis (LSIL/HSIL), the clinician could contact the pathologist to further classify the HSIL as CIN2 or CIN3.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If HSIL is unspecified as CIN2 or CIN3, observation or treatment is acceptable.If colposcopy for HSIL is unsatisfactory, cytology and colposcopy should be repeated in 6 months.If HSIL persists and colposcopy is still unsatisfactory at 1 year, LEEP should be offered.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# 7.2 Pregnant women The aim of colposcopy in pregnant women is to exclude the presence of invasive cancer.Cancer risk is relatively low among pregnant women with ASCUS/LSIL, hence deferring colposcopy for ASCUS/LSIL is acceptable (at least beyond 6 weeks after delivery).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Pregnant women with ASC-H, HSIL, AGC, AIS or positive oncogenic HPV 16/18 test result should have a colposcopic examination as non-pregnant women to rule out malignancy.Endocervical curettage is contraindicated.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Repeat colposcopy at early third trimester may be considered.Pregnancy does not seem to alter the risk for or rate of progression from cervical precancer to cancer.The only indication of therapy for cervical neoplasia is invasive cancer.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Treatment for highgrade disease can be deferred to the postpartum period.Colposcopy guided biopsy or diagnostic excisional procedure is indicated only if malignant lesion is suspected.# 7.3 Chronically Immunocompromised Women who are chronically immunosuppressed, including those with human immunodeficiency virus (HIV), solid organ transplant, allogeneic haematopoietic stem cell transplant, and autoimmune diseases requiring current immunosuppressive agents, are at higher risk of persistent HPV infection, leading to progression to CIN and cervical cancer.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "They should be educated regarding the increased risk from HPV infection and encouraged to attend for regular screening.In view of the limited literature on cervical cancer screening for non-HIV immunocompromised women, screening and management guidelines generally follow those for women with HIV (79).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# 7.3.1 Women with HIV A large study published in 2021 showed that cervical cancer rates among women with HIV were elevated across all age groups between ages 25 and 54 years but there were zero cases among ages less than 25 years (80).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Although evidence on the benefit of cervical cancer screening for the younger age group is limited and inconsistent, there may be merit to screen women aged 21-24 to provide a few years’ window prior to age 25, when the risk of cervical cancer in women with HIV exceeds that of the general population (80).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Annual screening was recommended in the previous 2016 guidelines, however, recent data suggests that screening intervals can be widened (81).A 3-year interval can be considered after two consecutive normal annual cytology results (82) or a negative HPV-based (HPV co-test or HPV standalone) screening test.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Subsequent management for any screening abnormality should follow the guidelines for non-immunocompromised individuals.Treatment for high-grade abnormal cytology in this group should be the same as in immunocompetent women.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Low-grade lesions should be observed as they respond poorly to treatment.These should be monitored regularly for progression.# 8 LOCAL CERVICAL SCREENING PROGRAMME To reduce the local incidence and mortality of cervical cancer, the Government has been promulgating cervical screening in collaboration with the healthcare sector.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "In 2004, the Department of Health launched a territory-wide Cervical Screening Programme (CSP) together with the public, private and non-governmental sectors to facilitate and encourage women to have regular screening.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "To facilitate the sharing of information among healthcare providers, the Cervical Screening Information System (CSIS) was developed.It is a computerised registry for keeping and processing related data, including participants’ personal information, screening results and screening recommendations.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "After registering with the CSIS, the women can review their screening records, receive screening reminders and authorise service providers to review their screening records for more coordinated care (83).",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# REFERENCE LIST 1.de Sanjose S, Quint WG, Alemany L, et al.Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.Lancet Oncol.2010;11(11):1048-56.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "10.1016/S1470- 2045(10)70230-8.2.Serrano B, de Sanjose S, Tous S, et al.Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.Eur J Cancer.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "2015;51(13):1732-41.10.1016/j.ejca.2015.06.001.3.Arbyn M, Xu L, Simoens C, Martin-Hirsch PP.Prophylactic vaccination against human papillomaviruses to prevent cervical cancer Rev.2018;5(5):CD009069.10.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "1002/14651858.CD009069.pub3.4.Drolet M, Benard E, Perez N, Brisson M, Group HPVVIS.Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Lancet.2019;394(10197):497- 509.10.1016/S0140-6736(19)30298-3.5.Lei J, Ploner A, Elfstrom KM, et al.HPV Vaccination and the Risk of Invasive Cervical Cancer.N Engl J Med.2020;383(14):1340-8.10.1056/NEJMoa1917338.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "6.Falcaro M, Castanon A, Ndlela B, et al.The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Lancet.2021;398(10316):2084-92.10.1016/S0140- 6736(21)02178-4.7.Hildesheim A, Herrero R, Wacholder S, et al.Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "JAMA.2007;298(7):743-53.10.1001/jama.298.7.743.8.Lichter K, Krause D, Xu J, et al.Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Obstet Gynecol.2020;135(5):1070-83.10.1097/AOG.0000000000003833.9.Jentschke M, Kampers J, Becker J, Sibbertsen P, Hillemanns P.Prophylactic HPV vaccination after conization: A systematic review and meta-analysis.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Vaccine.2020;38(41):6402-9.10.1016/j.vaccine.2020.07.055.10.Di Donato V, Caruso G, Petrillo M, et al.Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Vaccines (Basel).2021;9(5).10.3390/vaccines9050410.11.Bartels HC, Postle J, Rogers AC, Brennan D.Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Int J Gynecol Cancer.2020;30(6):777-82.10.1136/ijgc-2020-001197.12.Kechagias KS, Kalliala I, Bowden SJ, et al.Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and metaanalysis.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "BMJ.2022;378:e070135.10.1136/bmj-2022-070135.13.World Health Organization.Human papillomavirus vaccines: WHO position paper (2022 update).Weekly Epidemiological Record, No 50.2022(97):645-72.14.Scientific Committee on Vaccine Preventable Diseases.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Updated Recommendations on the Use of 9-valent Human Papillomavirus Vaccine in Hong Kong (As of 30 November 2022).Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region; 2022.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Contract No.: 8 August 2023.15.Cheung TH, Cheng SSY, Hsu DC, et al.The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong.Cost Eff Resour Alloc.2021;19(1):75.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "10.1186/s12962-021-00328-x.16.Mzarico E, Gomez-Roig MD, Guirado L, Lorente N, Gonzalez-Bosquet E.Relationship between smoking, HPV infection, and risk of Cervical cancer.Eur J Gynaecol Oncol.2015;36(6):677-80.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "17.Su B, Qin W, Xue F, et al.The relation of passive smoking with cervical cancer: A systematic review and meta-analysis.Medicine (Baltimore).2018;97(46):e13061.10.1097/MD.0000000000013061.18.Chidharla A, Agarwal K, Abdelwahed S, et al.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Cancer Prevalence in E-Cigarette Users: A Retrospective Cross-Sectional NHANES Study.World J Oncol.2022;13(1):20-6.10.14740/wjon1438.19.Roura E, Castellsague X, Pawlita M, et al.Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Int J Cancer.2014;135(2):453-66.10.1002/ijc.28666.20.Hong Kong Cancer Registry.Hong Kong Cancer Statistics - Cervical Cancer [Available from: https://www3.ha.org.hk/cancereg/default.asp#.21.Control of cancer of the cervix uteri.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "A WHO meeting.Bull World Health Organ.1986;64(4):607-18.22.Katki HA, Kinney WK, Fetterman B, et al.Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Lancet Oncol.2011;12(7):663-72.10.1016/S1470- 2045(11)70145-0.23.Elfstrom KM, Smelov V, Johansson AL, et al.Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "BMJ.2014;348:g130.10.1136/bmj.g130.24.Dijkstra MG, van Zummeren M, Rozendaal L, et al.Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "BMJ.2016;355:i4924.10.1136/bmj.i4924.25.Chan KKL, Liu SS, Wei N, et al.Primary HPV testing with cytology versus cytology alone in cervical screening-A prospective randomized controlled trial with two rounds of screening in a Chinese population.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Int J Cancer.2020;147(4):1152-62.10.1002/ijc.32861.26.Cheung AN, Szeto EF, Leung BS, Khoo US, Ng AW.Liquid-based cytology and conventional cervical smears: a comparison study in an Asian screening population.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Cancer.2003;99(6):331-5.10.1002/cncr.11786.27.Wong OGW, Tsun OKL, Tsui EY, Chow JNK, Ip PPC, Cheung ANY.HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening populationCobas and Aptima HPV tests.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "J Clin Virol.2018;109:13-8.10.1016/j.jcv.2018.10.004.28.Wong OGW, $\\mathrm { N g }$ IFY, Tsun OKL, Pang HH, Ip PPC, Cheung ANY.Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "J Clin Microbiol.2019;57(12).10.1128/JCM.00997-19.29.Nayar R, Wilbur DC.The Bethesda system for reporting cervical cytology : definitions, criteria, and explanatory notes.Cham: Springer; 2015.30.Chiaffarano JM, Alexander M, Rogers R, et al.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "\"Low-grade squamous intraepithelial lesion, cannot exclude high-grade:\" TBS says \"Don't Use It!\" should I really stop it?Cytojournal.2017;14:13.10.4103/cytojournal.cytojournal_48_16.31.Alrajjal A, Pansare V, Choudhury MSR, Khan MYA, Shidham VB.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of Uterine Cervix and Bethesda System.Cytojournal.2021;18:16.10.25259/Cytojournal_24_2021.32.World Health Organisation.Female genital tumours.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "5th edition.Lyon: International Agency for Research on Cancer; 2020.33.Stolnicu S, Talia KL, McCluggage WG.The Evolving Spectrum of Precursor Lesions of Cervical Adenocarcinomas.Adv Anat Pathol.2020;27(5):278-93.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "10.1097/PAP.0000000000000266.34.Yuan CT, Lin MC, Kuo KT, Wang TH, Mao TL.Gastric-type adenocarcinoma in situ of uterine cervix: cytological and histopathological features of two cases Virchows Arch.2016;469(3):351-6.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "10.1007/s00428-016-1978-x.35.Schwock J, Starova B, Khan ZF, et al.Cytomorphologic Features of Gastric-Type Endocervical Adenocarcinoma in LiquidBased Preparations.Acta Cytol.2021;65(1):56-66.10.1159/000511003.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "36.Arbyn M, Ronco G, Anttila A, et al.Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer.Vaccine.2012;30:F88-F99.10.1016/j.vaccine.2012.06.095.37.Petry KU, Cox JT, Johnson K, et al.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Evaluating HPV-negative $\\mathrm { C I N } 2 +$ in the ATHENA trial.Int J Cancer.2016;138(12):2932-9.10.1002/ijc.30032.38.World Health Organization.WHO technical guidance and specifications of medical devices for screening and treatment of precancerous lesions in the prevention of cervical cancer.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Geneva: World Health Organization; 2020.Contract No.: 978-92-4- 000263-0.39.Salazar KL, Duhon DJ, Olsen R, Thrall M.A review of the FDA-approved molecular testing platforms for human papillomavirus.J Am Soc Cytopathol.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "2019;8(5):284-92.10.1016/j.jasc.2019.06.001.40.Arbyn M, Simon M, Peeters E, et al.2020 list of human papillomavirus assays suitable for primary cervical cancer screening.Clin Microbiol Infect.2021;27(8):1083-95.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "10.1016/j.cmi.2021.04.031.41.Meijer CJ, Berkhof J, Castle PE, et al.Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.Int J Cancer.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "2009;124(3):516-20.10.1002/ijc.24010.42.World Health Organization.WHO guideline for screening and treatment of cervical precancer lesions for cervical cancer prevention, second edition.Geneva: World Health Organization; 2021.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "43.National Pathology Accreditation Advisory Council.Requirements for Validation of SelfCollected Vaginal Swabs for Use in the National Cervical Screening Program.Canberra: National Pathology Accreditation Advisory Council; 2019.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "44.Molina MA, Carosi Diatricch L, Castany Quintana M, Melchers WJ, Andralojc KM.Cervical cancer risk profiling: molecular biomarkers predicting the outcome of hrHPV infection.Expert Rev Mol Diagn.2020;20(11):1099-120.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "10.1080/14737159.2020.1835472.45.Peeters E, Wentzensen N, Bergeron C, Arbyn M.Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of $\\mathrm { C I N } 2 { + } / \\mathrm { C I N } 3 { + }$ in triage of women with minor abnormal cytology.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Cancer Cytopathol.2019;127(3):169-80.10.1002/cncy.22103.46.Ebisch RM, van der Horst J, Hermsen M, et al.Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Mod Pathol.2017;30(7):1021-31.10.1038/modpathol.2017.16.47.Group A-LTS.Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Am J Obstet Gynecol.2003;188(6):1383-92.10.1067/mob.2003.457.48.Solomon D, Schiffman M, Tarone R, group AS.Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "J Natl Cancer Inst.2001;93(4):293-9.10.1093/jnci/93.4.293.49.Perkins RB, Guido RS, Castle PE, et al.2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "J Low Genit Tract Dis.2020;24(2):102-31.10.1097/LGT.0000000000000525.50.Group A-LTS.A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations.Am J Obstet Gynecol.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "2003;188(6):1393-400.10.1067/mob.2003.462.51.Katki HA, Schiffman M, Castle PE, et al.Five-year risks of CIN $^ { 2 + }$ and CIN $^ { 3 + }$ among women with HPV-positive and HPV-negative LSIL Pap results.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "J Low Genit Tract Dis.2013;17(5 Suppl 1):S43-9.10.1097/LGT.0b013e3182854269.52.Lew JB, Simms KT, Smith MA, et al.Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Lancet Public Health.2017;2(2):e96-e107.10.1016/S2468-2667(17)30007-5.53.Ronco G, Dillner J, Elfstrom KM, et al.Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Lancet.2014;383(9916):524-32.10.1016/S0140- 6736(13)62218-7.54.Egemen D, Cheung LC, Chen X, et al.Risk Estimates Supporting the 2019 ASCCP RiskBased Management Consensus Guidelines.J Low Genit Tract Dis.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "2020;24(2):132-43.10.1097/LGT.0000000000000529.55.Rodriguez AC, Schiffman M, Herrero R, et al.Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections.J Natl Cancer Inst.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "2008;100(7):513-7.10.1093/jnci/djn044.56.Wright TC, Jr., Stoler MH, Sharma A, et al.Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk $\\mathrm { H P V + }$ cytology-negative results.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Am J Clin Pathol.2011;136(4):578-86.10.1309/AJCPTUS5EXAS6DKZ.57.Khan MJ, Castle PE, Lorincz AT, et al.The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "J Natl Cancer Inst.2005;97(14):1072-9.10.1093/jnci/dji187.58.Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS.Screening for Cervical Cancer With HighRisk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "JAMA.2018;320(7):687-705.10.1001/jama.2018.10400.59.Castle PE, Stoler MH, Wright TC, Jr., Sharma A, Wright TL, Behrens CM.Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Lancet Oncol.2011;12(9):880-90.10.1016/S1470- 2045(11)70188-7.60.Wright TC, Jr., Behrens CM, Ranger-Moore J, et al.Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Gynecol Oncol.2017;144(1):51-6.10.1016/j.ygyno.2016.10.031.61.Demarco M, Egemen D, Raine-Bennett TR, et al.A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "J Low Genit Tract Dis.2020;24(2):144-7.10.1097/LGT.0000000000000530.62.Lee SS, Collins RJ, Pun TC, Cheng DK, Ngan HY.Conservative treatment of low grade squamous intraepithelial lesions (LSIL) of the cervix.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Int J Gynaecol Obstet.1998;60(1):35-40.10.1016/s0020- 7292(97)00219-1.63.Ostor AG.Natural history of cervical intraepithelial neoplasia: a critical review.Int J Gynecol Pathol.1993;12(2):186-92.64.Katki HA, Gage JC, Schiffman M, et al.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Follow-up testing after colposcopy: five-year risk of CIN $^ { 2 + }$ after a colposcopic diagnosis of CIN 1 or less.J Low Genit Tract Dis.2013;17(5 Suppl 1):S69-77.10.1097/LGT.0b013e31828543b1.65.Kyrgiou M, Athanasiou A, Kalliala IEJ, et al.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease.Cochrane Database Syst Rev.2017;11(11):CD012847.10.1002/14651858.CD012847.66.Kwok ST, Chan KKL, Tse KY, et al.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Outcome after loop electrosurgical excision procedure for cervical high-grade squamous intraepithelial lesion.Taiwan J Obstet Gynecol.2023;62(1):45-9.10.1016/j.tjog.2022.10.004.67.Palmer JE, Ravenscroft S, Ellis K, et al.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Does LLETZ excision margin status predict residual disease in women who have undergone post-treatment cervical cytology and high-risk human papillomavirus testing?Cytopathology.2016;27(3):210-7.10.1111/cyt.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "12260.68.Arbyn M, Ronco G, Anttila A, et al.Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.Vaccine.2012;30 Suppl 5:F88-99.10.1016/j.vaccine.2012.06.095.69.Kocken M, Helmerhorst TJ, Berkhof J, et al.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study.Lancet Oncol.2011;12(5):441-50.10.1016/S1470-2045(11)70078-X.70.Strander B, Andersson-Ellstrom A, Milsom I, Sparen P.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study.BMJ.2007;335(7629):1077.10.1136/bmj.39363.471806.BE.71.Henrique LQ, Campaner AB, d'Avila FS.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Cervical Cancer Screening of Adolescents Should Not Be Encouraged.J Low Genit Tract Dis.2017;21(1):21-5.10.1097/LGT.0000000000000273.72.Hosier H, Sheth SS, Oliveira CR, Perley LE, Vash-Margita A.Unindicated cervical cancer screening in adolescent females within a large healthcare system in the United States.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Am J Obstet Gynecol.2021;225(6):649 e1- e9.10.1016/j.ajog.2021.07.005.73.Campaner AB, Fernandes GL.Cervical Cancer Screening of Adolescents and Young Women: Further Evidence Shows a Lack of Clinical Value.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "J Pediatr Adolesc Gynecol.2021;34(1):6-11.10.1016/j.jpag.2020.10.006.74.Moscicki AB, Cox JT.Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "J Low Genit Tract Dis.2010;14(1):73-80.10.1097/lgt.0b013e3181cec411.75.Loopik DL, Doucette S, Bekkers RL, Bentley JR.Regression and Progression Predictors of CIN2 in Women Younger Than 25 Years.J Low Genit Tract Dis.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "2016;20(3):213-7.10.1097/LGT.0000000000000215.76.Loopik DL, Bekkers RLM, Massuger L, Melchers WJG, Siebers AG, Bentley J.Justifying conservative management of CIN2 in women younger than 25 years - A population-based study.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Gynecol Oncol.2019;152(1):82-6.10.1016/j.ygyno.2018.10.038.77.Lee MH, Finlayson SJ, Gukova K, Hanley G, Miller D, Sadownik LA.Outcomes of Conservative Management of High Grade Squamous Intraepithelial Lesions in Young Women.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "J Low Genit Tract Dis.2018;22(3):212-8.10.1097/LGT.0000000000000399.78.Ehret A, Bark VN, Mondal A, Fehm TN, Hampl M.Regression rate of high-grade cervical intraepithelial lesions in women younger than 25 years.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Arch Gynecol Obstet.2023;307(3):981-90.10.1007/s00404-022- 06680-4.79.Moscicki AB, Flowers L, Huchko MJ, et al.Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.J Low Genit Tract Dis.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "2019;23(2):87-101.10.1097/LGT.0000000000000468.80.Stier EA, Engels E, Horner MJ, et al.Cervical cancer incidence stratified by age in women with HIV compared with the general population in the United States, 2002-2016.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "AIDS.2021;35(11):1851-6.10.1097/QAD.0000000000002962.81.Massad LS, D'Souza G, Tian F, et al.Negative predictive value of pap testing: implications for screening intervals for women with human immunodeficiency virus.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Obstet Gynecol.2012;120(4):791-7.10.1097/AOG.0b013e31826a8bbd.82.Centre for Health Protection - Cancer Expert Working Group on Cancer Prevention and Screening (CEWG).Recommendations on Prevention and Screening for Cervical Cancer For Health Professionals 2021 [Available from: https://www.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "chp.gov.hk/files/pdf/cervical_can cer_professional_hp.pdf.83.Department of Health.Cervical Screening Programme [Available from: http://www.cervicalscreening.gov.hk.84.Panel of the Medical Devices Advisory Committee.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "FDA Executive Summary New Approaches in the Evaluation for High-Risk Human Papillomavirus Nucleic Acid Detection Devices.2019.# ACKNOWLEDGEMENT: This document was revised by:- Dr CHAN Kar Loen Karen (Department of O&G, HKU) Prof CHEUNG Nga Yin Annie (Department of Pathology, HKU) Dr JONG Kwok Kwan (Department of Health, HKSAR) Dr LAW Jessica Yun Pui (Department of O&G, PYNEH) Dr LEE Ying Andrea (Department of Health, HKSAR) Dr LEE Ho Sze Jacqueline (Department of O&G, PWH) Dr LI Wai Hon (Department of O&G, QEH) Dr MA Vinci (Department of Health, HKSAR) Dr NGU Siew Fei (Department of O&G, HKU) Dr WONG Ching Yin Grace (Family Planning Association, HK) Dr WONG Wing Cheuk Richard (Department of Pathology, UCH) This guideline was produced by the Hong Kong College of Obstetricians and Gynaecologists as an educational aid and reference for obstetricians and gynaecologists practicing in Hong Kong.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The guideline does not define a standard of care, nor is it intended to dictate an exclusive course of management.It presents recognized clinical methods and techniques for consideration by practitioners for incorporation into their practice.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "It is acknowledged that clinical management may vary and must always be responsive to the need of individual patients, resources, and limitations unique to the institution or type of practice.Particular attention is drawn to areas of clinical uncertainty where further research may be indicated.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "First version published December 1999 Second version published November 2002 Third version published November 2008 Fourth version published November 2016 Table 1.Routine screening recommendation <html><body><table><tr><td>Under 25</td><td> Screen as per physician's assessment of risk</td></tr><tr><td>25-29</td><td>Cytology annually for 2 consecutive years, then 3 yearly cytology HPV-based test (HPV stand-alone or HPV co-test with</td></tr><tr><td>30-64</td><td>vaccination Cytology annually for 2 consecutive years, then 3 yearly cytology OR</td></tr><tr><td></td><td>Co-test (HPV test + Cytology) every 5 years OR HPV stand-alone every 5 years</td></tr><tr><td>≥65 & previous negative screening</td><td>Can discontinue screening if routine screening results are negative within the last 10 years</td></tr><tr><td>≥ 65, never had cervical cancer screening and with history of being sexually active</td><td> Offer routine screening</td></tr><tr><td>Previous LSIL (histological findings)</td><td>Continue follow up as per guidelines</td></tr><tr><td></td><td>Exit from screening at the age ≥ 65 provided that all routine screening are negative for the last 10 years</td></tr><tr><td>Previous HSIL (histological findings)</td><td>Continue follow up as per guidelines</td></tr><tr><td></td><td>Exit from screening at the age ≥ 65 provided that all routine</td></tr><tr><td>Have hysterectomy with removal of</td><td> screening smears are negative for the last 25 years</td></tr><tr><td>cervix for benign diseases and without a prior history of cervical dysplasia</td><td>Can discontinue screening</td></tr><tr><td></td><td></td></tr><tr><td> Chronically immunosuppressed should be screened regardless of age when they have become sexually</td><td></td></tr></table></body></html> Table 2.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "1.Management of cytology results - Normal and squamous lesions <html><body><table><tr><td colspan=\"2\">Cervical cytology Negative for Cytology alone: repeat cytology every 3 years (after 2 initial annual screen) intraepithelial lesion or Co-testing: malignancy If high-risk HPV (hrHPV) negative, repeat co-testing every 5 years (NILM) (normal</td></tr><tr><td>cytology)(Fig.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "1 ) Normal but</td><td>If hrHPV negative, but history of hrHPV positive or cytology abnormality in the last screening, repeat screening (co-testing or cytology) in 3 years If hrHPV positive, then 3 options: 0 Repeat cytology in 6 months for 3 times 0 Repeat co-testing in 12 months 0 Do genotyping for HPV16/18 If HPV 16/18 positive, refer colposcopy If HPV 16/18 negative, repeat co-testing or cytology in 1 year, then in 3 years, then routine screening</td></tr><tr><td>transformation zone absent ASCUS</td><td>If age <30 years: manage as normal smears If age ≥30 years: HPV testing (preferred) or manage as normal smears Cytology alone: repeat cytology in 6 months and 12 months </td></tr><tr><td>(Fig.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "2） LSIL（Fig.3）</td><td>HPV triage or co-testing : hrHPV positive, refer for colposcopy hrHPV negative, repeat screening (co-testing or cytology) in 3 years Cytology alone: refer for colposcopy</td></tr><tr><td>ASC-H (including cases with</td><td>Co-testing: hrHPV positive, refer for colposcopy hrHPV negative, repeat co-testing or cytology in 12 months o If any result is abnormal, refer for colposcopy 0 If result is normal, repeat co-testing or cytology in 3 years, then routine screening Refer for colposcopy Obtain endocervical sampling if unsatisfactory colposcopy</td></tr><tr><td>HSIL</td><td>3 years, then return to routine screening Repeat colposcopy if persistent abnormal cytology or hrHPV positive Diagnostic excisional procedure is recommended if ASC-H persists at 2 years Refer for colposcopy If there is no significant pathology explaining the source of abnormal cells, review of material is recommended.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If no change in diagnosis, diagnostic</td></tr><tr><td>Squamous cell carcinoma</td><td>excisional procedure is recommended Biopsy if frank growth, otherwise early referral for colposcopy and biopsy</td></tr></table></body></html> Table 2.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "2.Management of Cytology results - Glandular lesions (also refer Fig.8) <html><body><table><tr><td>AGC-NOS (or atypical endocervical cells)</td><td>Refer for colposcopy, endometrial sampling and endocervical sampling For AGC-FN and AIS: if there is no significant pathology explaining the source of abnormal cells, a diagnostic excisional procedure is</td></tr><tr><td>AGC-favour neoplastic (AGC-FN)</td><td> recommended.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Cold knife conisation is preferred.</td></tr><tr><td>Adenocarcinoma in-situ (AIS)</td><td></td></tr><tr><td>Atypical endometrial cells</td><td>Endometrial and endocervical sampling should be performed If no endometrial pathology is identified, refer for colposcopy</td></tr><tr><td>Adenocarcinoma</td><td>Biopsy if frank growth, otherwise early referral for colposcopy, endometrial sampling and endocervical sampling</td></tr><tr><td rowspan=\"2\">Endometrial cells (in a woman ≥ 45 years of age)</td><td>Postmenopausal women: endometrial assessment is recommended Asymptomatic premenopausal women: no further investigation is required</td></tr><tr><td>Endometrial assessment may be offered to those who are at increased risk of endometrial pathology, such as presence of abnormal vaginal bleeding or obesity (BMI ≥ 25 kg/m?",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": ").</td></tr></table></body></html> Table 2.3.Management of Cytology results – others <html><body><table><tr><td>Unsatisfactory</td><td>Cytology alone: repeat cytology in 2-4 months.If 2 consecutive unsatisfactory cytology, refer for colposcopy Co-testing: If HPV 16/18 positive, refer for colposcopy - If other high-risk/untyped HPV positive, repeat cytology in 2-4 months or refer for colposcopy If HPV negative, repeat cytology in 2-4 months.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "If 2 consecutive unsatisfactory cytology, refer for colposcopy</td></tr><tr><td>Other malignant neoplasms</td><td>Biopsy if frank growth, otherwise early referral for colposcopy and biopsy</td></tr></table></body></html> Appendix 1.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Examples of commercially available HPV tests (39, 84) <html><body><table><tr><td>HPV test</td><td>Method and target</td><td>HPV genotypes detected</td><td>Genotyping capacity</td><td>FDA approval status</td></tr><tr><td>Hybrid Capture 2</td><td>DNA (non-PCR based)</td><td>16, 18,31, 33, 35,39,45, 51, 52, 56, 58, 59,68</td><td>No</td><td>Approved for reflex testing or co-testing (2001)</td></tr><tr><td>Cervista HPV HR test</td><td>DNA (non-PCR based)</td><td>16,18,31,33, 35,39,45,51, 52, 56,58, 59, 66, 68</td><td>Yes with additional test (16 and 18)</td><td>Approved for reflex testing or co-testing (2009)</td></tr><tr><td>Cobas 4800 or 6800/8800 HPV test</td><td>DNA (PCR based)</td><td>16, 18,31, 33, 35,39,45,51, 52,56,58,59, 66, 68</td><td>Yes (16 and 18)</td><td>Approved for reflex testing or co-testing (2011) Approved for primary screening (for ThinPrep, 2014; for</td></tr><tr><td>Aptima HPV Assay</td><td>RNA (PCR based)</td><td>16, 18,31, 33, 35,39,45,51, 52, 56, 58, 59, 66, 68</td><td>Yes with additional test (16 and 18/45)</td><td>SurePath, 2018) Approved for reflex testing or co-testing (2011)</td></tr><tr><td>Onclarity HPV Assay</td><td>DNA (PCR based)</td><td>16, 18,31, 33, 35,39,45,51, 52,56,58,59, 66, 68</td><td>Yes (16, 18, 31, 45,51, 52,33/58, 56/59/66, 35/39/68)</td><td>Approved for reflex testing or co-testing (2018) Approved for primary screening (for SurePath, 2018; for ThinPrep 2023)</td></tr></table></body></html> FDA, U.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "S.Food and Drug Administration; PCR, polymerase chain reaction.# Remarks: It should be noted that examples of HPV tests listed in this table are NOT specifically endorsed or recommended by this guideline.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "The information on the testing platform, genotype coverage and regulatory status may be subject to changes and laboratory users are advised to verify the latest information regarding any specific products.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "Apart from the above examples, a broad range of HPV tests (such as HPV chips and PCR-sequencing using consensus primers) may also be used by clinical laboratories.Considerations should be given to the clinical purpose of HPV testing, analytical and clinical validation of the HPV test, laboratory accreditation and regulatory status.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "![](images/b3a7c1f4e424ffe33794132cd477e3322f8305358d8823441e1d0773a7d51f64.jpg) Fig.1 Management of normal cytology with or without HPV test ![](images/306944effd41f63d5b74ef2400200d70e088aa9d9fdfcc617474d1133b4e66a3.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "jpg) Fig.2 Management of ASCUS smear (with or without HPV triage or co-testing) ![](images/4b3a07c8016f17a1a2ded19a7c218067371b11dfc69c5f8345d0c8e1f73d6df7.jpg) Fig.3 Management of LSIL smears ![](images/821b72c5c357c5d58155f5f805db6c8e83db3e7cee21235c8e61e655f9784e96.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "jpg) Fig.4 Management options in HPV as a stand-alone test \\* Only applies to specific tests approved for primary screening ( Refer to Appendix 1 ) ![](images/8af2c4a86da37380111a764a2acabeb11cf2db3d56bd380d06b0783d13fa5cb2.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "jpg) Fig.5 Management after colposcopy ^ For women who had low-grade cytology leading to colposcopy \\* Irrespective of cytology results ![](images/a13658b4266a40c715c34478bae46acd7340286ca4a6118cb533d0751c677fed.",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "jpg) ![](images/dc9dbd3e75b8622627607d085e7caa67bc39f84471dbeb30a9668d0e365eb498.jpg) Fig.7 Management of women with Atypical Squamous Cells-Cannot Exclude High grade SIL (ASC-H) \\* Irrespective of HPV genotyping results # Diagnostic excisional procedure if AsC-H persists at 2 years ![](images/73b049ccd9c4b61307c9f9c5c08f300f2fb9472a1c46eb08818b31b7a6eb76e0.jpg) Fig.8 Management of women with Cytology showing Atypical Glandular Cells",
    "source": "Guidelines for Cervical Cancer Prevention - HKCOG Guidelines",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines/Guidelines for Cervical Cancer Prevention - HKCOG Guidelines.md"
  },
  {
    "text": "# 医学信息速递Medical Information Express # 《NCCN肿瘤学临床实践指南： 宫颈癌2024.V3》 产品战略&医学与信息部2024-7 ![](images/75fbf15ca760b78bc6e763ef97695e4ea1a0d01f1aad9fde24140e7c8369c338.jpg) # 01 文献简介 文献基本信息NCCN分类标准 # 02 文献重点内容 更新概况 分期 分期治疗 病理学原则 影像学原则 评估与手术分期原则 放射治疗原则 宫颈癌的全身治疗 （药物治疗） # NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines $\\textcircled{8}$ )：Cervical Cancer Version 3.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "2024 NCCN肿瘤学临床实践指南(NCCN指南 $\\textcircled{8}$ )： 宫颈癌2024.V3 ![](images/53f3a18ca0c082c68b27891f8feb81e012419b07caa3ce3731f1858d7f58d585.jpg) 发表机构美国国立综合癌症网络 （NCCN） 发表时间2024年5月 # NCCN分类标准 <html><body><table><tr><td colspan=\"2\">NCCN对证据和共识的分类</td></tr><tr><td>1类</td><td>基于高水平证据，NCCN一致认为此项治疗合理。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "</td></tr><tr><td>2A类</td><td>基于低水平证据，NCCN一致认为此项治疗合理。</td></tr><tr><td>2B类</td><td>基于低水平证据，NCCN基本认为此项治疗合理。</td></tr><tr><td>3类</td><td>基于任何水平证据，NCCN 对此项治疗是否合理存在重大分歧。</td></tr></table></body></html> <html><body><table><tr><td colspan=\"2\">NCCN优先使用分类</td></tr><tr><td>首选干预方法</td><td>若适当、可负担，则基于疗效、安全性和证据更优的干预方法。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "</td></tr><tr><td>推荐的其他干预方法</td><td>其他干预方法可能疗效较低、毒性更多，或依据的数据不太成熟；或者具有相似疗效，但费用明显较高。</td></tr><tr><td>某些情况下有用</td><td>其他干预方法可能会用于选定的患者人群（根据推荐类型定义）。</td></tr></table></body></html> 所有推荐均为 2 A 类，除非另有说明。![](images/d90acbec535b548e4d59b1a0cef846c88702e5e9d52106a61013f20852a5995b.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "jpg) # 01 文献简介 文献基本信息NCCN分类标准 # 02 文献重点内容 更新概况 分期 分期治疗 病理学原则 影像学原则 评估与手术分期原则 放射治疗原则 宫颈癌的全身治疗 （药物治疗） # 指南重点内容 ![](images/e7d0a82f9218fa805e43e7268bdf2c67a951dc15ebeac0e53f74b1c68dde399f.jpg) # NCCN宫颈癌指南2024.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "V3版较2024.V2版更新内容 # National Comprehensive NCCN Guidelines Version 3.2024 Cancer Cervical Cancer Network?<html><body><table><tr><td>This discussion corresponds to the NCCN Guidelines for Cervical Table of Contents Cancer (V3.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "2024).Last updated on May 06, 2024</td><td>Locoregional Recurrence.</td></tr><tr><td>Overview..</td><td>MS-23 Therapy for MetastaticDisease.....MS-24 MS-2</td></tr><tr><td> Guidelines Update Methodology.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "..</td><td>.MS-3</td></tr><tr><td>Literature Search Criteria...</td><td>ChemoradiationforLocallyAdvancedCervical Cancer MS-25 ...MS-3</td></tr><tr><td>Sensitive/lnclusive Language Usage .</td><td>SystemicTherapyforRecurrent orMetastaticCervical Cancer.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "...MS-26 ..MS-3</td></tr><tr><td>Diagnosis and Workup.</td><td>First-Line Systemic Therapy Options for Recurrent or Metastatic Disease...MS-26 MS-4</td></tr><tr><td> Principles of Staging and Surgery..",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "</td><td>Second-line/SubsequentSystemicTherapy OptionsforRecurrent orMetastatic ..MS-4</td></tr><tr><td> Clinical Staging ..</td><td>Cervical Cancer....MS-29 ..MS-4</td></tr><tr><td>Surgical Staging.</td><td>Principles of Radiation Therapy.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "...MS-32 MS-5</td></tr><tr><td></td><td>Radiation Treatment Planning....MS-32</td></tr><tr><td></td><td>Normal TissueConsiderations MS-35</td></tr><tr><td>Non-Fertility-SparingApproaches.........-.</td><td>Incidental Cervical Cancer.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "..MS-36</td></tr><tr><td>Lym.p.NodeMaing and.Ddissection...MS-7</td><td>Sm.a..NeuroendocrineC.arcinom.of.theC.ervix..S.3.</td></tr><tr><td>Principles ofPathology...MS-9</td><td></td></tr><tr><td>PathologicAssessment.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "........MS-9</td><td>Primary Workup....MS-37</td></tr><tr><td></td><td>Principlesof Pathology..........MS-38</td></tr><tr><td>HPV-IndependentAdenocarcinoma.MS-15</td><td>Syte.icT.......8</td></tr><tr><td>Primary Treatment.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "..MS-16</td><td>Cervical Cancer andPregnancy..MS-39</td></tr><tr><td>Important Phase Ill Clinical Trials Underpinning Treatment Recommendations...MS-16</td><td>Drug Reactions.....MS-39</td></tr><tr><td>Early-Stage Disease.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": ".MS-17</td><td>Gynecologic Survivorship.MS-40</td></tr><tr><td>Adjuvant Treatment...MS-21</td><td>Best Supportive Care MS-40</td></tr><tr><td>Surveillance....MS-22</td><td>Summary.MS-40</td></tr><tr><td>Therapy for Relapse .",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "..MS-23</td><td></td></tr><tr><td>Version3.2024 2024National Comprehensive Cancer Network (NCCN), Allrights reserved.NCCN Guidelines and this illustration may not be reproduced in any form without the express wrilten permission of NcCN.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "</td><td>References ...MS-42 MS-1</td></tr></table></body></html> # MS-1 ❖新增病理性原则板块：新增宫颈癌预后及预测性生物标记物目录及相关内容详细介绍了PD1/PD-L1、MSI/dMMR、TMB、NTPK融合基因、HER2、RET融合基因、HPV状态/p16等标记物及相关药物试验研究进行详细的叙述和讨论。这些相关的新型药物在前一版本己加入到治疗流程图。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "❖增加了宫颈神经内分泌小细胞癌的综述：该部分介绍了宫颈神经内分泌小细胞癌的来源、病理学特征以及系统治疗。# NCCN宫颈癌指南2024.V2版较2024.V1版更新内容 ![](images/11e22be59aaab273b64ac774752e5fc6ff9d6a849fa673e677e59e75a0c77fca.jpg) CERV-6 ❖脚注t修订：同步含铂化疗联合EBRT，推荐使用顺铂作为单一药物（顺铂不耐受情况下，可改用卡铂）。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "仅对于FIGO 2014分期III-IVA期宫颈癌患者，可在放化疗中加用帕博利珠单抗。# NCCN宫颈癌指南2024.V2版较2024.V1版更新内容 # SYSTEMICTHERAPYFORCERVICALCANCERa FOONOTESFORCERV-F1OF3 aCila l sdt onureaa CROsyurraci aet FGOaduddiaont Prescribinginformation:https://www.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "accessdata.fda.gov/drugsatfdadocs/label/2024/125514s147lbl.pdf hkiar maintenancetherapydosingschedules e These agents may be considered when cisplatin and carboplatin are unavailable.flfnotsedprevoustheseagentscanbesedasecond-ineoruequnt thrapyaslnicalyappropriat gAnFDA-approvedbiosimilaris an appropriatesubstitute forbevacizumab.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "h NCCN Guidelines for the Management of Immunotherapy-Related Toxicities.Redseaaayv laboratory.J Additional references for second-line therapy are provided in the Discussion Fothat aa alternative treatment options.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "# CERV-F 1/3 宫颈癌的全身治疗 ❖放化疗；首选方案：在“顺铂”和“对顺铂不耐受的患者使用卡铂”的推荐中增加了以下脚注。❖脚注c新增：同步含铂化疗联合EBRT，推荐使用顺铂作为单一药物（顺铂不耐受情况下，可改用卡铂）。指南推荐对于FIGO2014分期III-IVA期宫颈癌患者，可在放化疗中加用帕博利珠单抗。依据为KEYNOTE-A18（NCT04221945）是一项多中心、 随机、双盲、安慰剂对照的III期临床试验，针对未曾接受过根治性手术、放疗或系统治疗的596名FIGO 2014分期III-IVA期宫颈癌患者，评价了使用顺铂作为单一药物化疗及EBRT联合帕博利珠单抗治疗的疗效，主要终点为无进展生存期（PFS）和总生存期（OS），次要终点包括完全缓解率、 客观缓解率和安全性。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "❖脚注d：本方案中包含的检查点抑制剂和/或单克隆抗体可作为维持治疗继续使用。关于维持治疗给药方案，请参阅原始研究方案。# NCCN宫颈癌指南2024.V2版较2024.V1版更新内容 SYSTEMICTHERAPYFORCERVICALCANCERa <html><body><table><tr><td>NCCN</td><td>NCCNGuiline Version 32024</td><td></td></tr></table></body></html> <html><body><table><tr><td colspan=\"3\">Small Cell NECC</td></tr><tr><td rowspan=\"2\">Chemoradiationm</td><td colspan=\"2\">RecurrentorMetastaticDisease</td></tr><tr><td>First-line Therapy Preferred Regimens</td><td>Second-lineorSubsequentTherapy</td></tr><tr><td>Preferred Regimens Other Recommended Regimens ·Carboplatin+etoposideif patient is cisplatinintolerant ·Cisplatin +etoposidel22</td><td>·Cisplatin/etoposide ·Carboplatin/etoposide OtherRecommended Regimens ·Cisplatin/etoposide+atezolizumab (or durvalumab)d,h,23,24</td><td>Other Recommended Regimens ·Bevacizumab9 ·Albumin-bound paclitaxel ·Docetaxel ·Topotecan ·Topotecan/paclitaxel ·Cisplatin/topotecan</td></tr></table></body></html> # CERV-F 2/3 宫颈癌的全身治疗 ❖新增脚注a：顺铂、卡铂、多西他赛和紫杉醇可能会引起药物反应。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "❖新增脚注d：本方案中包含的检查点抑制剂和/或单克隆抗体可作为维持治疗继续使用。关于维持治疗给药方案，请参阅原始研究方案。删除脚注：顺铂或卡铂可能会引起药物反应。# NCCN宫颈癌指南2024.V1版较2023.V1版更新内容 CERV-ESystemicTherapyforCervical Cancer CERV-F 1'of 3 Squamous Cell Carcinoma, Adenocarcinoma, or Adenosquamous Carcinoma · Chemoradiation Newsectionadded: Other Recommended Regimens (if cisplatin and carboplatin are unavailable) Capecitabine/mitomycin Gemcitabine -Paclitaxel # ·RecurrentorMetastaticDisease # First-line Therapy: Section reformatted to denote PD-L1-positive tumors as a separate bullet Second-line or Subsequent Therapy Preferred Regimens: Cemiplimab added Other Recommended Regimens: lrinotecan changed from category 2B to category 2A Useful in Certain Circumstances Sectionrevised toseparateout regimensby mutationtype Fam-trastuzumab deruxtecan-nxki added for HER2-positive tumors (IHC $^ { 3 + }$ or $^ { 2 + }$ ） NTRK gene fusion-positive tumors: Single agent Larotrectinib and Entrectinib changed fromcategory 2Btocategory 2A !",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "[](images/e3b57efe3db38c1b9276b15521e6d3449f3e654faf577f461c84930f7602ff4f.jpg) # NCCN Guidelines Version 3.2024 Cervical Cancer # Updates in Version 1.2024 of the NCCN Guidelines for Cervical Cancer from Version 1.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "2023 include: CERV-ESystemicTherapyfor Cervical Cancer-continued CERV-F 1A of 3 ·Footnterevised:standtoxicityeciallywheningextendedfiedshoulbecarfullycnsidered.New footnote c added: These agents may be considered when cisplatin and carboplatin are unavailable.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "FototrevisenddrxpedeindnAaDaovd or a validated test performed in a CLIA-certified laboratory.Fotknlndiide original study protocol for maintenance therapy dosing schedules.Fotaaav laboratorythathaveprogressdfollwingpriotreatmentandwhhavesatisfatoryalnativetreatmentptins.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "# NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗 鳞状细胞癌、腺癌或腺鳞癌 ![](images/5f3249131da5b7102251609d0c3f7f2fd153a2a89bf8517ac68126c2586aaade.jpg) # NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗——宫颈小细胞神经内分泌癌 # CERV-F 2 of 3 Small Cell NECC ↓ Recurrent or Metastatic Disease Second-line orSubsequent Therapy; OtherRecommended Regimens:lrinotecanchanged fromcategory 2Btocategory A Footnote f added: NCCN Guidelines for the Management of Immunotherapy-Related Toxicities.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "# SYSTEMIC THERAPYFOR CERVICALCANCERa <html><body><table><tr><td colspan=\"3\">Small Cell NECC!</td></tr><tr><td rowspan=\"2\">Chemoradiationm</td><td colspan=\"2\">Recurrent or Metastatic Disease</td></tr><tr><td>First-line Therapyf Preferred Regimens</td><td>Second-line or Subsequent Therapy Other Recommended Regimens</td></tr><tr><td>Preferred Regimens Other Recommended Regimens · Carboplatin + etoposide if patient is cisplatin intolerant' ·Cisplatin + etoposidel222</td><td>· Cisplatin/etoposide · Carboplatin/etoposide Other Recommended Regimens ·Cisplatin/etoposide+atezolizumab</td><td>·Bevacizumab9 · Albumin-bound paclitaxel · Docetaxel · Topotecan ·Topotecan/paclitaxel</td></tr></table></body></html> # 指南重点内容 !",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "[](images/c21f224d42e440b4cf7544a686677f22ca9b3dfbdd1e8c7e9d0dbf4049ca3167.jpg) # 宫颈癌分期 （FIGO 2018） # Ⅰ期 癌变局限于宫颈 （扩散至宫体应忽略） • ⅠA——仅在显微镜下可见浸润癌，最大浸润深度＜5mm ⅠA1 ![](images/bb0e16bf6736576a31e72e8ad832413f444d7d2d56411258b08b79647312832e.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "jpg) ⅠA1：间质浸润深度 $< 3 ~ \\mathsf { m m }$ ⅠA2：间质浸润深度 $> 3 \\ \\mathsf { m m } ,$ ≤5 mm # 宫颈癌分期 （FIGO 2018） # Ⅰ期 癌变局限于宫颈 （扩散至宫体应忽略） ⅠB——浸润癌浸润深度＞5 mm(超过ⅠA) ⅠB1 ![](images/c66c44f58ff67f76eebfcf959bb8234a0abfad09ab52634da6faedf2c4db85b0.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "jpg) ![](images/4a1b8c68e2656a7f3e90721535546efbcc317fe08f899ca1d9dcc8b566f7402e.jpg) 间质浸润深度 $>$ 5mm, 病灶最大径线≤2cm 病灶最大径线＞2 cm, ≤4 cm # 宫颈癌分期 （FIGO 2018） Ⅱ期 癌灶超越子宫， 但未达阴道下1/3 或未达骨盆壁 ⅡA— 一 侵犯上2/3阴道，无宫旁浸润 !",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "[](images/2aaa38b845fa7403fdba184ed4b817cc45e313ce52aef6704b61097a7a8aaf60.jpg) ⅡA1：病灶最大径线≤4cmⅡA2：病灶最大径线 $>$ 4cm # 宫颈癌分期 （FIGO 2018） Ⅱ期 癌灶超越子宫， 但未达阴道下1/3 或未达骨盆壁 ![](images/bf13491660357dfc25924416d672f5f0d9c3971fe8f1e7d047ee83e469381ec8.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "jpg) 有宫旁浸润，未达盆壁 # 宫颈癌分期 （FIGO 2018） Ⅲ期 癌灶累及阴道下1/3和(或)扩展到骨盆壁和(或)引起肾盂积水或肾无功能和(或)累及盆腔和(或)主动脉旁淋巴结 ⅢB ![](images/4e710f47b8dc79970f7f4e04d63dbd17dc8312a421a596a029b8b28d3b8f0c87.jpg) ![](images/933ff4b343ad7b8afc7cb527d0c22d5d3fb3a679acb9e7a06fd6b7a4dfc8111a.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "jpg) 癌灶累及阴道下1/3，没有扩展到骨盆壁 # 宫颈癌分期 （FIGO 2018） Ⅲ期 癌灶累及阴道下1/3和(或)扩展到骨盆壁和(或)引起肾盂积水或肾无功能和(或)累及盆腔和(或)主动脉旁淋巴结 ⅢC— —不论肿瘤大小和扩散程度，累及盆腔和（或）主动脉旁淋巴结 ⅢC ![](images/f93fc5511ec7cf60475cb16e25171c6625447e18a6f1119f7bb1694e11d0c9fe.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "jpg) ⅢC1：仅累及盆腔淋巴结 ⅢC2：主动脉旁淋巴结转移 # 宫颈癌分期 （FIGO 2018） Ⅳ期 肿瘤侵犯膀胱黏膜或直肠黏膜(活检证实)和(或)超出真骨盆（泡状水肿不分为Ⅳ期） ![](images/649f0a91b713ac006688ec6bf5158edea75048cb5dc5350d87cefdf5f5e640d0.jpg) # 指南重点内容 ![](images/ce75e25a8a050f7a615869286e65c72797292a016ecda12496aedb91cc983ae1.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "jpg) # 临床分期治疗选择 ![](images/9577c40e420c5c4800301dbc44ada499164074fc88768ff1a6b4bb8e7cf586d3.jpg) 指南中的所有分期标准均基于FIGO 2018版发布的分期 # IA1期 考虑再次锥切活检，更好的评估浸润深度，$+$ 切缘肿瘤阳性行盆腔淋巴结切除术（可行SLN） ![](images/de0865d3de53c10c3230e2fe23e73dadc352e9e27d2a261cdb2d929b562c25a4.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "jpg) LVSI：淋巴管间隙浸润 # IA2、IB1、IB2期 ![](images/c85ebecc3de02ddf2b075d05ff097c69eb007431a90bda46c9769e7734660b38.jpg) 切缘阴性的锥切活检 $^ +$ 盆腔淋巴结清扫术或SLN显影 同IA1期 LVSI（+） 根治性宫颈切除术 $^ +$ 盆腔淋巴结清扫术±主动脉淋巴结清扫术（可行SLN） 筋膜外子宫切除术 $+$ 盆腔淋巴结清扫术（或SLN） 改良根治性子宫切除术+盆腔淋巴结清扫术（可行SLN） 盆腔EBRT+近距离放射治疗 （不可手术者） 根治性子宫切除术+盆腔淋巴结清扫术（考虑SLN） ±主动脉旁淋巴结清扫术（考虑SLN） 盆腔EBRT+近距离放疗政府同步含铂化疗（不可手术者） # IB3、IIA1、IIA2 !",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "[](images/2eb899782e1d08d5403b8224438819765ec844296e82ddf8c5bc3f4dc293620a.jpg) # IIB期、III期、 IVA期 ![](images/4e6bbe1724f61b2080c64175054cd6f277182ad5091f0b5767c4ac36bc1724ba.jpg) 指南推荐对于FIGO 2014分期III-IVA期宫颈癌患者，可在放化疗中加用帕博利珠单抗。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "依据为KEYNOTE-A18（NCT04221945）是一项多中心、随机、双盲、安慰剂对照的III期临床试验，针对未曾接受过根治性手术、放疗或系统治疗的596名FIGO 2014分期III-IVA期宫颈癌患者，评价了使用顺铂作为单一药物化疗及EBRT联合帕博利珠单抗治疗的疗效，主要终点为无进展生存期（PFS）和总生存期（OS），次要终点包括完全缓解率、客观缓解率和安全性。局部消融治疗±个体化EBRT 个体化EBRT±同步含铂化疗 !",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "[](images/d3ac78ff3fe0dfea4a45294ca36aa41bf2bcbf4b3fa5d31c569f3d20e0308d5a.jpg) # 传递最有价值的医学信息 # 手术分期 # 手术结果 # 辅助治疗 ![](images/3856e4eb6da89f293a37bd8766f836608026615681475fa964ce8dc5a1895278.jpg) # 影像学分期 # 辅助治疗 !",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "[](images/3d15cce9a18760729517b22be67ab8e5e9618dd5c03fe3da1c1f0a3b05397bd0.jpg) 影像结果 # 指南重点内容 ![](images/01c552e99f1ec62ab0b60f28de47d11a8908d3d51ce8715216249453ba3785e7.jpg) # 病理学原则— 鳞状细胞癌、腺癌或腺鳞癌 <html><body><table><tr><td>手术</td><td colspan=\"2\">根治性子宫切除术</td></tr><tr><td rowspan=\"7\">病理解析</td><td rowspan=\"10\"></td><td>子宫切除术类型 (适时)</td></tr><tr><td>肿瘤部位</td></tr><tr><td>肿瘤大小，包括最大径和其他两个径向</td></tr><tr><td>组织学类型</td></tr><tr><td>组织学分级</td></tr><tr><td>间质浸润 (浸润深度[单位：mm]/宫颈壁厚度[单位：mm])</td></tr><tr><td>肿瘤扩散宽度(单位：mm) 手术切缘状态</td></tr><tr><td>如果切缘阴性，包括最近的切缘和距最近切缘的距离 (单位：mm) √如果切缘阳性，包括阳性切缘的位置</td></tr><tr><td colspan=\"2\">LVSI (不影响 FIGO 2018分期) 其他组织／器官受累(宫旁、阴道断端、输卵管、卵巢、腹膜、大网膜、其他)</td></tr></table></body></html> # 病理学原则 鳞状细胞癌、腺癌或腺鳞癌 （续） <html><body><table><tr><td rowspan=\"7\"></td><td rowspan=\"4\">淋巴结 (已切除标本)</td><td>应对前哨淋巴结（SLN）进行超分期以检测是否有微小转移</td></tr><tr><td>非-SLNs不需要超分期，可按照常规程序进行处理</td></tr><tr><td>包括肿瘤细胞分离、微转移和宏转移的淋巴结数目</td></tr><tr><td>分离的肿瘤细胞分期记为pNO(i+)</td></tr><tr><td>对于复发、进展或转移性疾病患者</td><td>推荐行 PD-L1检测</td></tr><tr><td>病理解析 对于复发、进展或转移性宫颈癌患者</td><td>建议进行错配修复（MMR）/微卫星不稳定性（MSI）检测；对于宫颈肉瘤患者，建议进 行 NTRK基因融合检测。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "</td></tr><tr><td>建议对所有宫颈腺癌患者</td><td>进行人乳头瘤病毒（HPV）状态检测。首选HPV原位杂交（ISH）或分子测试，但如果 HPV检测不可用，可进行p16免疫标记。</td></tr><tr><td>对于晚期、转移性或复发性宫颈癌</td><td>建议进行HER2免疫组织化学（IHC）检测（对于IHC结果不明确的，建议进行HER2变光 原位杂交[FISH]作为补充）。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "</td></tr><tr><td>对于局部晚期或转移性宫颈癌患者 考虑采用FDA批</td><td>建议进行RET基因融合测试</td></tr><tr><td colspan=\"2\">分子谱分析</td></tr></table></body></html> # 一般原则 # 鳞状细胞癌 # 宫颈内膜腺癌 # 腺鳞癌 # 宫颈神经内分泌癌 宫颈鳞状细胞癌 （SCC） 是一种鳞状上皮肿瘤， 具有间质浸润和/或外生性浸润。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "约占全球宫颈癌的80% -90%。大多数宫颈鳞状细胞癌（ $\\Xi ^ { ( 9 ) } { } ^ { ( 9 ) }$ 与人乳头瘤病毒 （HPV） 相关，其中高危型HPV 16和18是最常见的类型。非HPV相关的宫颈鳞状细胞癌是近来才发现的疾病类型，据报道5%-7%的宫颈鳞状细胞癌HPV呈阴性。通常在生命后期 （第七个十年）才被发现，且处于晚期阶段。• 宫颈内膜腺癌是一种形成腺体的肿瘤，通常起源于移行带，表现出间质浸润和/或膨胀型浸润。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "• 推荐确定HPV状态，因为与HPV相关的宫颈内膜腺癌相比HPV无关的腺癌具有更好的临床预后。• 宫颈腺癌可能与HPV相关（最常见的高危HPV类型18、16和45），也可能与HPV无关。• 宫颈内膜腺癌极其可能表现为溃疡、外生性肿块，或当存在内生性生长时呈桶状宫颈。具有鳞状和腺状分化的上皮肿瘤 。约占所有宫颈癌的5%-6%临床预后与宫颈腺癌相似• 尽管罕见，仅占不到宫颈癌的$5 \\%$ ，但在女性生殖道中，宫颈是高级别神经内分泌癌（如小细胞和大细胞神经内分泌癌）最常见的发生部位。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "• 在临床上常具有高侵袭性、转移快及预后不良的特点。• 多与 HPV-相关，其中16型和18型最为常见（18 型比16更常见）。• 该肿瘤形态上与肺部的神经内分泌癌相似 # 指南重点内容 ![](images/34077111d637350b48ceeaaddc68f031374cb1901ed0d47ed450d3cac2311933.jpg) # 初始检查 # I期 不保留生育功能 考虑行盆腔MRI含造影剂扫描以评估局部病灶范围 （首推推荐用于FIGO IB1-IB3期患者）。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "• FIGO IB1-IB3期患者，行颈/胸/腹/盆腔/腹股沟FDG-PET/CT（首选）或胸/腹/盆腔CT 或 FDG-PET/MRI。全子宫切除术后意外发现的宫颈癌，考虑行颈/胸/腹/盆腔/腹股沟PET/CT或胸/腹/盆腔CT以评估转移情况，行盆腔MRI以评估盆腔残留病 其他影像学检查应根据症状和临床对疾病转移的关注而进行。保留生育能力 • 进行骨盆MRI（首选）以评估局部病变程度及肿瘤与宫颈内口的距离；若有MRI禁忌，则行经阴道盆腔超声检查。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "处于FIGO IB1-IB3期的患者，进行颈/胸//腹/盆腔/腹股沟FDG-PET/CT（首选）或胸/腹/盆腔CT。考虑行胸部CT（有无造影剂均可） 其他影像学检查应根据症状和临床对疾病转移的关注而进行。# II-IVA期 行含造影剂的盆腔 MRI 以评估局部病灶范围 （首选）。• 行颈/胸/腹/盆腔/腹股沟FDG-PET/CT（首选）或胸/腹/盆腔CT以评估疾病转移情况。其他影像学检查应根据据症状和临床对疾病转移的关注而进行。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "全子宫切除术后意外发现的宫颈癌，考虑行颈/胸/腹/盆腔/腹股沟PET/CT或胸/腹/盆腔CT以评估转移情况，行盆腔MRI以评估盆腔残留病灶。如果首次治疗后的FDG-PET/CT结果不明确，考虑3个月后重复检查。# 随访/监测 # I期 不保留生育能力 • 影像学检查应基于症状和临床对疾病复发/转移的关注而进行。• 对于FIGO分期为IB3或因高危因素而需要术后辅助放疗或放化疗的患者，可在治疗结束后3\\~6个月内进行颈/胸/腹/盆腔/腹股沟的FDG-PET/CT检查。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "保留生育能力 • 考虑在术后6个月进行盆腔增强MRI检查，然后在接下来的2-3年中每年进行一次。• 其他影像学检查应根据症状和临床对复发/转移性疾病的关注而进行。# II-IV期 • 在治疗结束后 $3 \\sim 6$ 个月内，行颈/胸/腹/盆腔/腹股沟的FDG-PET/CT（首选）或胸/腹/盆腔增强CT检查。• 在完成治疗后的 $3 \\sim 6$ 个月后，考虑行盆腔增强 MRI检查。• 其他影像学检查应根据症状和临床对复发/转移性疾病的关注而进行。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "# IVB期或复发 • 酌情行影像学检查（CT、MRI或FDG-PET/CT）以评估疗效或决定下一步治疗。• 如果首次治疗后的FDG-PET/CT结果不确定，那么考虑在3个月后再次进行检查 # 怀疑复发或转移 颈/胸/腹/盆腔/腹股沟 FDG-PET/CT。考虑行盆腔MRI。# 影像学原则 ——小细胞NECC # 附加影像学 颈/胸/腹/盆腔/腹股沟PET/CT $^ +$ 脑MRI（首选） 胸/腹/盆腔 CT $^ +$ 脑MRI # 治疗效果评估 如果初级治疗是放化疗，行颈/胸/腹/盆腔/腹股沟PET/CT±脑MRI（首选）或胸/腹/盆腔CT±脑MRI 如果采用新辅助化疗，考虑在放化疗和近距离放疗前再次评估以排除转移性疾病 颈/胸/腹/盆腔/腹股沟PET/CT $^ +$ 脑MRI（首选） 胸/腹/盆腔 CT $^ +$ 脑MRI # 监测 # 指南重点内容 !",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "[](images/28adc8b98d356b31a24d7b9e593f3bb9eccaaa490df484aefb6145d13137fea2.jpg) # 评估与手术分期原则 # 宫颈癌前哨淋巴结显影 在全球广泛用于妇科肿瘤医治实践中，SLN显影作为特定I期宫颈癌手术治疗的一部分。尽管这项技术已被用于最大直径达4cm的肿瘤，但在小于2cm的肿瘤中，检测率和显影结果最佳。此技术操作简单，直接在宫颈注射染料或放射性胶体锝-99（99Tc），通常在2或4个点注射，如图1（下方）所示。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "在手术时，通过直接观察有色染料来识别SLN；如果使用了吲哚菁绿（ICG）染料，则采用荧光摄像显影；如果使用了99Tc，则使用Y探针探测。宫颈注射后的SLN通常位于外髂血管内侧，髂血管腹侧，或闭孔空间的上部（图2）。SLN通常经过病理医师的超分期处理，这有助于检测更多的微转移，这些微转移可能会改变术后管理。![](images/46f8c0afe9a6ee5a4eab2f2095f9d14be8d1c1c4bbed78da10ff3916fa81bd94.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "jpg) 图1.前哨淋巴结宫颈注射部位的选择 ![](images/d780a821603eb5d8f20f43e2e0f7ac7da1b08a49ae5f898bb0902d8bd740b7fa.jpg) 图2.宫颈注射显影剂后，前哨淋巴结（蓝色，箭头所指）通常在髂外血管内侧，髂内血管的自公测或闭孔窝的表面显影 # 采用SLN显影时，评估与手术分期原则 • SLN显影成功显影的关键在于遵守前哨淋巴结的检测流程，当一侧淋巴结显影失败时，切除该侧的淋巴结，以及切除任何可疑或增大的淋巴结，无论其是否显影。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "H&E：苏木精-伊红染色法 LND：淋巴结切除术 SLN：前哨淋巴结 ![](images/8e94b645d588a62f2bf83244e9029a5a443c3f7787cb1d14844bf9406e7df379.jpg) 宫颈癌切缘切除术作为初始治疗 <html><body><table><tr><td rowspan=\"2\"></td><td colspan=\"3\">子宫切除术类型比较（不保留子宫）</td><td colspan=\"2\">子宫切除术类型比较（保留子宫）</td></tr><tr><td>筋膜外子宫切除术 (A型)</td><td>筋膜外子宫切除术 (A型)</td><td>根治性子宫切除术 （C1型）</td><td>单纯宫颈切除</td><td>根治性颈切除</td></tr><tr><td>适应证</td><td>IA1期</td><td>IA1期伴LVSI和IA2</td><td>IB1-IIB期 部分IB3-IIIA1期</td><td>原位癌和IA1期</td><td>IA2-IB1期 部分IB2期</td></tr><tr><td>目的</td><td>微浸润根治</td><td>小病灶根治</td><td>大病灶根治</td><td>微浸润根治 保留生育功能</td><td>部分 IA2-IB2 期根治 保留生育功能</td></tr><tr><td>子宫</td><td>切除</td><td>切除</td><td>切除</td><td>保留</td><td>保留</td></tr><tr><td>卵巢</td><td>选择性切除</td><td>选择性切除</td><td>选择性切除</td><td>保留</td><td>保留</td></tr><tr><td>宫颈</td><td>完全切除</td><td>完全切除</td><td>选择性切除</td><td>大部分切除（距离宫颈 头侧方约5mm，通常留 作环扎)</td><td>大部分切除（距离宫颈 头侧方约5mm，通常留 作环扎）</td></tr><tr><td>阴道切缘</td><td>极小切缘</td><td>1-2cm切缘</td><td>阴道上1/4-1/3</td><td>极小切缘</td><td>1-2cm切缘</td></tr></table></body></html> 宫颈癌切缘切除术作为初始治疗 （续） 传递最有价值的医学信息 <html><body><table><tr><td rowspan=\"2\"></td><td colspan=\"3\">子宫切除术类型比较（不保留子宫）</td><td colspan=\"2\">子宫切除术类型比较（保留子宫）</td></tr><tr><td>筋膜外子宫切除术 (A型)</td><td>筋膜外子宫切除术 (A型)</td><td>根治性子宫切除术 （C1型）</td><td>单纯宫颈切除</td><td>根治性颈切除</td></tr><tr><td>游离输尿管</td><td>未涉及</td><td>将输卵管从宫颈分离</td><td>将输卵管从宫颈和宫旁侧方 分离</td><td>未涉及</td><td>将输卵管从宫颈分离</td></tr><tr><td>切除宫颈旁/宫 旁组织</td><td>不切除</td><td>在输卵管床水平切除（水 平切除1-2cm)</td><td>在骼内血管内侧方分离，深 切缘是子宫静脉</td><td>在宫颈边缘处切除</td><td>在输卵管床水平切除 (水平切除1-2cm)</td></tr><tr><td>直肠-子宫（宫 骶韧带)</td><td>宫颈边缘处分离</td><td>宫颈背侧1-2cm（保留腹 下神经丛)</td><td>C1型保留神经，在宫颈背 侧至少2cm处分离</td><td>宫颈边缘处分离</td><td>宫颈背侧1-2cm（保留 腹下神经丛)</td></tr><tr><td>膀胱</td><td>分离至宫颈外口</td><td>分离至阴道上部</td><td>分离至阴道中部</td><td>分离至腹膜反折</td><td>分离至阴道上部</td></tr><tr><td>直肠</td><td>未涉及</td><td>分离至宫颈下方</td><td>分离至阴道中部下</td><td>分离至腹膜反折</td><td>分离至宫颈下方</td></tr><tr><td>手术途径</td><td>经阴道或开腹或微创</td><td>开腹</td><td>开腹</td><td>经阴道或开腹或微创</td><td>经阴道或开腹或微创 (微创手术是2B类推荐)</td></tr></table></body></html> 无远端转移的局部复发性宫颈癌切除 传递最有价值的医学信息 <html><body><table><tr><td rowspan=\"2\"></td><td colspan=\"3\">肛提肌下廓清术类型比较</td><td colspan=\"2\">肛提肌上廓清术类型比较</td></tr><tr><td>前盆腔</td><td>后盆腔</td><td>全盆腔</td><td>后盆腔</td><td>全盆腔</td></tr><tr><td>适应症</td><td colspan=\"5\">盆腔中心复发，适用于经筛选的FIGOIVA期患者的初级治疗（当初放疗不可行时)</td></tr><tr><td>目的</td><td colspan=\"5\">根治</td></tr><tr><td>子宫、输卵管、卵巢</td><td colspan=\"5\">如果仍然存在则切除</td></tr><tr><td>阴道</td><td></td><td></td><td>切除</td><td></td><td></td></tr><tr><td>膀胱和尿道</td><td>切除</td><td>保留</td><td>切除</td><td>保留</td><td>切除</td></tr><tr><td>直肠</td><td>保留</td><td>切除</td><td>切除</td><td>切除</td><td>切除</td></tr><tr><td>肛门括约肌</td><td>保留</td><td>切除</td><td>切除</td><td>保留，如果可以，则与结肠吻合</td><td></td></tr><tr><td>泌尿系统重建方案</td><td>回肠代膀胱术或可控 性 流道术</td><td>N/A</td><td>双管湿性结肠造口术， 回肠代膀胱术或可控性 尿流改道术</td><td>N/A</td><td>双管湿性结肠造口术, 回肠代膀胱术或可控性 尿流改道术</td></tr><tr><td>胃肠道系统重建方案</td><td>N/A</td><td>末端结肠造口术</td><td>双管湿性结肠造口术或 末端 结肠造口术</td><td>末端结肠造口术或吻合 术联合临时回肠造口术</td><td>双管湿性结肠造口术， 末端结肠造口术或吻合 术联合临时回肠造口术</td></tr><tr><td>阴道重建方案</td><td colspan=\"5\">肌皮瓣（腹直肌、股薄肌等），或带大网膜瓣中厚皮片移植</td></tr></table></body></html> # 指南重点内容 !",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "[](images/c2110794e35302fb3e0ec7357eed0771b896fa15bdea9f7324413fa32e84023e.jpg) # 放射治疗原则 # 一般原则 • 基于CT的治疗计划和适形技术是外照射放疗（EBRT）的标准治疗方法。MRI是确定晚期肿瘤患者软组织和宫旁组织受累的最佳成像方式。对于未进行手术分期的患者，FDG-PET成像有助于确定淋巴结覆盖范围，并可能在术后用于确认异常淋巴结的切除。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "• 放疗针对已知或疑似肿瘤浸润的部位。EBRT针对骨盆区域，可包括或不包括主动脉旁区域。• 为减少骨盆区域（无论是否包括主动脉旁区域）根治性治疗中的毒性，首选采用IMRT技术。在治疗过程中常规使用图像引导放射治疗（IGRT），包括正交成像和/或常规体积成像（如锥形束CT），以确保靶区得到适当覆盖，同时保护正常组织。• 对于所有接受原发性宫颈癌根治性放疗的患者，腔内放疗和/或间质放疗是根治性放疗的关键组成部分。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "• 对于大多数接受宫颈癌EBRT的患者，在放疗期间给予含铂类的同时化疗。在8周内完成治疗可获得最佳结果。# 放射治疗原则 # 般治疗信息 靶区 在适形放疗中，特别是强度调控放疗（IMRT）中，定义了关于肿瘤靶区（GTV）、临床靶区（CTV）、计划靶区（PTV）、风险器官（OARs）、内部器官运动和剂量体积直方图（DVH）的概念。EBRT的照射范围应覆盖肿瘤原发灶（如果存在）、宫旁组织、子宫骶骨韧带、从肿瘤原发灶延伸至阴道的足够边界（至少3厘米）、骶前淋巴结和其他,有风险的淋巴结区域。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "对于手术或放射影像学显示淋巴结阴性的患者，放疗范围应包括整个外骼、内骼、闭孔和骶前淋巴结区域。对于被认为淋巴结受,累风险较高的患者（例如，体积较大的肿瘤；疑似或确诊的局限于下真骨盆的淋巴结），应扩大放疗范围以覆盖骼总淋巴结。对于已证实有骼总和/或,主动脉旁淋巴结受累的患者，建议进行扩展野的盆腔和主动脉旁放疗，直至肾血管水平（或根据受累淋巴结的分布情况，甚至更高）。对于阴道下1/3,受累的患者，还应覆盖双侧腹股沟区。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "# 剂量处方方案-外照射 为覆盖显微镜下淋巴结病变，需要大约40-45Gy的EBRT剂量（在每天1.8-2.0Gy的常规分割中，如果使用IMRT则可能包括SIB），并且可以考虑对有限,体积的未切除的粗大淋巴结进行高度适形的额外10-20Gy的加强照射，同时考虑近距离放射治疗的剂量。对于大多数接受宫颈癌EBRT治疗的患者，在,EBRT治疗期间会同时给予含铂的化疗。# 放射治疗原则 # 一般治疗信息-续 对于完整子宫的根治性RT • 对于宫颈完好的患者（即未接受手术的患者），通常给予其原发肿瘤及有转移风险的区域淋巴结根治性外照射放疗（EBRT），剂量大约45Gy（40,50Gy）。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "EBRT的靶区范围取决于通过手术或影像学确定的淋巴结状态（如前文所述）。• 然后，使用近距离疗法对原发宫颈肿瘤进行推量照射，使用图像，引导（首选）推量30\\~40Gy或至A点（在低剂量率[LDR]等效剂量中），使宫颈小肿瘤的A点总剂量达到80Gy，或者大肿瘤的A点总剂量285Gy（根据,指南中的建议）。• 对于非常小的肿瘤（医学上不可切除的IA1或IA2期）等效剂量（EQD2）D90的剂量可考虑为75-80Gy。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "• 对不可切除的淋巴结进行评,估，可以通过高度适形的（或者减少照射区域的）EBRT给予额外推量10-15Gy。# 子宫切除术后的辅助放疗 在原发性子宫切除术后，存在一个或多个病理风险因素时需行辅助放疗。放射野至少需要包括如下范围：阴道断端上3-4cm、宫旁组织、以及紧邻的淋,巴结引流区（如内、外淋巴结区、闭孔和骶前）。对于已确定的淋巴结转移，放射野的上界还需要相应延伸（如前所述）。通常建议标准分割的IMRT,剂量为45-50Gy。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "对于未切除的大转移淋巴结，采用高度适形的外照射技术（并且缩野）推量10-20Gy。对于阴道切缘阳性或接近阳性的情况，可以考虑使用阴道断端近距离放疗。# 放射治疗原则 # 一般治疗信息-续 治疗信息-近距离放疗 • 近距离放疗是所有不适合手术的初治宫颈癌根治性放疗的关键部分。对于更加晚期的患者或者肿瘤退缩不理想的患,者，组织间插植可以提高靶区剂量并且最大限度减小正常组织受量。近距离放疗前或放疗中行MRI检查有助于勾画残留肿瘤形状。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "如果联合EBRT，近距离放疗通常安排在EBRT后，因为原发肿瘤退缩理想可以更好地放置近距离放疗施源器。对于经过仔细筛选的非常早期的患者（例如IA2期），单纯近距离放,疗（不联合EBRT）也是一种选择。对于少数由于解剖学或肿瘤形状不能实施腔内近距离放疗的患者，最好采用组织间插植的方式进行治疗；但是，组织间插植近距离放疗只能在有条件,的医疗机构由有经验的专家来施行，否则，应尽早转诊、及时接受这种专业治疗，这至关重要。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "对于部分经过筛选的子宫切除术后患者（尤其是阴道黏膜切缘阳性或切缘靠近病灶者），EBRT后可使用阴道柱状施源器进行推量近距离放射治疗。通,常在阴道粘膜表面或阴道粘膜表面下5mm位置施用处方。典型的分割方案是5.5Gyx2次（阴道粘膜下5mm）或者 $6 \\mathsf { G y } \\times 3$ 次（阴道表面）。SBRT不适合作为近距离放疗的常规替代治疗。• 在为完整的宫颈癌放置近距离放疗施药器时，请考虑使用术中成像技术。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "# 放射治疗原则— 宫颈癌的正常组织剂量限制指南 <html><body><table><tr><td rowspan=\"2\">风险器官</td><td colspan=\"2\">剂量推荐</td></tr><tr><td>软约束</td><td>硬约束</td></tr><tr><td rowspan=\"3\">肠道</td><td>高达30%的组织接收到了40Gy的剂量</td><td>不超过70%的组织接收到了40Gy的剂量</td></tr><tr><td>V45≤ 200 cc</td><td>V45< 250 cc</td></tr><tr><td>针对淋巴结的加强剂量：V55<5cc</td><td>针对淋巴结的加强剂量：V55<15cc</td></tr><tr><td>膀胱</td><td>V45< 50%</td><td>Dmax < 115%</td></tr><tr><td>直肠</td><td>V45< 50% V30 < 60%</td><td>Dmax < 115%</td></tr><tr><td>股骨头</td><td>V30< 15%</td><td>Dmax < 115%</td></tr><tr><td rowspan=\"2\">骨髓 (可选的)</td><td>V10 < 80%</td><td>V10 < 90%</td></tr><tr><td>V20 < 66%</td><td>V20 < 75%</td></tr><tr><td>脊髓</td><td>Dmax 45 Gy</td><td></td></tr><tr><td>肾脏</td><td>Dmean < 10 Gy</td><td>Dmean <15 Gy</td></tr><tr><td>十二指肠</td><td>V55<5 cc</td><td>V55<15 cc</td></tr></table></body></html> # 放射治疗原则 宫颈癌的正常组织剂量限制指南 <html><body><table><tr><td colspan=\"2\">风险器官</td><td>剂量推荐</td></tr><tr><td>宫颈术后</td><td>软约束</td><td>硬约束</td></tr><tr><td>肠道</td><td>高达30%的组织收到了40Gy的剂量</td><td>不超过70%的组织收到了40Gy的剂量</td></tr><tr><td>膀胱</td><td>高达35%的组织收到了45Gy的剂量</td><td>不超过70%的组织收到了45Gy的剂量</td></tr><tr><td>直肠</td><td>高达80%的组织收到了40Gy的剂量</td><td>不是100%都收到了40Gy的剂量</td></tr><tr><td>股骨头</td><td>高达15%的组织收到了30Gy的剂量</td><td>最多有20%的组织收到的剂量达到或超过30Gy</td></tr><tr><td>骨髓 (可选的)</td><td>高达90%的组织收到了10Gy的剂量</td><td>90%的组织)收到的剂量不超过25Gy</td></tr><tr><td>骨髓 (可选的)</td><td>高达37%的组织收到了40Gy的剂量</td><td>不超过60%的组织收到了40Gy的剂量</td></tr><tr><td>脊髓</td><td>Dmax 45 Gy</td><td></td></tr><tr><td>肾脏</td><td>Dmean < 10 Gy</td><td>Dmean < 15 Gy</td></tr><tr><td>十二指肠</td><td>V55<5 cc</td><td>V55<15 cc</td></tr></table></body></html> 临床医生必须在正常组织毒性的风险与肿瘤控制之间取得平衡，并会提供建议的剂量限制。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "研究表明，20%至30%的病例可能无法满足所有限制条件。<html><body><table><tr><td>风险器官</td><td>剂量推荐</td></tr><tr><td>外阴</td><td>仅软约束 硬约束</td></tr><tr><td>肛直肠</td><td>Dmax < 65 Gy</td></tr><tr><td>股骨头</td><td>Dmax < 55 Gy</td></tr><tr><td>膀胱</td><td>Dmax < 65 Gy</td></tr></table></body></html> # 放射治疗原则— 宫颈癌的正常组织剂量限制指南 <html><body><table><tr><td colspan=\"4\">近距离放疗</td></tr><tr><td>器官风险</td><td>理想剂量限制(cGy)(EQD2_3)</td><td>最大剂量限制(cGy)(EQD2_3)</td><td>ICRU点(cGy)(EQD2_3)</td></tr><tr><td>直肠</td><td><6500 D2cc</td><td><7500 D2cc</td><td><6500点剂量</td></tr><tr><td>膀胱</td><td>7500-8000</td><td>D2cc<9000</td><td>D2cc<7500 点剂量</td></tr><tr><td>阴道(阴道-直肠点)</td><td><6500点剂量</td><td><7500点剂量</td><td></td></tr><tr><td>乙状结肠</td><td>< 7000 D2cc</td><td>< 7500 D2cc</td><td></td></tr><tr><td>肠道</td><td><7000 D2cc</td><td><7500 D2cc</td><td></td></tr></table></body></html> # 术后辅助治疗：Sedlis标准 对于淋巴结、 切缘、 宫旁组织均阴性的病例，在根治性子宫切除术后进行外照射盆腔放疗的Sedlis标准。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "<html><body><table><tr><td>LVSI</td><td>间质浸润</td><td>肿瘤尺寸 （临床查体）</td></tr><tr><td>+</td><td>深1/3</td><td>任何</td></tr><tr><td>+</td><td>中1/3</td><td>≥2</td></tr><tr><td>+</td><td>浅1/3</td><td>≥5</td></tr><tr><td></td><td>中或深1/3</td><td>≥4</td></tr></table></body></html> LVSI：淋巴管间隙浸润 • Sedlis 标准主要是针对鳞状细胞癌制定的。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "鳞状细胞癌和腺瘤病变的组织学特异性列线图可能提供了更现代的工具来模拟复发的风险，并基于这些风险给出辅助治疗建议。• 浸润深度是鳞状细胞癌复发的重要风险因素。肿瘤大小是宫颈腺癌的重要风险因素，而且在有LVSI的情况下，这种风险变得更加明显。# 指南重点内容 ![](images/80fe5f42829a125166c2be688d937ad1c4fe13ae388e0859b58f940f603dc390.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "jpg) # 宫颈癌的全身治疗 鳞状细胞癌、腺癌或鳞腺癌 # 首选方案 顺铂 # 吉西他滨紫杉醇 <html><body><table><tr><td colspan=\"5\"></td></tr><tr><td colspan=\"5\">复发或转移性疾病</td></tr><tr><td>放化疗</td><td>一线治疗 首选方案 首选方案</td><td colspan=\"3\">二线治疗</td></tr><tr><td>(如果不能耐受顺铂) 方案（如果顺铂和卡铂不可用） 他滨/丝裂霉素 他滨 醇</td><td>PD-L1-阳性肿瘤 ■帕博利珠单抗+顺铂/紫杉醇+贝伐 珠单抗 (1类) ■帕博利珠单抗+卡铂/紫杉醇+贝伐 珠单抗 (1类) 顺铂/紫杉醇/贝伐珠单抗 卡铂/紫杉醇/贝伐珠单抗 其他推荐方案 顺铂/紫杉醇 (1类) 卡铂/紫杉醇 (对于之前接受过顺铂 治疗的患者为1类推荐) 托泊替康/紫杉醇/贝伐珠单抗 (1类) 托泊替康/紫杉醇 顺铂/托泊替康 顺铂 卡铂</td><td colspan=\"3\">帕博利珠单抗适用于TMB-H肿瘤或PD-L1-阳性或MSI-H/dMMR肿瘤 维替索妥单抗 西米普利单抗 其他推荐方案 贝伐珠单抗 氟尿嘧啶 托泊替康 紫杉醇 吉西他滨 长春瑞滨 白蛋白结合型紫杉醇 · 培美曲塞二钠 伊立替康 多西他赛 某些情况下有用 PD-L1-阳性肿瘤 RET 基因融合-阳性肿瘤 ■纳武利尤单抗 ■塞普替尼 HER2-阳性肿瘤 ·NTRK基因融合-阳性肿瘤 德曲妥珠单抗 ■拉罗替尼、恩曲替你</td></tr></table></body></html> # 宫颈癌的全身治疗——宫颈小细胞NECC <html><body><table><tr><td rowspan=\"2\">放化疗</td><td colspan=\"2\">复发或转移性疾病</td></tr><tr><td>一线治疗</td><td>二线或后续治疗</td></tr><tr><td>首选方案 顺铂+依托泊苷</td><td>首选方案 ·顺铂/依托泊苷 ·卡铂/依托泊苷</td><td>其他推荐方案 · 贝伐珠单抗</td></tr><tr><td>其他推荐方案</td><td>·其他推荐方案 顺铂/依托泊苷+阿替利珠单抗（或度伐</td><td>白蛋白结合型紫杉醇 多西他赛 · 托泊替康 · 托泊替康/紫杉醇</td></tr><tr><td>卡铂+依托泊苷 (如果不耐受顺铂)</td><td>利尤单抗) ·卡铂/依托泊苷+阿替利珠单抗（或度伐 利尤单抗) 托泊替康/紫杉醇/贝伐珠单抗 ）顺铂/紫杉醇 卡铂/紫杉醇(对于之前接受过顺铂治疗 的患者)</td><td>顺铂/托泊替康 ·顺铂 卡铂 紫杉醇 伊立替康</td></tr></table></body></html> # 妇科肿瘤患者的生存原则 # 躯体影响 妇科肿瘤的治疗通常包括手术、化疗、激素治疗、放疗和/或免疫治疗。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "这些治疗会引起急性、短期和长期毒性。• 外科手术范围大、风险高，例如：形成粘连（可引起疼痛和小肠梗阻）、尿路或胃肠道并发症（如尿失禁、腹泻）、盆底功能障碍（表现为排尿、排便和/或性功能问题）以及淋巴水肿。• 化疗药物多种多样，常用的方案可能增加神经毒性、心脏毒性、继发血液系统恶性肿瘤以及认知功能障碍等疾病风险。• 长期雌激素剥夺可能会引起潮热、阴道干燥和骨质流失等症状。• 放疗可能会引起长期并发症（例如纤维化、外阴萎缩），还可能导致诱发临近放射野的皮下组织和/或下层器官的继发肿瘤。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "• 既往盆腔放疗可能导致骨质流失并增加骨盆骨折的风险。考虑进行骨密度检查和预防性使用双膦酸盐，尤其对于骨质疏松患者。• 免疫治疗是新兴的治疗方法，迄今为止，免疫疗法的长期作用尚不可知。# 社会心理影响 • 患癌后患者的社会心理影响表现为：心理层面的（例如，抑郁、焦虑、对复发及身体形象改变的恐惧）；经济层面（例如，重返工作、保险问题）和/或人际层面（例如，人际交往、性生活、亲密感）。# 妇科肿瘤患者的生存原则 # 临床方法 肿瘤的生存者应常规接受全科医疗护理，重点管理慢性疾病、监测心血管疾病危险因素、建议接种疫苗并鼓励养成健康的生活方式。",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "科肿瘤的远期和长期影响，临床医生应全面记录患者的病史，进行全面体检，并提供任何必要的影像学和/或实验室检查。• 对于所有患者（无论患者是否有性行为），均应询问关于泌尿生殖系统症状（包括外阴阴道干燥的问题）。建议转诊至合适专业医护人士（例如，物理治疗、盆底治 疗、性疗法、心理治疗）。• 由于大多数妇科肿瘤的治疗方法都会导致性功能障碍、早期停经和不孕，因此需要特别关注由此产生的医疗和社会心理影响。对于治疗相关出现更年期症状的患者，应考虑激素替代治疗。• 参与肿瘤生存者治疗的所有临床医生（包括初级保健临床医生）的沟通和合作是至关重要的。建议向肿瘤生存者提供其治疗的总结，并提供随访建议。# 谢谢关注！thanks for your attention.",
    "source": "NCCN肿瘤学临床实践指南：宫颈癌2024.V3",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/NCCN肿瘤学临床实践指南：宫颈癌2024.V3/NCCN肿瘤学临床实践指南：宫颈癌2024.V3.md"
  },
  {
    "text": "![](images/d528742cb59584f3c41ff9d951ee102c6394f72c8865047bf7177f28bec9bdff.jpg) In May 2018, the World Health Organization (WHO) called for a global initiative to eliminate cervical cancer as a public health problem.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "To achieve this goal, global scale-up of effective vaccination against the human papillomavirus (HPV) as well as screening for and treatment of cervical cancer are required.Cervical cancer screening was evaluated in 2005 by the International Agency for Research on Cancer (IARC) Handbooks program,1 and a reevaluation was deemed to be timely given the major advances in the field since then.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The new handbook provides updated evaluations of the effectiveness of screening methods, which were used as a basis for the update of the WHO Guideline for Screening and Treatment of Cervical Pre-cancer Lesions for Cervical Cancer Prevention.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "2 We convened an IARC Working Group of 27 scientists from 20 countries to assess the evidence on the current approaches to and technologies used in cervical cancer screening with the use of the newly updated Handbooks Preamble3 (Fig.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "1) and Table 1).Cervical cancer is the second most common cancer and the second most common cause of death from cancer in women of reproductive age worldwide.4 The highest incidence and mortality rates are generally observed in countries with the lowest values on the Human Development Index5; these rates also correlate with a high prevalence of infection with the human immunodeficiency virus (HIV).",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "6 The natural history of cervical cancer is well understood, and a multistep carcinogenesis model is widely accepted, with HPV infection, progression to precancer, and invasion to cancer viewed as critical steps (Fig.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "2).Cervical cancer is largely preventable through both vaccination and screening for precursor lesions, with appropriate follow-up and treatment.7 As a secondary objective, screening may lead to early detection of cancer, which may allow for earlier treatment and a reduction in the risk of death from cervical cancer.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The prevention of cervical cancer and death through screening typically relies on a multistep process that includes screening, triage of patients with positive results on screening, confirmation on biopsy, and treatment of patients with precancerous lesions.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Delivery of screening and treatment is available in many countries through programs that are population based (organized) or nonpopulation based (unorganized) or through opportunistic screening; settings with limited resources may adopt a screen-and-treat approach (testing immediately followed by treatment, without confirmation on biopsy).",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Participation rates and coverage vary widely across countries and settings.8 The main determinants of participation are socioeconomic status, ethnic group, <html><body><table><tr><td colspan=\"3\">Participants</td></tr><tr><td>Category</td><td>Description</td><td>Role</td></tr><tr><td>IARCSecretariat</td><td>Scientistswho aredesignatedby IARCorWHOandwho haverelevantexpertise</td><td>Providescientificguidanceandsupportwithadministration documentation,and publication Coordinatellaspectsfreparatonevelopmentand publicationof Handbook</td></tr><tr><td>WorkingGroupmembers</td><td>Independentinternationalinterdisciplinaryscientistsselected onpublicationrecordsandwithoutconflictofinterest</td><td>Writestudysummaries,reviewbodyofevidence,and develop evaluations</td></tr><tr><td>InvitedSpecialists</td><td>Scientistswithexpertknowledgebutconflictinginterest; providetechnicalexpertiseonspecificaspectsof topic</td><td>Writetextnotpertainingtoevaluations;donotparticipate in evaluations</td></tr><tr><td>Representatives</td><td>Scientistsofnationalandinternationalhealthagencies</td><td>Donot draftext orparticipateinevaluations</td></tr><tr><td>Observers</td><td>Scientistswithcompetinginterest</td><td>Donot draftext orparticipateinevaluations</td></tr></table></body></html> !",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "[](images/ec92c9be0c416829dc9e60c26ae35dfa1f0afa5e636501a077d60995d14e29db.jpg) The New England Journal of Medicine is produced by NEJM Group, a division of the Massachusetts Medical Society.Downloaded from nejm.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "org on April 28, 2025.For personal use only.No other uses without permission.Copyright $\\circledcirc$ 2021 Massachusetts Medical Society.All rights reserved.<html><body><table><tr><td colspan=\"3\">Table1.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "EvaluationCriteriafortheIARCHandbooks.</td></tr><tr><td>Group</td><td>Method The cancer screening method</td><td>Comment A causal preventive association between the use of screening method and cancer incidence or</td></tr><tr><td>A</td><td>is established to reduce the incidence of cancer of the target organ or to reduce mor- talityfromcancer of thetarget organ.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "</td><td>mortality is established — that is, a preventive association has been observed consistently in the body ofevidence onuse ofthe screening method or methods and cancerincidence ormortality, and chance, bias, and confounding have been ruled out with reasonable confidence as explana- tions for the association.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "When the evidence is classified in Group A, the evaluation is followed by separate statements as to the screening regimen to which each evaluation of a screening method applies or applies most strongly; as to whether the effectiveness of that screening method has been established; as to the magnitudes ofthe benefits and the harms ofthe screening method, in as nearly comparable terms as possible, for people adhering fully to the screening approach most commonly implemented in practice; and as to whether the benefits outweigh the harms.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "</td></tr><tr><td>B</td><td>The cancer screening method may reduce the incidence of cancer of the target organ or mayreducemortalityfrom cancer of the target organ.</td><td>A causal preventive association between use ofthe screening method and cancer incidence or mortality is credible,but chance, bias, or confounding could not be ruled out with reasonable confidence as explanations for the association, or a causal preventive association between use of the screening method and the incidence of precancer or clinically advanced cancer has been es- tablished in the absence of an established association for cancer incidence or mortality, respec- tively.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "When the evidence is classified in Group B, a sentence is included that states the screen- ing regimen to which each evaluation of a screening method applies or applies most strongly.</td></tr><tr><td>C</td><td>The cancer screening method is not classifiable as to its ca- pacity toreduce the incidence of cancer of the target organ or of the target organ.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "</td><td>Either the available studies are of insuffcient quality, consistency, or statistical precision to en- able a conclusion to be drawn about the presence or absence of a causal preventive association between the screening method or methods and cancer incidence or mortality, or there is some evidence that the screening method or methods have a preventive effect, based on precancer or toreducemortalityfrcancer clnicallyadvancedcancerasoutcoes,but ntenughevidencetoqualiffortheGrouplas sification.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The first of the above conditions indicates that relevant studies are available but all are of poor quality or uninformative or that there are relevant studies available of sufficient quality, but their results are inconsistent or otherwise inconclusive.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "</td></tr></table></body></html> \\* \u0007IARC denotes International Agency for Research on Cancer.health insurance status, and education level; access to services may also be a problem for some women owing to a lack of power, authority, or control,9,10 which in some settings represent major barriers to participation.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Although we remain cognizant that successful reduction in the incidence of cancer can occur only with appropriate follow-up and treatment of screen-positive women, the aim of this evidence review is to evaluate primary screening tests for their effectiveness in reducing the incidence of cervical cancer and the risk of death associated with cervical cancer.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Postscreening components of care (i.e., management, including colposcopy, and treatment) and issues related to implementation have not been assessed; these topics are considered in the updated WHO Guideline for Screening and Treatment of Cervical Precancer Lesions for Cervical Cancer Prevention.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "2 Here, we briefly summarize the scientific evidence reviewed by the Working Group and discuss the rationale and considerations that underlie the evaluations (Table 2) and the comparative statements (see Table 3).",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The full report will be published as part of the IARC series of handbooks on cancer prevention.11 # Effec tiveness of Screening The Working Group reviewed and evaluated the evidence relative to the efficacy and effectiveness of screening by conventional cytology, liquidbased cytology, visual inspection with acetic acid, nucleic acid testing, and cytology based on Romanovsky–Giemsa staining.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "A summary of the evidence is presented below.# Conventional Cytology Cervical cytologic analysis (Papanicolaou testing) was widely introduced as a screening test during the 20th century without having been assessed in randomized, controlled trials.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The previous IARC Handbook on cervical cancer screening (2005)1 identified 7 cohort studies and 20 case–control studies conducted in multiple countries and concluded that there was sufficient evidence that screening by conventional cytology had reduced the incidence of and mortality associated with cervical cancer.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Since then, a randomized, controlled trial12,13 and numerous population-based observational studies (5 cohort studies and 20 case–control studies) conducted in multiple countries and settings have compared the incidence of cervical cancer and mortality among women who were screened with those among women who were not screened.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "14 This body of evidence is supported by ecologic data on the incidence of cervical cancer and on the mortality associated with cervical cancer from population-based registries obtained after the introduction or expansion of cytologic screening.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The aggregate evidence from all sources shows that the use of conventional cytologic analysis consistently reduces the incidence of and mortality associated with cervical cancer, with greater effects observed in organized screening programs.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "On the basis of these results, the Working Group confirmed the previous evaluation and concluded that screening with cytology is established to reduce the incidence of and mortality from cervical cancer (Group A).",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The Working Group, recognizing the subjective nature of the test and the strong need for appropriate training and systems to ensure and maintain high quality, noted that this evaluation applies to conventional cytologic screening performed within a quality-assured laboratory system with appropriate follow-up and treatment.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "# Liquid-Based Cytology Eight randomized, controlled trials15-22 and numerous observational studies in a populationbased, nationwide program have compared the accuracy of liquid-based and conventional cytologic analysis.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The studies were conducted in settings that use cytologic analysis as a stand-alone, first-level test, with different strategies of referral for colposcopy.Overall, as compared with conventional cytologic analysis, liquid-based cytologic analysis had a similar or higher sensitivity for the detection of cervical intraepithelial neoplasia (CIN) of grade 2 or higher $( \\mathrm { C I N } 2 + )$ and grade 3 or higher $( \\mathrm { C I N } 3 + )$ , a similar or lower specificity and positive predictive value, and a lower proportion of unsatisfactory slides.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "In addition, one randomized, controlled trial18 and two observational studies in which the longitudinal outcomes of liquidbased cytologic analysis were assessed showed that there was a good correlation between the baseline detection rate and reduced incidence of CIN2, CIN3, and invasive cancers in subsequent screening rounds.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "On the basis of the similar performance of liquid-based cytologic analysis and conventional cytologic analysis, the Working Group extended the previous evaluation and concluded that screening with liquid-based cytology reduces the incidence of and the mortality associated with cervical cancer (Group A).",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "# Visual Inspection with Acetic Acid Three population-based, cluster-randomized intervention trials conducted in India assessed the effectiveness of visual inspection with acetic acid (VIA) as compared with no screening in reducing the incidence of or mortality associated with cervical cancer.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "13,23,24 In two of the three trials, there was a consistent and significant reduction in mortality as compared with no screening after a single round13,23 or multiple rounds24 of VIA screening.A reduction in mortality may have resulted from the detection and treatment of precancerous lesions, the downstaging of invasive cervical cancer (i.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "e., a shifting of the stage distribution of cancers detected toward a lower stage), or both.The reduction in the incidence of cervical cancer after VIA screening was observed in only one of the three randomized trials.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "23 In addition, a smaller randomized, controlled trial conducted in a “screen-and-treat” setting in South Africa showed a reduction in the detection of $\\mathrm { C I N } 2 + 6$ months after VIA screening as compared with the control (standard care).",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "25 On the basis of these results, the Working Group updated the previous evaluation and concluded that VIA is established to reduce the mortality associated with cervical cancer (Group A) and may reduce the incidence of cervical cancer (Group B).",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The Working Group, recognizing the subjective nature of the test, noted that this evaluation applies to VIA screening implemented with the use of quality assurance, performed by welltrained health care workers, and conducted with appropriate follow-up and treatment.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "# HPV Nucleic Acid Testing A single randomized, controlled trial conducted in India13 evaluated thebeneficial effects among women of nucleic acid testing for high-risk HPV genotypes as compared with no screening on the mortality associated with cervical cancer and showed that a single round of screening reduced mortality by nearly half.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "All other available studies relied on the comparison of HPV testing with cytologic analysis, VIA, or both.In a pooled analysis of four European randomized trials, HPV testing led to a greater reduction in the incidence of cervical cancer than did cytologic analysis.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "26 Furthermore, numerous cohort studies conducted in screening settings, as well as diagnostic-test accuracy studies that compared HPV testing (including HPV DNA and mRNA testing) with cytologic analysis, VIA, or both, showed that HPV testing is more effective in detecting cervical precancers and in subsequently reducing the incidence of cervical cancer as compared with other screening approaches.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "On the basis of these results, the Working Group extended a previous evaluation and concluded that HPV nucleic acid testing is established to reduce the incidence of and mortality associated with cervical cancer (Group A).",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "![](images/9a250a5b8720c229c9f4003fbb6e4a231ccbc1a2fdf841d5d816973c1beb3a28.jpg) Cytology Based on Romanowsky–Giemsa Staining Romanowsky–Giemsa staining has been used for a long time to stain many types of cytologic The age at onset of human papillomavirus (HPV) infections is roughly the average societal age of first intercourse (Panel A).",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "HPV infections are very common, and infections — even with carcinogenic types — are usually benign.A high proportion of infections disappear within a few months, with a median clearance of most screen-detected infections of about 1 year and a large fraction undetectable within 2 to 3 years.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Only a very small proportion of carcinogenic HPV infections are detectable after more than 5 years (without progression to precancer).Pro‑ gression to precancer depends on the HPV type and time of persistence; most precancers will regress with time.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Only a very small proportion of precancers will evolve into cancer, again depending on HPV type and the duration of persistent infection.The whole process from HPV acquisition to cancer diagnosis typically takes decades, although more rapid transitions have also been observed.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The measurable transitions between the normal cervix and HPV infection can be named simply appearance and disappearance of HPV detection, to acknowledge the limitations of existing measurement assays and the potential for reactivation of latent infections.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The transitions between infection and pre‑ cancer can be described as progression to and regression of precancer (Panel B).Invasion is considered a typically irreversible natural history transition when HPV-positive cells cross the basement membrane.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The currently available tests for cervical cancer screening detect lesions at different stages in the process of carcinogenesis (Panel C).HPV tests (DNA or mRNA) detect the presence of the virus immediately after infection.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The abnormal cells that are observed with conventional or liquid-based cytologic screening typically appear at a later stage after in‑ fection.Lesions that are further advanced may be detected on visual inspection with acetic acid, but the performance of this test is highly variable.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The tests used for triage of screen-positive women are more specific molecular biomarkers of carcinogenesis.<html><body><table><tr><td colspan=\"4\">Table 2.Evaluation of the Effectiveness of Cervical Cancer Screening Methods.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "*</td></tr><tr><td colspan=\"2\">Screening Method Body of Evidence</td><td colspan=\"2\">Group</td></tr><tr><td colspan=\"2\"></td><td>Reduction in Mortality</td><td>Reduction in Incidence</td></tr><tr><td>Conventional cytology 7 cohort studies</td><td></td><td>A</td><td>A</td></tr><tr><td>Data from Cervix Cancer Screening (2005) 1</td><td> 20 case-control studies</td><td></td><td></td></tr><tr><td>Additional data</td><td>1 RCT 5 cohort studies 20 case-control studies Numerous ecologic studies</td><td></td><td></td></tr><tr><td>Liquid-based cytology</td><td></td><td>A</td><td>A</td></tr><tr><td>Liquid-based cytology alone Comparison of liquid-based</td><td>1 RCT 2 observational studies 8 RCTs</td><td></td><td></td></tr><tr><td colspan=\"2\">cytology with conventional Numerous observational studies cytology</td><td></td><td></td></tr><tr><td colspan=\"2\">HPV nucleic acid testing</td><td>A</td><td>A</td></tr><tr><td>HPV alone 1 RCT Comparison of HPV testing with cytology (conventional or liquid-based), with vi-</td><td>1 pooled analysis of 4 European RCTs (vs.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "cytology) 4 additional RCTs (vs.cytology) 10 cohort studies (vs.cytology) 1 pooled analysis of 7 cohort studies (cotesting vs.cytology)</td><td></td><td></td></tr><tr><td>Visual inspection with acetic acid</td><td>6 additional cohort studies (cotesting vs.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "cytology) Numerous studies of diagnostic-test accuracy 3 cluster-randomized trials (cancer incidence or mortality)</td><td>A</td><td>B</td></tr><tr><td>Cytology based on Romanowsky- Trend studies Giemsa staining</td><td> 1 RCT (precancerous lesion detection rate)</td><td>C</td><td>C</td></tr></table></body></html> \\* \u0007HPV denotes human papilloma virus, and RCT randomized, controlled trial.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "specimens.It remains in use in some states of the former Soviet Union in screening for cervical cancer because of the lower costs of a single examination and the wider availability of materials as compared with Papanicolaou staining.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "However, no comparative study on the accuracy, efficacy, or effectiveness of the technique in cervical cancer screening was available to the Working Group.Furthermore, data on the screening performance of programs adopting this method suggest low reproducibility and low specificity.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "27-29 On the basis of this information, the Working Group con The New England Journal of Medicine is produced by NEJM Group, a division of the Massachusetts Medical Society.Downloaded from nejm.org on April 28, 2025.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "For personal use only.No other uses without permission.Copyright $\\circledcirc$ 2021 Massachusetts Medical Society.All rights reserved.<html><body><table><tr><td colspan=\"2\">Table 3.Comparative Effectiveness ofthe Established Cervical Cancer Screening Methods.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "\"</td></tr><tr><td>Methods Compared</td><td>Comparison ofBenefit-to-HarmBalances</td></tr><tr><td>HPV DNA testing vs.VIA</td><td>HPV DNA testing >> VIA</td></tr><tr><td>HPVDNA testing vs.cytology</td><td>HPV DNA testing > cytology</td></tr><tr><td>HPV DNA testing vs.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "cotestingt</td><td>HPV DNA testing ≥ cotesting</td></tr></table></body></html> \\* \u0007The symbol $\\gg$ indicates that the benefits of testing clearly outweigh the harms, the symbol $>$ that the benefits outweigh the harms, and the symbol $\\geq$ that the ben‑ efits do not outweigh the harms.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "VIA denotes visual inspection with acetic acid.† \u0007Cotesting involves screening and cytologic analysis combined.cluded that screening with cytology based on Romanowsky–Giemsa staining is not classifiable as to its capacity to reduce the incidence of or the mortality from cervical cancer (Group C).",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "# Bal ance of Benefits and Harms The benefits of cervical cancer screening outlined above need to be balanced against possible harms.All the screening methods reviewed may cause pain or discomfort during examination or sample collection30; self-sampling (collection of the sample by the woman herself) for HPV testing may reduce discomfort.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "31 Screening for cervical cancer may also generate anxiety related to the screening procedure itself, the receipt of results, and any subsequent diagnostic and treatment pathways.A positive result is associated with increased levels of anxiety and distress and may arouse concerns about cancer; it may also trigger feelings of stigma and shame, particularly after a positive HPV test result.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "32 Potential physical harms associated with subsequent diagnostic procedures and treatment include risks of bleeding, infection, and adverse obstetric outcomes.33 A common measure of harm is the rate of referral to colposcopy and treatment.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Tests with higher proportions of false positive or unsatisfactory results are associated with additional potential harms, such as increased costs to patients, loss to followup, and loss of confidence in the service.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Overall, the Working Group concluded that the benefits of screening with HPV nucleic acid testing or with cytologic analysis outweigh the harms for women 30 years of age or older.There is less certainty regarding the value of either technique for women younger than 30 years of age, especially when triage testing of HPV-positive women is not in place.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "With VIA, the benefits in terms of reduction in the incidence of and mortality associated with cervical cancer, as well as the harms related to false positive test results, are highly variable and observer-dependent; therefore, whether the benefits of VIA will consistently outweigh its harms is unclear.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "34 # Comparison of Screening Methods In addition to evaluating these screening methods separately, for each comparison for which evidence was available, the Working Group assessed the comparative effectiveness.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The relative benefits and harms as well as the balance of benefits and harms were considered.HPV DNA Testing as Compared with Cytology The effectiveness of HPV DNA testing has been compared with that of cytologic analysis (conventional or liquid based) in eight randomized, controlled trials involving routine settings in which screening for cervical cancer was provided35-44 (one of the trials involved a previously unscreened population13); in 10 cohort studies that used results from regional, national, and pilot primary HPV DNA screening programs; in six cohort studies in which cotesting (HPV DNA screening and cytologic analysis combined) was compared with cytologic analysis alone; in one pooled analysis of seven other such cohorts; and in numerous studies of the accuracy of diagnostic tests.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Overall, HPV DNA testing is more sensitive than cytologic analysis for the detection of $\\mathrm { C I N } 2 +$ and is associated with reduced detection rates of $\\mathrm { C I N } 2 +$ in subsequent screening rounds and with a greater reduction in the incidence of cervical cancer than cytologic analysis when the same screening interval is used.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The risk of $\\mathrm { C I N } 3 +$ over a period of 3 to 10 years is lower after a negative HPV DNA test result than after a negative cytologic test result.Overall, the benefits of the greater reduction in the incidence of and mortality associated with cervical cancer outweigh the harms related to the increase (mainly in the first round) in positive results and colposcopy referrals and the potential increase in psychological harms observed with HPV DNA testing.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "With the infrastructure permitting, the use of adequate triage tests can greatly reduce colposcopy referral rates while ensuring a high sensitivity for the detection of precancerous lesions.45 The balance is expected to be even more favorable after several rounds of HPV DNA–based screening, since HPV DNA testing allows for longer intervals between screenings than cytologic analysis.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "# HPV DNA Testing as Compared with VIA Two randomized, controlled trials, three crosssectional studies, and a pooled analysis of two cohorts have been conducted to assess the effectiveness of HPV DNA testing as compared with that of VIA in cervical cancer screening.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "12,13,25,46-50 Overall, a greater number of high-grade cervical lesions $\\mathrm { ( C I N } 2 \\cdot$ , $\\mathrm { C I N } 3 + ;$ , or both) were detected with HPV DNA testing.In randomized trials, as compared with VIA, HPV DNA testing led to a greater reduction in detection rates of $\\mathrm { C I N } 2 +$ at both 6 months25 and 36 months46 and to a greater reduction in cervical cancer of stage II or higher and in mortality associated with cervical cancer.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "12,51 Because of the high variability of VIA, the test positivity was inconsistent across studies, and the respective harms associated with the methods could not be compared.Thus, HPV DNA testing results in greater benefits than VIA, and these benefits outweigh the potential increase in both true and false positive results.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "VIA has other substantial limitations, such as subjectivity, heterogeneity, and potential misclassification of outcomes.# HPV DNA Testing Alone as Compared with Cotesting Cotesting is defined as simultaneous HPV DNA testing and cytologic testing conducted with the use of the same sample.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The comparative effectiveness of HPV DNA testing alone and cotesting has been assessed in numerous studies, including a meta-analysis52 of three randomized, controlled trials.53-55 The studies spanned nearly 15 years and differed regarding the referral strategies used, the follow-up time established, and the outcomes examined $( \\mathrm { C I N } 2 + ,$ , $\\mathrm { C I N } 3 + ,$ and invasive cancer).",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "As compared with HPV DNA testing alone, there is a minimal increase in sensitivity and a lower specificity for the detection of $\\mathrm { C I N } 2 +$ and $\\mathrm { C I N } 3 +$ with cotesting, which has led to an increase in referrals for colposcopy and possibly treatment and a decrease in positive predictive value in referred women (increased detection of regressive lesions).",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The difference in sensitivity affects very few cases, which suggests that the effect of the cytologic component of cotesting is very limited and that the effect on cancer incidence is unclear.56 Furthermore, over a longer follow-up period, the cumulative risks of $\\mathrm { C I N } 2 +$ and $\\mathrm { C I N } 3 +$ differ minimally between women with cotest-negative results and women with HPV-negative results.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "57 The benefits of cotesting do not outweigh the harms.# Consider ations Regarding the Evaluation Several approaches to cervical cancer screening were classified in Group A.Considerations as to which technology to implement include test performance and factors such as reproducibility, barriers to implementation, scalability, and cost, among others.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "2 Cytology is effective and is still widely used.However, it is prone to subjective assessment and lacks reproducibility.Conventional cytologic analysis may result in a large proportion of unsatisfactory slides; in contrast, liquid-based cytologic analysis overcomes some of these quality issues and provides the opportunity to perform both molecular and cytologic tests with a single sample (e.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "g., both when HPV testing is used for triage of atypical or mildly abnormal cytologic analysis and when cytologic analysis is used for triage of HPV-positive women).As compared with HPV-based screening, cytologic screening requires more frequent testing and thus a greater number of tests over a lifetime to achieve the same reduction in cancer incidence.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "In addition, cytologic analysis cannot be conducted on patient-collected specimens.Thus far, owing to its low cost, low infrastructure requirements, and potential to reduce loss to follow-up in screen-and-treat approaches, VIA has been implemented in resource-constrained settings and countries with limited access to health care.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "However, the evidence that VIA reduces the incidence of cervical cancer is weak.In addition, proper training is needed to implement VIA screening, and harmonized interpretation criteria still need to be defined.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "In settings that have implemented VIA-based screening, the transition to HPV testing will accelerate the reduction in the cancer burden.HPV detection involves an objective molecular test.As mentioned, HPV testing allows for longer intervals between screenings than cytologic analysis.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "HPV DNA testing can also be performed on vaginal samples that women collect themselves, an approach that extends access to screening to underserved populations.A systematic review and meta-analysis of 56 studies of diagnostictest accuracy58 and several additional, more recent studies59-62 have shown that as compared with tests performed with the use of cervical samples collected by a clinician, tests performed with the use of vaginal samples collected by women them The New England Journal of Medicine is produced by NEJM Group, a division of the Massachusetts Medical Society.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Downloaded from nejm.org on April 28, 2025.For personal use only.No other uses without permission.Copyright $\\circledcirc$ 2021 Massachusetts Medical Society.All rights reserved.selves can achieve a similar sensitivity and specificity for the detection of $\\mathrm { C I N } 2 +$ or $\\mathrm { C I N } 3 +$ when polymerase-chain-reaction assays are used for the detection of HPV but not when signal amplification or HPV mRNA tests are used.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "HPV mRNA testing has been shown to have similar cross-sectional sensitivity and higher specificity than HPV DNA testing for the detection of $\\mathrm { C I N } 3 + ,$ , but evidence regarding longitudinal outcomes is limited.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Although a negative HPV mRNA test indicates a lower risk of $\\mathrm { C I N } 2 +$ over a period of 3 years than a negative result on cytologic analysis,63-66 it is not clear whether the beneficial effect is equivalent to that of a negative result on an HPV DNA test.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "It is important to use triage when determining which HPV-positive women need colposcopy, which need treatment, and which need both.Triage helps to maximize the benefits of cervical screening and to limit the harms, and it can have a substantial effect on the performance of a screening program.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "There are several triage strategies, each of which is associated with different performance characteristics.They include the use of genotyping for HPV16/18, cytologic analysis, p16/Ki67 dual staining, colposcopy, VIA, and combinations thereof.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "2,45 The age at which screening is started or stopped varies in programs around the world.The Working Group did not evaluate the best age at which screening should be started or stopped.The appropriate starting age may depend on the natural history of HPV infections in a population, the duration and coverage of the vaccination program, and other factors.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "The Working Group noted that the screening of older women (i.e., $\\geq 6 5$ years of age) with the use of cytologic (conventional or liquid-based) analysis or HPV testing may continue to be effective, particularly in women without a history of regular normal screens.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "67 Special consideration is required when screening women living with HIV, since they are at increased risk for HPV infection, precancerous cervical lesions, and cancer, particularly women who have a history of immunosuppression.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "6,68,69 Therefore, in settings in which there is a high prevalence of HIV (e.g., in sub-Saharan Africa), a screen-and-treat approach based on the results of an HPV test may lead to substantial overtreatment.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "On the basis of the scant evidence available on screening in this population, the WHO suggests using an HPV DNA primary screening test, with triage of HPV-positive women; triage may reduce the proportion of test-positive women for whom referral and treatment are warranted.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "70-72 Both overtreatment and undertreatment may occur when VIA is used to screen women living with HIV.Whereas there can be many false positive results, VIA may not detect precancerous lesions that are at high risk for progression.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Although several methods currently used in screening are effective in reducing the incidence of and the mortality associated with cervical cancer, HPV testing alone is the most effective given its balance of benefits and harms.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "It is noteworthy that most of the evidence used to inform these evaluations comes from high-income settings, whereas the burden of disease and death is highest in low-resource settings, where data are scant.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Even when interventions that have been established to be effective are used, successful prevention of cervical cancer requires quality-assured health systems that can provide adequate follow-up, including triage when necessary, and appropriate treatment for women with positive screens, all of which can pose major challenges in resourcelimited settings.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "73 Alongside the scaling up of HPV vaccination and cancer treatment, increasing global levels of screening and treatment will bring the elimination of cervical cancer as a public health problem within reach.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Although the authors are identified as personnel of the International Agency for Research on Cancer and the World Health Organization, the authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policies, or views of these organizations.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Supported by the United Kingdom Medical Research Council, the American Cancer Society, and the Canadian Partnership Against Cancer.Disclosure forms provided by the authors are available with the full text of this article at NEJM.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "org.From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) — both in France; the Na‑ tional Cancer Institute, Rockville, MD (N.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "W., M.Schiffman); Pub‑ lic Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J.Berkhof); VCS Foun‑ dation, Melbourne, VIC (J.Brotherton), Australia; Azienda Unità Sanitaria Locale — IRCCS Reggio Emilia, Reggio Emilia, Italy (P.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R.Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M.Saraiya) — all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council — both in Buenos Aires (S.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "A.); the Casablanca Cancer Registry, Casablan‑ ca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King’s Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare, Zimbabwe (Z.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S.de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Mon‑ treal (E.F.); Teikyo University, and the National Cancer Center — both in Tokyo (C.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S.San‑ grajrang); Research Triangle Institute International, New Delhi, India (R.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Sankaranarayanan); Chinese Academy of Medical Sci‑ ences, Beijing (F.Z.); and Sciensano, Brussels (M.A.).Dr.LaubySecretan can be reached at secretanb@iarc.fr or at the Interna‑ tional Agency for Research on Cancer, Evidence Synthesis and Classification Branch, IARC Handbooks Program, 150 Cours Al‑ bert Thomas, 69372 Lyon CEDEX 8, France.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "1.Cervix cancer screening.IARC handbooks of cancer prevention.Vol.10.Lyon, France: International Agency for Research on Cancer, 2005 (https://publications.​i­arc.​­fr/​­380).2.WHO guideline for screening and treatment of cervical precancer lesions for cervical cancer prevention.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Geneva:​ World Health Organization, 2021.3.Preamble for secondary prevention.IARC handbooks of cancer prevention.Lyon, France:​International Agency for Research on Cancer, 2019 (https://handbooks.​i­arc.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "​­fr/​­docs/​­HB​-­Preamble -­Secondary​-­Prevention.​­pdf).4.Arbyn M, Weiderpass E, Bruni L, et al.Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.Lancet Glob Health 2020;​8(2):​e191-e203.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "5.Global cancer observatory.Lyon, France:​ International Agency for Research on Cancer, 2018 (https://gco.​i­arc.​­fr/​­).6.Stelzle D, Tanaka LF, Lee KK, et al.Estimates of the global burden of cervical cancer associated with HIV.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Lancet Glob Health 2021;​9(2):​e161-e169.7.Schiffman M, Doorbar J, Wentzensen N, et al.Carcinogenic human papillomavirus infection.Nat Rev Dis Primers 2016;​2:​16086.8.Serrano B, Roura E, Guijarro P, et al.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "National cervical cancer screening programs and coverage worldwide.Presented at the 33rd International Papillomavirus Conference, virtual, July 20–24, 2020.9.Gakidou E, Nordhagen S, Obermeyer Z.Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "PLoS Med 2008;​5(6):​e132.10.Arrossi S, Thouyaret L, Herrero R, et al.Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Lancet Glob Health 2015;​3(2):​e85-e94.11.Cervical cancer screening.IARC handbooks of cancer prevention.Vol.18.Lyon, France:​International Agency for Research on Cancer (in press).12.Sankaranarayanan R, Nene BM, Dinshaw KA, et al.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India.Int J Cancer 2005;​116:​617-23.13.Sankaranarayanan $\\begin{array} { r } { \\mathbb { R } , } \\end{array}$ Nene BM, Shastri SS, et al.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "HPV screening for cervical cancer in rural India.N Engl J Med 2009; 360:​1385-94.14.Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R.Screening for cervical cancer: a systematic review and meta-analysis.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Syst Rev 2013;​2:​35.15.Obwegeser JH, Brack S.Does liquid-based technology really improve detection of cervical neoplasia?A prospective, randomized trial comparing the ThinPrep Pap Test with the conventional Pap Test, including follow-up of HSIL cases.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Acta Cytol 2001;​45:​709-14.16.Taylor S, Kuhn L, Dupree W, Denny L, De Souza M, Wright TC Jr.Direct comparison of liquid-based and conventional cytology in a South African screening trial.Int J Cancer 2006;​118:​957-62.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "17.Ronco G, Cuzick J, Pierotti P, et al.Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial.BMJ 2007;​335:​28.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "18.Strander B, Andersson-Ellström A, Milsom I, Rådberg T, Ryd W.Liquid-based cytology versus conventional Papanicolaou smear in an organized screening program: a prospective randomized study.Cancer 2007;​111:​285-91.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "19.Maccallini V, Angeloni C, Caraceni D, et al.Comparison of the conventional cervical smear and liquid-based cytology: results of a controlled, prospective study in the Abruzzo Region of Italy.Acta Cytol 2008;​52:​568-74.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "20.Sykes PH, Harker DY, Miller A, et al.A randomised comparison of SurePath liquid-based cytology and conventional smear cytology in a colposcopy clinic setting.BJOG 2008;​115:​ 1375-81.21.Siebers AG, Klinkhamer PJ, Grefte JM, et al.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial.JAMA 2009;​302:​1757-64.22.Klug SJ, Neis KJ, Harlfinger W, et al.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance.Int J Cancer 2013;​132:​2849-57.23.Sankaranarayanan $\\begin{array} { r } { \\mathbb { R } , } \\end{array}$ Esmy PO, Rajkumar R, et al.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial.Lancet 2007;​370: 398-406.24.Shastri SS, Mittra I, Mishra GA, et al.Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "J Natl Cancer Inst 2014;​106(3):​dju009.25.Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC Jr.Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "JAMA 2005;​294:​2173-81.26.Ronco G, Dillner J, Elfström KM, et al.Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.Lancet 2014;​383:​524- 32.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "27.Ferlay J, Colombet M, Soerjomataram I, et al.Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018.Eur J Cancer 2018;​103:​356-87.28.La Vecchia C, Bosetti C, Lucchini F, et al.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975.Ann Oncol 2010;​21:​1323-60.29.Bruni L, Albero G, Serrano B, et al.Human papillomavirus and related diseases report.Summary report 17 June 2019.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Barcelona:​L’Hospitalet de Llobregat, 2019 30.Korfage IJ, van Ballegooijen M, Wauben B, Looman CW, Habbema JD, Essink-Bot ML.Having a Pap smear, quality of life before and after cervical screening: a questionnaire study.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "BJOG 2012;​119:​936-44.31.Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon $\\begin{array} { r } { \\mathbb { R } , } \\end{array}$ Arnold LD.The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Sex Transm Infect 2017;​ 93:​56-61.32.Arrossi S, Almonte M, Herrero R, et al.Psycho-social impact of positive human papillomavirus testing in Jujuy, Argentina results from the Psycho-Estampa study.Prev Med Rep 2020;​18: 101070.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "33.Kyrgiou M, Athanasiou A, Kalliala IEJ, et al.Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease.Cochrane Database Syst Rev 2017;​11(11):​CD012847.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "34.Monitoring national cervical cancer prevention and control programmes:​ quality control and quality assurance for visual inspection with acetic acid (VIA)-based programmes.Geneva: World Health Organization, 2013 (https://apps.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "​­who.​i­nt/i​­ris/​ ­handle/​­10665/​­79316).35.Ronco G, Segnan N, Giorgi-Rossi P, et al.Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "J Natl Cancer Inst 2006;​98:​765-74.36.Ronco G, Giorgi-Rossi P, Carozzi F, et al.Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "J Natl Cancer Inst 2008;​ 100:​492-501.37.Ronco G, Giorgi-Rossi P, Carozzi F, et al.Efficacy of human papillomavirus testing for the detection of invasive cervical can The New England Journal of Medicine is produced by NEJM Group, a division of the Massachusetts Medical Society.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Downloaded from nejm.org on April 28, 2025.For personal use only.No other uses without permission.Copyright $\\circledcirc$ 2021 Massachusetts Medical Society.All rights reserved.cers and cervical intraepithelial neoplasia: a randomised controlled trial.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Lancet Oncol 2010;​11:​249-57.38.Ogilvie GS, van Niekerk D, Krajden M, et al.Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "JAMA 2018;​320:​43-52.39.Leinonen MK, Nieminen P, Lönnberg S, et al.Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "BMJ 2012;​345:​e7789.40.Canfell K, Caruana M, Gebski V, et al.Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "PLoS Med 2017;​14(9):​e1002388.41.Rijkaart DC, Berkhof J, Rozendaal L, et al.Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Lancet Oncol 2012;​13:​78-88.42.Naucler P, Ryd W, Törnberg S, et al.Human papillomavirus and Papanicolaou tests to screen for cervical cancer.N Engl J Med 2007;​357:​1589-97.43.Kitchener HC, Almonte M, Gilham C, et al.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.Health Technol Assess 2009;​13:​1-150.44.Chan KKL, Liu SS, Wei N, et al.Primary HPV testing with cytology versus cytology alone in cervical screening — a prospective randomized controlled trial with two rounds of screening in a Chinese population.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Int J Cancer 2020;​147:​1152-62.45.Wentzensen N, Schiffman M, Palmer T, Arbyn M.Triage of HPV positive women in cervical cancer screening.J Clin Virol 2016;​76:​Suppl 1:​S49-S55.46.Denny L, Kuhn L, Hu C-C, Tsai W-Y, Wright TC Jr.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial.J Natl Cancer Inst 2010;​102:​1557-67.47.Sarian LO, Derchain S, Shabalova I, et al.Optional screening strategies for cervical cancer using standalone tests and their combinations among low- and medium-income populations in Latin America and Eastern Europe.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "J Med Screen 2010;​17:​195-203.48.Asthana S, Labani S.Adjunct screening of cervical or vaginal samples using careHPV testing with Pap and aided visual inspection for detecting high-grade cervical intraepithelial neoplasia.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Cancer Epidemiol 2015;​39:​104-8.49.Basu P, Mittal S, Banerjee D, et al.Diagnostic accuracy of VIA and HPV detection as primary and sequential screening tests in a cervical cancer screening demonstration project in India.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Int J Cancer 2015;​137:​859-67.50.Zhao YQ, Dai Y, Dang L, et al.Real-world research on cervical cancer screening program and effect evaluation for Chinese population.Zhonghua Zhong Liu Za Zhi 2018;​40:​764-71.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "(In Chinese.) 51.Bhatla N, Gulati A, Mathur SR, et al.Evaluation of cervical screening in rural North India.Int J Gynaecol Obstet 2009;​105:​145-9.52.Arbyn M, Ronco G, Anttila A, et al.Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Vaccine 2012;​30:​Suppl 5:​F88-F99.53.Elfström KM, Smelov V, Johansson AL, et al.Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "BMJ 2014;​ 348:​g130.54.Dijkstra MG, van Zummeren M, Rozendaal L, et al.Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "BMJ 2016;​355:i​4924.55.Han L, Chang X, Song P, et al.An on-going study of three different cervical cancer screening strategies based on primary healthcare facilities in Beijing China.J Infect Public Health 2020;​13:​577-83.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "56.Schiffman M, Kinney WK, Cheung LC, et al.Relative performance of HPV and cytology components of cotesting in cervical screening.J Natl Cancer Inst 2018;​110:​501-8.future risk of precancer and cancer conferred by a negative human papillomavirus test.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "J Natl Cancer Inst 2014;​106(8):​dju153.58.Arbyn M, Smith SB, Temin S, Sultana F, Castle P.Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "BMJ 2018;​ 363:​k4823.59.El-Zein M, Bouten S, Louvanto K, et al.Validation of a new HPV self-sampling device for cervical cancer screening: the Cervical and Self-Sample In Screening (CASSIS) study.Gynecol Oncol 2018;​149:​491-7.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "60.Polman NJ, Ebisch RMF, Heideman DAM, et al.Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screenpositive, non-inferiority trial.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Lancet Oncol 2019;​20:​229-38.61.Sargent A, Fletcher S, Bray K, Kitchener HC, Crosbie EJ.Cross-sectional study of HPV testing in self-sampled urine and comparison with matched vaginal and cervical samples in women attending colposcopy for the management of abnormal cervical screening.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "BMJ Open 2019;​9(4):​e025388.62.Zhang L, Xu X-Q, Hu S-Y, et al.Durability of clinical performance afforded by self-collected HPV testing: a 15-year cohort study in China.Gynecol Oncol 2018;​151:​221-8.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "63.Cook DA, Smith LW, Law JH, et al.Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial.J Clin Virol 2018;​108:​32-7.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "64.Forslund O, Miriam Elfström K, Lamin H, Dillner J.HPVmRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri.Int J Cancer 2019;​ 144:​1073-81.65.Iftner T, Neis K-J, Castanon A, et al.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Longitudinal clinical performance of the RNA-based Aptima human papillomavirus (AHPV) assay in comparison to the DNA-based Hybrid Capture 2 HPV test in two consecutive screening rounds with a 6-year interval in Germany.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "J Clin Microbiol 2019;​57(1):​e01177-18.66.Zorzi M, Del Mistro A, Giorgi-Rossi P, et al.Risk of CIN2 or more severe lesions after negative HPV-mRNA E6/E7 overexpression assay and after negative HPV-DNA test: concurrent cohorts with a 5-year follow-up.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Int J Cancer 2020;​146:​3114-23.67.Pankakoski M, Anttila A, Sarkeala T, Heinävaara S.Effectiveness of cervical cancer screening at age 65 — a registerbased cohort study.PLoS One 2019;​14(3):​e0214486.68.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P.Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Lancet HIV 2018;​5(1):​e45-e58.69.Rohner E, Bütikofer L, Schmidlin K, et al.Cervical cancer risk in women living with HIV across four continents: a multicohort study.Int J Cancer 2020;​146:​601-9.70.Kelly HA, Chikandiwa A, Sawadogo B, et al.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Diagnostic accuracy of cervical cancer screening and screening-triage strategies among women living with HIV-1 in Burkina Faso and South Africa: a cohort study.PLoS Med 2021;​18(3):​e1003528.71.Luckett R, Mogowa N, Li HJ, et al.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Performance of two-stage cervical cancer screening with primary high-risk human papillomavirus testing in women living with human immunodeficiency virus.Obstet Gynecol 2019;​134:​840-9.72.Firnhaber C, Mayisela N, Mao L, et al.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Validation of cervical cancer screening methods in HIV positive women from Johannesburg South Africa.PLoS One 2013;​8(1):​e53494.73.Arrossi S, Paolino M, Laudi R, et al.Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "Lancet Glob Health 2019;​7(6):​e772-e783.The New England Journal of Medicine is produced by NEJM Group, a division of the Massachusetts Medical Society.Downloaded from nejm.org on April 28, 2025.For personal use only.No other uses without permission.Copyright $\\circledcirc$ 2021 Massachusetts Medical Society.All rights reserved.",
    "source": "The IARC Perspective on Cervical Cancer Screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/The IARC Perspective on Cervical Cancer Screening/The IARC Perspective on Cervical Cancer Screening.md"
  },
  {
    "text": "# • 调查报告与分析 • # “一带一路”沿线国家宫颈癌流行病学负担现状分析 徐婷婷1,2，詹行天3，贺小宁1，吴晶1 1.天津大学药物科学与技术学院，天津 300072；2.天津医科大学肿瘤医院，天津 300060；3.中国人民大学公共管理学院，北京 100872通信作者：吴晶，Email：jingwu@tju.edu.cn 【摘 要】目的 了解和掌握“一带一路”沿线国家宫颈癌流行病学负担现状。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "方法 对照2018 年世界卫生组织（WHO）癌症登记数据库，从“一带一路”政务网中选取 127 个宫颈癌流行病学数据较为完整的“一带一路”沿线国家作为研究对象。按照WHO 划分的世界区域标准，对127 个“一带一路”沿线国家进行归类。运用统计学参数检验法，比较分析不同WHO 区域2018 年“一带一路”沿线国家宫颈癌流行病学负担差异，应用聚类分析法分析不同 WHO 区域国家的宫颈癌流行程度。结果 不同 WHO 区域“一带一路”沿线国家宫颈癌的流行病学负担差异性显著。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "WHO 非洲区域国家的宫颈癌平均标化发病率和标化死亡率最高，分别是 32.4/10 万和21.9/10 万；相反，东地中海地区国家的平均标化发病率为4.4/10 万，标化死亡率为2.9/10 万，位居六大WHO区域最低。WHO 美洲区域的伤残调整寿命年（DALYs）最高（458.2/10 万），东地中海地区最低（69/10 万）。聚类分析结果表明，WHO 非洲区域国家的宫颈癌多为中、高度流行；低度流行国家主要分布在 WHO 欧洲、西太平洋和东地中海地区。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "讨论 地理区域是影响“一带一路”沿线国家宫颈癌流病负担的主要因素，但并不是唯一因素，未来将综合考虑国家社会经济发展水平、自然和社会环境等因素，并纳入研究范畴。【关键词】 宫颈癌；流行病学；负担；\"一带一路\"沿线国家 # Disease burden of cervical cancer in Belt and Road surrounding countries in 2018 XU Tingting1,2, ZHAN Xingtian3, HE Xiaoning1, WU Jing1 (1.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China; 2.Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; 3.School of Public Administration and Policy, Renmin University of China, Beijing 100872, China) Corresponding author: WU Jing, E-mail: jingwu@tju.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "edu.cn 【Abstract】 Objective To examine the disease burden of cervical cancer in 127 countries along the Belt and Road.Methods The 127 countries involved in the analysis were determined based on the information from the website of China's Belt and Road Initiative and the countries were assigned into one of the 6 World Health Organization (WHO) regions.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "The country-specific data of 2018 on world population based age standardized incidence and mortality rate and disability-adjusted life years (DALYs) of cervical cancer were extracted from WHO cancer registry database for analyzing and comparing between country disparities in disease burden of cervical cancer using descriptive statistics.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "Cluster analysis was used to assess prevalence intensity of cervical cancer among the countries in different WHO regions.Results The disease burden of cervical cancer in 2018 was significantly different among the 127 countries in various WHO regions along the Belt and Road.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "The mean age-standardized incidence rate $( 3 2 .4 / 1 0 0 \\ 0 0 0 )$ and mortality rate (21.9/100 000) of cervical cancer were the highest for the countries in the WHO African region; while, those for the countries in the WHO Mediterranean region were the lowest (age-standardized incidence and mortality rate: $4 .",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "4 / 1 0 0 \\ 0 0 0$ and 2.9/100 000).The mean DALYs of cervical cancer was the highest (458.2/100 000) for the countries in the WHO region of America but the lowest $( 6 9 / 1 0 0 0 0 0 )$ for countries in the WHO Eastern Mediterranean region.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "The results of cluster analysis showed that the prevalence of cervical cancer was at medium-high level for countries in WHO African region and at low level for countries in the WHO European, Western Pacific and Eastern Mediterranean regions.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "Conclusion Geographical region is the main, but not the only factor affecting the disease burden of cervical cancer for countries along the Belt and Road and the influences of country-specific social and economic development, natural and social environment should be considered in cervical cancer control.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "【Keywords】 cervical cancer; epidemiology; disease burden; the Belt and Road surrounding countries 宫颈癌是严重威胁女性健康的恶性肿瘤，主要致病原因是高危型人乳头瘤状病毒（HumanPapilloma Virus，简称 HPV）持续感染[1]。宫颈癌的发病和死亡也有不平等特征，2018 年全球癌症登记报告数据显示，大约 $8 5 \\%$ 的宫颈癌新发病例发生在中低收入国家，而中低收入国家的宫颈癌发病率几乎是高收入国家的2 倍，死亡率则是3 倍[2]。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "预计在不采取任何干预措施的情况下，未来50 年中、低收入国家将有超过 4 400 万妇女被诊断为宫颈癌[3]。中国是“一带一路”倡议发起国，着眼于与沿线国家共建人类健康命运共同体，高度关注女性的健康与权益[4]。“一带一路”沿线国家中，中、低收入国家占比较大，女性宫颈癌流行病学负担形势更为严峻。鉴于此，本研究从“一带一路”政务网中选取 127 个宫颈癌流行病学数据较为完整的沿线国家作为研究对象，按照 WHO 区域标准进行划分和归类，分析各地区间世界年龄标化发病率（简称标化发病率）、世界年龄标化死亡率（简称标化死亡率）和伤残调整寿命年（disabilityadjusted life years，简称 DALYs）存在的差异，并探析不同地理区域对宫颈癌流行程度的影响。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "# 1 资料与方法 1.1 资料来源 对照 WHO 发布的 2020 癌症登记数据库，从“中国一带一路网”中选取 127 个参与“一带一路”倡议国家的 2018 年女性宫颈癌标化发病率、标化死亡率和 DALYs 的流行病学数据，依据WHO 六大地理区域的划分标准，即非洲、东南亚、美洲、西太平洋、欧洲和东地中海地区，对127 个“一带一路”沿线国家进行分类，其中，WHO非洲区域国家 29 个，WHO 东南亚区域国家 9 个，WHO 美洲区域国家 16 个，WHO 西太平洋区域国家 17 个，WHO 欧洲区域国家 34 个，以及 WHO东地中海区域国家 22 个[5 – 6]。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "# 1.2 分析方法 1.2.1 统计学参数检验法 本研究采用 GraphpadPrism 8.3.0 软件对不同 WHO 区域国家宫颈癌的标化发病率、标化死亡率和 DALYs 数据进行统计学参数检验分析，重点参考各指标的中位数及其$9 5 \\% C I _ { \\setminus }$ 上四分位数、下四分位数，分析不同 WHO区域“一带一路”沿线国家宫颈癌流行病学负担现状的差异。中位数反映了各区域国家的宫颈癌标化发病率、标化死亡率和 DALYs 的集中趋势，四分位距（inter quartile range，简称 IQR）反映其离散趋势。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "1.2.2 聚类分析 K-means 聚类算法通过迭代（设置最大迭代次数为 50 次）将样本划分到 k 个类别中，使得每个样本与其所属类的中心或均值最近，从而得到 $\\mathbf { k }$ 个层次化的类别[7]。K-means 聚类时一般使用“手肘法”或者“轮廓系数法”选取最优$\\mathbf { k }$ 值。SSE（Sum of the Squared Errors，误差平方和）是手肘法的核心指标： $$ S S E = \\sum _ { i = 1 } ^ { k } \\sum _ { p \\in C _ { i } } | p - m _ { i } | ^ { 2 } $$ 其中， $C _ { i }$ 是第 $i$ 个簇， $p$ 是 $C _ { i }$ 中的样本点， $m _ { i }$ 是 $C _ { i }$ 中所有样本的均值， $S S E$ 为所有聚类样本的聚类误差，代表聚类效果的好坏程度。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "聚类数 $\\mathbf { k }$ 的增大，使样本划分更加精细，每个簇的聚合程度逐渐提高，误差平方和 SSE 会逐渐变小。当 $\\mathbf { k }$ 值增加到一定程度时，SSE 的下降幅度会骤减，并逐渐趋于平缓，从而出现一个拐点，即最优的 $\\mathbf { k }$ 。依次设置 ${ \\bf k } = ( 2 , 3 , 4 ^ { \\dots } 8 )$ ，本研究发现当 $\\mathbf { k } = 3$ 时，SSE 与k 之间的变化曲线开始变得平缓，因此在后续的分析中，k 值设置为 3，如图 1 所示。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "![](images/55ef84ea102dc081564388908442d2ef3878eef6d434bb372861db0a61cd9daf.jpg) 图 1 SSE 随分类数变化曲线 Fig.1 The curve of K-value dependent sum of the squared errors in K-means clustering algorithm # 2 结 果 2.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "1 宫颈癌流病负担现状分析（表 1） WHO 非洲区域国家的宫颈癌标化发病率中位数水平最高（32.4/10 万），而东地中海区域国家水平最低（4.4/10 万）。WHO 六个区域中非洲区域国家标化死亡率中位数水平最高（21.9/10 万），东地中海区域最低（2.9/10 万）。DALYs 的中位数水平以美洲区域国家最高（458.2/10 万），其次是非洲区域（371.3/10 万），东地中海区域最低（69.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "0/10 万）。非洲区域国家标化发病率 IQR 达 21.2，该区域国家间的标化发病率波动较大；东地中海区域的 IQR仅为 4.0，该区域国家间标化发病率波动较小。标化死亡率 IQR 以非洲区域较高（17.0），该区域国家间标化死亡率波动较大；东地中海区域标化死亡率 IQR 最低（3.4），该区域国家间标化死亡率波动较小。DALYs 的 IQR 以美洲区域最高（233.8），其次为西太平洋区域（184.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "8），东地中海区域最低（66.5）。<html><body><table><tr><td rowspan=\"2\">WHO区域</td><td colspan=\"3\">标化发病率(1/10万)</td><td colspan=\"3\">标化死亡率(1/10万)</td><td colspan=\"3\">DALYs(1/10万)</td></tr><tr><td>范围</td><td>M</td><td>IQR</td><td>范围</td><td>M</td><td>IQR</td><td>范围</td><td>M</td><td>IQR</td></tr><tr><td>非洲</td><td>7.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "9~65.5</td><td>32.4</td><td>21.2</td><td>4.5~43.4 </td><td>21.9</td><td>17.0</td><td>54.5~633.5</td><td>371.3</td><td>117.6</td></tr><tr><td>东南亚</td><td>9.2~24.5</td><td>15.8 a</td><td>9.9</td><td>4.9~14.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "4</td><td>8.6 d</td><td>7.0</td><td>93.5~299.9</td><td>197.1 bc</td><td>79.8</td></tr><tr><td>美洲</td><td>11.1~36.6</td><td>17.0 a</td><td>8.9</td><td>5.2~18.0</td><td>10.3 a</td><td>6.3</td><td>252.9~660.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "8</td><td>458.2 a</td><td>233.8</td></tr><tr><td>西太平洋</td><td>5.6~29.8</td><td>12.2 bd</td><td>12.2</td><td>1.8~20.7</td><td>6.3 b</td><td>9.1</td><td>99.7~669.6</td><td>296.1 b</td><td>184.8</td></tr><tr><td>欧洲</td><td>3.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "7~26.2</td><td>11.4 bd</td><td>9.1</td><td>1.1~9.4</td><td>5.2 bc</td><td>3.6</td><td>72.6~552.2</td><td>253.3 bcd</td><td>133.4</td></tr><tr><td>东地中海</td><td>2.2~25.1</td><td>4.4 b</td><td>4.0</td><td>1.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "5~18.7</td><td>2.9 b</td><td>3.4</td><td>32.5~529.4</td><td>69.0 b</td><td>66.5</td></tr></table></body></html> 注：与东地中海区域比较，a $P < 0 .0 1$ ，d $P < 0 .0 5$ ；与非洲区域比较，b $P < 0 .0 0 1$ ；与美洲比较，c $P < 0 .0 0 1$ 。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "2.2 聚类分析结果及流行强度的划分（表 2） 根据聚类分析的结果，可得出 3 个类别的宫颈癌标化发病率、标化死亡率和 DALYs 的均值，根据每个类别中 3 个指标均值的大小进行排序，并以此作为划分宫颈癌流行强度的标准。本研究根据指标均值大小将宫颈癌流行程度分成中度流行、低度流行以及高度流行 3 档。III 类为高度流行国家，标化发病率、标化死亡率和 DALYs 的均值最高。II 类为低度流行国家，3 个指标的均值最低。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "I 类为中度流行国家，3 个指标的均值较其他两个类别处于中间位置。具体数值详见表 2。分析结果显示，在标化发病率、标化死亡率和伤残调整寿命年 3 个指标中，三类流行程度之间存在显著差异，说明此分类结果具有一定合理性。表 1 不同WHO 区域国家宫颈癌标化发病率、标化死亡率和DALYs Tbl.1 WHO region-specific age-standardized (world population) incidence, mortality, DALYs of cervical cancer in 127 Belt and Road surrounding countries in 2018 表 2 聚类分析结果（均值）（1/10 万） <html><body><table><tr><td>流行强度</td><td>标化发病率</td><td>标化死亡率</td><td>DALYs</td></tr><tr><td>I中度流行</td><td>20.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "45</td><td>12.18</td><td>302.81</td></tr><tr><td>Ⅱ低度流行</td><td>7.24</td><td>3.87</td><td>104.18</td></tr><tr><td>III高度流行</td><td>31.47</td><td>20.67</td><td>534.18</td></tr><tr><td>F值</td><td>42.76</td><td>32.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "09</td><td>419.34</td></tr><tr><td>P值</td><td>0.00</td><td>0.00</td><td>0.00</td></tr></table></body></html> 2.3 不同 WHO 区域分布“一带一路”沿线国家宫颈癌流行程度分布（表3） 127 个“一带一路”沿线国家中，第I 类中度流行国家共计63 个，占 $4 9 .6 1 \\%$ ，其中非洲区域国家20 个，欧洲22 个，占比较多；第II类低度流行国家41 个，占 $3 2 .",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "5 6 \\%$ ，东地中海区域国家占 $5 3 .7 \\%$ ，欧洲占比 $2 2 \\%$ ，除美洲没有代表性国家之外，非洲、东南亚和西太平洋区域国家合计占比$2 4 .3 \\%$ ；第 III 类“高度流行”国家有 23 个，占 $1 7 .8 3 \\%$ $6 0 .9 \\%$ 的国家分布于非洲区域，其他 $3 9 .1 \\%$ 位于美洲地区。整体而言，WHO 非洲区域国家多是宫颈癌中、高度流行国家；而分布于 WHO 欧洲区域国家的宫颈癌流行程度整体较低，特别是西欧地区国家，例如葡萄牙、意大利、卢森堡等国家的宫颈癌流行程度低，而东欧地区包括爱沙尼亚、波兰、捷克共和国、拉脱维亚等国家的宫颈癌则呈中度流行趋势。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "WHO 美洲区域国家宫颈癌流行程度较高，例如多米尼加、委内瑞拉宫颈癌的流病负担指标相对较高。WHO 东南亚和东地中海区域国家的宫颈癌流行程度则较低，特别是阿联酋、阿曼等经济较发达的中东地区国家。WHO西太平洋区域整体向好，诸如新西兰、韩国和新加坡，只有斐济是唯一一个宫颈癌高度流行的“一带一路”沿线国家。Tbl.2 Prevalence intensity category of cervical cancer based on mean age-standardized incidence and mortality rate (1/100 000) and DALYs in 127 Belt and Road surrounding countries – clustering analysis 表 3 不同WHO 区域分布“一带一路”沿线国家宫颈癌流行程度分布 Tbl.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "3 WHO region-specific number (ratio) of countries with moderate, low, and high prevalence intensity of cervical cancer in 2018 in 127 Belt and Road surrounding countries <html><body><table><tr><td rowspan=\"2\">WHO区域</td><td colspan=\"2\">I中度流行</td><td colspan=\"2\">Ⅱ低度流行</td><td colspan=\"2\">ⅢI高度流行</td></tr><tr><td>国家数</td><td>占比(%)</td><td>国家数</td><td>占比(%)</td><td>国家数</td><td>占比(%)</td></tr><tr><td>非洲</td><td>20</td><td>31.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "7</td><td>2</td><td>4.9</td><td>14</td><td>60.9</td></tr><tr><td>欧洲</td><td>22</td><td>34.9</td><td>9</td><td>22.0</td><td>一</td><td>一</td></tr><tr><td>西太平洋</td><td>9</td><td>14.3</td><td>4</td><td>9.7</td><td>一</td><td>一</td></tr><tr><td>美洲</td><td>7</td><td>11.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "1</td><td>一</td><td>一</td><td>9</td><td>39.1</td></tr><tr><td>东南亚</td><td>4</td><td>6.4</td><td>4</td><td>9.7</td><td>一</td><td>一</td></tr><tr><td>东地中海</td><td>1</td><td>1.6</td><td>22</td><td>53.7</td><td>一</td><td>一</td></tr><tr><td>合计</td><td>63</td><td>100.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "0</td><td>41</td><td>100.0</td><td>23</td><td>100.0</td></tr></table></body></html> 注：“—”代表此区域无研究国家，数据为零。# 3 讨 论 2018 年全球癌症报告数据显示，世界平均标化发病率为 13.3/10 万，平均标化死亡率为 7.3/10 万[8]。与之相比，本研究计算得出的WHO 非洲地区国家宫颈癌平均标化发病率和平均标化死亡率是世界平均水平的 3 倍，而东地中海地区国家的平均发病和死亡率均是 6 个 WHO 区域中最低，且低于世界平均水平。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "WHO 非洲区域国家宫颈癌标化死亡率中位数水平高于东南亚、西太平洋、欧洲地区国家中位数近 3 倍，是美洲中位数水平的2 倍。WHO 美洲地区国家宫颈癌 DALYs 的中位数水平最高，而东地中海地区 DALYs 则最低。聚类分析结果也表明，WHO 非洲区域主要是宫颈癌中、高度流行国家，而低度流行国家分布在欧洲、西太平洋和东地中海地区。不同地理区域国家的宫颈癌流行程度不同，可能与多种因素有关，例如风土人情、饮食文化、生活习惯、遗传基因等，但是能够影响其病因发展的主要因素是与近年来 WHO 在全球范围内推广实施的三级预防策略。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "三级预防策略通过干预疾病诱因，大大降低了宫颈的癌前病变和恶性发展。例如，韩国实施了基于人群的癌症登记和国家宫颈癌筛查计划，1999 — 2017 年的宫颈癌发病率和死亡率变化趋势显示，韩国发病率趋势先是急剧下降 $[ 1 9 9 9 - 2 0 0 7$ 年的年度百分比变化（annualpercentage change，简称 $\\mathrm { A P C } ) = - 4 .5 3 \\% ]$ ，然后稳步下降（2007 — 2017 年的 $\\mathrm { A P C } = - 2 .",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "7 1 \\% )$ 。死亡率也显著下降（2003 — 2008 年 $\\mathrm { A P C } = - 6 .6 3 \\% )$ ，然后保持稳定下降 $( 2 0 0 8 - 2 0 1 7$ 年 $\\mathrm { A P C } = - 3 .7 8 \\% ) ^ { [ 9 ] }$ 。2005 年，泰国卫生部与国家卫生保障办公室合作，开展了全国76 个省的宫颈癌普查工作，对 $3 0 { \\sim } 6 0$ 岁和 $3 5 { \\sim } 4 5$ 岁的妇女每隔5 年分别进行一次巴氏涂片检查和醋酸目视检查（Visual Inspection withAcetic Acid，简称 VIA）的筛查。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "2005 — 2014 年，共计筛查妇女 10 762 081 人，10 年间宫颈癌发病情况有所改善，2014 年宫颈癌发病率降至 11.7/10 万[10]。但并不是所有国家的宫颈癌预防干预效果都比较理想，这可能与国家经济发展水平、卫生资源配置的情况有关[11]。以中国为例，近年来尽管在宫颈癌二级和三级预防工作方面做了很多努力，但是由于推广 HPV 疫苗起步较晚，疫苗成本高等原因，使得接种人群数量相对较少，因此我国目前的宫颈癌疾病负担还未有较大幅度的改善。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "相反，在经济发展水平较高的欧洲和西太平洋地区国家，由于高卫生资源的投入，全民 HPV 疫苗接种的普及和推广，女性宫颈癌的流行程度明显得到改善。例如，新西兰在执行 $\\langle \\langle 2 0 0 5 - 2 0 1 0$ 新西兰癌症防控战略》后，2009 — 2013 年宫颈癌的发病率较20 年前下降了 $5 6 \\% ^ { [ 1 2 ] }$ 。2018 年统计数据显示，新西兰 15 岁少女 HPV 疫苗接种覆盖率已达到 $6 8 \\% ^ { [ 1 2 ] }$ 。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "近20 年来，新西兰已有30 万女性接种了 HPV 疫苗，这是新西兰宫颈癌发病率和死亡率稳步下降的主要原因[12]。奥地利、新加坡、韩国等“一带一路”沿线国家还相继批准 HPV 疫苗应用于男性计划免疫的政策，这从根本上有助于遏制女性宫颈的感染，从而降低患病的概率。本研究聚焦“一带一路”沿线国家的宫颈癌流行病学负担研究，提出地理区域是影响宫颈癌流行病学负担的主要因素这一假设，并运用统计学参数检验法和聚类分析法分别验证假设的合理性。",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "研究结果显示，不同 WHO 地理区域的大多数“一带一路”沿线国家的宫颈癌流行病学负担确实存在显著性差异，但是地理区域应该不是唯一影响因素，未来将综合考虑国家社会经济发展水平、自然和社会环境等因素，并纳入研究范畴。# 参考文献 [ 1 ] 李玉兰, 刘晓, 韩逢皎, 等.高危型人乳头瘤病毒阴性宫颈癌的研 究进展 [J].国际生殖健康/计划生育杂志, 2022, 41(4): 342 – 346.[ 2 ] Ginsburg O, Bray F, Coleman MP, et al.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "The global burden of women's cancers: a grand challenge in global health[J].The Lancet, 2017, 389(10071): 847 – 860.[ 3 ] 刘宗超, 李哲轩, 张阳, 等.2020 全球癌症统计报告解读 [J].肿瘤 综合治疗电子杂志, 2021, 7(2): 1 – 13.[ 4 ] 张宇薇, 李辉, 孙晓丽, 等.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "“一带一路”沿线 66 国全民健康覆盖 现状与预测 [J].中国公共卫生, 2019, 35(10): 1388 – 1392.[ 5 ] International Agency for Research on Cancer, World Health Organization.Global cancer observatory: cancer today[DB/OL].[2023 – 03 – 20].",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "http://gco.iarc.fr/today.[ 6 ] 中国一带一路网.“一带一路”大数据指数 [DB/OL].[2022 – 01 – 11].https://www.yidaiyilu.gov.cn/dataChart [ 7 ] 伍信怡, 汪璐, 史富存.基于 K-means 聚类分析法的三峡货物分 类研究 [J].中国水运, 2021(6): 97 – 99.[ 8 ] World Health Organization.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "Global strategy to accelerate the elimination of cervical cancer as a public health problem[EB/OL].(2020 – 11 – 17)[2023 – 04 – 06].http://www.wgo.int/publications/ i/item/9789240014107.[ 9 ] Tran KN, Park Y, Kim BW, et al.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "Incidence and mortality of cervical cancer in Vietnam and Korea (1999 – 2017)[J].Epidemiology and Health, 2020, 42: e2020075.[ 10 ] Ploysawang P, Rojanamatin J, Prapakorn S, et al.National cervical cancer screening in Thailand[J].",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "Asian Pac J Cancer Prev, 2021, 22(1): 25 – 30.[ 11 ] 邱增辉, 蒋祎, 刘娅莉, 等.“一带一路”国家公共卫生与卫生服务 现况 [J].中国公共卫生, 2020, 36(12): 1755 – 1758.[ 12 ] Ministry of Health, New Zealand.New Zealand cancer plan: better, faster cancer care 2015 –2018[EB/OL].[2023 – 04 – 28].https:// www.health.govt.nz/publication/new-zealand-cancer-plan-betterfaster-cancer-care-2015–2018.",
    "source": "“一带一路”沿线国家宫颈癌流行病学负担现状分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/“一带一路”沿线国家宫颈癌流行病学负担现状分析/“一带一路”沿线国家宫颈癌流行病学负担现状分析.md"
  },
  {
    "text": "·专家论坛· # 《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读 胡尚英 赵雪莲 张勇 乔友林 赵方辉 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院 流行病学研究室，北京100021 通信作者：赵方辉，Email：zhaofangh@cicams.ac.cn 【摘要】 宫颈癌是严重威胁全球女性健康的恶性肿瘤之一，也是目前唯一可通过三级预防措施予以消除的恶性肿瘤。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "2020 年11 月，“加速消除宫颈癌全球战略”正式启动，针对宫颈癌前病变的筛查和治疗是消除宫颈癌的关键举措。2021 年7 月，世界卫生组织（WHO）发布《预防宫颈癌：WHO 宫颈癌前病变筛查和治疗指南（第二版）》，为全球各国宫颈癌消除战略的制定提供重要方向和指导。本文将从指南制定方法学、指南中关于宫颈癌筛查和治疗策略方面的推荐/良好实践声明（包括筛查起止年龄、筛查方法、筛查间隔、筛查异常人群管理及癌前病变治疗等）以及指南的国际影响等方面进行解读，为我国宫颈癌防控指南的更新和相关策略的制定提供参考。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "【关键词】 宫颈肿瘤； 癌前病变； 筛查； 治疗； 指南基金项目：国家自然科学基金（81761128006、81773533） Interpretation of“WHO guideline for screening and treatment of cervical pre‐cancer lesions for cervical cancer prevention，second edition” Hu Shangying, Zhao Xuelian, Zhang Yong, Qiao Youlin, Zhao Fanghui Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China Corresponding author: Zhao Fanghui, Email: zhaofangh@cicams.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "ac.cn 【Abstract】 Cervical cancer can be eliminated through primary, secondary, and tertiary prevention.Yet it remains one of the gravest threats to women′s lives worldwide.In November 2020, the World Health Organization (WHO) officially launched the global strategy to accelerate the elimination of cervical cancer, and underlined that screening and treatment for cervical pre‐cancer lesions are two of three key measures for the elimination.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "In July 2021, WHO issued the second edition of\"WHO guideline for screening and treatment of cervical pre‐cancer lesions for cervical cancer prevention\"to provide important guidance to countries to support them in achieving the target of cervical cancer elimination in all women.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "This article will interpret the methods for the guideline development, the recommendations/good practice statements on screening and treatment to prevent cervical cancer (including the age to start/stop screening, screening methods, screening interval, the management of screen‐positive women and treatment of the precancerous lesions, etc.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": ") and its impact globally, providing reference for the updates of guideline and policy making on cervical cancer prevention and control in China.【Key words】 Uterine cervical neoplasms; Precancerous lesions; Screening; Treatment; Guideline Fund program: National Natural Science Foundation of China (81761128006, 81773533) 宫颈癌由高危型人乳头瘤病毒（HPV）持续感染引起，可通过三级预防措施得到有效控制。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "但一些中低收入国家由于缺少高质量的筛查且覆盖率低，宫颈癌仍是主要的公共卫生问题［1］。为了改变这种健康不公平性，2018 年世界卫生组织（WHO）发布了消除宫颈癌的行动呼吁，并于2020 年11 月正式启动“加速消除宫颈癌全球战略”，提出到2030 年 达 到“90‑70‑90”目 标（即 $9 0 \\%$ 的女孩在15 岁之前完成HPV 疫苗接种， $70 \\%$ 的妇女在35 和45岁之前各接受一次高精度的筛查， $9 0 \\%$ 筛查阳性和宫颈癌变确诊病例得到有效治疗），才有望在本世纪末全球实现公共卫生问题层面的宫颈癌消除（即发病率降低至4/10 万以下）［2］。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "然而，现实与这一目标存在较大差距。因此，WHO 组织全球专家，调研、整合最新研究证据和长期实践经验，对2013年发布的《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第一版）》进行更新，并于2021 年7 月6 日发布第二版，以期指导全球各国制定筛查和治疗策略，提高策略效率，助力实现2030 年战略目标［3］。本文将从指南制定方法学、对筛查和治疗策略的推荐/良好实践声明（包括筛查起止年龄、筛查方法、筛查间隔、筛查异常人群管理及癌前病变治疗等）等方面对第二版指南进行解读，为我国宫颈癌防控指南的更新和相关策略的制定提供参考。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "# 一、指南制定方法 新版指南的制定遵循《WHO 指南制定手册》（第二版）的方法要求，分为以下3个步骤： 1.审查现有指南，确定需更新或新增的推荐和建议。指南制定小组（GDG）审查旧版指南，根据最新研究证据确定哪些推荐需要删除、验证、编辑或更新，以及是否添加新的推荐。推荐和建议涉及主要内容包括筛查起止年龄、优先考虑人群、筛查方法、治疗策略、随访间隔、筛查异常人群管理和癌前病变治疗策略。最终GDG 确定对两大类7 种筛查和治疗策略进行评价和比较（表1）。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "GDG 由全球52 名成员组成（34 名女性，18 名男性），代表WHO全球6 大区域以及民间社会组织、妇女团体和人免疫缺陷病毒（HIV）感染女性人群。2.针对需更新或新增的推荐/建议，提出需要进行证据综述的研究问题。对应拟提出的每项推荐 ，根 据 PICO 原 则（P：population，研 究 对 象 ；I：intervention，干预措施；C：comparison，比较组；O：Outcome，结局）确定了14 个研究问题，并分别针对普通女性和HIV 感染女性人群进行系统综述。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "在无 法 进 行 系 统 综 述 时 ，采 用 Policy‑Cervix 和Policy‑Cervix HIV‑HPV 数学模型估算各种策略在不同筛查年龄和筛查间隔情况下卫生经济学效果、宫颈癌发病死亡风险、癌前病变治疗以及所引发早产的影响等。此外，通过检索文献，评估各种策略的可接受性、可行性和成本。通过实施一项调查研究，收集策略的可行性、获益和风险的价值以及筛查女性、医生和其他利益相关方的偏好。3.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "评价证据可靠性，制定推荐和建议。运用推荐、评估、制定与评价的分级体系（GRADE）评估证据的可靠性。采用证据‑决策（EtD）表汇总所有以上证据，经GDG 讨论后对各项推荐达成一致意见。最终推荐和建议将基于不同策略的收益和潜在危害、筛查方法的准确性、证据的可靠性、可获得的资源与花费的成本、可接受性、可行性与持续性、对公平性的影响等因素进行综合考虑。GDG 就这些推荐和建议或声明达成一致后，外部审查小组（ERG）对完整草案进行审查并给予反馈。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "# 二、指南推荐和良好实践声明 指南主要面向国家、区域或地区各级机构负责宫颈癌防控战略规划的政策制定者、方案管理者和执行者以及卫生部门其他相关专业人员。从事生殖健康、产前和产后服务、计划生育服务、HIV/艾滋病（AIDS）控制以及在地区或初级保健机构为女性提供健康护理的医生、护士和社区保健工作者，也可查阅本指南，以了解指南制定过程，以及选择和执行以证据为基础的宫颈癌防控战略的重要性。表1 指南证据收集过程中评价的七种宫颈癌前病变筛查和治疗策略 <html><body><table><tr><td>治疗策略</td><td>具体方法</td></tr><tr><td>筛查-治疗策略：仅依靠初筛阳性结果，即可对女性进行治疗</td><td>VIA+治疗</td></tr><tr><td rowspan=\"5\">筛查-分流-治疗策略：对初筛阳性且分流阳性女性(有或无病细胞学检查+阴道镜分流+治疗 理)进行治疗</td><td>HPVDNA检测（自采样或医生采样)+治疗</td></tr><tr><td></td></tr><tr><td>HPVDNA检测（可同时实现HPV分型检测)+HPV16/18分流/非HPV16/18 阳性VIA分流+治疗</td></tr><tr><td>HPVDNA检测+VIA分流+治疗</td></tr><tr><td>HPVDNA检测+阴道镜分流+治疗 HPVDNA检测+细胞学分流+阴道镜+治疗</td></tr></table></body></html> 注：VIA为醋酸染色肉眼观察；HPV为人乳头瘤病毒 指南通过对两大类7 种宫颈癌前病变筛查和治疗策略进行评价和比较（表1），针对普通女性与HIV 感染女性提出23 项推荐和7 项良好实践声明。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "在筛查方面主要涵盖：筛查策略，筛查方法（初筛技术和采样方式），筛查异常人群管理（分流、治疗、随访），筛查人群（起始年龄、终止年龄和优先考虑人群），筛查间隔，治疗后人群随访，并对HPV 引入过渡时期筛查技术的选择给出了良好实践声明；在治疗方面主要增加了既往指南中未涉及的针对宫颈病变治疗时限的良好实践声明，以及关于宫颈原位腺癌治疗方法的建议。本指南更新主要有两个方面的重要推荐：首先，WHO 推荐方法有重要转变，指南推荐基于HPV DNA 的检测技术作为宫颈癌筛查的首选方法，而不是目前全球常用的醋酸染色肉眼观察（VIA）或细胞学检查（通常称为“巴氏涂片”）。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "指南强调，HPV DNA 检测可检测出高危型HPV，这些型别导致了几乎所有宫颈癌，其检测结果准确，同时可实现自我采样，在提高筛查准确性的同时可进一步提高宫颈癌筛查覆盖率，挽救更多生命，更具成本效益。其次，指南针对HIV感染女性给予了宫颈癌筛查和治疗方面的详细建议。免疫功能低下的女性，如HIV 感染者，比普通女性更有可能发生持续性HPV 感染，并更迅速地发展为宫颈癌前病变甚至宫颈癌，导致其罹患宫颈癌的风险较普通女性增加6 倍。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "本指南针对HIV 感染妇女建议较普通女性提前筛查年龄（25 岁），缩短筛查间隔，采用HPV DNA检测初筛‑分流‑治疗的策略。总体来看，指南建议普通女性可采用以下任何一种策略预防宫颈癌的发生：（1）“筛查‑治疗”策略（即筛即治）：从30 岁开始，采用HPV DNA 检测进行初筛，每5\\~10年定期筛查一次；（2）筛查‑分流‑治疗策略：从30 岁开始，采用HPV DNA 检测进行初筛，并结合一定的分流方法，每5\\~10 年定期筛查一次。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "建议HIV 感染女性采用筛查‑分流‑治疗策略，从25 岁开始，以HPV DNA 检测方法为初筛并结合一定的分流方法，每3\\~5 年定期筛查一次。针对普通女性与HIV 感染女性的具体筛查和治疗建议详见表2。在“加快消除宫颈癌全球战略”的国际背景下，这一指南的更新对于全球各个国家有计划地实现2030 年的阶段性目标尤为重要。指南中的建议将为各国宫颈癌消除战略规划的制定提供重要方向和指导，集全球权威证据助力各国更新或改进宫颈癌防控指南或相关政策。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "本指南与其他指南［4］相比不同之处主要体现在：（1）初筛方法：明确推荐高准确性的HPV DNA检测作为初筛方法，有条件地区要尽快过渡到HPV检测；（2）筛查间隔：延长了HPV 检测阴性人群的再次筛查间隔，其他指南大多数是5 年，本指南中对普通女性是5\\~10 年，HIV 感染女性是3\\~5 年；延长了HPV 检测阳性但分流阴性人群的筛查间隔，大多数指南推荐为12 个月后复查，本指南对普通女性的推荐为 24 个月后复查，HIV 感染女性为12 个月后复查；（3）筛查起始和终止年龄：大多数指南中推荐宫颈癌筛查起始年龄为25 岁，终止年龄为65 岁。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "本指南推荐对起始和终止年龄的推荐分别为30岁和49岁，在资源允许情况下，可考虑对50\\~65岁中从未接受筛查女性进行筛查；（4）对HIV感染人群的筛查推荐：针对HIV 感染女性，美国阴道镜和宫颈病理学会（ASCCP）建议在首次插入式性行为后1 年内开始接受筛查，采用细胞学检查（ $\\leq$ 30 岁女性）或HPV 和细胞学联合筛查策略（ $> 3 0$ 岁女性），起始筛查间隔为1 年1 次，如连续3 年检查结果正常，则转为3 年1 次。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "其他指南对HIV 感染女性大多建议与普通女性相同的筛查策略，或缩短筛查间隔。本指南对HIV 感染妇女建议25 岁开始筛查，采用HPV DNA 检测初筛“筛查‑分流‑治疗”的策略，每3\\~5 年重复筛查，不建议采用“筛查‑治疗”策略。我国宫颈癌前病变筛查项目与相关指南的发展历经20余年的历程。2004年原国家卫生部疾病控制司委托中国癌症基金会组织全国专家制定了首个《中国子宫颈癌筛查及早诊早治技术指南》，并用于实践。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "2006—2009 年开展中央财政地方转移支付癌症早诊早治项目，采用VIA 为筛查方法，子宫颈癌筛查项目点由2006 年的5 个增加到2009 年覆盖31 个省份的43 个点。2009 年，全国重大公共卫生专项农村“两癌检查”（宫颈癌和乳腺癌）项目启动，采用每3年进行1次细胞学检查；在资源匮乏和没有细胞学检查条件地区，采用每年1 次VIA/VILI 检查的宫颈癌筛查策略。2014 年起开展农村HPV 检测试点项目推广HPV 检测技术，2019年，农村“两癌检查”项目被纳入基本公共卫生服务，宫颈癌筛查工作的连续性得到提升［5］。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "在此期间，原国家卫生计生委妇幼健康服务司委托中华预防医学会妇女保健分会组织制定的《子宫颈癌综合防控指南》于2017 年正式发布［6］；中国抗癌协会妇科肿瘤专业委员会组织编写的《宫颈癌诊断与治疗指南（第四版）》于2018年完成更新［7］。表2 《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》中针对普通女性与HIV感染女性宫颈癌前病变筛查和治疗方面的推荐和良好实践声明 <html><body><table><tr><td>项目</td><td></td><td>普通女性</td><td>HIV感染女性</td></tr><tr><td>筛查推荐和良好 实践声明</td><td>筛查策略</td><td>“筛查-治疗”或“筛查-分流（基因分型、阴仅“筛查-分流（基因分型、阴道镜检 道镜检查、VIA或细胞学检查)-治疗\"(推“查、VIA或细胞学检查)-治疗 荐3)</td><td>（推荐23）</td></tr><tr><td></td><td>筛查方法(初筛)</td><td>HPVDNA检测（自采样或医生采样均可），同普通女性 不推荐VIA或细胞学检查（推荐1,4;21， 24)</td><td></td></tr><tr><td></td><td>筛查异常人群的管理</td><td></td><td></td></tr><tr><td></td><td>HPV DNA初筛阳性</td><td>不分流或分流(推荐2)</td><td>分流(推荐22)</td></tr><tr><td></td><td>HPVDNA阳性-分流阳性</td><td>直接治疗或组织学诊断后治疗(推荐3)</td><td>同普通女性(推荐23)</td></tr><tr><td></td><td>HPVDNA阳性-分流阴性</td><td>24个月后重新HPVDNA检测，如阴性则转12个月后重新HPVDNA检测，如 到常规筛查(推荐11)</td><td>阴性则转到常规筛查(推荐31)</td></tr><tr><td></td><td>细胞学初筛异常-阴道镜正常</td><td>12个月后重新HPVDNA检测，如阴性则转同普通女性 到常规筛查(推荐12,32)</td><td></td></tr><tr><td></td><td>筛查人群</td><td></td><td></td></tr><tr><td>终止年龄</td><td>起始年龄</td><td>30岁(推荐5)</td><td>25岁(推荐25)</td></tr><tr><td></td><td></td><td>>50岁，按照推荐筛查间隔定期筛查连续同普通女性 两次筛查结果阴性即可停止筛查(推荐 6,26)</td><td></td></tr><tr><td></td><td>优先人群(良好实践声明)</td><td>30~49岁；资源允许时，可再考虑50-65岁25~49岁；资源允许时，可再考虑 中从未接受过筛查女性(声明7)</td><td>50-65岁中从未接受过筛查女性 （声明27)</td></tr><tr><td></td><td>筛查间隔</td><td></td><td></td></tr><tr><td></td><td>HPV DNA初筛</td><td>5~10年(推荐8)</td><td>3~5年(推荐28)</td></tr><tr><td></td><td>VIA和细胞学初筛（尚无条件开展 HPV DNA检测地区）</td><td>3年(推荐9,29)</td><td>同普通女性</td></tr><tr><td>良好实践声明</td><td></td><td>过渡到定期筛查前，一生两次筛查也是有同普通女性 益的（声明10,30）</td><td></td></tr><tr><td></td><td>治疗后人群随访</td><td>因组织学确诊CIN2/3/AIS治疗后的女性，因组织学确诊CIN2/3/AIS治疗后的 或因筛查结果阳性治疗的女性，12个月 后重新HPVDNA检测（非VIA或细胞 学），如阴性则转到常规筛查（推荐13)</td><td>女性,或因筛查结果阳性治疗的 女性12个月后重新HPVDNA检 测（非VIA或细胞学），如阴性 12个月后再次进行HPVDNA检 测，再次阴性后则转到常规筛查</td></tr><tr><td></td><td>HPV引I人过渡时期的方法选择</td><td>在HPVDNA检测可被引人时，即立即引同普通女性 人，无论之前采用何种检测方法；在其未 被引人前，应继续使用现有方案进行筛 查（以细胞学检查或VIA作为初筛方</td><td>（推荐33）</td></tr><tr><td>治疗推荐和良好</td><td>治疗时限</td><td>法），直到HPVDNA技术可被引人（声明 14,34) 确诊后6个月内尽快进行治疗；孕妇可推同普通女性</td><td></td></tr><tr><td>实践声明</td><td>原位腺癌治疗方法</td><td>迟至产后(声明41) 转化区环形切除术或冷刀锥切(推荐42) 同普通女性</td><td></td></tr></table></body></html> 注：括号中的推荐/声明序号与原版英文指南文件中的表1（针对普通女性和HIV感染女性的宫颈癌前病变筛查和治疗推荐和良好实践声明）和表2（第一版指南中未包括的治疗推荐和良好实践声明）中的序号相对应；VIA 为醋酸染色肉眼观察；HPV 为人乳头状瘤病毒；HIV 为人免疫缺陷病毒；CIN2为中度宫颈上皮内瘤样病变；CIN3为重度宫颈上皮内瘤样病变；AIS为原位腺癌 我国宫颈癌前病变筛查和治疗相关证据的更新为进一步指导和规范我国宫颈癌防控工作提供了重要依据。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "截至目前，我国农村宫颈癌筛查项目已累计筛查1 亿余人次妇女［8］，十年数据（2009—2018 年）显示与细胞学检查比较，HPV 检测方法可检出更多的宫颈癌和癌前病变［9］。2020 年，1 项全国多中心、开放、随机临床研究也证实了高危型HPV DNA 检测是初级保健医疗中心一种有效的初筛方法，将高危型HPV DNA 检测纳入国家宫颈癌筛查计划是合理有效的［10］。2020—2021 年，我国学者结合国内宫颈癌防控情况进行策略分析的模型研究进一步验证了采用HPV DNA 检测作为初筛方法的筛查策略结合HPV 疫苗接种，是实现我国宫颈癌消除的最优路径［11‑12］。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "然而，目前我国仍面临着宫颈癌筛查覆盖率低、大规模筛查所采用的技术落后、基层服务能力有限及妇女筛查可及性差等现实问题。最新数据显示，2015年我国20\\~64岁妇女既往接受过宫颈癌筛查的比例仅为 $2 5 .7 \\%$ ，其中35\\~64 岁筛查比例为 $3 1 .4 \\% ^ { [ 1 3 ] }$ ，距离2030 年拟实现的阶段性目标—— $7 0 \\%$ 宫颈癌筛查覆盖率仍有较大差距。全球宫颈癌消除战略及WHO指南更新对我国宫颈癌防控事业的借鉴意义。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "2020 年，WHO 发布《加速消除宫颈癌全球战略》后，国务院于2020 年12月发布“中国支持《加速消除宫颈癌全球战略》”［14］，表明我国将与193个国家携手通过HPV 疫苗接种、筛查和治疗等三级防治路径，推动全球实现消除宫颈癌的目标。在此基础上，全国爱卫办、健康中国行动推进办正以宫颈癌防治为重点内容，在全国启动健康城市建设创新模式试点工作，探索在健康城市建设中推动健康中国行动的有效工作模式，进一步推动在全国范围内早日实现宫颈癌消除的2030 年阶段性目标。",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "本次WHO 指南的发布，可帮助我国在借鉴全球最新证据的同时，依据我国医疗资源配置现状，进一步更新我国宫颈癌筛查和治疗相关指南，助力我国早日实现消除宫颈癌的美好愿景。利益冲突 所有作者均声明不存在利益冲突 # 参 考 文 献 [1] Arbyn M, Weiderpass E, Bruni L, et al.Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "Lancet Glob Health, 2020, 8(2): e191‐e203.DOI: 10.1016/S2214‐109X(19)30482‐6.[2] World Health Organization.Global strategy to accelerate the elimination of cervical cancer as a public health problem [EB/OL].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "[2021‐07‐14].https://www.who.int/ publications/i/item/9789240014107.[3] World Health Organization.WHO guideline for screening and treatment of cervical pre‐cancer lesions for cervical cancer prevention, second edition[EB/OL].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "[2021‐07‐07].https://www.who.int/publications/i/item/ 9789240030824 [4] 任文辉, 赵雪莲, 赵方辉.全球宫颈癌筛查指南制定现状的 系统综述[J].中华医学杂志, 2021, 101(24):1882‐1889.DOI: 10.3760/cma.j.cn112137‐20210115‐00134.[5] 国家卫生健康委员会.关于做好2019 年基本公共卫生服 务 项 目 工 作 的 通 知 [EB/OL].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "[2021‐07‐14].http://www.nhc.gov.cn/jws/s7881/201909/83012210b4564f26a 163408599072379.shtml.[6] 中华预防医学会妇女保健分会.子宫颈癌综合防控指南 [M].北京: 人民卫生出版社, 2017.[7] 中国抗癌协会妇科肿瘤专业委员会.宫颈癌诊断与治疗指 南(第四版)[J].中国实用妇科与产科杂志, 2018, 34(6): 613‐622.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "DOI: 10.19538/j.fk2018060111.[8] 国家卫生健康委员会 .对十三届全国人大二次会议第 6194 号建议的答复[EB/OL].[2021‐07‐14].http://www.nhc.gov.cn/wjw/jiany/202007/f96cf2aa5e8b45c5a9d 176029194c4c4.shtml.[9] 赵艳霞, 马兰, 任文辉, 等.2009—2018 年中国农村妇女宫 颈癌检查项目数据分析[J].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "中华医学杂志, 2021, 101(24): 1863‐1868.DOI: 10.3760/cma.j.cn112137‐ 20210111‐ 00075.[10] Zhang J, Zhao Y, Dai Y, et al.Effectiveness of high‐risk human papillomavirus testing for cervical cancer screening in China: a multicenter, open‐label, randomized clinical trial[J].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "JAMA Oncol, 2021, 7(2): 263‐270.DOI: 10.1001/jamaoncol.2020.6575.[11] Xia C, Xu X, Zhao X, et al.Effectiveness and cost‐effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study[J].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "BMC Med, 2021, 19(1):62.DOI: 10.1186/s12916‐021‐01930‐9.[12] Xia $\\mathbf { C } ,$ Hu S, Xu $\\mathrm { ~ X , }$ et al.Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study[J].",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "Lancet Public Health, 2019, 4(9): e462‐e472.DOI: 10.1016/ S2468‐2667(19)30162‐8.[13] Zhang M, Zhong Y, Zhao Z, et al.Cervical cancer screening rates among Chinese women — China, 2015[J].China CDC Weekly, 2020, 2(26): 481‐486.DOI: 10.46234/ ccdcw2020.128.[14] 国家人民政府网.中国支持《加速消除宫颈癌全球战略》 [EB/OL].[2021‐07‐16].http://www.gov.cn/xinwen/ 2020‐12/10/content_5568770.htm.",
    "source": "《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读/《预防宫颈癌：WHO宫颈癌前病变筛查和治疗指南（第二版）》解读.md"
  },
  {
    "text": "议程项目7 EB156/CONF./13 2025 年 2 月 4 日 # 世界消除宫颈癌日 亚美尼亚、孟加拉国、博茨瓦纳、埃及、埃塞俄比亚、牙买加、莱索托、尼日利亚、巴勒斯坦、菲律宾、卢旺达、南非、坦桑尼亚联合共和国和赞比亚提出的决定草案 执行委员会审议了总干事的报告1，决定建议第七十八届世界卫生大会通过下述决议： 第七十八届世界卫生大会，(PP1) 审议了总干事的报告； (PP2) 回顾WHA73.",
    "source": "世界消除宫颈癌日",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/世界消除宫颈癌日/世界消除宫颈癌日.md"
  },
  {
    "text": "2 号决议（2020 年），其中除其他外，通过了《加速消除作为公共卫生问题的宫颈癌全球战略》，敦促会员国采取行动，通过预防，包括接种疫苗、发现和治疗，以及对宫颈癌规划采取整体系统方法，加速消除宫颈癌；呼吁国际组织和利益攸关方优先开展活动，通过预防，包括接种疫苗、发现和治疗，消除宫颈癌；请总干事支持会员国实施全球战略并加强利益攸关方的参与，以实现 2030 年目标； (PP3) 回顾《2030 年可持续发展议程》，特别是目标 1（在全世界消除一切形式的贫困）、目标 3（确保健康的生活方式，促进各年龄段人群的福祉）、目标 5（实现性别平等，增强所有妇女和女童的权能）和目标 10（减少国家内部和国家之间的不平等）； (PP4) 认识到每个人都有权不受歧视地享有能达到的最高标准身心健康； (PP5) 还认识到必须优先重视妇女和女童，特别是感染艾滋病毒的妇女和女童的健康，并解决相关的污名和性别不平等问题，消除影响获得宫颈癌相关卫生保健服务的障碍，根据国家重点和国情，作为综合卫生保健系统的一部分，促进普遍提供性和生殖卫生保健服务、人乳头状瘤病毒疫苗接种、宫颈癌筛查和治疗； (PP6) 认识到感染艾滋病毒的女性承受过重的负担，她们更有可能罹患宫颈癌； (PP7) 认识到宫颈癌如果得到及早发现和充分治疗，是可以预防、治疗和治愈的，但它仍然是全世界女性癌症相关发病和死亡的最常见原因之一，并可增加不孕症，给发展中国家造成过重的负担； (PP8) 还认识到世卫组织（包括其区域和国家办事处）、国际癌症研究机构和其他国际组织在通过对筛查和治疗技术进行培训以及疫苗教育，努力加强一线卫生工作者的能力； (PP9) 认识到需要促进获得宫颈癌筛查服务，这可能包括提供自我采样工具，从而给予一种赋权和参与感； (PP10) 认识到人乳头状瘤病毒是女性宫颈癌的主要原因，也可能导致男性和女性的其他癌症，尽管有疫苗，但 15 岁以下女童的人乳头状瘤病毒疫苗接种覆盖率与 2030 年$90 \\%$ 的目标相距甚远； (PP11) 认识到有效的一级预防（人乳头状瘤病毒疫苗接种）和二级预防（癌前病变筛查和治疗）措施可防止大多数宫颈癌病例。",
    "source": "世界消除宫颈癌日",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/世界消除宫颈癌日/世界消除宫颈癌日.md"
  },
  {
    "text": "(PP12) 强调接种人乳头状瘤病毒疫苗以及筛查和治疗癌前病变是预防宫颈癌的极具成本效益的策略； (PP13) 认识到提高公众认识、获得信息和服务是在生命全程预防和控制疾病的要素； (PP14) 注意到WHA73.2 号决议的历史意义，这是有史以来第一项旨在全球消除一种癌症的决议，而且随此决议于 2020 年 11 月 17 日推出了《加速消除作为公共卫生问题的宫颈癌全球战略》； (PP15) 注意到所有区域都对推出全球战略作出了积极响应，并且继续在每年 11 月17 日这一天开展持续的宣传、计划、行动和健康促进活动以示纪念，由此鼓励社区合作，促进对宫颈癌的预防、早期发现和治疗服务，并始终重视团结各国共同努力实现在全世界首次消除一种癌症的目标， # (OP)1.",
    "source": "世界消除宫颈癌日",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/世界消除宫颈癌日/世界消除宫颈癌日.md"
  },
  {
    "text": "敦促会员国： (1) 将 11 月 17 日定为世界消除宫颈癌日，自 2025 年 11 月起每年举办纪念活动，以进一步促进和维持全球消除宫颈癌的努力； (2) 根据国家重点和国情，并在努力实现全民健康覆盖的背景下，提供充足/适当的资源，以扩大卫生保健服务，促进消除宫颈癌的努力；以及 (3) 促进和支持每年举办世界消除宫颈癌日纪念活动，以公平实现全民健康覆盖； # (OP)2.要求总干事： (1) 利用世界消除宫颈癌日，适当根据《与非国家行为者交往的框架》继续加强利益攸关方的参与，促进协调、创新和资源调动，以支持会员国根据 WHA73.",
    "source": "世界消除宫颈癌日",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/世界消除宫颈癌日/世界消除宫颈癌日.md"
  },
  {
    "text": "2 号决议和适用的任务授权努力消除宫颈癌； (2) 继续强调会员国应努力加速消除宫颈癌这一公共卫生问题，加强基于人口的癌症登记系统，并采用宫颈癌疫苗接种和筛查登记系统，同时需要衡量实现消除目标的进展，包括通过可衡量的进展指标，并强调这是确保及早和便捷获取人乳头状瘤病毒疫苗接种的一项关键措施；以及 (3) 协调世卫组织所有三个层级的努力和参与，包括在区域一级，目的是协调开展活动，促进合作，最大限度发挥宣传和预防运动的影响，以消除宫颈癌； (OP)3.",
    "source": "世界消除宫颈癌日",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/世界消除宫颈癌日/世界消除宫颈癌日.md"
  },
  {
    "text": "建议利益攸关方和/或合作伙伴： (1) 加强多边和国际合作，促进人人享有知识以及安全、负担得起的优质服务、卫生保健产品和干预措施，以便根据实现全民健康覆盖的目标和其他相关区域承诺，并考虑到任何利益冲突，加快消除宫颈癌这一公共卫生问题；以及(2) 关注或致力于消除宫颈癌的国际和区域组织和机构利用世界消除宫颈癌日，根据国家重点和国情加深其对会员国的支持和参与，以便实现相关目标； (OP)4.决定，根据 OP1(1)将 11 月 17 日定为世界消除宫颈癌日，并自 2025 年 11 月起每年举办纪念活动，以进一步促进和维持全球消除宫颈癌的努力。",
    "source": "世界消除宫颈癌日",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/世界消除宫颈癌日/世界消除宫颈癌日.md"
  },
  {
    "text": "# • 专题报道 —— 综合施策，科学防癌 • # 中国宫颈癌筛查服务政策量化分析 张晓晗，胡尚英，赵方辉，周彩虹 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院流行病学研究室， 北京 100021 通信作者：周彩虹，E-mail：13521290838@126.com 【摘 要】目的 分析中国宫颈癌筛查服务政策的内容与不足，为后续优化宫颈癌筛查服务政策体系提供建议。方法 收集中国政府网、国家卫生健康委、中国疾病预防控制中心等官网以及北大法宝数据库等平台2006 年1 月 1 日 — 2023 年 5 月 31 日发布的宫颈癌筛查服务相关政策文件，采用内容分析法构建“政策工具 – 政策目标 – 政策力度”三维框架对国家层面颁布的宫颈癌筛查服务政策文件进行量化分析。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "结果 本研究共纳入37 份宫颈癌筛查服务相关政策文件，政策工具维度编码 174 条，其中环境型政策工具使用最多 $( 5 0 .5 7 \\% )$ ，需求型政策工具使用最少（ $1 4 .9 5 \\%$ ），无政府采购和医保支付等子工具；政策目标维度编码 149 条，其中健全筛查长效工作机制占比最大 $5 2 .3 4 \\%$ ）；政策力度平均分数为 2.54 分，我国现行宫颈癌筛查服务相关政策文件基本以“通知”等非立法性文件形式发布， $\\geqslant 4$ 分的政策文件仅占 $2 1 .",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "6 2 \\%$ 且条款较少涉及宫颈癌筛查服务。政策工具、目标和力度的交叉分析结果显示，在政策工具维度中，环境型政策工具政策力度最大（2.83 分），需求型和供给型政策工具分别为 2.47 分和 2.33 分；在政策目标维度中，除推动信息化管理的政策力度最低（2.00 分）外，其他目标的政策力度分布相对均衡，均在 2.59 分上下浮动。结论 中国宫颈癌筛查服务政策工具内部结构不均衡，政策目标结构有待优化，不同政策主体对宫颈癌筛查服务政策使用工具和关注点侧重不同，部门间协作不足，应进一步加强政策顶层设计以推进我国宫颈癌筛查服务政策的落地实施。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "【关键词】 宫颈癌；筛查服务；政策；量化分析 # Cervical cancer screening service policies in China, 2006 – 2023: a quantitative analysis of government documents ZHANG Xiaohan, HU Shangying, ZHAO Fanghui, ZHOU Caihong (National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China) Corresponding author: ZHOU Caihong, E-mail: 13521290838@126.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "com 【 Abstract】 Objective To analyze the content and shortcomings of policy documents for cervical cancer screening service issued by government agencies in China and to provide suggestions for optimizing policies for cervical cancer screening service in the future.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "Methods We retrieved policy documents on cervical cancer screening services issued by government agencies from 2006 to 2023 through official websites such as the Chinese Government Network, the National Health Commission of China, the Chinese Center for Disease Control and Prevention, and platforms such as the PKU Law database.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "Content analysis was used to construct a three-dimensional policy instrument – policy objective – policy strength framework for quantitative analysis of national-level cervical cancer screening policy documents.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "Results This study included 37 policy documents related to cervical cancer screening services, with 174 policy items coded.Among them, the policy items for cervical cancer screening service environment were mentioned most $( 5 0 .",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "5 7 \\%$ of all coded items), and the items for government objective were mentioned least $( 1 4 .9 5 \\% )$ , and no items were mentioned for cancer screening service-related government procurement and medical insurance payment.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "A total of 149 items for cancer screening service-related administrative objective were coded, among which the proportion of items for optimizing the long-term operation mechanism of screening is the highest $( 5 2 .",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "3 4 \\% )$ .The average policy strength score for all retrieved documents is 2.54.The analyzed policy documents are mainly issued in the form of non-legislative documents, such as notices.Policy documents with a strength score of $\\geqslant 4$ points account for only $2 1 .",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "6 2 \\%$ of all documents, and there are few items related to cervical cancer screening services in the documents.In terms of the three dimensions of the documents, the mean strength score (2.83) was highest for policies on the operating environment of screening services, followed by 2.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "47 for those on government objective and 2.33 for those on provision; on the aspect of government objective, the lowest strength score (2.00) was for policies on promoting relevant information management; the strength scores fluctuated around 2.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "59 for policies on other aspects related to screening services.Conclusion The internal structure of policy instruments for cervical cancer screening services in China is uneven, and the structure of policy objectives needs to be optimized.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "Different policy units have different focuses on the implementation and concern for cervical cancer screening services, and there is insufficient cooperation among different departments.Therefore, it is necessary to further strengthen the top-level policy design to promote the implementation of cervical cancer screening services in China.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "【Keywords】 cervical cancer; screening service; policy; quantitative analysis 宫颈癌是女性癌症死亡的第四大原因，研究显示，中国宫颈癌的发病率和死亡率在世界中均处于较高水平，疾病负担较重[1 – 3]。目前以筛查为主的二级预防措施仍是宫颈癌预防的主要方法，但我国尚未建立全覆盖的宫颈癌筛查体系，且存在部分地区筛查方法较单一[4]、基层卫生服务人员能力建设不足[5]、信息系统不互通[6] 等问题。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "近年来，我国政府出台了一系列政策措施规范宫颈癌筛查服务以促进筛查的长效化发展，但目前关于宫颈癌筛查服务政策文件量化分析的研究较少，无法全面了解宫颈癌筛查政策的现状和进展。因此，本研究收集中国政府网、国家卫生健康委、中国疾病预防控制中心等官网以及北大法宝数据库等平台 2006 年 1 月 1 日 — 2023 年 5 月31 日发布的宫颈癌筛查服务相关政策文件，采用内容分析法构建“政策工具 – 政策目标 – 政策力度”三维框架对国家层面颁布的宫颈癌筛查服务政策文件进行了量化分析，旨在分析中国宫颈癌筛查服务政策的内容与不足，为后续优化宫颈癌筛查服务政策体系提供建议。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "结果报告如下。# 1 资料与方法 1.1 资料来源 收集中国政府网、国家卫生健康委、中国疾病预防控制中心等官网以及北大法宝数 据 库 等 平 台 2006 年 1 月 1 日 — 2023 年 5 月31 日发布的宫颈癌筛查服务相关政策文件。所纳入政策文件均为国家层面颁布的政策内容明确提到宫颈癌筛查的规范政策文件，政策文本形式主要为法律法规、意见、通知等，排除不属于原政策的文件（如政策解读等）以及政策内容仅出现关键词而无实质性具体内容的文件。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "1.2 统计分析（图 1、表 1） 应用 Excel 2019 软件进行统计分析。采用内容分析法，以政策文件中各项条目为分析单元，按照“政策文件编号 – 章节 –条目”进行编码。例如，将第 1 份政策文件《关于印发加速消除宫颈癌行动计划（2023 — 2030 年）的通知》的“五、完善宫颈癌综合防治体系，提高防治能力”中的“（二）推动宫颈癌防治信息化管理”编码为“1 – 5 – 2”。若同一条目表达不同意义，则进行第四级编码；若同一条目对应不同指标，则重复编码。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "研究表明，政策工具、政策目标和政策力度三者之间的协调运用有助于产生最佳的政策协同效应[7]，政策工具、目标、力度三维分析框架近年来亦被应用于癌症防治政策分析的研究中[8]，因此本研究以政策工具为 X 轴、政策目标为Y 轴、政策力度为Z 轴，从3 个维度构建宫颈癌筛查服务政策分析框架（见图 1）对国家层面颁布的宫颈癌筛查服务政策文件进行了量化分析。（1）政策工具（X 维度）：政策工具是实现政策目标的具体手段和方法[9]，Rothwell 等[10] 提出将政策工具分为供给型、环境型和需求型 3 类。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "其中，供给型政策工具对宫颈癌筛查服务起直接推动作用，指政府主动提供人才、资金、信息和技术等支持；需求型政策工具对宫颈癌筛查服务起直接拉动作用，指政府通过政府采购、示范经验、医保支付和宣传推广等措施释放宫颈癌筛查的需求；环境型政策工具是通过规划目标和实施法律等方法为政策实施提供基本条件，间接影响宫颈癌筛查服务。政策工具名称及含义具体见表 1。（2）政策目标（Y 维度）：政策目标代表政策制定和实施的预期结果[11]，通过对所纳入政策文件中涉及宫颈癌筛查的全部条目进行阅读思考，最终本研究将政策目标归纳为普及筛查知识、健全筛查长效工作机制、加强筛查能力建设、推动信息化管理、促进新技术参与和加强组织实施 6 个方面。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "（3）政策力度（Z 维度）：政策力度是衡量政策法律效力和重要程度的指标[12]，本研究以国务院 《 规 章 制 定 程 序 条 例 》 [13] 和 相 关 研 究 [7 – 8, 14]中政策力度量化标准为依据，按照政策颁布机构层级和数量将政策力度分为以下 5 级：全国人大及常委会颁布的法律法规或中共中央、国务院颁布的纲要评分为 5 分；国务院颁布的规划、规定和意见评分为 4 分；国务院颁布的方案、办法以及各部委颁布的规定、意见或 3 个及以上部委联合发文评分为 3 分；国务院颁布的通知、公告以及各部委颁布的方案、办法或 2 个部委联合发文评分为 2 分；各部委单独颁布的通知和公告评分为1 分。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "![](images/d5f94399577fcbcb08e990d7dff1bd68efd9ffc576c54ae0ddcefc07fee69223.jpg) 图 1 宫颈癌筛查服务政策三维分析框架 Fig.1 Framework for three-dimensional analysis of cervical cancer screening service policy in China (X, Y,and Z axes denote policy instruments, objective, and strength) 表 1 宫颈癌筛查服务各类政策工具含义 Table 1 Definitions for 17 terms of policy instruments for cervical cancer screening service in China in three aspects of service provision, environment and administrative intention <html><body><table><tr><td>政策工具</td><td>项目</td><td>含义</td></tr><tr><td>供给型</td><td>资金投入</td><td>政府为宫颈癌筛查服务提供资金支持，如专项资金和经费补助等</td></tr><tr><td></td><td>人才培养</td><td>政府通过教育培训和技术指导等建设宫颈癌筛查人才队伍</td></tr><tr><td></td><td>信息化支持</td><td>政府通过构建信息化系统为宫颈癌筛查服务提供信息化支持</td></tr><tr><td></td><td>标准规范</td><td>政府为宫颈癌筛查服务制定指导方案、技术方案和筛查指南等</td></tr><tr><td></td><td>公共服务</td><td>向妇女提供包括妇科检查、宫颈癌初筛、阴道镜检查还未异常或可疑病例随访等在内的宫颈癌筛查相关公共服务</td></tr><tr><td></td><td>硬件建设</td><td>包括宫颈癌筛查机构与培训基地的建设和筛查相关设施的配备等</td></tr><tr><td>环境型</td><td>目标规划</td><td>政府为宫颈癌筛查服务设定总体目标和未来规划</td></tr><tr><td></td><td>法规管制</td><td>政府通过落实法律和法规等强制措施加强对宫颈癌筛查服务的监督管理</td></tr><tr><td></td><td>策略性措施</td><td>政府为宫颈癌筛查水平的提升而制定的系列措施，如鼓励创新和技术引进等</td></tr><tr><td></td><td>质控评价</td><td>政府针对宫颈癌筛查具体内容制定监督指标，完善考核方法，加强对宫颈癌筛查服务的数据监测及考核评估与质量控制</td></tr><tr><td></td><td>组织协作</td><td>政府强化相关工作的组织实施，加强各部门沟通协调，提高工作效率</td></tr><tr><td>需求型</td><td>政府采购</td><td>政府直接或委托其他组织利用经济手段降低采购成本,如检测试剂集采和服务项目价格谈判等</td></tr><tr><td></td><td>示范经验</td><td>开展宫颈癌筛查服务试点工作并总结推广试点经验</td></tr><tr><td></td><td>产业发展</td><td>政府推动宫颈癌筛查新技术发展，促进其与多领域的对接与融合</td></tr><tr><td></td><td>医保支付</td><td>政府通过提高报销比例和扩大报销范围等方式提高宫颈癌筛查服务利用</td></tr><tr><td></td><td>宣传推广</td><td>政府对宫颈癌筛查相关工作进行宣传教育，对高风险妇女进行筛查和早诊早治</td></tr><tr><td></td><td>市场塑造</td><td>政府鼓励社会力量参与宫颈癌筛查服务，集中各方力量推动宫颈癌防治事业</td></tr></table></body></html> # 2 结 果 2.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "1 中国宫颈癌筛查服务政策基本情况（表 2） 本研究共纳入中国宫颈癌筛查服务相关政策文件37 份 ，其 中 2006、 2007、 2018 和 2023 年 各 1 份 ，2015、 2016、 2020 和 2022 年 各 2 份 ，2011 和 2012年各 3 份，2009、2010 和 2019 年各 4 份，2021 年纳入最多为 7 份，2008、2013、2014 和 2017 年均未纳入相关政策文件，具体见表 2；发文部门主要包括国家卫生健康委（包括原国家卫生计生委、原卫生部）、国务院、财政部、健康中国行动推进委员会等，其中 27 份为单独发文 $( 7 2 .",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "9 7 \\% )$ ），10 份为联合发文 $( 2 7 .0 3 \\% )$ 。表 2 宫颈癌筛查服务政策文件文本示例 Table 2 Year of issue, document name header, issuing agency, and document number for 37 policy documents on cervical cancer screening services in China published from 2006 to 2023 in descending order <html><body><table><tr><td>序号</td><td>年份</td><td>政策名称</td><td>发文机构</td><td>政策文号</td></tr><tr><td>1</td><td></td><td>2023关于印发加速消除宫颈癌行动计划(2023－2030年)的通知</td><td>国家卫生健康委、教育部、 民政部等10个部门</td><td>国卫妇幼发（2023）1号</td></tr><tr><td>2</td><td></td><td>2022国家卫生健康委关于印发贯彻2021－2030年中国妇女儿童发展纲要 实施方案的通知</td><td>国家卫生健康委</td><td>国卫妇幼函（2022）56号</td></tr><tr><td>3</td><td></td><td>2022健康中国行动推进委员会办公室关于印发健康中国行动2022年工作要点健康中国行动推进委员会 的通知</td><td>办公室</td><td>国健推委办发（2022）2号</td></tr><tr><td>4</td><td></td><td>2021国家卫生健康委办公厅关于印发宫颈癌筛查工作方案和乳腺癌筛查工作国家卫生健康委办公厅 方案的通知</td><td></td><td>国卫办妇幼函（2021）635号</td></tr><tr><td>5</td><td></td><td>2021国务院关于印发中国妇女发展纲要和中国儿童发展纲要的通知（2021一 2030年）</td><td>国务院</td><td>国发（2021）16号</td></tr><tr><td>6</td><td></td><td>2021关于印发《健康城市建设推动健康中国行动创新模式试点工作方案》的 通知</td><td>公室、健康中国行动推进委</td><td>全国爱国卫生运动委员会办全爱卫办函（2021）5号</td></tr><tr><td>7</td><td></td><td>2021健康中国行动推进委员会办公室关于印发健康中国行动2021年工作</td><td>员会办公室 健康中国行动推进委员会</td><td>国健推委办发（2021）1号</td></tr><tr><td>8</td><td></td><td>要点的通知 2021 健康中国行动推进委员会关于印发健康中国行动2019－2020年试考核</td><td>办公室 健康中国行动推进委员会</td><td>国健推委发（2021）2号</td></tr><tr><td>9</td><td></td><td>实施方案的通知 2021健康中国行动推进委员会关于印发健康中国行动监测评估实施方案和健健康中国行动推进委员会</td><td></td><td>国健推委发（2021）1号</td></tr><tr><td>10</td><td></td><td>康中国行动监测评估指标体系(试行)的通知 2021中华人民共和国国民经济和社会发展第十四个五年规划和2035年远景</td><td>全国人民代表大会</td><td></td></tr><tr><td>11</td><td></td><td>目标纲要 2020国家卫生健康委办公厅关于通报\"云上妇幼\"典型经验做法的通知</td><td>国家卫生健康委办公厅</td><td>国卫办妇幼函（2020）966号</td></tr><tr><td>12</td><td></td><td>2020关于开展健康城市建设推动健康中国行动创新模式试点工作的通知</td><td>全国爱国卫生运动委员会办 公室、健康中国行动推进委</td><td></td></tr><tr><td>13</td><td></td><td>2019国家卫生健康委、国家发展改革委、教育部等关于印发健康中国</td><td>员会办公室 国家卫生健康委员会、 财政部、教育部等</td><td>国卫疾控发（2019）57号</td></tr><tr><td>14</td><td></td><td>行动—癌症防治实施方案(2019—2022年)的通知 2019关于做好2019年基本公共卫生服务项目工作的通知（新划入基本公共</td><td>10个部门 国家卫生健康委、财政部、</td><td>国卫基层发（2019）52号</td></tr><tr><td>15</td><td></td><td>卫生服务工作规范（2019年版)） 2019健康中国行动(2019－2030年)</td><td>国家中医药局 健康中国行动推进委员会</td><td></td></tr><tr><td>16</td><td></td><td>2019关于印发全国基层医疗卫生机构信息化建设标准与规范(试行)的通知</td><td></td><td>国家卫生健康委、中医药局国卫规划函（2019）87号</td></tr><tr><td>17</td><td></td><td>2018关于印发健康扶贫三年攻坚行动实施方案的通知</td><td>改革委、财政部、国家医疗</td><td>国家卫生健康委、国家发展国卫财务发（2018）38号</td></tr><tr><td></td><td></td><td></td><td>保障局、国务院扶贫办</td><td></td></tr><tr><td>18</td><td></td><td>2016关于发布《远程医疗信息系统基本功能规范》等7项卫生行业标准的通告国家卫生计生委</td><td></td><td>国卫通（2016）21号</td></tr><tr><td>19 20</td><td></td><td>2016国务院关于印发\"十三五\"脱贫攻坚规划的通知 2015关于印发中国癌症防治三年行动计划(2015－2017年)的通知</td><td>国务院 国家卫生计生委、国家发展国卫疾控发（2015）78号</td><td>国发（2016）64号</td></tr><tr><td></td><td></td><td></td><td>改革委等16个部门</td><td></td></tr><tr><td>21</td><td></td><td>2015国家卫生计生委妇幼司关于印发农村妇女两癌检查项目管理方案 (2015年版)的通知</td><td>国家卫生计生委</td><td>国卫妇幼妇卫便函（2015） 71号</td></tr><tr><td>22</td><td></td><td>2012国务院关于落实《政府工作报告》重点工作部门分工的意见</td><td>国务院</td><td>国发（2012）13号</td></tr><tr><td>23</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>24</td><td></td><td>2012关于印发贯彻2011－2020年中国妇女儿童发展纲要实施方案的通知</td><td>卫生部</td><td>卫妇社发（2012）12号</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>计划执行情况与2012年国民经济和社会发展计划的决议</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>2012第十一届全国人民代表大会第五次会议关于2011年国民经济和社会发展全国人民代表大会</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr></table></body></html> 续表 2 Table 2 Continued <html><body><table><tr><td>序号</td><td>年份</td><td>政策名称</td><td>发文机构</td><td>政策文号</td></tr><tr><td>26</td><td>2011</td><td>国务院关于落实《政府工作报告》重点工作部门分工的意见</td><td>国务院</td><td>国发（2011）7号</td></tr><tr><td>27</td><td>2011</td><td>第十一届全国人民代表大会第四次会议关于2010年国民经济和社会发展全国人民代表大会 计划执行情况与2011年国民经济和社会发展计划的决议</td><td></td><td></td></tr><tr><td>28</td><td>2010</td><td>国务院关于深化医药卫生体制改革工作情况的报告</td><td>国务院</td><td></td></tr><tr><td>29</td><td>2010</td><td>卫生部办公厅关于落实2010年医改任务做好农村卫生服务有关工作的</td><td>卫生部办公厅</td><td>卫办农卫发（2010）120号</td></tr><tr><td>30</td><td>2010</td><td>通知 卫生部、全国妇联关于印发《2010年农村妇女“两癌\"检查项目管理方案》</td><td>卫生部、全国妇联</td><td></td></tr><tr><td>31</td><td>2010</td><td>的通知 国务院办公厅关于印发医药卫生体制五项重点改革2010年度主要工作安国务院办公厅</td><td></td><td>国办函（2010）67号</td></tr><tr><td>32</td><td>2009</td><td>排的通知 卫生部办公厅关于印发《农村妇女宫颈癌检查项目技术方案(试行)》的</td><td>卫生部办公厅</td><td>卫办妇社发（2009）135号</td></tr><tr><td></td><td></td><td>通知</td><td></td><td></td></tr><tr><td>33 34</td><td>2009 2009</td><td>关于印发《农村妇女\"两癌\"检查项目管理方案》的通知 国务院办公厅关于印发医药卫生体制五项重点改革2009年工作安排的</td><td>卫生部、全国妇联 国务院办公厅</td><td>卫妇社发（2009）61号 国办函（2009）75号</td></tr><tr><td>35</td><td></td><td>通知 卫生部办公厅关于印发《2009年中西部地区农村卫生人员培训项目管理</td><td>卫生部办公厅</td><td>卫办农卫发（2009）163号</td></tr><tr><td>36</td><td></td><td>方案》的通知 卫生部办公厅关于印发《癌症早诊早治项目管理办法》试行)及部分癌症 卫生部办公厅</td><td></td><td>卫办疾控发（2007）12号</td></tr><tr><td>37</td><td></td><td>早诊早治技术方案的通知 卫生部疾病控制司关于下发2006年疾病预防控制(爱国卫生)工作要点的卫生部疾病控制司</td><td></td><td></td></tr></table></body></html> 2.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "2 政策工具维度分析（表3） 政策工具维度共编码 174 条，其中使用频率最高的为环境型政策工具，编码 88 条，占 $5 0 .5 7 \\%$ ；其次为供给型政策工具，编码 60 条，占 $3 4 .4 8 \\%$ ；需求型政策工具使用频率最低，编码 26 条，占 $1 4 .9 5 \\%$ 。环境型政策工具使用策略性措施最多，其次为目标规划、质控评价和组织协作，法规管制关注较少；供给型政策工具运用最多的为标准规范，公共服务和人才培养运用相对较多；需求型政策工具整体使用最少，仅宣传推广占 $6 .",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "9 0 \\%$ ，且缺乏政府采购和医保支付等子工具。表 3 宫颈癌筛查服务政策工具分布 Table 3 Number and proportion of policy items grouped by three aspects of service delivery, environment, and administrative intent in 37 documents on cervical cancer screening services issued by government agencies in China from 2006 to 2023 <html><body><table><tr><td>工具类型</td><td>项目</td><td>编码数</td><td>比例(%)</td></tr><tr><td>供给型</td><td>资金投入</td><td>5</td><td>2.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "87</td></tr><tr><td></td><td>人才培养</td><td>11</td><td>6.32</td></tr><tr><td></td><td>信息化支持</td><td>5</td><td>2.87</td></tr><tr><td></td><td>标准规范</td><td>23</td><td>13.22</td></tr><tr><td></td><td>公共服务</td><td>14</td><td>8.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "05</td></tr><tr><td>环境型</td><td>硬件建设</td><td>2</td><td>1.15</td></tr><tr><td rowspan=\"5\"></td><td>目标规划</td><td>25</td><td>14.37</td></tr><tr><td>法规管制</td><td>1</td><td>0.57</td></tr><tr><td>策略性措施</td><td>34</td><td>19.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "54</td></tr><tr><td>质控评价</td><td>15</td><td>8.62</td></tr><tr><td>组织协作</td><td>13</td><td>7.47</td></tr><tr><td rowspan=\"6\">需求型</td><td>政府采购</td><td>0</td><td>0.00</td></tr><tr><td>示范经验</td><td>6</td><td>3.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "45</td></tr><tr><td>产业发展</td><td>6</td><td>3.45</td></tr><tr><td>医保支付</td><td>0</td><td>0.00</td></tr><tr><td>宣传推广</td><td>12</td><td>6.90</td></tr><tr><td>市场塑造</td><td>2</td><td>1.15</td></tr></table></body></html> 2.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "3 政策目标维度分析 政策目标维度共编码149 条，其中国家政策最为重视健全筛查长效工作机制共编码 78 条，占 $5 2 .3 4 \\%$ ；其次为加强组织实施、普及筛查知识和加强筛查能力建设，分别编码 30 条、16 条和 14 条，分别占 $2 0 .1 3 \\%$ 、 $1 0 .7 4 \\%$ 和 $9 .4 0 \\%$ ；而促进新技术参与和推动信息化管理的关注度较低，分别编码 6 条和 5 条，分别占 $4 .",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "0 3 \\%$ 和 $3 .3 6 \\%$ 。# 2.4 政策力度维度分析（表 4） 根据政策力度量 化标准对 37 份政策文件的效力进行计算，得出政策力度的平均分数为 2.54 分。我国现行宫颈癌筛查服务相关政策文件基本以“通知”等非立法性文件形式发布，政策力度 $\\geqslant 4$ 分的政策文件仅占$2 1 .6 2 \\% ( 8 / 3 7 )$ ，且条款较少涉及宫颈癌筛查服务；另外 $7 8 .",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "3 8 \\% ( 2 9 / 3 7 )$ 政策力度 $\\leqslant 3$ 分的政策文件虽有国务院单独发布或国家卫生健康委、全国妇联、财政部等联合发布的政策文件，但多为通知，政策效力较低。表 4 中国宫颈癌筛查服务政策力度得分情况 Table 4 Year-specific number and mean score of documents rated by five levels of administrative strength for 37 documents on cervical cancer screening services issued by government agencies in China from 2006 to 2023 <html><body><table><tr><td rowspan=\"2\">年份</td><td colspan=\"5\">不同政策力度下政策分布频数(n)</td><td rowspan=\"2\">力度平均分(分)</td></tr><tr><td>1</td><td>2</td><td>3</td><td>4</td><td>５</td></tr><tr><td>2006</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "00</td></tr><tr><td>2007</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>2.00</td></tr><tr><td>2009</td><td>0</td><td>4</td><td>0</td><td>0</td><td>0</td><td>2.00</td></tr><tr><td>2010</td><td>1</td><td>3</td><td>0</td><td>0</td><td>0</td><td>1.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "75</td></tr><tr><td>2011</td><td>0</td><td>0</td><td>0</td><td>1</td><td>2</td><td>4.67</td></tr><tr><td>2012</td><td>0</td><td>1</td><td>0</td><td>1</td><td>1</td><td>3.67</td></tr><tr><td>2015</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>2.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "50</td></tr><tr><td>2016</td><td>1</td><td>0</td><td>0</td><td>1</td><td>0</td><td>2.50</td></tr><tr><td>2018</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>3.00</td></tr><tr><td>2019</td><td>0</td><td>2</td><td>2</td><td>0</td><td>0</td><td>2.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "50</td></tr><tr><td>2020</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1.50</td></tr><tr><td>2021</td><td>1</td><td>4</td><td>0</td><td>0</td><td>2</td><td>2.71</td></tr><tr><td>2022</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "50</td></tr><tr><td>2023</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>3.00</td></tr><tr><td>合计</td><td>6</td><td>18</td><td>5</td><td>3</td><td>5</td><td>2.54</td></tr></table></body></html> 2.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "5 政策工具、目标和力度的交叉分析 政策工具、目标和力度的三维分析结果显示，供给型政策工具在健全筛查长效工作机制中使用最多，环境型政策工具的使用集中在健全筛查长效工作机制和加强组织实施 2 个方面，需求型政策工具在 3 种政策目标中使用比较均衡。在政策工具维度，环境型政策工具政策力度最大（2.83 分），需求型和供给型政策工具分别为 2.47 和 2.33 分；在政策目标维度，除推动信息化管理的政策力度最低（2.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "00 分）外，其他目标的政策力度分布相对均衡，均在 2.59 分上下浮动。# 3 讨 论 中国宫颈癌筛查服务政策对环境型政策工具依赖较大，内部组合待调整。随着健康中国行动的落地实施，带动了全国的癌症防控工作[15]，而宫颈癌消除需要综合施策，故应采取系列措施优化其筛查策略。完善宫颈癌防控体系的前提是提高政策保障，其中新西兰和英国在上位法中已有宫颈癌筛查的相关规定，美国亦为宫颈癌筛查专门立法[4]，但我国在妇女健康的法律法规中未涵盖预防宫颈癌的具体规定 [4]，法规管制政策工具占 $0 .",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "5 7 \\%$ ，仅涉及推动落实女职工宫颈癌筛查工作，低于我国肿瘤防治和慢性病健康促进政策工具中的法规管制水平[8, 16 – 17]，政策落实保障力不足。本研究结果显示，供给型政策工具使用较为均衡，部分环节有待加强。在标准规范制定方面，我国通过制定宫颈癌筛查、早诊早治、综合防治指南和技术方案等保障了筛查工作的顺利推进，但基层医疗人员技术能力依然不足，现有服务网络不足以支撑更大规模的妇女筛查[18]。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "目前资金投入、信息化支持和硬件建设等工具作为筛查的必备要素，使用稍有不足，我国大部分地区未注重信息化平台发展，癌症防治信息化平台建设尚无相关专项经费支持[6]，因此各类医疗机构信息系统大多不互通，全过程信息管理无法实现[4]。需求型政策工具使用不足，部分工具缺失。其中，市场塑造政策工具使用最少，当前政府积极鼓励社会资本投入宫颈癌防治，但尚未明确具体路径和举措，反映出该工具尚处于发展阶段，有待进一步完善。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "目前美国和英国等国家主要采用医疗保险筹资模式进行宫颈癌筛查[19 – 20]，而我国则采用政府出资的单一筹资模式，包括政府出资为城乡适龄妇女提供“两癌”筛查项目、城镇单位女职工体检和科研团队开展的筛查项目等；且国家层面未发布政府采购相关政策文件，多为地方政府自行采购，弱化了国家统筹计划下对地方政府宫颈癌筛查服务的拉动作用。本研究结果还显示，政策目标结构有待进一步优化。健全筛查长效工作机制主要包括提高筛查精度、关注未筛人群和优化筛查策略等，该目标贯彻筛查政策的始终。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "但我国在促进新技术参与方面存在一些不足，如人工智能阴道镜辅助诊断技术中数据集相对较少，研究单一[21 – 23]；“互联网 $^ +$ 医疗健康”技术内部管理混乱，缺乏合理监管机制等问题[24]。同时，我国近年来开始关注宫颈癌防控信息化平台的建设，但信息系统依然存在“孤岛”效应，因此应加大前沿技术和信息化平台建设的政策支持力度，对政策目标结构进一步优化。此外，政策力度有待提高，政策工具、政策目标与政策力度之间匹配性较差。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "政策力度的高低反映出不同政策主体对宫颈癌筛查政策使用工具和关注点均有所侧重，近年来政府主要把重心放在环境型工具的使用上，供给型和需求型政策工具则多在通知中出现。不同的政策目标也需要不同的政策手段实施，目前国家信息化建设较为滞后，政策文件少且多部门协作不足，因此政策力度较低。为优化宫颈癌筛查服务政策内部结构，需协调使用不同类型的政策工具并加强薄弱环节。在供给型政策工具方面，可通过增加专项资金和向医疗保险筹资模式转变等方式加强经费保障；在环境型政策工具方面，要积极推动如女职工劳动保护等相关立法，提高政策保障；在需求型政策工具方面，鼓励民营资本和社会力量参与宫颈癌筛查服务，并通过国家层面价格谈判和集中采购等政府采购措施共同推动宫颈癌防治。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "与此同时，还应构建宫颈癌筛查服务信息平台，开发适宜不同地区使用的筛查技术；实现数据标准化，推动细胞学和组织病理学数字化平台建设；推动普及以高危型人乳头瘤状病毒检测技术为初筛方法，鼓励开发使用更低成本、简便与快捷的即时检测系统，使“即筛即治”成为可能。此外，建议相关部门从长效筹资、法律保障、医疗保障等方面完善政策顶层设计，形成政府主导、部门协同、机构支持、社会共担的宫颈癌防治工作模式，不断推进宫颈癌筛查服务政策的落地实施。",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "# 参考文献 [ 1 ] International Agency for Research on Cancer.GLOBOCAN 2022 [EB/OL].(2024 – 02 – 08)[2024 – 02 – 08].https://gco.iarc.fr/.[ 2 ] 徐婷婷, 詹行天, 贺小宁, 等.\"一带一路\"沿线国家宫颈癌流行病 学负担现状分析 [J].中国公共卫生, 2023, 39(10): 1311 – 1314.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "[ 3 ] 于洗河, 张景茹, 降海蕊, 等.中国女性 1990 — 2019 年宫颈癌和 乳腺癌疾病负担分析 [J].中国公共卫生, 2022, 38(5): 534 – 538.[ 4 ] 包鹤龄, 方利文, 王临虹.全球建立子宫颈癌防控体系的现况及 策略思考 [J].中华预防医学杂志, 2017, 51(1): 96 – 100.[ 5 ] 马兰, 宋波, 吴久玲, 等.中国农村妇女两癌检查项目服务能力现 状分析 [J].",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "中国公共卫生, 2018, 34(9): 1250 – 1253.[ 6 ] 薛鹏, 唐朝, 江宇, 等.数字化时代建设宫颈癌防治信息化平台的 必要性 [J].中国医学科学院学报, 2021, 43(4): 649 – 652.[ 7 ] 石敏, 徐梦丹, 许星莹, 等.我国医联体政策量化研究: 基于政策 目标、工具和力度的内容分析 [J].中国卫生事业管理, 2021, 38(5): 352 – 356,374.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "[ 8 ] 李悦, 许星莹, 赖云锋, 等.基于政策工具视角的我国癌症防治政 策分析 [J].医学与社会, 2022, 35(8): 32 – 38.[ 9 ] 陈振明.政策科学: 公共政策分析导论 [M].2 版.北京: 中国人民 大学出版社, 2003.[ 10 ] Rothwell R, Zegveld W.Reindustrialization and technology[M].Armonk: M.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "E.Sharpe, 1985.[ 11 ] 李浩, 戴遥, 陶红兵.我国 DRG 政策的文本量化分析 — 基于 政策目标、政策工具和政策力度的三维框架 [J].中国卫生政策 研究, 2021, 14(12): 16 – 25.[ 12 ] 张娜, 马续补, 张玉振, 等.基于文本内容分析法的我国公共信息 资 源 开 放 政 策 协 同 分 析 [J].情 报 理 论 与 实 践 , 2020, 43(4): 115 – 122.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "[ 13 ] 中华人民共和国国务院.规章制定程序条例 [EB/OL].(2017 – 12 – 22)[2024 – 02 – 08].https://www.gov.cn/zhengce/202203/content_ 3338199.htm.[ 14 ] 彭纪生, 仲为国, 孙文祥.政策测量、政策协同演变与经济绩效: 基于创新政策的实证研究 [J].管理世界, 2008(9): 25 – 36.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "[ 15 ] 魏文强, 沈洪兵.中国癌症防控历史、现状与展望 [J].中华疾病 控制杂志, 2019, 23(10): 1165 – 1168, 1180.[ 16 ] 刘军军, 王高玲.基于政策工具的慢性病健康促进政策文本量化 研究 [J].中国卫生经济, 2019, 38(2): 12 – 16.[ 17 ] 邓清文, 郑炆苅, 魏艳, 等.政策工具视角下我国肿瘤防治领域政 策文本研究 [J].",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "中国卫生政策研究, 2022, 15(7): 16 – 23.[ 18 ] 罗晓敏, 宋莉, 吴久玲, 等.中国农村妇女宫颈癌检查项目 2012 和 2013 年上报数据结果分析 [J].中华预防医学杂志, 2016, 50(4): 346 – 350.[ 19 ] Centers for Disease Control and Prevention.National breast and cervical cancer early detection program (NBCCEDP)[EB/OL].",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "(2023 – 03 – 29)[2023 – 06 – 02].https://www.cdc.gov/cancer/ nbccedp/.[ 20 ] National Health Service.Your choices in the NHS[EB/OL].(2023 – 05 – 10)[2023 – 06 – 02].https://www.nhs.uk/using-the-nhs/aboutthe-nhs/your-choices-in-the-nhs/.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "[ 21 ] Aramendía-Vidaurreta V, Cabeza R, Villanueva A, et al.Ultrasound image discrimination between benign and malignant adnexal masses based on a neural network approach[J].Ultrasound in Medicine and Biology, 2016, 42(3): 742 – 752.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "[ 22 ] Pergialiotis V, Pouliakis A, Parthenis C, et al.The utility of artificial neural networks and classification and regression trees for the prediction of endometrial cancer in postmenopausal women[J].",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "Public Health, 2018, 164: 1 – 6.[ 23 ] Shen WC, Chen SW, Wu KC, et al.Prediction of local relapse and distant metastasis in patients with definitive chemoradiotherapytreated cervical cancer by deep learning from [18F]-fluorodeoxyglucose positron emission tomography/computed tomography[J].European Radiology, 2019, 29(12): 6741 – 6749.[ 24 ] 周元元, 陈大方.“互联网 $^ +$ 医疗健康”中法律与政策保障现状分 析与建议 [J].中国癌症防治杂志, 2020, 12(6): 606 – 610.",
    "source": "中国宫颈癌筛查服务政策量化分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/中国宫颈癌筛查服务政策量化分析/中国宫颈癌筛查服务政策量化分析.md"
  },
  {
    "text": "# 人乳头瘤病毒疫苗临床应用中国专家共识 中华医学会妇科肿瘤学分会，中国优生科学协会阴道镜和宫颈病理学分会【摘要】 人乳头瘤病毒（human papilloma virus，HPV）疫苗接种是预防HPV感染和相关疾病的有效方法，是防控HPV感染相关疾病的一级预防措施。低龄人群接种HPV疫苗的效果优于高龄人群，性暴露前接种免疫效果最佳。HPV疫苗不仅适用于一般普通人群，同样推荐用于高危、特殊人群。对具有遗传易感、高危生活方式和人类免疫缺陷病毒感染的适龄女性应优先推荐接种HPV疫苗。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "不论是否有HPV感染、细胞学是否异常的适龄女性均可接种HPV疫苗。近期有妊娠计划和妊娠期、哺乳期女性不宜接种HPV疫苗。接种HPV疫苗后仍应进行子宫颈癌筛查。【关键词】 人乳头瘤病毒；疫苗；临床应用；高危；特殊人群 # Chinese expert consensus on clinical application of human papilloma virus vaccine Gynecological Oncology Society of Chinese Medical Association, Chinese Society for Colposcopy and Cervical Pathology Corresponding author: Ma Ding, E-mail: ma@tjh.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "tjmu.edu.cn; Wei Lihui, E-mail: weilhpku@163.com; Xie Xing, E-mail: xiex@zju.edu.cn; Kong Beihua, E-mail: kongbeihua@sdu.edu.cn 【Abstract】 Human papilloma virus (HPV) vaccination is an effective method to prevent HPV infection and the related diseases, and is a primary preventive measure for HPV infection related diseases.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "The vaccination effect of young women is better, and the immune efficacy of vaccination for teenagers before sexual exposure is the best.HPV vaccine is not only suitable for the general population, but also recommended for high-risk and special groups.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "HPV vaccination should be recommended for women in appropriate age with genetic susceptibility, high-risk lifestyle and human immunodeficiency virus infection.No matter whether they have HPV infection or abnormal cytology, suitable-age women can be vaccinated.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Women with pregnancy plan in the near future, or pregnant and lactating women should not be vaccinated.Cervical cancer screening recommendations should be carried out after HPV vaccination.【Key words】 Human papilloma virus; Vaccine; Clinical application; High risk; Special population 人乳头瘤病毒（human papilloma virus，HPV）疫苗接种是预防HPV感染的有效方法，是防控HPV感染相关疾病的一级预防措施。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "对于一般人群的HPV疫苗接种已有规范性指南，但对于高危、特殊人群如何接种HPV疫苗，尚未达成共识。中华医学会妇科肿瘤学分会与中国优生科学协会阴道镜和宫颈病理学分会组织专家，依循医学证据，结合我国国情和临床实际，达成以下共识。# 1 人乳头瘤病毒及其流行病学 HPV是双链DNA病毒，可引起人体皮肤黏膜上皮增生[1]。HPV主要通过性生活或密切接触传播。$80 \\%$ 以上的女性一生中至少有过一次HPV感染，$90 \\%$ 以上的HPV感染可在2年内自然清除，仅不足 $1 \\%$ 的患者发展至子宫颈癌前病变和子宫颈癌[2,3]。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "高危型HPV持续性感染是下生殖道高级别上皮内病变和癌发生的必要因素，已成为严重威胁女性健康的公共卫生问题。1.1 HPV基因型别和分类 目前已确定的HPV型别有200余种，根据有无致癌性，将HPV分为高危型和低危型。我国国家药品监督管理局根据世界卫生 组 织（World Health Organization，WHO） 国 际癌症研究机构（International Agency for Research onCancer，IARC）的建议，将HPV 16/18/31/33/35/39/45/51/52/56/58/59/68定义为高危型，而将HPV 26/53/66/73/82定义为中危型[4]，其中以HPV 16/18诱发癌变的风险最高。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "1.2 HPV感染率和基因型分布 一项纳入了194项研究、1 016 719名女性的荟萃分析结果显示，子宫颈细胞学正常的女性，高危型HPV感染率为 $1 1 .7 \\% ^ { [ 5 ] }$ 。随着病变级别的加重，HPV感染率明显上升，在子宫颈细胞学结果为无明确意义的非典型鳞状上皮细胞（atypical squamous cells of undetermined signi-ficance，ASCUS）改变的女性中为 $52 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "5 \\%$ ，在低级别鳞状上皮内病变（low-grade squamous intraepith-elial lesion，LSIL）的女性中为 $7 4 .8 \\%$ ，在高级别鳞状上皮内病变（high-grade squamous intraepitheliallesion，HSIL）的女性中高达 $8 8 .9 \\% ^ { [ 6 ] }$ 。子宫颈癌患者中HPV 16感染率为 $5 5 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2 \\%$ ，HPV 18感染率为 $1 4 .2 \\%$ ，其他型别按感染率排序依次为HPV 45、33、58、31、52、35、39、 $5 9 ^ { [ 7 ] }$ 。此外，HPV 16的感染率，鳞癌（ $6 1 .7 \\%$ ）高于腺癌（ $50 .0 \\%$ ）；而HPV 18、HPV 45的感染率，腺癌（ $( 3 2 .3 \\% , 1 1 .9 \\%$ ）高于鳞癌（ $8 .3 \\%$ 、5.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "4%）[8]。在中国170万例一般人群中开展的HPV流行病学研究发现，最常见的5种HPV型别分别为HPV 16（ $3 .5 2 \\%$ ）、HPV 52（ $2 .2 0 \\%$ ）、HPV 58（ $2 .1 0 \\%$ ）、HPV 18（ $1 .2 0 \\%$ ）和HPV 33（ $1 .0 2 \\%$ ）。我国子宫颈细胞学正常女性高危型HPV的感染率约为 $7 .1 \\%$ ，而ASCUS女性感染率为 $3 7 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "1 \\%$ ，LSIL女性感染率为$90 .9 \\%$ ，HSIL女性感染率为 $9 3 .0 6 \\% ^ { [ 9 ] }$ 。$6 9 .1 \\%$ 的子宫颈浸润癌归因于HPV 16/18感染[8]。子宫颈鳞癌中，HPV 16（ $7 6 .7 \\%$ ）和HPV 18（ $7 .8 \\%$ ）感染最常见，其次是HPV 31（ $3 .2 \\%$ ）、HPV 52（ $2 .2 \\%$ ）、HPV 58（ $2 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2 \\%$ ）和HPV 33（ $1 .0 \\%$ ）；子宫颈腺癌中HPV 16和HPV 18的感染率分别为 $3 5 .1 \\%$ 和 $3 0 .6 \\% ^ { [ 1 0 ] }$ 。1.3 HPV感染相关疾病负担 HPV感染相关疾病在世界范围内造成了巨大的卫生和经济负担。HPV感染所致癌症比例存在显著地域差异，在澳大利亚、新西兰和美国，不足 $3 \\%$ 的女性癌症归因于HPV感染；在印度和撒哈拉以南非洲地区，超过 $30 \\%$ 的女性癌症归因于HPV感染[11]。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "高危型HPV感染与全球约 $4 .5 \\%$ 的癌症新发病例相关（约63万例），其中女性约57万例（ $8 .6 \\%$ ），男性约6万例（ $0 .8 \\%$ ）[12]。据报道，2018年全球范围内子宫颈癌新发病例约57.0万例[13]，死亡病例约31.1万例，已成为 $1 5 \\sim 4 4$ 岁女性第2位常见肿瘤和第3位死亡原因[14]。我国子宫颈癌新发病例约10.6万例，每年死亡病例约4.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "8万例[15]。几乎 $100 \\%$ 的子宫颈癌、 $88 \\%$ 的肛门癌、 $50 \\%$ 的阴茎癌、 $43 \\%$ 的外阴癌以及口咽癌等肿瘤均与高危型HPV持续性感染有关[16]。低危型HPV感染引起生殖器疣等良性病变，约$90 \\%$ 的生殖器疣由HPV 6/11感染引起[17]。全球生殖器疣患病率（包括新发和复发病例）为（ $1 6 0 \\sim 2 8 9$ ）/10万（中位数为194.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "51/10万）。其中男性新发生殖器疣发病率为（ $1 0 3 \\sim 1 6 8$ ）/10万（中位数为137/10万），女 性 发 病 率 为（ $7 6 \\sim 1 9 1$ ） $/ 1 0$ 万（ 中 位 数 为120.5/10万）[12]。# 2 人乳头瘤病毒疫苗 2.1 HPV疫苗免疫机制 HPV疫苗主要诱导机体体液免疫反应，产生的中和性抗体在HPV进入机体时即可与病毒抗原结合，从而防止HPV感染。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "通过预防初次HPV感染和减少持续性HPV感染来阻断子宫颈癌前病变的发生和发展。疫苗产生的抗体可透过血管壁，在局部上皮组织形成较高浓度。当HPV通过黏膜上皮的细微伤口接触基底层细胞时，位于上皮组织中的抗体即可与病毒结合，发挥中和作用。2.2 HPV疫苗免疫原性 国内外研究显示，双价、四价和九价HPV疫苗在完成全程免疫接种后，均可观察到较高的疫苗相关型别抗体阳转率和血清学抗体滴度（ $\\mathrm { \\langle 9 6 \\% \\sim 1 0 0 \\% \\rangle ^ { [ 1 8 - 2 0 } }$ 0]。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "我国临床研究结果显示，$9 \\sim 1 7$ 岁女性接种双价和四价HPV疫苗后免疫应答较强，血清学抗体滴度是 $1 8 \\sim 2 6$ 岁女性的 $1 .4 2 \\sim 3 .0 0$ 倍，而 $1 8 \\sim 2 5$ 岁女性与 $2 6 \\sim 4 5$ 岁女性抗体滴度相似[21-23]。目前关于国内九价HPV疫苗免疫原性的数据有限。一项国外Ⅲ期临床试验显示， $1 6 \\sim 1 7$ 岁女性接种九价HPV疫苗后HPV 6/11/16/18的抗体滴度均高于 $1 8 \\sim 2 6$ 岁女性，免疫应答与接种四价HPV疫苗相当[24]。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "东亚女性的随机对照试验（randomizedcontrolled trial，RCT）也显示 ：接种四价和九价HPV疫苗后，抗HPV 6/11/16/18的抗体阳转率均 $> 9 6 \\% ^ { [ 2 5 ] }$ 。2.3 HPV疫苗保护效力 HPV疫苗在预防HPV型别相关疾病的临床试验中显示出 $8 7 .3 \\% \\sim 1 0 0 .0 \\%$ 的保护效力[26-28]。2.3.1 双价HPV吸附疫苗 一项针对 $1 8 \\sim 2 5$ 岁中国女性的临床研究随访72个月的结果显示，双价HPV吸附疫苗对HPV 16/18相关的子宫颈上皮内瘤变（cervical intraepithelial neoplasia，CIN） $2 \\sim 3$ 级或原位腺癌（adenocarcinoma in situ，AIS）的保护效力为87.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "3%[29]。2.3.2 国产双价HPV疫苗（大肠杆菌） 国产双价HPV疫苗（大肠杆菌）对 $1 8 \\sim 4 5$ 岁中国女性的HPV 16/18相关CIN $2 \\sim 3$ 级、AIS或子宫颈癌的保护效力为100%[30]。2.3.3 四价HPV疫苗 四价HPV疫苗对 $1 8 \\sim 2 5$ 岁女性有很好的保护作用。一项针对 $2 0 \\sim 4 5$ 岁中国女性的临床研究随访78个月的结果显示，四价HPV疫苗对HPV 16/18相关CIN $2 \\sim 3$ 级、AIS和子宫颈癌的保护效力为 $1 0 0 \\% ^ { [ 2 0 ] }$ 。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "在完成针对小年龄组的免疫桥接和安全性试验后，2020年11月国家药品监督管理局批准四价HPV疫苗应用于 $9 \\sim 1 9$ 岁女性。全球针对 $1 6 \\sim 2 6$ 岁女性的Ⅲ期临床研究显示，四价HPV疫苗对HPV 16/18相关的CIN 2 $+$ 的保护效力为$9 8 .2 \\% ^ { [ 3 1 ] }$ 。2020年，一项纳入近170万例的瑞典真实世界研究显示，至少接种1剂四价HPV疫苗即可大幅降低浸润性子宫颈癌患病风险；17岁之前接种的女性获益更显著，浸润性子宫颈癌发病率降低达 $8 8 \\% ^ { [ 3 2 ] }$ 。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2.3.4 九价HPV疫苗 目前尚无中国临床研究数据。国外临床研究显示，九价HPV疫苗对 $1 6 \\sim 2 6$ 岁女性的HPV 6/11/16/18相关持续性感染和子宫颈癌的保护效力与四价HPV疫苗相当[33]。九价HPV疫苗对 $1 6 \\sim 2 6$ 岁东亚女性亚组的HPV 31/33/45/52/58相关CIN 1 ＋的保护效力为 $100 \\%$ ，对HPV 31/33/45/52/58相关的6个月及以上子宫颈、阴道、外阴、肛门持续性感染的保护效力为 $9 5 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "8 \\% ^ { [ 3 4 ] }$ 。目前全球尚无关于 $2 6 \\sim 4 5$ 岁女性的九价HPV疫苗相关免疫原性和保护效力的数据。2.4 HPV疫苗安全性 2017年WHO发布的HPV疫苗立场文件指出，现有证据表明目前已上市的HPV疫苗安全性良好，不良反应与其他疫苗相似[20,35-37]。# 3 一般人群人乳头瘤病毒疫苗接种 3.1 国内现有HPV疫苗 2019年《子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识（简版）》指出：接种HPV疫苗是子宫颈癌防控工作的重要组成部分[37]。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "目前，HPV疫苗在我国属于非免疫规划疫苗（第二类疫苗），接种单位应遵照《疫苗流通和预防接种管理条例》和《预防接种工作规范》的要求，按照疫苗说明书和“知情同意、自愿自费”原则，科学告知受种者或其家长后，为受种者及时提供疫苗接种。目前，我国国家药品监督管理局已批准上市4种HPV疫苗：国产双价HPV疫苗（大肠杆菌）、双价HPV吸附疫苗、四价和九价HPV疫苗（表1）。# 3.2 一般人群HPV疫苗接种 3.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2.1 国外权威指南对于成年女性接种HPV疫苗的推荐 WHO建议主要目标接种人群为未暴露于疫苗相关HPV基因型的青春期女性[7]。2019年美国疫苗免疫实践咨询委员会（Advisory Committee onImmunization Practices，ACIP）[39]和美国疾病预防控制中心[40]均建议在11岁或12岁开始接种HPV疫苗，也可从9岁开始接种。HPV疫苗可对尚未感染的HPV型别提供保护，即使感染了1种或多种HPV型别的受种者仍可从疫苗接种中获得保护。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2017年美国妇产科医师协会（American College of Obstetriciansand Gynecologists，ACOG）指南提出，不论有无性行为或既往暴露于HPV，均推荐接种HPV疫苗[41]。2019年《人乳头瘤病毒：加拿大免疫指南》提出在性行为开始后进行HPV疫苗接种也是有益的[42]。表1 我国国家药品监督管理局批准上市的HPV疫苗特点和接种程序 <html><body><table><tr><td>项目</td><td>国产双价HPV疫苗 （大肠杆菌）</td><td>进口双价HPV吸附疫苗</td><td>进口四价HPV疫苗</td><td>进口九价HPV疫苗</td></tr><tr><td>全球上市时间</td><td></td><td>2007年</td><td>2006年</td><td>2014年</td></tr><tr><td>中国上市时间</td><td>2019年</td><td>2016年</td><td>2017年</td><td>2018年#</td></tr><tr><td>预防HPV型别</td><td>16/18</td><td>16/18</td><td>6/11/16/18</td><td>6/11/16/18/31/33/45/52/58</td></tr><tr><td>中国女性适宜接种年龄</td><td>9～45岁</td><td>9～45岁</td><td>9～45岁&</td><td>16～26岁</td></tr><tr><td>预防HPV感染相关疾病 (中国批准)</td><td>子宫颈癌、CIN1级、CIN2/3级、 AIS，HPV16/18持续性感染</td><td>子宫颈癌、CIN1级、 CIN 2/3级、AIS</td><td>子宫颈癌、CIN1级、 CIN 2/3级、AIS</td><td>子宫颈癌、CIN1级、CIN2/3级、 AIS，9种HPV相关亚型感染</td></tr><tr><td>表达系统</td><td>大肠杆菌</td><td>杆状病毒</td><td>酿酒酵母</td><td>酿酒酵母</td></tr><tr><td>免疫量</td><td>共接种3剂，每剂0.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "5ml</td><td>共接种3剂，每剂0.5ml</td><td></td><td>共接种3剂，每剂0.5ml共接种3剂，每剂0.5ml</td></tr><tr><td>接种方法和部位</td><td>肌内注射，首选上臂三角肌</td><td>角肌</td><td>角肌</td><td>肌内注射，首选上臂三肌内注射，首选上臂三肌内注射，首选上臂三角肌</td></tr><tr><td></td><td>免疫程序（接种方案）”第0、第1、第6个月，9～14第0、第1、第6个月 岁接种2剂</td><td></td><td>第0、第2、第6个月</td><td>第0、第2、第6个月</td></tr></table></body></html> 注：HPV为人乳头瘤病毒 ；CIN为子宫颈上皮内瘤变 ；AIS为原位腺癌 ；\\*1年内接种3剂为完成免疫接种； $^ { \\# } 2 0 1 8$ 年10月美国食品药品监督管理局批准九价HPV疫苗可用于 $9 \\sim 4 5$ 岁女性[38] ； $^ { \\mathrm { \\tiny ~ \\ g ~ } } 2 0 2 0$ 年11月国家药品监督管理局批准四价HPV疫苗应用于 $9 \\sim 1 9$ 岁女性。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2020年美国癌症协会（American Cancer Society，ACS）发布了《人乳头瘤病毒疫苗接种指南更新》，其中最重要的变化是，不再建议 $> 2 6$ 岁人群补种HPV疫苗[43]。主要原因是： $\\textcircled{1}$ 此年龄段人群通过接种HPV疫苗预防癌症的获益很低； $\\textcircled{2}$ 患者与医生沟通过程中的不同观点可能干扰常规人群接种； $\\textcircled{3}$ 对于究竟哪些人群接种HPV疫苗能获益缺乏充分指引。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2019年ACIP也明确指出：不建议所有 $> 2 6$ 岁人群补种HPV疫苗；HPV疫苗未批准用于 $> 4 5$ 岁人群[39]。3.2.2 我国HPV疫苗接种背景 我国城市女性初次性行为中位年龄为22岁，农村为21岁，超过 $10 \\%$ 的 $1 5 \\sim 1 9$ 岁女性已有性生活[44]。国产双价HPV疫苗（大肠杆菌）研究显示， $9 \\sim 1 4$ 岁女性接种2剂次可获得与接种3剂次相同的免疫效果[23]。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "因此，$1 3 \\sim 1 5$ 岁女性在首次性行为前接种HPV疫苗的获益可最大化。纳入约5.1万例中国女性的198项研究的汇总数据显示， $2 5 \\sim 4 5$ 岁女性高危型HPV感染率高达$1 9 .9 \\% ^ { [ 4 5 ] }$ ；随着年龄变化，高危型HPV感染呈现 $1 7 \\sim$ 24岁和 $4 0 \\sim 4 4$ 岁双峰分布[46] ；且中国女性以单一HPV型别感染为主（ $7 3 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "6 \\%$ ）[19]。结合我国女性高危型HPV感染流行病学特点和HPV疫苗在 $2 7 \\sim 4 5$ 岁女性中的保护效力，加之我国接种政策和子宫颈癌筛查覆盖率低等国情，个体化接种策略是必要的，不应完全否定 $2 7 \\sim 4 5$ 岁女性接种HPV疫苗的意义。推荐意见：依据以上证据，优先推荐 $9 \\sim 2 6$ 岁女性接种HPV疫苗，特别是17岁之前的女性；同时推荐 $2 7 \\sim 4 5$ 岁有条件的女性接种HPV疫苗。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "# 4 高危、特殊人群人乳头瘤病毒疫苗接种 4.1 HPV感染/细胞学异常女性 因免疫原性过低，HPV自然感染所产生的抗体难以预防相同型别HPV再次感染[18,47]。然而，HPV疫苗对既往疫苗型别HPV再感染（一过性或持续性HPV感染）的女性具有显著保护效力。在 $1 6 \\sim 2 6$ 岁既往感染疫苗型别HPV（血清HPV抗体阳性而子宫颈HPVDNA阴性）的女性中，四价HPV疫苗对疫苗型别 HPV再感染或其他未感染疫苗型别HPV所致CIN $1 +$ 的保护效力达 $1 0 0 \\% ^ { [ 2 8 ] }$ 。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "对 $2 4 \\sim 4 5$ 岁既往感染疫苗型别HPV的女性，四价HPV疫苗对HPV 16/18相关CIN $1 +$ 的保护效力为 $6 6 .9 \\% ^ { [ 4 8 ] }$ 。对 $1 6 \\sim 2 6$ 岁已感染疫苗型别HPV的女性，九价HPV疫苗对覆盖型别中其他未感染型别所致的CIN 2 ＋的保护效力为$9 1 .1 \\% ^ { [ 4 9 ] }$ 。HPV疫苗对细胞学异常女性同样具有较高保护效力。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "一项针对约1.4万例 $1 6 \\sim 2 6$ 岁年轻女性的国际多中心RCT显示：接种九价HPV疫苗6个月后，初始细胞学异常者HPV 31/33/45/52/58持续性感染率在HPV疫苗组和对照组分别为8/639（42/万人•年）和138/649（770.5/万人•年），高危型HPV持续性感染风险在疫苗组下降 $9 4 .6 \\%$ （ $9 5 \\% C I$ ：89.3% ～ 97.7%）[50]。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "推荐意见：依据以上证据，无论是否存在HPV感染或细胞学异常，对适龄女性均推荐接种HPV疫苗（接种之前无需常规行细胞学及HPV检测）。# 4.2 妊娠期与哺乳期女性 4.2.1 妊娠期女性 妊娠期女性接种HPV疫苗的研究数据有限。虽然动物实验未发现接种HPV疫苗对母体和子代造成直接或间接不良影响，然而囿于伦理，不可能实施临床研究评估HPV疫苗接种对妊娠期女性及其子代预后的影响。双价HPV疫苗在动物实验中未见不良妊娠和子代结局，但缺乏人类研究数据。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "一项2015年长期随访研究发现，与未接种HPV疫苗的女性相比，接种双价HPV疫苗且3个月内受孕女性的流产风险无明显增加[51]。国际相关机构曾对妊娠期间意外接种双价HPV疫苗的女性进行注册随访，发现此人群中胎儿先天畸形和自然流产的发生率与普通人群相比并无差异[52]。四价HPV疫苗在动物实验中亦未发现不良妊娠和子代结局。国际相关机构同样对妊娠期间意外接种四价HPV疫苗的女性进行了注册随访[53]。一项纳入5项 $1 5 \\sim 4 5$ 岁女性Ⅲ期临床试验的联合分析显示，接种四价HPV疫苗组和安慰剂组女性妊娠后自然流产率（ $1 8 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2 \\% : 1 9 .5 \\% )$ ）和胎儿先天发育异常率（ $( 2 .0 \\% : 1 .5 \\% )$ ）均无显著差异，胎儿晚期死亡率均低于 $1 \\% ^ { [ 5 4 ] }$ 。丹麦对近65万例妊娠女性进行的为期7年的四价HPV疫苗接种的安全性观察研究未发现接种HPV疫苗会增加不良妊娠结局[55]。接种九价HPV疫苗是否会导致不良妊娠结局同样尚无定论。2014—2017年美国疫苗不良事件报告系统（vaccine adverse event reporting system，VAERS）记录了82例接种九价HPV疫苗的妊娠女性信息，自然流产3例（ $3 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "7 \\% \\cdot$ ），阴道出血2例（ $2 .4 \\%$ ），提示接种九价HPV疫苗不增加不良妊娠结局风险[56]。然而，也有研究发现受孕前或受孕后30 d内接种九价HPV疫苗者自然流产风险有所增加（ $R R = 2 .0 4 \\AA$ ）[57]。2014年美国ACIP[58]和2017年WHO发表的HPV疫苗立场文件[7]声明，基于妊娠期HPV疫苗接种数据有限，不推荐妊娠期女性预防性接种HPV疫苗，应将疫苗接种推迟至妊娠结束后。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "近期计划妊娠者不推荐接种HPV疫苗，且在完成最后一剂接种2个月内应尽量避免受孕。若疫苗接种后发现已怀孕，应将未完成接种剂次推迟至分娩后再行补充接种。接种HPV疫苗前无需妊娠检测。若妊娠期间完成接种，则无需干预。推荐意见 ：依据以上证据，不推荐妊娠期女性预防性接种HPV疫苗。若近期准备妊娠，建议推迟至哺乳期后再行接种。若接种后意外妊娠，应停止未完成剂次的接种；已完成接种者，无需干预。4.2.2 哺乳期女性 哺乳期女性接种HPV疫苗研究数据尤为缺乏。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2017年ACOG指出哺乳期女性可接种HPV疫苗，该重组疫苗不影响母乳喂养的安全性[41]。韩国妇科肿瘤学会也认为哺乳期女性可接种九价HPV疫苗[59]。推荐意见：虽然目前临床试验尚未观察到血清HPV抗体经母乳分泌，但鉴于多种药物可经母乳分泌，且缺乏哺乳期女性接种HPV疫苗的安全性研究数据，因此，慎重推荐哺乳期女性接种HPV疫苗。# 4.3 HPV相关病变治疗史人群 4.3.1 下生殖道癌前病变/癌治疗史人群 既往下生殖道HSIL的女性是一类特殊群体，治疗后可能再次发生HPV感染或感染持续存在。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "HSIL经局部保守治疗后， $\\mathrm { C I N } 2 +$ 复发率高达 $5 \\% \\sim 1 0 \\%$ ，浸润癌风险较普通人群高 $2 \\sim 4$ 倍[25]。一项在韩国开展的 $2 0 \\sim 4 5$ 岁既往HSIL行子宫颈环形电切术（loopelectrosurgical excision procedure，LEEP）治疗后接种四价HPV疫苗的回顾性分析显示，与未接种者相比，接种四价HPV疫苗可显著降低HPV 16/18相关HSIL（ $\\mathrm { C I N } 2 \\sim 3 )$ ）复发风险（ $( P < 0 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "0 5 )$ ），治疗后未接种HPV疫苗是CIN $2 +$ 复发的独立危险因素$( H R : 2 .8 4 0 \\ : ; \\ : 9 5 \\% C I : 1 .3 3 5 \\sim 6 .0 4 2 \\ : ; P < 0 .0 1 )$ ）[60]。一项PATRICIA研究的事后分析结果表明，对于 $1 5 \\sim$ 25岁女性在接种双价HPV疫苗前，不论HPV DNA、HPV 16/18血清学或子宫颈细胞学状态，随访4年中发生HSIL，接受切除性治疗，术前接种HPV疫苗可使术后CIN 2 $+$ 复发风险降低 $8 8 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2 \\%$ （ $9 5 \\% C I$ ：$1 4 .8 \\% \\sim 9 9 .7 \\%$ ）[61]。这表明接种HPV疫苗后接受LEEP的HSIL患者可能继续受益，从而降低术后CIN 2 ＋复发风险。2018年意大利前瞻性病例对照研究表明，宫颈病变术后接种四价HPV疫苗对于预防CIN $2 +$ 复发的保护效力达 $8 1 .2 \\%$ （ $9 5 \\%$ CI ：$3 4 .3 \\% \\sim 9 5 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "7 \\%$ ）[62]。一项2018年意大利前瞻性RCT研究结果显示，接种四价HPV疫苗显著减低HSIL者接受LEEP术后的LSIL复发率（ $P < 0 .0 5 \\$ ）[63]。既往HSIL患者手术治疗后立即接种HPV疫苗，可诱导子宫颈基底层细胞内产生大量抗体，阻止再生组织自身感染，避免HPV进入未感染的基底层细胞，从而避免CIN 2 $^ +$ 复发[60]。推荐意见 ：依据以上证据，推荐既往HSIL接受过消融或切除性治疗的适龄女性接种HPV疫苗。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "对于子宫颈癌治疗后接种HPV疫苗是否获益尚需进一步研究证实。4.3.2 肛门癌前病变/癌治疗史人群 目前针对女性 肛 门 上 皮 内 瘤 变（anal intraepithelial neoplasia，AIN）/癌治疗史的临床研究有限，研究多以男性为主。临床研究发现，与未接种疫苗的男性相比，四价HPV疫苗可显著降低男男性交（men who have sexwith men，MSM）患者AIN 2 ＋复发[64]。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "对27岁以上既往AIN 2 ＋的人类免疫缺陷病毒（human immu-nodeficiency virus，HIV）阳性的MSM患者接种四价HPV疫苗可使肛门癌的终身风险降低60.77%[65]。推荐意见 ：依据以上证据，推荐既往AIN$2 +$ 适龄女性，特别是肛门鳞状上皮性癌高风险人群[包括HIV阳性的女性，既往阴道上皮内瘤变（vaginal intraepithelial neoplasia，VaIN）2 ＋和外阴上皮内瘤变（vulvar intraepithelial neoplasia，VIN）$2 +$ 的女性患者]接种HPV疫苗。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "# 4.4 遗传易感人群、高危生活方式人群 4.4.1 遗传易感人群 遗传易感因素可能影响HPV感染的敏感性、持续性以及子宫颈癌的发展速度。环境因素是肿瘤发生的始动因素，而个体遗传特征决定了肿瘤的易感性[66]。瑞典国家癌症数据库登记了约12.5万例子宫颈原位癌和1.4万例子宫颈浸润癌，以此评估的子宫颈癌家族相关危险度（familialrelative risk，FRR）分别为1.8和 $2 .3 ^ { [ 6 7 ] }$ ，共有基因遗传度占子宫颈癌易感性总变异的 $2 7 \\%$ （ $9 5 \\% C I$ ：$2 6 \\% \\sim 2 9 \\%$ ）[68]。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "子宫颈癌遗传度估计值明显高于结直肠癌、肺癌和黑色素瘤[68]。子宫颈癌的全基因组遗传变异关联性研究（genome-wide associationstudy，GWAS）分析已识别的多个遗传易感变异位点，发现其多与免疫反应基因有关。瑞典人群GWAS发现 $H L A$ 基因（HLA-DPB2等）突变与子宫颈癌易感性显著相关，可能通过免疫应答影响子宫颈癌的发生[69]。中国人群GWAS除证实了先前报道的6p21.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "32位点突变，新发现了2个位于EXOC1和GSDMB基因（4q12和17q12）区段的遗传易感变异位点，其编码的蛋白分别与固有免疫和肿瘤细胞增殖有关[70]。推荐意见 ：依据以上证据，优先推荐遗传易感位点变异的适龄女性（HLA-DPB2、EXOC1和GSDMB基因突变等）接种HPV疫苗。建议遗传易感人群在首次性行为之前接种，即使性暴露后亦应尽早接种。4.4.2 高危生活方式人群 性生活过早、多性伴、多孕、多产、吸烟、长期口服避孕药、性传播疾病者等是子宫颈癌的高危因素[71]。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "$50 \\%$ 以上的年轻女性在开始性行为后的3年内就会发生HPV感染[72]。青春期女孩下生殖道发育尚未成熟，过早性生活会使子宫颈上皮多次重复暴露于某些细菌或病毒，产生潜在细胞变异[44]。性生活过早、多性伴等因素是HPV感染的重要协同因素[44]。口服避孕药与HPV感染明显相关，用药时间长（5年以上）者HPV感染风险增加[73]。推荐意见：依据以上证据，优先推荐高危生活方式的适龄女性尽早接种HPV疫苗，即使已知HPV感染/细胞学异常及既往接受过HSIL治疗者也推荐接种。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "4.5 免疫功能低下人群 包括 ：HIV感染者；自身免疫性疾病患者，如自身免疫炎性风湿病（auto-immune inflammatory rheumatic diseases，AIIRD）、桥本甲状腺炎等；肥胖、糖尿病、肾衰竭血液透析者；器官/骨髓移植后长期服用免疫抑制剂患者。4.5.1 HIV感染者 HIV以人体免疫系统 $\\mathrm { C D 4 ^ { + } T }$ 细胞为攻击目标，没有 $\\mathrm { C D 4 ^ { + } T }$ 细胞辅助的免疫系统将难以杀灭入侵的病原体及体内癌细胞，导致继发感染或恶性肿瘤。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "$\\mathrm { C D 4 ^ { + } T }$ 细胞计数低于 $2 0 0 ~ \\mathrm { c e l l s } / \\mathrm { m m } ^ { 3 }$ 时，细胞免疫几乎完全失去功能[74]。$1 8 \\sim 2 5$ 岁HIV感染女性接种双价HPV疫苗后免疫反应不受 $\\mathrm { C D 4 ^ { + } T }$ 细胞计数和HIV病毒载量的影响[75]。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "$1 3 \\sim 4 5$ 岁HIV感染女性接种四价HPV疫苗是安全的，且具有免疫原性，其中 $\\mathrm { C D 4 ^ { + } T }$ 细胞 $> 2 0 0$ cells $\\langle \\mathrm { m } \\mathrm { m } ^ { 3 }$ 者的抗体应答率为 $8 5 \\% \\sim 1 0 0 \\%$ ， $\\mathrm { C D 4 ^ { + } T }$ 细胞≤ 200 cells/mm³者的抗体应答率为 $7 5 \\% \\sim 9 3 \\% ^ { [ 7 6 ] }$ 。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "四价HPV疫苗可有效减少HIV感染女性的HPV疫苗相关型别的持续性感染，接种组HIV感染女性HPV6/11/16/18持续性感染比率低于未接种组[2.3/（100人•年）∶ 6.0/（100人•年）][77]。推荐意见：依据以上证据，优先推荐HIV感染的适龄女性接种HPV疫苗。4.5.2 自身免疫性疾病患者 包括AIIRD、桥本甲状腺炎等。AIIRD指系统性红斑狼疮（systemiclupus erythematosus，SLE）、风湿性关节炎、幼年特发性关节炎、结缔组织病、干燥综合征、抗磷脂综合征、系统性硬化、大细胞动脉炎、多发性结节性动脉炎、白塞综合征、复发性多软骨炎、周期性发热综合征等。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "针对AIIRD患者的HPV疫苗接种证据主要源于SLE的研究。$1 8 \\sim 3 5$ 岁SLE女性接种四价HPV疫苗后安全性良好，疫苗相关型别的抗体应答率可达 $7 6 \\% \\sim 9 5 \\% ^ { [ 7 8 ] }$ 。推荐意见：依据以上证据，推荐患有自身免疫性疾病的适龄女性接种HPV疫苗。4.5.3 糖尿病、肾衰竭接受血液透析者等 糖尿病是一种代谢性疾病。1型糖尿病属于自身免疫性疾病；2型糖尿病因体重过重或缺乏运动，随病情进展胰岛素分泌逐渐不足。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "糖尿病患者免疫力随血糖升高而下降。推荐意见：推荐患有1型和2型糖尿病的适龄女性接种HPV疫苗。一项纳入57例 $9 \\sim 2 1$ 岁慢性肾脏病（chronickidney disease，CKD）、血液透析和肾移植患者的四价HPV疫苗研究显示，CKD组和透析组患者的4种抗体应答率均为 $100 \\%$ ；肾移植组患者抗体应答率为 $5 0 \\% \\sim 7 5 \\% ^ { [ 7 9 ] }$ 。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "另一项纳入60例Ⅳ期、Ⅴ期和ⅤD期CKD患者的四价HPV疫苗研究显示，接种后抗体应答率为 $9 8 .2 \\% \\sim 1 0 0 .0 \\% ^ { \\mathrm { \\tiny { 8 0 } ] } }$ 。推荐意见：依据以上证据，推荐肾功能衰竭接受血液透析的适龄女性在病情允许时接种HPV疫苗。对全身脏器功能差、预期寿命有限者不推荐接种。4.5.4 器官/骨髓移植后长期服用免疫抑制剂患者 器官/骨髓移植后长期服用免疫抑制剂者在HPV疫苗领域的临床试验样本量小，与正常人群相比，此类人群接种HPV疫苗的抗体应答率低。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "肾移植者发生肛门生殖区癌前病变/癌的风险显著升高（ $( H R : 2 .1 \\sim 5 1 .1 )$ ）[81]。$1 8 \\sim 3 5$ 岁接受过器官（包括肾、肺、心、肝）移植的女性接种四价HPV疫苗安全性好，接种后疫苗相关型别抗体应答率为$52 \\% \\sim 6 8 \\%$ ；与移植1年后接种相比，移植1年内接种HPV疫苗呈低免疫反应（ $8 5 .2 \\% : \\ 5 4 .5 \\% )$ ）[82]，因此，移植1年后接种HPV疫苗更为有利。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "推荐意见：依据以上证据，建议临床医生与患者共同探讨，根据疾病轻重差别给予个体化建议。对于预期寿命长的适龄女性，推荐移植1年后接种HPV疫苗；对于预期寿命有限者，不推荐接种。# 5 不良反应和不良事件及其处理 疫苗不良反应（adverse reaction，AR）指合格疫苗在正常用法用量下出现与疫苗接种有明确因果关系的有害反应，一般可预见，与剂量相关。疫苗所含外来抗原和佐剂均可引起AR。疫苗不良事件（adverse event，AE）指疫苗接种过程中或之后出现的不良临床事件，但该事件未必与疫苗接种有因果关系。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "严重不良事件（serious adverse events，SAE）包括死亡、危及生命、残疾或丧失劳动力等。AR和AE均可发生在临床试验中和上市后两个阶段。按国际医学科学组织委员会（Council for Inter-national Organizations of Medical Sciences，CIOMS）的推荐描述AR和AE频率，分为十分常见 $( \\geqslant 1 0 \\%$ ）、常见（ $\\langle 1 \\% \\sim 1 0 \\%$ ，含 $1 \\%$ ）、偶见（ $( 0 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "1 \\% \\sim 1 .0 \\%$ ，含 $0 .1 \\%$ ）、罕见（ $( 0 .0 1 \\% \\sim 0 .1 0 \\%$ ，含 $0 .0 1 \\%$ ）和十分罕见（＜ 0.01%）[83]。5.1 临床试验中的AR和AE 与其他疫苗一样， HPV疫苗在临床试验中出现的AR包括接种部位AR和全身AR，接种部位AR更为常见。十分常见的接种部位AR依次为局部疼痛、肿胀和红斑；常见的接种部位AR有瘙痒和硬结。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "在四价HPV疫苗的安慰剂对照临床试验中，接种部位AR包括疼痛（ $84 \\%$ ）、肿胀（ $2 5 \\%$ ）和红斑（ $( < 2 5 \\%$ ）；疫苗组疼痛较安慰剂组更常见：生理盐水对照组疼痛发生率为 $49 \\%$ ，铝佐剂对照组疼痛发生率为 $7 5 \\% ^ { [ 8 4 ] }$ 。九价HPV疫苗组接种者局部AR发生率略高于四价HPV疫苗组[33] ；双价HPV疫苗组接种者局部AR发生率也高于四价HPV疫苗组[85]。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "双价HPV疫苗组接种者局部疼痛、肿胀、红斑发生率分别为 $9 2 .9 \\%$ 、$3 6 .5 \\%$ 和 $44 .3 \\%$ ，四价HPV疫苗组分别为 $7 1 .6 \\%$ 、 $2 1 .8 \\%$ 和 $2 5 .6 \\%$ 。约 $6 \\%$ 的接种者报告了严重疼痛[84]。接种部位AR多发生于接种后15 d内，多为轻、中度，大多可自然缓解，一般无需特殊处理。全身AR有发热、头痛、眩晕、疲劳、肌肉痛、关节痛和胃肠道症状（恶心、呕吐、腹痛）等。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "四价HPV疫苗临床试验中仅发热十分常见，为 $10 .1 \\%$ ，对照组为 $8 .4 \\%$ ，其他AR的发生率均 $< 0 .5 \\% ^ { [ 8 4 ] }$ 。九价和四价HPV疫苗组接种者全身AR发生率相近，分别为 $2 9 .5 \\%$ 和 $2 7 .3 \\%$ ；常见的全身AR为头痛，分别为 $1 4 .6 \\%$ 和 $1 3 .7 \\%$ ，发热分别为 $5 .0 \\%$ 和 $4 .",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "3 \\% ^ { [ 3 3 ] }$ 。双价和四价HPV疫苗的全身AR发生率也相似，但双价HPV疫苗组接种者疲劳和肌肉痛较四价HPV疫苗组多见，分别为 $4 9 .8 \\% : \\ 3 9 .8 \\%$ 和 $2 7 .6 \\% : 1 9 .6 \\% ^ { 8 6 ] } .$ 。眩晕或晕厥在青少年中更明显。这些全身AR常很轻微，有自限性，一般无需特殊处理。中国双价HPV疫苗临床试验显示总体耐受性良好，尚无严重 $\\mathrm { A R } ^ { [ 8 7 ] }$ 。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "一项随访长达90个月的中国Ⅲ期RCT显示：四价HPV疫苗在成年女性中耐受性良好，安全性结果与全球临床试验和安全性监测研究所得结果一致[88]。临床试验中四价和双价HPV疫苗未报告疫苗相关 $\\mathrm { S A E ^ { [ 7 ] } }$ ，九价疫苗相关的SAE发生率 $< 0 .1 \\% ^ { [ 8 9 ] }$ 。死亡报告率极低，且未证实与HPV疫苗接种相关[90]。5.2 上市后的AR与AE 全球已有超过2亿支HPV疫苗被使用，迄今收集到的数据显示，局部和全身AR与临床试验结果基本一致。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "随着大规模人群接种，也监测到一些罕见AE，如吉兰-巴雷综合征（Guillain-Barré syndrome，GBS）、复杂性区域疼痛综合征、体位性心动过速综合征、静脉血栓栓塞、卵巢功能早衰、肌痛性脑脊髓炎、慢性疲劳综合征等，各国报道发生率不同，但基本不超过3/100万剂次。一项美国多中心研究显示，2006—2013年 $9 \\sim 2 6$ 岁女性共接种四价HPV疫苗1 423 399剂，接种后77 d内53例确诊静脉血栓栓塞，其中30例接种前有静脉血栓栓塞风险，发生率为0.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "2/100万[91]。目前尚无证据证明接种HPV疫苗增加这些疾病或症状的风险[92]，也尚无证据证明其影响女性生殖功能。由于现有HPV疫苗均由抗原蛋白与佐剂组成，因此不能完全排除部分AE可能与佐剂有关，需要加强监测予以排除。# 6 注意事项 6.1 HPV疫苗接种注意事项 对疫苗的活性成分或任何辅料成分有超敏反应者禁止接种HPV疫苗，注射本品后有超敏反应症状者，不应再次接种本品。对于以下人群，需慎用HPV疫苗： $\\textcircled{1}$ 有血小板减少症或其他可成为肌内注射禁忌证的凝血功能障碍者不宜接种； $\\textcircled{2}$ 妊娠期女性或备孕女性推迟至妊娠期结束后再接种，哺乳期女性接种时应谨慎； $\\textcircled{3}$ 急性疾病常伴有发热等全身症状，接种疫苗可能会加重症状，建议在痊愈后接种； $\\textcircled{4}$ 因部分女性有不同程度的经期不适，建议非经期接种。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "6.2 接种HPV疫苗后仍应进行子宫颈癌筛查 $\\textcircled{1}$ HPV疫苗对未暴露于疫苗相关HPV型别的人群保护效力较好，但对于存在HPV感染或相关疾病危险因素（如多性伴、既往感染过疫苗相关HPV型别、免疫缺陷等）的人群有效性降低； $\\textcircled{2}$ HPV疫苗是预防性疫苗，不能治疗已感染的HPV及相关疾病，不能预防所有HPV型别感染，也不能阻止HPV感染至疾病进展；$\\textcircled{3}$ 少数子宫颈癌可能与HPV感染无关，特别是HPV阴性的特殊类型癌； $\\textcircled{4}$ 自2006年HPV疫苗上市以来，长期随访研究证实了HPV疫苗14年的保护效力，但目前尚无证据证实HPV疫苗有终身保护效力； $\\textcircled { 5 } \\mathrm { H P V }$ 疫苗所含型别有限，即使接种了HPV疫苗，机体仍处于对非疫苗型别HPV的感染风险中，因此，接种HPV疫苗后仍需继续进行子宫颈癌筛查。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "HPV疫苗接种是预防HPV感染和相关疾病的有效、安全方法。低龄人群接种效果优于高龄人群，性暴露前接种免疫效果最佳。HPV疫苗不仅适用于一般普通人群，同样推荐用于高危、特殊人群（表2）。对具有遗传易感、高危生活方式和HIV感染的适龄女性应优先推荐接种HPV疫苗。不论是否有HPV感染、细胞学是否异常的适龄女性均可接种HPV疫苗。有HPV相关病变治疗史的适龄女性患者，接种HPV疫苗可能降低复发率。近期有妊娠计划和妊娠期、哺乳期女性不宜接种HPV疫苗。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "接种HPV疫苗后仍应进行子宫颈癌筛查。执笔人： 李 双 李明珠 丛 青 杨 帆 刘 红李克敏 宋 坤 尹如铁 王新宇 张国楠隋 龙 刘继红 孔北华 谢 幸 魏丽惠马 丁 共识专家组成员（以姓氏笔画为序）：万小平 上海市第一妇婴保健院 表2 普通和特殊人群（女性）HPV疫苗接种的推荐级别# <html><body><table><tr><td colspan=\"3\">不同特征 优先推荐</td></tr><tr><td>普通人群 9～26岁女性</td><td colspan=\"2\"></td></tr><tr><td></td><td>27～45岁女性</td><td>推荐</td></tr><tr><td rowspan=\"9\">特殊人群</td><td colspan=\"2\">HPV感染/细胞学异常的适龄女性</td><td>推荐</td></tr><tr><td colspan=\"2\">妊娠期女性</td><td>不推荐</td></tr><tr><td colspan=\"2\">哺乳期女性</td><td>谨慎推荐</td></tr><tr><td colspan=\"2\">有HPV相关病变治疗史的适龄女性</td><td>推荐</td></tr><tr><td colspan=\"2\">有遗传易感和宫颈癌发病高危因素的适龄女性*</td><td>优先推荐</td></tr><tr><td colspan=\"2\">免疫功能低下的适龄 HIV感染者 自身免疫性疾病：系统性红斑狼疮、风湿性关节炎、</td><td>优先推荐</td></tr><tr><td colspan=\"2\">女性# 结缔组织病、干燥综合征、桥本甲状腺炎等</td><td>推荐</td></tr><tr><td colspan=\"2\">1型和2型糖尿病</td><td>推荐</td></tr><tr><td colspan=\"2\">肾衰竭血液透析者</td><td></td></tr><tr><td colspan=\"2\">器官/骨髓移植后长期服用免疫抑制剂患者</td><td>与临床医生共同探讨</td></tr></table></body></html> 注：HPV为人乳头瘤病毒 ；HIV为人类免疫缺陷病毒 ；#全身脏器功能差、病情不乐观、预期寿命有限者，不推荐 ；\\*建议首次性暴露前或尽早接种。",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "梁志清 陆军军医大学第一附属医院 隋 龙 复旦大学附属妇产科医院 程文俊 南京医科大学第一附属医院/江苏省人民医院 谢 幸 浙江大学医学院附属妇产科医院 薛凤霞 天津医科大学总医院 魏丽惠 北京大学人民医院 # 参考文献 王丹波 辽宁省肿瘤医院 王世宣 华中科技大学同济医学院附属同济医院 王建六 北京大学人民医院 王临虹 中国疾病预防控制中心妇幼保健中心 王新宇 浙江大学医学院附属妇产科医院 尤志学 南京医科大学第一附属医院/江苏省人民 医院 尹如铁 四川大学华西第二医院 孔北华 山东大学齐鲁医院 丛 青 复旦大学附属妇产科医院 毕 蕙 北京大学第一医院 曲芃芃 天津市中心妇产科医院 乔友林 中国医学科学院肿瘤医院 向 阳 中国医学科学院北京协和医院 刘 红 四川省肿瘤医院/四川省第二人民医院 刘继红 中山大学肿瘤防治中心 李 双 华中科技大学同济医学院附属同济医院 李亚里 中国人民解放军总医院第一医学中心 李克敏 四川大学华西第二医院 李明珠 北京大学人民医院 李隆玉 江西省妇幼保健院 杨 帆 中山大学肿瘤防治中心 杨佳欣 中国医学科学院北京协和医院 吴小华 复旦大学附属肿瘤医院 吴令英 中国医学科学院肿瘤医院 沈丹华 北京大学人民医院 宋 坤 山东大学齐鲁医院 张国楠 四川省肿瘤医院/四川省第二人民医院 张淑兰 中国医科大学附属盛京医院 郄明蓉 四川大学华西第二医院 周 琦 重庆大学附属肿瘤医院/重庆市肿瘤医院 赵 霞 四川大学华西第二医院 郝 敏 山西医科大学第二医院 哈春芳 宁夏医科大学/宁夏医科大学总医院 徐丛剑 复旦大学附属妇产科医院 高雨农 北京大学肿瘤医院 郭瑞霞 郑州大学第一附属医院 崔 恒 北京大学人民医院 康 山 河北医科大学第四医院 [1] MCBRIDE A A.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Oncogenic human papillomaviruses[J].Philos Trans R Soc Lond B Biol Sci, 2017, 372(1732):20160273.[2] CHESSON H W, DUNNE E F, HARIRI S, et al.The estimated lifetime probability of acquiring human papillomavirus in the United States[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Sex Transm Dis, 2014, 41(11):660-664.[3] GARGANO J, MEITES E, WATSON M, et al.Manual for the Surveillance of Vaccine-Preventable Diseases: Human Papillomavirus[OL].(2020-04-28)[2020-11-28].https://www.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "cdc.gov/vaccines/pubs/surv-manual/chpt05-hpv.html.[4] World Health Organization.Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations[J].Vaccine, 2017, 35(43):5753-5755.[5] BRUNI L, DIAZ M, CASTELLSAGUÉ X, et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings[J].J Infect Dis, 2010, 202(12):1789-1799.[6] GUAN P, HOWELL-JONES R, LI N, et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer[J].Int J Cancer, 2012, 131(10): 2349-2359.[7] No authors listed.Human papillomavirus vaccines: WHO position paper, May 2017[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Wkly Epidemiol Rec, 2017, 92(19):241-268.[8] DE SANJOSE S, QUINT W G, ALEMANY L, et al.Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Lancet Oncol, 2010, 11(11):1048-1056.[9] WU E Q, LIU B, CUI J F, et al.Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Cancer Causes Control, 2013, 24(4):795-803.[10] CHEN W, ZHANG X, MOLIJN A, et al.Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18[J].Cancer Causes Control, 2009, 20(9):1705-1713.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[11] DE MARTEL C, GEORGES D, BRAY F, et al.Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis[J].Lancet Glob Health, 2020, 8(2):e180-e190.[12] DE MARTEL C, PLUMMER M, VIGNAT J, et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Worldwide burden of cancer attributable to HPV by site, country and HPV type[J].Int J Cancer, 2017, 141(4):664-670.[13] BRUNI L, ALBERO G, SERRANO B, et al.ICO/IARC Centre).Human Papillomavirus and Related Diseases in the World[OL].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "(2019-06-17)[2020-11-25].https://hpvcentre.net/ statistics/reports/XWX.pdf?t $\\mathbf { \\Psi } = \\mathbf { \\Psi }$ 1606721151283.[14] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "CA Cancer J Clin, 2018, 68(6):394-424.[15] BRUNI L, ALBERO G, SERRANO B, et al.ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre).Human Papillomavirus and Related Diseases in China[OL].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "(2019-06-17)[2020-11-25].https://hpvcentre.net/ statistics/reports/CHN.pdf?$\\mathrm { ?t } = 1 6 0 6 7 2$ 2464904.[16] GIULIANO A R, NYITRAY A G, KREIMER A R, et al.EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Int J Cancer, 2015, 136(12):2752-2760.[17] Centers for Disease Control and Prevertion.Human Papillomavirus (HPV) Infection[OL].(2015-06-04)[2020-11-25].https:// www.cdc.gov/std/tg2015/hpv.htm.[18] COLOMBARA D V, WANG S M.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "The impact of HPV vaccination delays in China: lessons from HBV control programs[J].Vaccine, 2013, 31(38):4057-4059.[19] ZENG Z, YANG H, LI Z, et al.Prevalence and Genotype Distribution of HPV Infection in China: Analysis of 51,345 HPV Genotyping Results from China's Largest CAP Certified Laboratory[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "J Cancer, 2016, 7(9):1037-1043.[20] WEI L, XIE X, LIU J, et al.Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Vaccine, 2019, 37(27):3617-3624.[21] ZHU F, LI J, HU Y, et al.Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years[J].Hum Vaccin Immunother, 2014, 10(7):1795-1806.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[22] LI R, LI Y, RADLEY D, et al.Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Vaccine, 2012, 30(28):4284-4291.[23] HU Y M, GUO M, LI C G, et al.Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs.3 doses in young women[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Sci China Life Sci, 2020, 63(4):582-591.[24] VAN DAMME P, MEIJER C J L M, KIENINGER D, et al.A phase Ⅲ clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Vaccine, 2016, 34(35):4205-4212.[25] JOURA E A, KYRGIOU M, BOSCH F X, et al.Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Eur J Cancer, 2019, 116:21-26.[26] BARR E, GAUSE C K, BAUTISTA O M, et al.Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Am J Obstet Gynecol, 2008, 198(3):261.e1-e11.[27] Australian Government Department of Health.Human papillomavirus (HPV) immunization service[OL].(2019-09- 26)[2020-11-25].https://www.health.gov.au/health-topics/ immunisation/immunisation-services/human-papillomavirushpv-immunisation.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[28] OLSSON S E, KJAER S K, SIGURDSSON K, et al.Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Hum Vaccin, 2009, 5(10):696-704.[29] ZHU F C, HU S Y, HONG Y, et al.Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase Ⅱ/Ⅲ, randomised, controlled trial[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Cancer Med, 2019, 8(14):6195-6211.[30] QIAO Y L, WU T, LI R C, et al.Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "J Natl Cancer Inst, 2020, 112(2):145-153.[31] FUTURE Ⅱ Study Group.Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions[J].N Engl J Med, 2007, 356(19):1915-1927.[32] LEI J, PLONER A, ELFSTRÖM K M, et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "HPV Vaccination and the Risk of Invasive Cervical Cancer[J].N Engl J Med, 2020, 383(14):1340-1348.[33] JOURA E A, GIULIANO A R, IVERSEN O E, et al.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "N Engl J Med, 2015, 372(8):711-723.[34] GARLAND S M, PITISUTTITHUM P, NGAN H Y S, et al.Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "J Infect Dis, 2018, 218(1):95-108.[35] RUIZ-STERNBERG Á M, MOREIRA E D J R, RESTREPO J A, et al.Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Papillomavirus Res, 2018, 5:63-74.[36] International Federation of Gynecology & Obstetrics.Global Guidance For Cervical Cancer Prevention and Control (2009)[OL].[2020-11-25].https://www.figo.org/sites/default/files/2020-07/ Control_English_version.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "pdf.[37] 中华预防医学会疫苗与免疫分会．子宫颈癌等人乳头瘤病 毒相关疾病免疫预防专家共识（简版）[J]．中华预防医学 杂志，2019，53（12）：1218-1235． [38] U.S.Food & Drug Administration.FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old [OL].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "(2018-10-05)[2020-11-25].https://www.fda.gov/ news-events/press-announcements/fda-approves-expanded-usegardasil-9-include-individuals-27-through-45-years-old.[39] MEITES E, SZILAGYI P G, CHESSON H W, et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Human Papillomavirus Vaccination for Adults: Updated Recom mendations of the Advisory Committee on Immunization Practices[J].MMWR Morb Mortal Wkly Rep, 2019, 68(32): 698-702.[40] Centers for Disease Control and Prevertion.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Vaccines at 11 to 12 Years[OL].(2020-02-25)[2020-11-25].https://www.cdc.gov/vaccines/parents/by-age/years-11-12.html.[41] Immunization Expert Work Group, Committee on Adolescent Health Care.Committee Opinion No.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "704: Human Papillomavirus Vaccination[J].Obstet Gynecol, 2017, 129(6):e173-e178.[42] Human papillomavirus vaccine: Canadian Immunization Guide[OL].[2020-11-25].https://www.canada.ca/en/ public-health/services/publications/healthy-living/canadianimmunization-guide-part-4-active-vaccines/page-9-humanpapillomavirus-vaccine.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "html.[43] ASLOW D, ANDREWS K S, MANASSARAM-BAPTISTE D, et al.Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation[J].CA Cancer J Clin, 2020, 70(4):274-280.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[44] ZHAO F H, TIGGELAAR S M, HU S Y, et al.A multi-center survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vaccination in China[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Cancer Epidemiol, 2012, 36(4):384-390.[45] LI K, LI Q, SONG L, et al.The distribution and prevalence of human papillomavirus in women in mainland China[J].Cancer, 2019, 125(7):1030-1037.[46] ZHAO F H, LEWKOWITZ A K, HU S Y, et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies[J].Int J Cancer, 2012, 131(12):2929-2938.[47] VISCIDI R P, SCHIFFMAN M, HILDESHEIM A, et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica[J].Cancer Epidemiol Biomarkers Prev, 2004, 13(2):324-327.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[48] CASTELLSAGUÉ X, MUÑOZ N, PITISUTTITHUM P, et al.End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Br J Cancer, 2011, 105(1):28-37.[49] GIULIANO A R, JOURA E A, GARLAND S M, et al.Ninevalent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Gynecol Oncol, 2019, 154(1):110-117.[50] HUH W K, JOURA E A, GIULIANO A R, et al.Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Lancet, 2017, 390(10108):2143-2159.[51] PANAGIOTOU O A, BEFANO B L, GONZALEZ P, et al.Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "BMJ, 2015, 351:h4358.[52] ANGELO M G, ZIMA J, TAVARES DA SILVA F, et al.Postlicensure safety surveillance for human papillomavirus-16/18- AS04-adjuvanted vaccine: more than 4 years of experience[J].Pharmacoepidemiol Drug Saf, 2014, 23(5):456-465.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[53] Centers for Disease Control and Prevention (CDC).FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "MMWR Morb Mortal Wkly Rep, 2010, 59(20):626-629.[54] GARLAND S M, AULT K A, GALL S A, et al.Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Obstet Gynecol, 2009, 114(6):1179-1188.[55] SCHELLER N M, PASTERNAK B, MØLGAARD-NIELSEN D, et al.Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes[J].N Engl J Med, 2017, 376(13):1223-1233.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[56] LANDAZABAL C S, MORO P L, LEWIS P, et al.Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Vaccine, 2019, 37(9):1229-1234.[57] TAN J, XIONG Y Q, HE Q, et al.Peri-conceptional or pregnancy exposure of HPV vaccination and the risk of spontaneous abortion: a systematic review and meta-analysis[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "BMC Pregnancy Childbirth, 2019, 19(1):302.[58] MARKOWITZ L E, DUNNE E F, SARAIYA M, et al.Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "MMWR Recomm Rep, 2014, 63(RR-05):1-30.[59] MIN K J, KWON S H, KIM K, et al.Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline[J].J Gynecol Oncol, 2019, 30(2):456.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[60] KANG W D, CHOI H S, KIM S M.Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[J].Gynecol Oncol, 2013, 130(2):264-268.[61] GARLAND S M, PAAVONEN J, JAISAMRARN U, et al.Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Int J Cancer, 2016, 139(12):2812-2826.[62] GHELARDI A, PARAZZINI F, MARTELLA F, et al.SPERANZA project: HPV vaccination after treatment for CIN2[J].Gynecol Oncol, 2018, 151(2):229-234.[63] PIERALLI A, BIANCHI C, AUZZI N, et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease[J].Arch Gynecol Obstet, 2018, 298(6): 1205-1210.[64] SWEDISH K A, FACTOR S H, GOLDSTONE S E.Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Clin Infect Dis, 2012, 54(7):891-898.[65] DESHMUKH A A, CHHATWAL J, CHIAO E Y, et al.LongTerm Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Clin Infect Dis, 2015, 61(10): 1527-1535.[66] MARKOWITZ L E, DUNNE E F, SARAIYA M, et al.Human Papillomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP)[OL].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "(2014- 08-29)[2020-11-25].https://www.cdc.gov/mmwr/preview/ mmwrhtml/rr6305a1.htm.[67] HEMMINKI K, DONG C, VAITTINEN P.Familial risks in cervical cancer: is there a hereditary component?[J].Int J Cancer, 1999, 82(6):775-781.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[68] MAGNUSSON P K, LICHTENSTEIN P, GYLLENSTEN U B.Heritability of cervical tumours[J].Int J Cancer, 2000, 88(5):698-701.[69] CHEN D, JUKO-PECIREP I, HAMMER J, et al.Genome-wide association study of susceptibility loci for cervical cancer[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "J Natl Cancer Inst, 2013, 105(9):624-633.[70] SHI Y, LI L, HU Z, et al.A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12[J].Nat Genet, 2013, 45(8):918-922.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[71] TOVAR J M, BAZALDUA O V, VARGAS L, et al.Human papillomavirus, cervical cancer, and the vaccines[J].Postgrad Med, 2008, 120(2):79-84.[72] MOSCICKI A B.Impact of HPV infection in adolescent populations[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "J Adolesc Health, 2005, 37(6 Suppl):S3-S9.[73] ZHAO F H, FORMAN M R, BELINSON J, et al.Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China[J].Int J Cancer, 2006, 118(2):442-448.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[74] How CD4 Counts Help Treat HIV and AIDS[OL].(2019-06- 23)[2020-11-26].https://www.webmd.com/hiv-aids/cd4-countwhat-does-it-mean.[75] DENNY L, HENDRICKS B, GORDON C, et al.Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Vaccine, 2013, 31(48):5745-5753.[76] KOJIC E M, KANG M, CESPEDES M S, et al.Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women[J].Clin Infect Dis, 2014, 59(1):127-135.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[77] MCCLYMONT E, LEE M, RABOUD J, et al.The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus[J].Clin Infect Dis, 2019, 68(5):788-794.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[78] MOK C C, HO L Y, FONG L S, et al.Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study[J].Ann Rheum Dis, 2013, 72(5):659-664.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[79] NELSON D R, NEU A M, ABRAHAM A, et al.Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD[J].Clin J Am Soc Nephrol, 2016, 11(5):776-784.[80] P R A D I T P O R N S I L PA K , K I N G WATA N A K U L P, DEEKAJORNDEJ T, et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombNephrol Dial Transplant, 2017, 32(1):132-136.[81] REINHOLDT K, THOMSEN L T, DEHLENDORFF C, et al.Human papillomavirus-related anogenital premalignancies and cancer in renal transplant recipients: A Danish nationwide, registrybased cohort study[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Int J Cancer, 2020, 146(9):2413-2422.[82] KUMAR D, UNGER E R, PANICKER G, et al.Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients[J].Am J Transplant, 2013, 13(9):2411-2417.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[83] CIOMS Working Groups.Guidelines for Preparing Core Clinical-Safety Information on Drugs[OL].[2020-11-26].https://cioms.ch/wp-content/uploads/2018/03/Guidelines-forPreparing-Core-Clinical-Safety-Info-Drugs-Report-of-CIOMSWorking-Group-Ⅲ-and-Ⅴ.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "pdf.[84] REITER P L, BREWER N T, GOTTLIEB S L, et al.How much will it hurt?HPV vaccine side effects and influence on completion of the three-dose regimen[J].Vaccine, 2009, 27(49):6840-6844.[85] EINSTEIN M H, BARON M, LEVIN M J, et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years[J].Hum Vaccin, 2009, 5(10):705-719.[86] EINSTEIN M H, BARON M, LEVIN M J, et al.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Comparative immunogenicity and safety of human papillomavirus (HPV)- 16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase Ⅲ randomized study of healthy women aged 18-45 years[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Hum Vaccin, 2011, 7(12):1343-1358.[87] ZHU F C, HU S Y, HONG Y, et al.Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Cancer Med, 2017, 6(1):12-25.[88] CHEN W, ZHAO Y, XIE X, et al.Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up[J].",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "Vaccine, 2019, 37(6):889-897.[89] MOREIRA E D J R, BLOCK S L, FERRIS D, et al.Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase Ⅲ Clinical Trials[J].Pediatrics, 2016, 138(2):e20154387.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[90] LU B, KUMAR A, CASTELLSAGUÉ X, et al.Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & metaanalysis[J].BMC Infect Dis, 2011, 11:13.",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "[91] YIH W K, GREENE S K, ZICHITTELLA L, et al.Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females[J].Vaccine, 2016, 34(1):172-178.[92] Centers for Disease Control and Prevertion.HPV Vaccine Safety and Effectiveness Data[OL].(2019-11-15)[2020-11-26].https://www.cdc.gov/hpv/hcp/vaccine-safety-data.html.收稿日期 ：2020-11-25本文编辑：张瑜",
    "source": "人乳头瘤病毒疫苗临床应用中国专家共识",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头瘤病毒疫苗临床应用中国专家共识/人乳头瘤病毒疫苗临床应用中国专家共识.md"
  },
  {
    "text": "# 人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌中的表达及其与HPV16 整合状态的关系 徐启英 郭桂兰 沙仁高娃 【摘要】 目的 探讨人宫颈癌基因（human cervical cancer oncogene,HCCR）在宫颈上皮内瘤变（CIN）和宫颈鳞癌（SCC）中的表达及其与HPV16 整合状态的关系。方法 选取2013 年1 月-2015 年3 月收治的HPV16 阳性宫颈炎患者20 例、CIN 患者44 例和SCC 患者20 例。",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "采用多重实时PCR 技术检测宫颈脱落细胞中的E2 和E6基因，通过E2 / E6 比值，评估HPVl6 型DNA 的体内整合状态。采用免疫组化SP 法测定各组患者宫颈脱落细胞HCCR 表达情况。结果 宫颈炎、CIN 和 SCC 组 HPV16 DNA 游离型分别是 $9 5 .0 0 \\%$ （19/20）、 $4 3 .1 8 \\%$ （19/44）和$1 5 .0 0 \\%$ （3/20），HPV16 DNA 混合型分别是 $5 .",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "0 0 \\% ( 1 / 2 0 ) .5 0 .0 0 \\% ( 2 2 / 4 4 )$ 和 $5 5 .0 0 \\%$ （11/20），HPV16 DNA 整合型分别是0、 $6 .8 2 \\%$ （3/44）和 $3 0 .0 0 \\%$ （6/20），各组间比较，差异有统计学意义（ $\\textstyle P < 0 .0 5$ ）；在 HPV16 DNA 游离型及混合型组患者中，宫颈炎、CIN 和SCC 组HCCR 表达逐渐增加，差异有统计学意义 $( P < 0 .",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "0 5 )$ 。SCC 组 HPVl6DNA 整合状态与年龄、临床期别、分化程度及淋巴结转移无关。结论 HPV 感染可能与HCCR 及HPV16 整合状态有关，HCCR 及HPV16 存在状态检测可能作为细胞学筛查的一种补充手段，以期早发现CIN 及SCC 的高危患者。【关键词】 子宫颈上皮内瘤变；子宫颈鳞癌；人子宫颈癌基因；人乳头瘤病毒；整合 Expression of HCCR in cervical intraepithelial neoplasia and cervical carcinoma and its relationship with HPV16 infection XUQiying，GUOGuilan，Sharengaowa.",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "（DepartmentofGynaecology，theAfiliatedHospitaofQinghaUniversity，Xining81001，China） 【Abstract】 Objective To investigate the expression of human cervical cancer oncogene(HCCR）in cervical intraepithelial neoplasia (CIN) and cervical carcinoma and its relationship with HPV16 infection.",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "Methods 84 cases including 44 cases with CIN ,20 cases with cervical cancer and 20 cases with cervicitis who were treated in our department from January 2013 to march 2015,recruited in this study.Cervical liquid-based cytological samples were collected to detect E2 and E6 genes of HPV type 16 by using multiple real PCR time polymerase chain reaction(PCR)．E2 / E6 ratio was used to evaluate the physical status of HPV16 DNA in host cell genome．The SP immunohistochemical method was used to detect the expression of HCCR in cervical 1esions.",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "Results The expression of free type of HPV16 DNA in cervicitis,CIN and SCC was $9 5 \\% , 4 3 .1 8 \\%$ and $1 5 \\%$ ,the expression of hybrid type of HPV16 DNA in cervicitis,CIN and SCC was $5 \\% 5 0 \\%$ and $5 5 \\%$ , the expression of integrated type of HPV16 DNA in cervicitis,CIN and SCC was 0, $6 .",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "8 2 \\%$ and $3 0 \\%$ .The difference was statistically significant.In the group of free and hybrid type of HPV16 DNA, the expression of HCCR grew with the disease progression．In SCC, HPVl6 DNA exists status had nothing to with age, clinical stage, differentiation, lymph node metastasis.",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "Conclusions The infection of HPV is related to the status of HCCR and HPV16, which may be a additional method for the screening of cervical cancer.【Key words】 cervical intraepithelial neoplasia; cervical squamous cell carcinoma; human cervical cancer oncogene; human papillomavirus; infection Chin J Clin Obstet Gynecol,2016,17:505-507 高危型HPV 持续感染对宫颈上皮内瘤变（CIN）的进展起着主要的促进作用，HPV 的整合状态被认为是宫颈病变恶性进展的重要标志[1]。",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "人宫颈癌基因（human cervical cancer oncogene,HCCR） 是 Ko等[2] 在2003 年新发现的癌基因，定位于 12q 染色体，其表达情况与宫颈癌及 CIN 等的发生和进展相关。HPV16 是宫颈癌最常见感染类型之一，然而对于 HPVDNA 整合状态与宫颈细胞的恶性转化仍是目前争议的问题。为进一步探讨宫颈癌患者 HPVDNA在宫颈癌组织中的表达及存在状态，本研究选择HPV16 阳性患者 84 例进行研究，探讨正常宫颈、CIN、宫颈鳞癌患者的 HPV16 DNA 存在状态及HCCR 表达情况。",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "# 资料与方法 # 一、一般资料 选择 2013 年 1 月－ 2015 年 3 月青海大学附属医院收治的HPV16 阳性患者84 例，分为宫颈炎组（20 例），CIN 组（44 例）和 SCC 组（20 例），患者的平均年龄分别为 $( 4 1 .2 \\pm \\ : 1 2 .7 )$ 岁（ $2 5 \\sim 6 0$ 岁）、 $( 3 8 .9 \\pm 7 .1 )$ 岁（ $2 8 \\sim 5 7$ 岁）和 $( 4 7 .",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "6 \\pm \\ : 9 .8 ) \\$ ）岁 $( 3 1 \\sim 5 9$ 岁），其中 CIN1 级 15 例、CIN2 级 18例、CIN3 级11 例。三组患者的年龄比较，差异无统计学意义 $( P > 0 .0 5 ) _ { \\circ }$ 。宫颈癌分期依据2009 年FIGO 分期，所选病例均经病理专家复核，临床资料完整，无子宫切除和宫颈手术史、初查时为非妊娠状态、无盆腔放化疗史。# 二、宫颈脱落细胞DNA 的提取 采用 DNA 提取试剂盒 ( 广州凯普有限公司 )，按推荐步骤行 HPV16DNA 的提取，所有细胞标本提取 DNA 后于 $- 8 0 ^ { \\circ } \\mathsf C$ 冰箱保存。",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "# 三、多重实时 PCR 技术检测 HPV16 DNA 整合状态 1.引 物 设 计：HPV16E2 上 游 引 物：C T T GG G C A C C G A A G A A A C A C，下游引物：C AT A T A C C T C A C G T C G C A G， 核 苷 酸 位 置：$3 4 3 8 \\sim 3 4 5 7$ ， $3 7 7 0 { \\sim } 3 7 8 9$ ，PCR 产物长度 352 bp；HPV16E6 上游引物：A A G G G C G T A A C C G A AA T C G G T，下游引物：C A T A T A C C T C A C GT C G C A G，核苷酸位置： $2 6 { \\sim } 4 6$ ，215\\~233，PCR产物长度 208 bp； $\\beta$ -actin 上游引物：C T C C A T C$\\mathsf { C T G G C C T C G C T G T }$ ，下游引物：G C T G TCA C C T T C A C C G T T C C，PCR 产物长度 $2 6 8 { \\mathsf { b p } } .",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "$ 。2.测定方法：应用多重 PCR 进行 HPVl6 整合状态检测，同时扩增 HPVl6 E2、E62 2 个基因。取$0 .5 ~ \\mathsf { m l }$ 离心管， 依次加入 $1 0 \\times P C R$ 缓冲液，dNTP、上下游引物、提取DNA 模板，离心，上PCR 仪扩增， $2 \\%$ 琼脂糖凝胶电泳观察结果。3.结果判断标准：应用凝胶电泳图像分析软件分析 HPV16E2、E6 基因 PCR 扩增所得的产物电泳条带面积灰度值，从而确定HPV16 的存在状态[3]。",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "游离型：E2/E6 比值 $> 0 .9$ ；整合型： $0 < \\tt E 2 / E 6$ 比值 $< 0 .1 5$ ；混合型： $0 .1 5 < \\mathtt { E } 2 / \\mathtt { E } 6$ 比值 $< 0 .9 \\AA$ 。# 四、免疫组化SP 法检测HCCR 的表达 采集宫颈液基细胞剩余液，SP 法对HCCR 表达情况进行分析， ${ \\mathsf { H C C R } }$ 蛋白定位于细胞质，黄棕色颗粒出现于细胞质内部即显示为阳性[4]。",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "# 五、统计学处理 采用SPSS17.0 统计软件进行数据处理。计数资料采用Fisher 确切概率法，以 $\\textstyle P < 0 .0 5$ 为差异有统计学意义。# 结 果 # 一、不同宫颈病变中HPV16DNA 存在状态 宫 颈 炎 组、CIN 组 和 SCC 组 中 HPV16 DNA存在状态比较，差异有统计学意义（ $\\ P < 0 .0 1 )$ ，其中，宫颈炎症组和 CIN1 组以游离型为主，CIN2/3组及SCC 组以混合型为主，见表1。",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "# 二、HPV 不同存在状态中HCCR 的表达情况 HPV 游 离 型、 混 合 型 中HCCR 阳 性 比 例在不同宫颈病变中比较，差异有统计学意义（ $\\textstyle P < 0 .0 5 )$ ，见表2。# 三、HPV16 DNA 整合状态与宫颈癌临床病理参数的关系 SCC 组不同 HPV16 型 DNA 整合状态与临床期别、分化程度、淋巴结转移有关 $( P < 0 .0 5 )$ ，而与年龄无关 $( P > 0 .",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "0 5 )$ ，见表3。# 讨 论 HPV 是宫颈癌发病的重要危险因素，尤以HPV16，18 危险性最高。E6 蛋白是一种 HPV 病毒癌基因，是宿主细胞转化的关键[5]。E2 基因的断裂或缺失导致其对病毒癌基因表达负调控作用缺失，促使E6 基因表达失控，从而促进了细胞转化或癌变。整合后病毒转录的E6、E7mRNA 末端嵌合了宿主细胞的一些序列，使其稳定性增强，更强化了E6、E7 蛋白的表达。从而使含有HPV 整合的细胞更易出现染色体不稳定，包括中心粒异常、间期桥联、染色体断裂和非整倍体[6]。",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "本研究结果显示随着病变程度加重HPV16-DNA 游离型比例逐渐下降，而HPV16-DNA 混合型及整合型比例逐渐增加，提示检测病毒的混合及整合状态比单纯HPV DNA 监测更具有临床意义和价值[3]。表1 不同宫颈病变中HPV16 DNA存在状态 <html><body><table><tr><td rowspan=\"2\">组别</td><td rowspan=\"2\">例数</td><td colspan=\"2\">游离型</td><td colspan=\"2\">混合型</td><td colspan=\"2\">整合型</td></tr><tr><td>例数</td><td>百分率（%）</td><td>例数</td><td>百分率（%）</td><td>例数</td><td>百分率（%）</td></tr><tr><td>宫颈炎组</td><td>20</td><td>19</td><td>95.",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "00</td><td>1</td><td>5.00</td><td>0</td><td>0</td></tr><tr><td>CIN1组</td><td>15</td><td>9</td><td>9/15</td><td>6</td><td>6/15</td><td>0</td><td>0</td></tr><tr><td>CIN2/3组</td><td>29</td><td>10</td><td>34.",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "48</td><td>16</td><td>55.17</td><td>3</td><td>10.34</td></tr><tr><td>SCC组</td><td>20</td><td>3</td><td>15.00</td><td>11</td><td>55.00</td><td>6</td><td>30.00</td></tr></table></body></html> 表2 不同宫颈病变中HPV存在状态与HCCR表达 <html><body><table><tr><td rowspan=\"3\">组别</td><td colspan=\"3\">游离型</td><td colspan=\"3\">混合型</td><td colspan=\"3\">整合型</td></tr><tr><td rowspan=\"2\">例数</td><td colspan=\"2\">HCCR阳性</td><td rowspan=\"2\">例数</td><td colspan=\"2\">HCCR阳性</td><td rowspan=\"2\">例数</td><td colspan=\"2\">HCCR阳性</td></tr><tr><td>例数</td><td>百分率（%）</td><td>例数</td><td>百分率（%）</td><td>例数</td><td>百分率（%）</td></tr><tr><td>宫颈炎组</td><td>19</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>CIN1组</td><td>9</td><td>0</td><td>0</td><td>6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>CIN2/3组</td><td>10</td><td>2</td><td>2/10</td><td>16</td><td>6</td><td>6/16</td><td>3</td><td>1</td><td>1/3</td></tr><tr><td>SCC组</td><td>3</td><td>2</td><td>2/3</td><td>11</td><td>8</td><td>8/11</td><td>6</td><td>4</td><td>4/6</td></tr><tr><td>合计</td><td>41</td><td>4</td><td>9.",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "76</td><td>34</td><td>14</td><td>41.18</td><td>9</td><td>5</td><td>5/9</td></tr></table></body></html> 表3 不同HPVl6型DNA存在状态与宫颈癌临床病理的关系（例数） <html><body><table><tr><td>临床病理特征</td><td>例数</td><td>游离型 （n=3）</td><td>混合型 (n=11)</td><td>整合型 （n=6）</td></tr><tr><td>年龄(岁)</td><td></td><td></td><td></td><td></td></tr><tr><td>≤ 45</td><td>7</td><td>1</td><td>4</td><td>2</td></tr><tr><td>> 45</td><td>13</td><td>2</td><td>7</td><td>4</td></tr><tr><td>FIGO期别</td><td></td><td></td><td></td><td></td></tr><tr><td>I期</td><td>12</td><td>2</td><td>7</td><td>3</td></tr><tr><td>Ⅱ期</td><td>8</td><td>1</td><td>4</td><td>3</td></tr><tr><td>分化程度</td><td></td><td></td><td></td><td></td></tr><tr><td>高分化</td><td>6</td><td>2</td><td>4</td><td>1</td></tr><tr><td>中分化</td><td>11</td><td>1</td><td>5</td><td>4</td></tr><tr><td>低分化</td><td>3</td><td>0</td><td>2</td><td>1</td></tr><tr><td>盆腔淋巴结转移</td><td></td><td></td><td></td><td></td></tr><tr><td>否</td><td>14</td><td>3</td><td>7</td><td>3</td></tr><tr><td>是</td><td>6</td><td>0</td><td>4</td><td>3</td></tr></table></body></html> 本研究将SCC 组患者的FIGO 分期、分化程度、淋巴结转移、年龄与HPV16 感染后病毒存在状态进行初步分析，显示HPVl6 型DNA 存在状态的与年龄、临床期别、分化程度、淋巴结转移均无关，可能与本研究病例数较少有关，需扩大样本量进一步研究。",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "HCCR 是 Ko 等 [2] 于 2003 年新发现的癌基因，定位于12q 染色体。HCCR 在宫颈癌、淋巴结转移及子宫颈癌CUMC-6 细胞系中强表达，在正常子宫颈组织中无表达，并且HCCR 在其它肿瘤如白血病，淋巴瘤等中均有过度表达，提示HCCR 与多种人类恶性肿瘤的发生有关[4]，HCCR 基因在宫颈肿瘤早期有参与作用，可能是肿瘤干细胞表达基因，因而其可能作为肿瘤治疗靶点[7]。本组结果显示，在HPV16-DNA 游离型及混合型组中，随着病变程度加重，HCCR 表达逐渐增加，说明通过检测HCCR 来辅助诊断CIN 及SCC 可能具有重要意义[8]。",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "本研究结果显示 HCCR 在正常组织及 CIN1中均无表达。在 $\\geq$ CIN2 组 及 SCC 组 中 HCCR 的表达较高，提示 HCCR 的检测数据可作为 CIN、SCC 临床诊断以及疗效评价、预后管理的指导因素[2]。目前对于 HCCR 与 SCC 发生的研究报道很少，其在CIN 及SCC 中的作用和意义尚不清楚，其与HPV 的关系均有待于进一步研究。本研究对 HCCR 基因在宫颈肿瘤进行了初步研究，鉴于HCCR 是新基因，其在宫颈肿瘤发病的作用机制、传导通路及其在 HPV 感染中作用仍需进一步研究。",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "# 参 考 文 献 [1] Woodman CB,Collins SI，Young LS．Nenatural history of cervicalHPV infection: unresolved issues.Nat Rev Cancer, 2007, 7: 11-22.[2] Ko J , Lee Y H, Hwang SY , et a1．Identification anddifferential expression of novel human cervical canceroncogene HCCR-2 in human cancers and its involvementin p53 stabilization.",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "Oncogene,2003,22, 4679–4689.[3] 陈庆云，卞美璐，陈志华，等．宫颈癌癌前病变中人乳头瘤病毒16 整合状态的检测，中华医学杂志，2005，85：400-404． [4] 杨姗姗, 孙立新, 赵宏伟，等.人类子宫颈癌基因、p16 及人乳头瘤病毒16/18 在子宫颈癌中表达的意义.肿瘤研究与临床，2010，22:383-387.[5] Boulet GA, Benoy IH, Depuydt CE, et a1．Human papillomavirns16 load and E2/E6 ratio in HPVl6, positive women： $\\because$ biomark-ers for eervical intraepithelial neoplasia in a liquid-based cytologysetting?",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "Cancer Epidemiol Biomarkers Prev, 2009, 18: 2992-2999.[6] Jackson R，Togtema M，Zehbe I.Subcellular localization and quan-titation of the human papillomavirus type 16 E6 oncoprotein throughimmunocytochemistry detection.Virology, 2013, 435: 425-432.[7] 张国新, 黄祖瑚.人宫颈癌癌基因在肿瘤早期诊断治疗中的应用 , 国际肿瘤学杂志 , 2006, 33: 536-537.[8] 崔艳艳, 霍山, 郭晓宁, 等.宫颈脱落细胞中 HCCR 的表达及意义 .中国组织化学与细胞化学杂志 ,2010,19:77-80.( 收稿日期：2015-12-25）",
    "source": "人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌/人子宫颈癌基因在子宫颈上皮内瘤变和子宫颈鳞癌.md"
  },
  {
    "text": "# 附件 1 # 宫颈癌筛查工作方案 # 一、工作目标 （一）总目标。坚持预防为主、防治结合、综合施策，以农村妇女、城镇低保妇女为重点，为适龄妇女提供宫颈癌筛查服务，促进宫颈癌早诊早治，提高妇女健康水平。# （二）具体目标。到2025 年底，实现以下目标： 1.逐步提高宫颈癌筛查覆盖率，适龄妇女宫颈癌筛查率达到 $5 0 \\%$ 以上。2.普及宫颈癌防治知识，提高妇女宫颈癌防治意识。适龄妇女宫颈癌防治核心知识知晓率达到 $8 0 \\%$ 以上。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "3.创新宫颈癌筛查模式，提高筛查质量和效率，宫颈癌筛查早诊率达到 $9 0 \\%$ 以上。绩效考核指标及其计算方法见附件1。# 二、服务对象 35-64 周岁妇女，优先保障农村妇女、城镇低保妇女。# 三、工作内容 # （一）宫颈癌筛查。各地应当对辖区内适龄妇女进行摸底调查，结合实际制 定年度筛查计划。积极动员目标人群到相关医疗机构接受宫颈癌筛查。1.妇科检查。包括询问病史、外阴及阴道检查、盆腔检查及阴道分泌物检查。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "# 2.宫颈癌初筛。可采用以下方法： （1）宫颈细胞学检查。包括取材、制片及阅片，采用子宫颈/阴道细胞学 TBS（The Bethesda System）报告系统对宫颈细胞进行评价。原则上每 3 年筛查一次。（2）高危型 HPV 检测。包括取材、保存、实验室检测及报告。HPV 检测所采用的技术平台及其产品至少要包含世界卫生组织明确确认的 14 种高危型别，包括：HPV16、18、31、33、35、39、45、51、52、56、58、59、66、68 等亚型。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "原则上每 5 年筛查一次。3.阴道镜检查。对宫颈细胞学检查初筛结果异常或可疑者、HPV 高危分型检测结果为 16/18 型阳性者、其他高危型阳性且细胞学结果异常或可疑者以及肉眼检查异常者进行阴道镜检查。4.组织病理学检查。对阴道镜检查结果异常或可疑者进行组织病理学检查。宫颈癌筛查流程见附件2-3。# （二）异常或可疑病例随访管理。宫颈癌筛查异常或可疑病例主要包括宫颈细胞学检查TBS 报告结果为未明确意义的不典型鳞状上皮细胞（以下简称 ASC-US）及以上者、高危型HPV 检测结果阳性者、肉眼检查异常或可疑者，阴道镜检查异常或可疑者以及组织病理学检查结果为宫颈高级别病变及以上者。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "对宫颈癌筛查异常或可疑病例进行追踪随访，督促其尽早接受进一步诊断及治疗，并及时记录病例相关情况。# （三）社会宣传和健康教育。充分利用电视、网络等媒体，广泛开展妇女宫颈癌防治相关政策和核心信息的宣传教育，形成全社会关心支持宫颈癌防治的良好氛围。充分发挥基层医疗机构和妇联等部门宣传教育、组织发动及追踪随访的作用，深入开展社会宣传和健康教育，增强妇女是自身健康第一责任人意识。科学指导广大妇女开展自我健康管理，组织动员适龄妇女接受宫颈癌筛查，指导宫颈癌高风险人群主动到医疗机构接受筛查。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "# （四）组织实施。及时掌握辖区35-64 周岁适龄妇女人数，有计划、有组织地安排其定期接受筛查。遴选具有筛查设施设备和专业技术人员的医疗机构承担宫颈癌筛查工作。加强组织管理，优化服务模式，方便妇女接受筛查服务，不断提高筛查效率和质量。# 四、保障措施 # （一）服务能力建设。各地要进一步健全宫颈癌综合防治网络，完善工作规范和服务流程，加强区域间、机构间转诊和协作。鼓励建立多种形式的宫颈癌防治联合体。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "提高各级特别是县级医疗机构在宫颈癌防治宣传教育、咨询指导、筛查及治疗等方面的能力。健全宫颈癌筛查专家队伍，加强对管理和专业技术人员的培训。积极运用互联网、人工智能等技术，提高基层宫颈癌防治能力。# （二）质量控制。各级卫生健康行政部门要制定宫颈癌筛查质量控制方案及年度工作计划。定期对参与宫颈癌筛查工作的医疗机构及外送检测机构开展全流程质量控制，及时反馈质控结果，指导改进服务质量。相关机构要完善自我检查和整改机制，定期开展自查，保证服务质量。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "宫颈癌筛查质量控制具体要求详见《宫颈癌筛查质量评估手册》。# （三）经费保障与管理。各地要落实主体责任，推动将宫颈癌筛查纳入政府民生工程，统筹协调多方资源，加强经费保障，不断扩大宫颈癌筛查覆盖面，合理提高筛查经费补助标准，积极推动宫颈癌筛查、宣传动员、随访管理、人员培训等各项工作。强化资金监管，规范经费使用，保障宫颈癌筛查工作顺利实施。# （四）信息管理。妥善保存宫颈癌筛查原始资料，推动建立个案信息管理系统，避免重复筛查。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "收集多种来源的宫颈癌筛查和治疗信息数据，实现信息数据的互联共享。应有专人负责信息管理工作，及时收集、汇总、整理、报送相关数据信息。宫颈癌筛查信息管理具体要求详见《两癌筛查信息管理手册》。# （五）考核评估。各级卫生健康行政部门定期开展考核评估，确保宫颈癌筛查工作落实。考核内容包括：具体目标完成情况、组织管理、筛查流程及服务质量、异常病例随访管理、质量控制、信息上报等。考核评估对象包括：宫颈癌筛查技术指导部门、初筛机构、转诊机构（含外送检测机构）等。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "# 五、职责分工 （一）卫生健康行政部门。国家卫生健康委妇幼司负责全国宫颈癌筛查工作的组织管理，制发工作方案和筛查质量评估手册。省级、地市级卫生健康行政部门负责本辖区宫颈癌筛查工作的组织、实施和监督管理，完善工作机制，开展质量控制。县级卫生健康行政部门负责辖区内宫颈癌筛查工作的具体组织实施，明确初筛机构和转诊机构，开展质量控制。各级卫生健康行政部门成立宫颈癌筛查专家组，组织开展业务指导、人员培训、健康教育、质量控制和评估等工作。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "（二）承担宫颈癌筛查技术指导工作的妇幼保健机构。受卫生健康行政部门委托，对辖区宫颈癌筛查工作进行业务管理和技术指导。掌握辖区妇女宫颈癌防治服务现状；为辖区宫颈癌初筛机构、转诊机构提供技术指导；开展宫颈癌筛查服务相关业务培训；对辖区宫颈癌筛查相关信息进行收集、汇总及分析上报；配合卫生健康行政部门开展宫颈癌筛查质控工作；推广宫颈癌防治适宜技术等。# （三）医疗机构。承担宫颈癌筛查服务的医疗机构应当配备与开展筛查服务相适应的场所、设施、设备和专业技术人员，建立健全内部管理制度，明确筛查服务流程，不断提高筛查质量和效率。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "1.初筛机构。主要负责采集病史、妇科检查、初筛取材等，针对筛查结果异常或可疑的妇女督促其接受进一步检查和治疗，做好追踪随访，并将相关信息及时上报。在转诊时应当提供转诊对象的基本信息及相关检查资料，填写转诊单。初筛机构获得转诊机构反馈的结果后，应当在 5 个工作日内通知异常或可疑病例进一步检查或治疗。2.转诊机构。负责接收初筛机构转诊的标本及异常或可疑病例，提供宫颈细胞学阅片、HPV 检测、阴道镜检查及组织病理学检查等相关服务。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "转诊机构应当在出结果后 5 个工作日内反馈初筛机构。附：1.宫颈癌筛查绩效考核指标表2.细胞学检查流程图3.高危型HPV 检测流程图4.宫颈癌防治健康教育核心知识 附 1 # 宫颈癌筛查绩效考核指标表 <html><body><table><tr><td>指标名称</td><td>指标定义</td><td>计算公式</td><td>指标评价 评分标准</td></tr><tr><td>宫颈癌 防治核心 知识知晓率</td><td>熟悉宫颈癌防治 核心知识的适龄 妇女所占比例</td><td>抽样调查妇女中能正 确回答80%及以上宫 颈癌防治健康教育核 心信息的人数/参与宫 颈癌防治健康教育核 心信息抽样调查的 35-64周岁妇女人数</td><td>≥80%</td></tr><tr><td>适龄妇女 宫颈癌 筛查率</td><td>35-64周岁妇女中 接受宫颈癌筛查 服务的妇女所占 比例</td><td>×100% 该地区在推荐间隔期 间接受宫颈癌筛查的 35-64周岁妇女人数/该 地区 35-64周岁妇女总 数×100%</td><td>≥50%</td></tr><tr><td>宫颈癌筛查 早诊率</td><td>宫颈癌筛查人群 中早期诊断比例</td><td>该地区统计年度内实 际进行宫颈癌筛查的 35-64周岁妇女中宫颈 组织病理检查结果为 高级别病变、原位腺癌 和微小浸润癌的人数/ 该地区统计年度内实 际进行宫颈癌筛查的 35-64周岁妇女中宫颈 组织病理检查结果为 高级别病变、原位腺 癌、微小浸润癌及浸润 癌的人数×100%</td><td>≥90%</td></tr></table></body></html> 附 2 # 细胞学检查流程图 !",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "[](images/7ca5ac0e5cad36e27e151e1203dcb3c40e4153ce4b704b8e57e7aafa54503545.jpg) 附 3 # 高危型 HPV 检测流程图 ![](images/20ad8db5f1a053225cdb07bdd664a0fbea64cc405fed555edbce649e1e2e08b2.jpg) # 附 4 # 宫颈癌防治健康教育核心知识 # 一、什么是宫颈癌？",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "宫颈癌是发生于宫颈部上皮组织的恶性肿瘤，高危型人乳头瘤病毒（HPV）持续感染是导致宫颈癌的主要原因。# 二、 宫颈癌有什么症状？宫颈癌早期常常没有明显症状，随着病情进展，逐渐出现阴道不规则出血、阴道排液等症状。# 三、哪些危险因素与宫颈病变相关？宫颈癌主要致病因素为高危型HPV 持续感染，其他高危因素还包括：1.有宫颈癌等疾病相关家族史；2.性生活过早；3.过早生育(18 周岁以前)；4.正在接受免疫抑制剂治疗；5.",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "多个性伴或性伴有多个性伴；6.HIV 感染；7.患有其他性传播疾病；8.吸烟、吸毒者。# 四、生活中怎样预防 HPV 感染？树立自我保护意识。安全性行为，正确使用避孕套，避免性传播疾病发生。提倡健康生活方式。# 五、接种 HPV 疫苗可以预防宫颈癌吗？可以。9-45 周岁女性均可接种HPV 疫苗，在此年龄段越早接种保护效果越好，其中 9-15 周岁女性是重点人群。# 六、定期宫颈癌筛查有必要吗？有必要。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "35-64 周岁妇女应定期接受宫颈癌筛查，并在发现癌前病变时及时治疗，可以阻断病情向宫颈癌发展。# 七、女性间隔多长时间做一次宫颈癌筛查？适龄妇女每 3-5 年进行一次宫颈癌筛查。八、接种HPV 疫苗后，是否还需要接受宫颈癌筛查？需要。无论是否接种HPV 疫苗，均需定期接受宫颈癌筛查。# 九、国家宫颈癌筛查项目包括哪些内容？包括妇科检查、宫颈癌初筛（宫颈细胞学检查或高危型HPV 检测），初筛结果异常还需要接受阴道镜检查，并根据检查结果确定是否需要进行组织病理学检查。# 十、细胞学检查或 HPV 检测结果异常需要治疗吗？细胞学检查或HPV 检测结果异常都不能作为疾病的最后诊断，应由专业人员结合检查结果和个体情况进行综合评估，再确定进一步检查或治疗方案。",
    "source": "宫颈癌筛查工作方案",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查工作方案/宫颈癌筛查工作方案.md"
  },
  {
    "text": "# 宫颈癌筛查质量评估手册 （2022 年版） 中国疾病预防控制中心妇幼保健中心 # 目录 一、评估目的 2 、主要原则 2 三、评估对象 2 四、评估内容.2 五、评估方法.4 六、评估管理 5 七、评估组成员 6 八、评估报告模板 7 附录1 评估指标说明 8 附录2 评估表.13 评估表1.组织管理.13 评估表2.妇科检查.21 评估表 3.HPV 检测 24 评估表4.细胞学检查 26 评估表5.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "阴道镜检查 28 评估表6.组织病理检查 32 为推动宫颈癌筛查工作规范实施，完善宫颈癌筛查质量控制 与评估机制，进一步提高筛查质量，制定本手册。# 一、评估目的 通过对宫颈癌筛查的各环节进行质量控制与评估，及时发现筛查工作中存在的问题，为进一步规范筛查工作提出改进建议，提升宫颈癌筛查工作管理和服务质量。# 二、主要原则 遵循国家《宫颈癌筛查工作方案》（国卫办妇幼函〔2021〕635号）有关要求；坚持科学、客观、公平、公开；外部评估与自评并重；现场评估与线上评估结合；加强多部门协作配合。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "# 三、评估对象 承担宫颈癌筛查技术指导工作的妇幼保健机构、承担宫颈癌筛查任务的医疗机构（初筛机构和转诊机构）、外送检测机构。# 四、评估内容 评估宫颈癌筛查工作组织管理和筛查各环节技术服务质量。具体内容如下： # （一）组织管理情况（详见附录 2-评估表1）。1.政府重视：政府主导；多部门合作；经费管理等。2.能力建设：专业培训；专业队伍等。3.督导质控：计划安排；组织实施；结果反馈等。4.宣传动员：健康教育形式、内容、方法等。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "5.信息管理：信息质量；数据利用；资料管理等。（二）技术服务情况（详见附录 2-评估表2～评估表6）。技术服务质控涉及宫颈癌筛查工作的各个环节，本节重点描述各筛查环节的质控内容，具体质控要点详见各筛查技术评估表。1.妇科检查：妇科检查人员要求、检查环境、设备物品、操作流程、理论知识水平等。详见评估表 2。2.HPV 检测：HPV 检测人员要求、执业许可、工作流程、检查环境、质量控制、工作内容、相关资料等。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "详见评估表3。3.细胞学检查：细胞学阅片人员要求、检查环境、设备物品、检查报告、质量控制、资料信息、相关指标、理论知识水平等。详见评估表 4。4.阴道镜检查：阴道镜检查人员要求、检查环境、设备物品、操作流程、检查结果和图文报告、信息登记、相关指标、理论知识水平等方面情况。详见评估表 5。5.组织病理检查：组织病理人员要求、检查环境、检查设备、基本技能、制度流程、质量控制、信息资料、理论知识水平等方面情况。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "详见评估表6。注：宫颈癌筛查质量评估总分为1000 分；其中，组织管理（评估表 1）300 分，妇科检查（评估表 2）130 分，HPV 检测（评估表3）150 分，细胞学检查（评估表4）150 分，阴道镜检查（评估表5）150 分，组织病理学检查（评估表 6）120 分。如某地仅采用细胞学检查作为宫颈癌初筛方法，则无需对 HPV检测情况进行质量评估，将细胞学检查评估得分 $^ * 2$ ，对于仅采用HPV 检测作为初筛方法的同理。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "# 五、评估方法 组织开展宫颈癌筛查工作前，各级卫生健康行政部门或其委托的技术指导单位应对初筛机构、转诊机构、外送检测机构及试剂厂家的资质进行评估，确定承担相应工作的机构符合资质要求。筛查工作开展后的评估可分为内部自我评估和外部评估，评估方法包括现场评估和利用信息系统在线评估。# （一）现场评估。# 1.评估前 筛查工作管理机构应按照工作规范等文件要求及相关行业标准、技术服务要求，制定评估计划、准备相关材料（如评估方案、评估表、在线数据结果等）； # 2.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "评估现场 评估组利用评估表，通过听取工作汇报、查阅相关资料、现场观察、现场考核、现场访谈等方式，了解工作开展情况及存在问题； # 3.评估后 及时对评估结果进行现场反馈，并针对发现的问题和建议形成书面反馈报告，注明整改期限，下次评估时重点查看整改落实情况。被评估地区应根据评估结果，制定整改措施、完善下一步工 作计划。# （二）信息系统数据评估。1.各级宫颈癌筛查管理机构应对本辖区上报的数据进行梳理、审核，并对相关在线评估指标进行计算、分析，通过指标结果的分析比较对本辖区筛查管理及服务质量进行实时监测评估，最终形成在线评估报告，并进行通报反馈。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "2.有条件的地区可利用互联网 $^ +$ 技术对筛查参与机构上传的细胞学涂片图像、病理切片图像、阴道镜图像及诊断报告等进行在线质控评估，并将复核结果以报告形式在辖区内进行通报反馈。# 六、评估管理 # （一）现场评估。1.国家级评估组每年抽取部分省份、每省至少抽取2 个县（市、区、旗）进行现场评估。2.省级评估组每年对辖区内开展宫颈癌筛查的县（市、区、旗）按照一定比例抽样进行现场评估。3.地市级评估组每年对辖区内所有开展宫颈癌筛查的县（市、区、旗）进行至少一次评估。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "4.县级评估组至少每半年对辖区内所有承担筛查工作的医疗机构、外送检测机构进行一次全面评估。5.外送检测机构每年至少接受一次省级/地市级／县级的评估。6.承担筛查工作的医疗机构开展半年度和年度自我评估。# （二）信息系统数据评估。各级妇幼保健机构至少每半年对辖区组织管理评估指标和技术服务评估指标进行数据分析比较，评估工作质量。# 七、评估组成员 各级成立宫颈癌筛查质量评估组，成员由管理人员和宫颈癌筛查各相关专业技术人员组成，包括管理、妇科（含阴道镜）、临床检验、病理（含细胞学、组织病理）和信息管理人员等。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "每年筛查工作开始前对评估组成员进行培训。评估组成员职责与分工如下： # （一）组长 负责质量评估总体工作、对质量评估情况进行反馈并组织专家撰写质量评估报告和最后审定报告。# （二）专家 负责对管理或技术服务质量进行评估，并进行现场指导及考核；负责撰写本专业领域的质量评估报告。1.管理专家：负责查阅宫颈癌筛查相关资料和文件，如工作方案、计划、各项制度流程、经费使用、培训相关资料、督导质控资料、健康教育资料等，了解相关政策落实、筛查网络、能力建设、宣传教育、经费管理、文档管理、信息管理等工作开展情况，发现筛查管理中存在的问题和困难，提出改进建议。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "2.专业技术专家：负责了解宫颈癌筛查中与本专业技术有关的人员、服务环境、设备设施、筛查流程、筛查内容、服务能力、相关技术资料登记归档情况等，对评估地区上报的相关数据结果进行分析比较，对评估过程中发现的问题提出改进建议。3.联络员：负责协调联络质量评估地点及行程安排，整理准备既往数据报告，收集评估过程中各类相关资料和专家评估报告，负责起草整体质量评估报告。# 八、评估报告模板 # 宫颈癌筛查质量评估报告 报告起草人： 报告提交时间：一、评估日期 年 月 日至 年 月 日二、评估地点 省（区/市） 市（州） 县（市/区） 三、评估组成员（姓名、单位、职务）： 四、评估地区主要参加人员（姓名、单位、科室、职务／职称） # 五、评估方法 （一）现场评估（二）信息系统数据评估 # 六、评估结果 （一）筛查工作开展情况（二）成绩、经验及亮点（三）存在的问题和改进建议 # 七、评估得分： 分 评估组长签名： # 附录 1 评估指标说明 <html><body><table><tr><td colspan=\"2\">评估内容 宫颈癌</td><td>序号</td><td colspan=\"2\">评估指标</td><td></td><td>相关标准或数据评估方法</td><td></td></tr><tr><td rowspan=\"5\">组织管理 指 标</td><td>防治核心 知识知晓 情况 覆盖情况</td><td></td><td rowspan=\"2\">宫颈癌防治核心知 识知晓率（%） 适龄妇女宫颈癌筛 查率（%）</td><td rowspan=\"2\">分子：抽样调查妇女中能正确回答80%及以上宫颈癌防治健康教育核心信息 的人数 数 数</td><td>分母：参与宫颈癌防治健康教育核心信息知晓抽样调查的 35-64 周岁妇女人</td><td>2025年底≥80%</td><td rowspan=\"6\">抽样调查</td></tr><tr><td>2</td><td>分母：该地区35-64周岁妇女总数</td><td>分子：某地区在推荐宫颈癌筛查间隔期间接受宫颈癌筛查的 35-64 周岁妇女 2025年底≥50%</td></tr><tr><td rowspan=\"6\">诊断情况</td><td rowspan=\"3\">3 4</td><td rowspan=\"3\">及前病变 官颈瘤检出率</td><td>分子：某地区统计年度内实际进行宫颈癌筛查的35-64周岁妇女中宫颈组织</td><td>宫颈癌检出率原</td><td rowspan=\"7\"></td></tr><tr><td>粉埋检查结果为高级别病度、原位摩癌、微小浸泪痛及浸润癌人数</td><td>则不低于本省</td></tr><tr><td></td><td></td></tr><tr><td rowspan=\"4\"></td><td>5</td><td>宫颈癌筛查早诊率 (%) HPV 检测高危亚型</td><td>分子：某地区统计年度内实际进行宫颈癌筛查的35-64周岁妇女中宫颈组织 病理检查结果为高级别病变、原位腺癌和微小浸润癌的人数 分母：该地区同一统计年度内实际进行宫颈癌筛查的35-64周岁妇女中宫颈 组织病理检查结果为高级别病变、原位腺癌、微小浸润癌及浸润癌的人数</td><td rowspan=\"2\">≥90% </td><td rowspan=\"4\">现场或 在线评估</td></tr><tr><td rowspan=\"2\">进一步检 查的随访 情况</td><td>6</td><td>阳性者细胞学检查 受细胞学检查的妇女人数 率（%）（使用未分 型 HPV检测方法） 查的妇女人数</td><td>分子：某时间段某地区宫颈癌初筛 HPV检测结果为高危亚型阳性者中实际接 分母：同期该地区宫颈癌初筛 HPV 检测结果为高危亚型阳性应接受细胞学检 ≥ 90%</td></tr><tr><td rowspan=\"2\">HPV 检测 16、18 7</td><td rowspan=\"2\">分子：某时间段某地区宫颈癌初筛 HPV 检测结果为 16、18 型阳性者中实际接 受阴道镜检查的妇女人数</td><td rowspan=\"2\">分母：同期该地区宫颈癌初筛 HPV 检测结果为 16、18 型阳性应接受阴道镜检</td></tr><tr><td>型阳性者阴道镜检 查率（%）（使用 分型 HPV检测方法）</td></tr></table></body></html> <html><body><table><tr><td></td><td>评估内容</td><td>序号</td><td></td><td>评估指标</td><td>相关标准或数据评估方法</td><td></td></tr><tr><td rowspan=\"9\">组 织 管 理 指标</td><td rowspan=\"5\">进一步检 查的随访</td><td rowspan=\"3\"></td><td rowspan=\"3\">HPV检测非16、18 型高危亚型阳性者 细胞学或其他分流 方法检查率（%（使 用分型 HPV 检测方 法） 细胞学检查异常者</td><td>分子：某时间段某地区宫颈癌初筛 HPV 检测结果为非16、18 型高危亚型阳性 者中实际接受细胞学检查的人数</td><td rowspan=\"3\">≥ 90%</td><td rowspan=\"3\">现场或 在线评估</td></tr><tr><td>分母：同期该地区宫颈癌初筛 HPV 检测结果为非 16、18 型高危亚型阳性应接 受细胞学检查的妇女人数</td></tr><tr><td>分子：某时间段某地区细胞学检查结果异常者中实际接受阴道镜检查的人数</td></tr><tr><td rowspan=\"2\">9 初筛方法）</td><td rowspan=\"2\">阴角检率（%为） 的妇女人数</td><td>分母：同期该地区细胞学检查结果异常（ASC-US 及以上）应接受阴道镜检查</td><td rowspan=\"2\">≥90% ≥ 90% </td><td rowspan=\"2\"></td></tr><tr><td>分子：某时间段某地区阴道镜检查结果异常者实际接受病理学检查的人数 阴道镜检查异常者</td></tr><tr><td rowspan=\"5\">治疗情况</td><td>10</td><td rowspan=\"2\">病理检查率（%） 宫颈癌检查早治率 (%)</td><td>分母：同期该地区阴道镜检查结果异常应接受病理学检查的妇女人数</td><td rowspan=\"4\"></td><td rowspan=\"4\">现场或 在线评估</td></tr><tr><td>11</td><td>分子：某时间段某地区筛查出异常并诊断为癌前病变或微小浸润癌中接受了 治疗的人数 分母：同期该地区筛查出异常并诊断为癌前病变或微小浸润癌的人数</td></tr><tr><td>12</td><td rowspan=\"2\">宫颈癌前病变治疗 率（%）</td><td>分子：某时间段某地区宫颈癌前病变患者接受了治疗的人数</td></tr><tr><td>13</td><td>分母：同期内该地区筛查出的宫颈癌前病变人数 分子：某时间段某地区宫颈癌患者接受了治疗的人数</td></tr><tr><td></td><td></td><td rowspan=\"2\">宫颈癌治疗率（%）</td><td rowspan=\"2\">分母：同期该地区筛查出的宫颈癌人数</td><td rowspan=\"2\"></td><td rowspan=\"2\"></td></tr><tr><td></td><td></td></tr></table></body></html> <html><body><table><tr><td colspan=\"17\">评估内容</td></tr><tr><td rowspan=\"9\">质量 评 估数据 指标</td><td rowspan=\"5\">HPV 检测 15</td><td>序号 14 </td><td rowspan=\"3\">HPV 检测阳性率(%)</td><td rowspan=\"3\"></td><td>分子：某时间段某地区 HPV 检测结果为高危亚型阳性的人数</td><td rowspan=\"3\">相关标准或数据评估方法 参考范围为 7.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "3% ~ 14.2% （文献）</td><td rowspan=\"3\">现场或 在线评估</td></tr><tr><td></td><td>分母：同期该地区接受 HPV 检测的妇女人数</td></tr><tr><td>分子：被抽查的细胞学涂片中满意涂片数 标本满意率（%）</td><td></td></tr><tr><td rowspan=\"2\"></td><td rowspan=\"2\">16 率（%)</td><td rowspan=\"2\">阳性涂片复查符合</td><td>分母：被抽查评估的细胞学涂片例数</td><td rowspan=\"2\">≥95% ≥85%(判读相差 两个级别及以</td><td rowspan=\"2\">现场评估</td></tr><tr><td>分子：被评估者细胞学阳性涂片阅片结果与评估者结果相符合的例数</td></tr><tr><td rowspan=\"2\">细胞学</td><td rowspan=\"2\">17</td><td rowspan=\"2\">性涂片复查符合</td><td>分母：所有被抽查评估的细胞学阳性涂片例数</td><td></td><td rowspan=\"2\"></td></tr><tr><td>分子学：我评在者查题学的长涂片闽任强果与评估者东果相行合的例效</td><td>≥ 95% </td></tr><tr><td></td><td>18 （%)</td><td>ASC 与 SIL 的比例</td><td>分子：某时间段某地区接受宫颈细胞学检查且进行TBS 分类的妇女中结果为 ASC的人数</td><td>参考范围为 ≤3：1（文献）</td><td rowspan=\"4\">现场或 在线评估</td></tr><tr><td></td><td>19</td><td>ASC-H 占 ASC 的比 例（%)</td><td>分母：同期该地区接受宫颈细胞学检查且进行TBS 分类的妇女中结果为 SIL 的人数 分子：某时间段某地区接受宫颈细胞学检查且进行TBS 分类的妇女中结果为 ASC-H的人数</td><td>参考范围为 5～10%（文献）</td></tr><tr><td></td><td>20</td><td rowspan=\"2\">细胞学结果为</td><td>分母：同期该地区接受宫颈细胞学检查且进行 TBS 分类的妇女中结果为 ASC 的人数 分子：某时间段某地区宫颈细胞学检查为 ASC-US 的妇女中，阴道镜活检组织</td><td></td></tr><tr><td></td><td>ASC-US，阴道镜活 检组织病理结果为 CIN2+的发生率（%）</td><td>病理结果为 CIN2 及以上的人数 分母：同期该地区宫颈细胞学检查结果为 ASC-US 的人数</td><td>参考范围为 3%～15%（文献）</td></tr></table></body></html> <html><body><table><tr><td>评估内容</td><td>序号</td><td colspan=\"2\">评估指标</td><td>相关标准或数据评估方法</td><td></td></tr><tr><td>检查</td><td rowspan=\"4\">21 细胞学</td><td rowspan=\"2\">细胞学结果为 ASC-H，阴道镜活检 组织病理结果为 CIN2+的发生率（%）</td><td>分子：某时间段某地区宫颈细胞学检查为 ASC-H的妇女中，阴道镜活检组织 病理结果为CIN2及以上的人数</td><td rowspan=\"4\">参考范围为 30%～40%(文献）</td><td rowspan=\"4\">现场或 在线评估</td></tr><tr><td rowspan=\"3\">22</td><td>分母：同期该地区宫颈细胞学检查结果为 ASC-H的人数</td></tr><tr><td>细胞学结果为 LSIL，阴道镜活检 组织病理结果为</td><td>分子：某时间段某地区宫颈细胞学检查为LSIL 的妇女中，阴道镜活检组织病 理结果为HSIL(CIN2)及以上的人数</td></tr><tr><td></td><td>参考范围为 14%～20%(文献） 分母：同期该地区宫颈细胞学检查结果为LSIL的人数</td></tr><tr><td rowspan=\"8\">质 量 评 估 数 据 指 标 阴道镜</td><td rowspan=\"3\">23</td><td rowspan=\"2\">CIN2+的检出率（%） 细胞学结果为 HSIL，阴道镜活检 组织病理结果为</td><td></td><td>参考范围为</td><td rowspan=\"3\"></td></tr><tr><td>分子：某时间段某地区宫颈细胞学检查为 HSIL 的妇女中，阴道镜活检组织病 理结果为HSIL (CIN2)及以上的人数</td><td>53%～66%文献）</td></tr><tr><td rowspan=\"2\">CIN2+的检出率（%） 阴道镜拟诊符合率</td><td>分母：同期该地区宫颈细胞学检查结果为HSIL的人数 分子：接受阴道镜检查操作评估时，检查者报告结果与评估者报告结果相符</td><td></td><td>现场评估</td></tr><tr><td rowspan=\"2\">24 (%)</td><td>合的例数 分母：所有接受阴道镜检查操作评估的例数</td><td rowspan=\"2\">≥ 80%</td><td rowspan=\"2\"></td></tr><tr><td>25</td><td>分子：某时间段某地区阴道镜检查结果异常人数 阴道镜异常检出率</td><td></td></tr><tr><td rowspan=\"2\">检查</td><td rowspan=\"2\">(%)</td><td rowspan=\"2\"></td><td>分母：同期该地区所有阴道镜检查人数</td><td rowspan=\"2\">≥70% </td><td rowspan=\"2\">现场或在 线评估</td></tr><tr><td>分子：某时间段某地区阴道镜检查结果为高度病变的妇女中，阴道镜活检组</td></tr><tr><td rowspan=\"2\"></td><td rowspan=\"2\">26</td><td rowspan=\"2\">阴道镜检查拟诊高 度病变与病理结果 符合率（%）</td><td>织病理结果为HSIL (CIN2)及以上的人数</td><td rowspan=\"2\">≥60%</td><td rowspan=\"2\">现场或 在线评估</td></tr><tr><td>分母：同期该地区阴道镜检查结果为高度病变的人数</td></tr></table></body></html> <html><body><table><tr><td>评估内容</td><td>序号</td><td></td><td>评估指标</td><td>相关标准或数据」评估方法</td><td></td></tr><tr><td rowspan=\"2\"></td><td rowspan=\"2\">组织病理 检查 27</td><td rowspan=\"2\">病理检查结果符合 率（%)</td><td>分子：被评估者组织病理切片阅片结果与评估者结果相符合的例数</td><td rowspan=\"2\">≥95%</td><td rowspan=\"2\">现场评估</td></tr><tr><td>分母：所有被抽查评估的切片例数</td></tr></table></body></html> # 附录 2 评估表 # 评估表1.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "组织管理 评估地点： 评估时间： 得分 <html><body><table><tr><td colspan=\"3\">评估内容</td><td>评估标准</td><td>分值</td><td>评估方法</td><td>评分标准 得分 本地区未制定方案扣3分；</td><td colspan=\"2\">备注</td></tr><tr><td colspan=\"3\" rowspan=\"4\">致税 政府 主导 （70分）</td><td rowspan=\"4\">相关政 策/实施 方案/计 出台相关政 划/流程 与方主 导的领导小 组和专家技 术指导组； 工作领「理部门共同组成（4分）</td><td rowspan=\"4\">按照国家宫颈癌筛查工作 工作方案及年度工作计划 （6分） 机制和流程（4分）</td><td rowspan=\"4\">方案有关要求，制定本地区 工作流程规范合理，明确初 筛及转诊机构，并建立转诊</td><td rowspan=\"4\">有本地的方 案和实施计</td><td rowspan=\"4\"></td><td>与国家方案技术流程不一致但又不 符合国内外宫颈癌筛查循证依据的 扣2分；</td><td></td></tr><tr><td>未制定年度计划扣3分; 本地区年度计划分配不合理酌情扣 分，扣完3分为止;</td><td></td></tr><tr><td>10 查阅项目相 关资料，访 谈项目管理</td><td>工作流程不合理酌情扣分，最多扣3 分；</td></tr><tr><td>“两癌”筛查工作纳入政府 相关考核范围（5分） 划才可给 成立工作领导小组 分)</td><td>相应文件未明确转诊机制和流程扣 “两癌”筛查工作纳入政府相关考 核范围，加5分，如未纳入不得分； 未成立工作小组扣10分（无工作领</td></tr></table></body></html> <html><body><table><tr><td colspan=\"3\">评估内容</td><td colspan=\"2\">评估标准</td><td>分值</td><td>评估方法</td><td>评分标准</td><td>得分备注</td></tr><tr><td></td><td colspan=\"2\"></td><td rowspan=\"2\"></td><td>领导小组成员分工明确，职 责清楚（2分）</td><td></td><td rowspan=\"6\"></td><td>小组成员分工和职责不明确酌情扣 分，最多扣2分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td></td><td rowspan=\"6\"></td></tr><tr><td rowspan=\"6\">政府 重视 （70分）</td><td rowspan=\"3\">政府 主导 导组；</td><td rowspan=\"3\">成立技术指」技术 指 导组</td><td>成立技术指导组</td><td></td><td rowspan=\"6\">查阅项目相</td><td>未成立技术指导组扣15分（无技术 指导组，以下三项无需再打分)</td></tr><tr><td>由辖区妇幼保健机构、综合 医院的专家组成（4分）</td><td></td><td>专家组成员仅由妇幼保健机构人员 构成，无综合医院人员扣2分</td></tr><tr><td>专家应来自妇幼保健、妇 科、阴道镜、临床检验、细 胞学、病理等多领域（6分）</td><td>15</td><td>专家构成不符合要求，缺少1个专 业扣１分，扣完6分为止;</td></tr><tr><td rowspan=\"2\">财政、民政、 好部门积 多部门 极配合支持 合作 相关工作，</td><td>专家组成员参与工作（5分）</td><td></td><td>参加工作的专家组成员人数占小组 人数的比例小于50%扣5分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "关资料，访 无多部门（3个及以上）参与，扣3</td></tr><tr><td rowspan=\"2\">，门各都财商应职明（3、）</td><td rowspan=\"2\">谈项目管理 5</td><td rowspan=\"2\">分；</td><td rowspan=\"2\">各部门职责不明确扣1分;</td></tr><tr><td rowspan=\"2\">经费 管理</td><td rowspan=\"2\">联合开展活 动； 分） 经费及时、 足额到位； （10分）</td><td rowspan=\"2\" colspan=\"2\">联合开展相关活动（2分） 经费足额（能够满足当地筛查需要）（20 资金应及时拨付（年度工作启动前拨付 至少50%的经费，剩余经费在年度工作 完成后 3个月内拨付到筛查参与机构)</td></tr><tr><td colspan=\"2\">30 未及时拨付，视延迟情况酌情扣分， 扣完10分为止。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td>1年内未开展合作活动扣1分； 无相关资料记录视为未开展多部门 合作，扣5分。经费不能满足当地筛查工作需要酌 情扣分，扣完为止;</td><td colspan=\"2\"></td></tr></table></body></html> <html><body><table><tr><td colspan=\"2\">评估内容</td><td>评估标准</td><td>分值</td><td>评估方法</td><td>评分标准</td><td>得分备注</td><td></td></tr><tr><td rowspan=\"5\">专业</td><td rowspan=\"5\">所有相关人 员定期接受 式多样；</td><td>培训内容全面、科学准确（4分)</td><td rowspan=\"7\">15</td><td rowspan=\"7\">查阅相关资 料，访谈项</td><td>培训内容应包含管理、信息管理及 妇科、HPV检测、细胞学、阴道镜等 方面，缺少一项扣０.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "5分，共２分</td><td></td></tr><tr><td>时间安排合理（管理培训班至少1天，专</td><td>扣完为止; 内容不科学准确扣2分;</td></tr><tr><td>业技术培训班至少2天）（2分）</td><td>时间安排不合理，根据情况酌情扣 分，共2分扣完为止;</td></tr><tr><td></td><td></td></tr><tr><td>参加逐级培训的人数、人员结构等符合要</td><td></td></tr><tr><td>、应息會人）相关人员（管</td><td>人数及人员结构不符合要求，缺少1 个专业的人员扣0.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "5分，扣完为止;</td></tr><tr><td rowspan=\"2\">队伍</td><td rowspan=\"2\">专业「相关技术人 员知识完备</td><td rowspan=\"2\">培训相关资料保存完整（2分） 参加培训人员书面考试合格（10分）</td><td rowspan=\"2\">10 加考试人员 的平均分</td><td rowspan=\"2\">档案不齐全（签到表、通知、PPT或 以理论试卷 形式对相关 人员（与技 术服务能力 考试相对 应）进行现 场书面考 试，以百分 制考核，得 分为所有参</td><td rowspan=\"2\">教材、试卷、培训照片等），每缺 一项扣0.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "5分，扣完为止。</td><td rowspan=\"2\"></td></tr><tr><td>考试平均分≥90分-8分，60-80-9 =6 分，<60分=0分（实得分—）</td></tr></table></body></html> <html><body><table><tr><td colspan=\"3\">评估内容</td><td>评估标准</td><td>分值 评估方法</td><td></td><td>评分标准</td><td colspan=\"2\">得分备注</td></tr><tr><td rowspan=\"10\">督导 （质）</td><td rowspan=\"10\">计划 安排</td><td rowspan=\"10\">质控;</td><td colspan=\"3\">能计划 制定督导质控计划（6分） 下发督导质控文件（4分）</td><td rowspan=\"6\">10 查阅项目相 文件） 20</td><td>制定督导质控计划或评估计划， 未下发督导文件扣4分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td rowspan=\"9\"></td></tr><tr><td>成立本级督导质控小组（10分） 小组成员应该包括管理、妇科（含阴道</td><td></td><td>未成立督导质控小组，扣10分;</td></tr><tr><td>镜）、临床检验、病理（含细胞学、组 织病理）和信息管理等专业专家（5分）</td><td></td><td>每缺少1个专业扣1分，扣完为止;</td></tr><tr><td rowspan=\"3\">能够按照督 导质控计 建 开展逐级督 导质控;</td><td>每年至少接受过一次上级（省级或地市</td><td>未接受过上级（省级或地市级）相 关内容的督导质控，扣10分; （以下2项无需再打分）</td></tr><tr><td rowspan=\"2\">级）相关内容的督导质控（10分） 35</td><td>省、市督导质控仅限于管理，扣5 分；</td></tr><tr><td>关资料，访 省、市督导质控仅限于部分技术操 谈项目 朱开展全县范围的督导质控，扣10</td></tr><tr><td rowspan=\"2\">每年至少开展过1次全县（区）范围督 导质控（10分）</td><td>或复印相关 分；（以下2项无需再打分）</td></tr><tr><td>县级督导质控仅限于管理，扣5分; 县级督导质控仅限于部分技术操</td></tr><tr><td rowspan=\"4\">督导质控有 结 根记 予及时反 馈；</td><td rowspan=\"4\">有相关的文字记录和反馈报告（10分） 督导质控报告内容有针对性（5分）</td><td>作，扣3分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "无反馈报告扣5分；</td></tr><tr><td>无相关文字记录扣5分;</td><td rowspan=\"3\"></td><td rowspan=\"3\"></td></tr><tr><td>督导质控报告内容无针对性，扣5</td></tr><tr><td>部分整改扣2分；</td></tr><tr><td rowspan=\"2\"></td><td rowspan=\"2\"></td><td rowspan=\"2\">改（5分）</td><td rowspan=\"2\">针对反馈报告提出整改措施，并落实整</td><td>无整改措施扣5分；</td><td rowspan=\"2\"></td><td rowspan=\"2\"></td></tr><tr><td>未整改扣3分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td></tr></table></body></html> <html><body><table><tr><td colspan=\"3\">评估内容</td><td>评估标准</td><td>分值</td><td>评估方法</td><td>评分标准 未开展活动扣10分（以下2项无需</td><td>得分备注</td><td></td></tr><tr><td rowspan=\"2\">宣传 动员 （20分）</td><td rowspan=\"2\">健康 教育</td><td rowspan=\"2\">多部门合作 开展，形式 多样、内容 丰富；制作 发放健康教 育材料，内 睿科对</td><td rowspan=\"2\">大 众 健 组织相关部门（包括媒体），开展 康 不同形式的宣传教育活动（10分） 教 育</td><td rowspan=\"2\">10</td><td rowspan=\"2\">查阅项目相 关资料，访 谈项目管理 人员（记录 具体活动)</td><td>再打分）； 无多部门合作开展的健康教育活动 扣5分；</td><td></td><td rowspan=\"2\"></td></tr><tr><td>无相关活动记录（资料、照片等）， 扣3分； 未向服务对象传递健康材料扣5分</td><td></td></tr><tr><td rowspan=\"3\"></td><td rowspan=\"3\">信息</td><td rowspan=\"3\">性； 专人管理， 人员</td><td>健教 分） 材 材料内容严谨准确，形式活泼易懂 料 （5分）</td><td rowspan=\"3\">健康教育材料传递给服务对象（5 10</td><td rowspan=\"3\">现场观察， 查阅项目相</td><td>压康材料包括纸质、多煤体、讲 内容不严谨或有错误信息由专家酌</td><td></td><td rowspan=\"3\"></td></tr><tr><td>配有专门的管理和信息上报人员（2分）</td><td>情扣分，扣完为止。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "没有专职人员，扣2分；</td><td></td></tr><tr><td>信息人员熟悉项目的各项指标计算（8 分）</td><td>从题库中随机抽取4个常用指标进 行考核，答错一个扣2分，扣完为</td><td></td></tr><tr><td rowspan=\"3\">信息 管理 （50分）</td><td rowspan=\"3\">信息</td><td rowspan=\"3\">信息指标计 算； 上报搬推</td><td>能够熟练操作系统、正确使用各种功能 （10分）</td><td rowspan=\"3\">20</td><td rowspan=\"3\">料人 （考核多人 分） 现场或提前 分析一年内</td><td>对个案录入、个案查询及下载、报 计算平均「表查询及下载等进行现场操作考 核，每机构考核1名人员，每有一</td><td></td><td rowspan=\"3\"></td></tr><tr><td></td><td>处不合格，扣2分，扣完为止;</td><td rowspan=\"2\"></td></tr><tr><td>上报准确（和报数之际检 查人数和上报人数相符合等）（10分）</td><td>的报和 根据数据上报错误情况酌情扣分， 行逻辑审「扣完为止。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "核，并在备 注中标明错</td></tr></table></body></html> <html><body><table><tr><td colspan=\"2\">评估内容</td><td>评估标准</td><td>分值</td><td>评估方法 现场分别随</td><td>评分标准</td><td>得分 备注</td></tr><tr><td rowspan=\"3\">信息 管理 （50分）</td><td rowspan=\"3\">上报数据准 信息 质量 确，无漏报 错报；</td><td>漏项率<5%（4分）</td><td rowspan=\"3\">10</td><td rowspan=\"3\">机抽查5份 阳性和 5 份 阴性纸质个 案表，了解 表格填写是 否完整有无 重要内容的 漏项、填写 是否有错 误，并现场 调取个案录 入数据，了 解有无录入 错误。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "(请在 备注注明实</td><td><5%=4 分，<10%=2 分，≥10%=0 分。（漏项率=漏填项目数/抽查表格的 总项目数*100%。）；</td><td rowspan=\"3\"></td></tr><tr><td>填写错误率<1%（4分）</td><td><1%=4 分，<5%=2分，≥5%=0分。(填写错误率=填写错误的项目数/ 抽查表格的总项目数*100%。）；</td></tr><tr><td>录入错误率<1%（2分）</td><td><1%=2分，<5%=1 分，≥5%=0分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "（录入错误率=录入错误的项目数/ 抽查表格的项目总数*100%）。</td></tr><tr><td>数据 利用</td><td>能够利用数 据开展相关 工作；</td><td>能够对数据进行进一步分析利用（如将 数据进行分析写入妇幼健康工作报告， 开展科研或发表文章）（5分）</td><td>5 5</td><td rowspan=\"2\">查阅项目相 关资料，访 谈信息管理</td><td>相关工作报告中数据计算错误，扣3 分； 相关报告中数据表达不清楚，扣2 分； 利用数据发表文章，加2分；</td><td rowspan=\"2\"></td></tr><tr><td>资料 管理</td><td>资料完整， 保存齐全；</td><td>可疑/阳性随访登记表、个案登记表和报 表完整，保存完好，便于查找（5分）</td><td>人员</td><td>利用数据开展相关研究，加3分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "表格记录不完整/不合理扣3分，查 找不方便扣2分。</td></tr></table></body></html> <html><body><table><tr><td>评估内容</td><td>评估标准</td><td>分值</td><td>评估方法</td><td>评分标准 1个筛查周期人群覆盖率≥50%=30</td><td>得分</td><td>备注</td></tr><tr><td rowspan=\"5\">相关 管理 指标 （70分） 指标</td><td>覆盖率≥国家相关要求（30分）</td><td rowspan=\"5\">55</td><td rowspan=\"5\">现场调查 前，对上报 的相关数据 资料进行计 算分析并在 备注中注明 实际结果.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td>分；40%-49%=20分；30%-39%=10分 <30%=0分; 宫颈癌人群筛查覆盖率： ：———%；</td><td></td><td rowspan=\"5\"></td></tr><tr><td rowspan=\"2\">进一步检查随访率≥90%（10分） 以初筛异常（HPV阳性、细胞学异常）进一步检查随访 率为主</td><td>随访率85%-89%扣2分；80%-85%扣 3分；70%-79%扣5分；<70%扣8分； <60%扣10分;</td></tr><tr><td>HPV 阳性者进一步检查随访 率%；细胞学检查异常者阴道</td></tr><tr><td>镜检查率-------%；阴道镜检查异 常者病理检查率— %; 早治率 80%-89%扣 2.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "5分;</td></tr><tr><td>早治率≥90%（5分）（由个案数据计算得出) 现场抽取</td></tr><tr><td colspan=\"2\"></td><td rowspan=\"5\"></td><td colspan=\"2\">早治率小于80%扣5分; 早治率：宫颈癌%;</td><td></td></tr><tr><td colspan=\"2\">知识知晓率≥80%（10分）</td><td>5-10名妇女 进行问卷调 查，计算知 果</td><td colspan=\"2\"></td><td></td></tr><tr><td colspan=\"2\"></td><td>识知晓率，</td><td>知识知晓率70%-79%扣5分; 知识知晓率小于70%扣10分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td></td><td rowspan=\"2\"></td></tr><tr><td colspan=\"2\"></td><td>并在备注中 注明实际结</td><td></td><td></td></tr></table></body></html> <html><body><table><tr><td colspan=\"2\">评估内容</td><td>评估标准</td><td>分值</td><td>评估方法 宫颈癌检出</td><td>评分标准</td><td>得分备注</td></tr><tr><td rowspan=\"3\">相关 指标 （70分）</td><td rowspan=\"2\">效果 指标</td><td rowspan=\"2\">宫颈癌及癌前病变检出率（5分)</td><td rowspan=\"2\">5</td><td rowspan=\"2\">率原则上不 低于本省宫 颈癌发病 率，发病率 参照本省的 肿瘤登记报 告结果。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td>根据实际情况酌情扣分，扣完为止;</td><td rowspan=\"2\"></td></tr><tr><td>宫颈癌检出率： 宫颈癌前病变检出率：_</td></tr><tr><td></td><td>宫颈癌早诊率≥90%（10分）</td><td>10</td><td>前，对上报 的相关数据 资料进行计 算分析并在 备注中注明 实际结果</td><td>早诊率80%-89%扣2.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "5分； 70%-79%扣5分；小于70%扣10分； 宫颈癌早诊率 %。</td><td></td></tr><tr><td>得分</td><td colspan=\"2\"></td><td colspan=\"3\">300</td><td></td></tr></table></body></html> # 专家总体意见： 一、亮点 二、问题与不足 三、建议 # 评估表2.妇科检查 评估地点： 评估时间： 得分 <html><body><table><tr><td>评估内容</td><td colspan=\"2\">评估标准</td><td>分值</td><td>评估方法</td><td>评分标准</td><td>得分 备注</td></tr><tr><td rowspan=\"5\">人员</td><td colspan=\"2\">医生须经过培训（2分）</td><td rowspan=\"4\">10</td><td rowspan=\"4\"></td><td>医生未经培训，扣2分； 无护士协助，扣1分；</td><td rowspan=\"4\"></td></tr><tr><td>医护配比合理（1:1或2:1）（1分） 医生熟悉筛查和转诊流程（2分）</td><td>现场观察，</td><td>不熟悉筛查和转诊流程，扣2分；</td></tr><tr><td>与懈建象转诊流征（3分）</td><td>不</td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td colspan=\"2\">每位医生每天检查人数不超过100人次（1分） 环境整洁，物品摆放整洁、合理有序（2分) 检查</td><td>环境杂乱，扣1分；</td><td>检查人数超过100人次，扣1分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td></tr><tr><td rowspan=\"5\">环境 （5分） 设备 (与物易）</td><td colspan=\"2\">有良好的通风、消毒、照明、冷暖条件（2分)</td><td rowspan=\"2\">5</td><td rowspan=\"2\">现场观察</td><td rowspan=\"2\">物品摆放杂乱无序，扣1分; 通风、消毒、照明、冷暖条件较差 酌情扣分，扣完为止; 无隐私保护，扣1分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td rowspan=\"2\"></td></tr><tr><td colspan=\"2\">检查室有保护隐私的措施（1分）</td></tr><tr><td>基本设备 与物品</td><td>妇科检查床、照明设备、一次性或高温消毒的妇科 检查器械（阴道窥器、手套、臀垫）、器械台、消 毒剂、棉球或长棉签、洗手设施和消毒液或肥皂、 污物桶、垃圾桶、黄色医用垃圾袋。</td><td>10 现场观察</td><td>每缺一项物品，扣0.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "5分，扣完为 止;</td><td></td></tr><tr><td>细胞学取 材物品</td><td>宫颈细胞取样器，载玻片、载玻片架、载玻片盒、 95%酒精，和（或）液基细胞学检测样本收集瓶及保 存液（5分）</td><td>5 现场观察</td><td>每缺一项物品，扣0.5分，扣完为 止；</td><td></td><td></td></tr><tr><td>HPV 检测 取材物品</td><td>可用于HPV检测要求的细胞保存液（5分）</td><td>5</td><td></td><td>细胞培养液不符合 HPV 检测要求， 扣5分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td>未进行 测，则此 项不评 分，细胞 学取材 物品得 分×2。</td></tr></table></body></html> <html><body><table><tr><td rowspan=\"15\">评估内容</td><td>评估标准 检查顺序正确（先观察外阴，暴露并观察阴道宫颈，</td><td></td><td>评估方法</td><td>评分标准</td><td></td><td></td></tr><tr><td></td><td>分值</td><td></td><td></td><td>得分备注</td><td></td></tr><tr><td>检查顺序 分）</td><td>阴道分泌物取材，宫颈细胞取材、妇科检查）（5</td><td>5 观察检查 医师对妇 女进行妇</td><td>检查顺序不正确，扣2分; 每缺一项检查扣1分，扣完为止;</td><td></td><td></td></tr><tr><td>妇科检查 操作流程</td><td>妇科检查：外阴、阴道、宫颈视诊和内诊、盆腔的 双合诊，必要时三合诊（10分） 10</td><td>科检查（包 括、盆胶绘 胞学取材、 涂片和固</td><td>每有一项不规范，扣5分，扣完为 止; 取材部位不正确，扣10分;</td><td></td><td></td></tr><tr><td rowspan=\"3\">巴氏涂片</td><td>聚手法轻柔正确，取材部位包括鳞柱交接处及官</td><td rowspan=\"3\">20 程。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "如果评估</td><td>定)的全过</td><td></td><td>此， 据当地</td></tr><tr><td>载玻片涂片手法规范（5分）</td><td>涂片制作不规范，扣5分;</td><td></td><td>实际初 筛方法 选取一</td></tr><tr><td>95%酒精固定15分钟以上，晾干保存（5分） 正确使用毛刷，手法轻柔，取材部位包括鳞柱交接</td><td>片子固定、保存不当，扣5分; 杨有则</td><td></td><td>项进行 评分，</td></tr><tr><td rowspan=\"4\">液细胞 （55分） 宫颈表面和颈管内取材（10分） HPV 检测</td><td>处及方须簧转（2分司（5分）</td><td rowspan=\"4\">20 程和内容</td><td>取材部位不准确，扣10分;</td><td></td><td></td></tr><tr><td></td><td>存得不准，扣.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "5分;</td><td></td><td></td></tr><tr><td>按说明保存刷头或充分震荡（5分）</td><td>没有充分震荡，扣2.5分；</td><td></td><td>均分。方法初</td></tr><tr><td></td><td>取材部位不准确，扣10分; 操人员 是否规范，</td><td></td><td>，则</td></tr><tr><td rowspan=\"2\"></td><td>同一方向旋转2-3圈（5分） 按说明保存刷头或充分震荡（5分）</td><td rowspan=\"2\">25</td><td rowspan=\"2\">检查内容 是否全面。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td>操作不当酌情扣分，扣完为止;</td><td></td><td>分；细胞 学取材</td></tr><tr><td></td><td>保存不当，扣2.5分； 没有充分震荡，扣2.5分。</td><td></td><td>得分× 2。</td></tr><tr><td rowspan=\"2\">结果反馈 （25分） 进一步检查及转诊建议合理（10分）</td><td rowspan=\"2\">临床诊断正确（15分）</td><td rowspan=\"2\"></td><td rowspan=\"2\">现场观察</td><td>临床诊断不正确，扣15分;</td><td></td><td></td></tr><tr><td>建议不合理扣10分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td></td><td></td></tr></table></body></html> <html><body><table><tr><td>评估内容</td><td>评估标准</td><td>分值</td><td>评估方法</td><td>评分标准</td><td>得分备注</td><td></td></tr><tr><td>污物处理 （5分）</td><td>医疗垃圾装黄色垃圾袋、非医疗垃圾装黑色垃圾袋（5分）</td><td>5</td><td>现场观察</td><td>每一项不符合要求扣2.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "5分。</td><td></td><td></td></tr><tr><td>理论知识 （10分） 理论考试合格（10分）</td><td></td><td>10</td><td>试卷考核 1-2名，20 分钟之内 完成答题， 以百分制 考核，基本 得分为所 有参加考 核人员的</td><td>考试平均分≥90分=10分，80-89 分=9分，70-79 分=8分，60-69分 =6分，<60分=0分（实际分 值 ）</td><td></td><td></td></tr><tr><td>得分</td><td>130</td><td>平均分</td><td></td><td></td><td></td><td></td></tr></table></body></html> # 专家总体意见： 一、亮点 # 二、问题与不足 三、建议 # 评估表 3.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "HPV 检测 评估地点： 评估时间： 得分 <html><body><table><tr><td>评估内容</td><td>评估标准</td><td>分值</td><td>评估方法</td><td>评分标准</td><td>得分</td><td>备注</td></tr><tr><td>人员 要求 (10分）</td><td>至少2人,采用 PCR方法检测的应有行政管理部门颁发的上岗证 （10分）</td><td>10</td><td>现场观 察，访谈 医务人员</td><td>只有1人扣5分；采用PCR方法检测 时人员均无行政管理部门颁发的上 岗证扣5分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td></td><td></td></tr><tr><td rowspan=\"3\">执业 许可 （30分） 工作</td><td>有辖区行政管理部门批准的HPV检测项目的许可（可以为认证 书，也可以为相关文件）（10分）</td><td></td><td>现场观</td><td>无行政管理部门批准的 HPV 检测项目 的许可扣10分； 采用 PCR方法的，无 PCR 实验室认证</td><td></td><td></td></tr><tr><td>如果为 PCR 检测方法，必须有 PCR 实验室认证，检测内容必须包 括 HPV 扩增项目（20分）</td><td>30</td><td>察，访谈 医务人员</td><td>扣10分； PCR 实验室检测内容不包括 HPV 扩增 项目扣10分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td></td><td></td></tr><tr><td>有检测操作流程图（10分） （10分）</td><td>10</td><td>现场观 察，查阅 相关资料</td><td></td><td>无相关流程图酌情扣分，扣完为止。</td><td></td></tr><tr><td rowspan=\"4\">检查 环境 （10分） 质量 控制</td><td>设备定期校验，有校准证书，有定期维护记录（5分）</td><td>10</td><td>现场观察</td><td>设备未定期校验扣5分；无校准证书 扣2分；无定期维护记录扣2分;</td><td></td><td></td></tr><tr><td>房间设置合理（5分）</td><td></td><td></td><td>房屋设置不合理酌情扣分扣完为止。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td></td><td></td></tr><tr><td>有室内质控（10分） 有每月总结报告（5分）</td><td>15</td><td>现场观</td><td>无室内质控扣10分;</td><td></td><td></td></tr><tr><td></td><td></td><td>察，查阅 相关资料</td><td>无每月总结报告扣5分； 未参加室间质量评估或比对扣25分；</td><td></td><td></td></tr><tr><td rowspan=\"4\">（40分） 工作 内容</td><td>采用PCR方法检测的应通过国家或区域质控中心的室间质量评 估或比对，并有比对报告（25分）</td><td>25</td><td></td><td>（不使用 PCR 检测方法的可不进行室 间质控，该项不扣分)</td><td></td><td></td></tr><tr><td>检测按照产品说明书要求进行，报告及时反馈（2周）（10分）</td><td></td><td></td><td>无室间比对报告扣20分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "两周之内未反馈报告扣10分；</td><td></td><td></td></tr><tr><td>建立HPV实验室SOP（10分）</td><td></td><td>现场观</td><td>未建立 SOP 扣10分;</td><td></td><td></td></tr><tr><td>SOP 制定合理（10分）</td><td>40</td><td>察，查阅</td><td>SOP 不合理酌情扣分，扣完为止;</td><td></td><td></td></tr><tr><td>（40分）</td><td>按照所制定的 SOP实施（10分）</td><td></td><td>相关资料</td><td>未按照所制定的 SOP开展工作酌情扣 分，共10分，扣完为止。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td></td><td></td></tr></table></body></html> <html><body><table><tr><td>评估内容</td><td>评估标准</td><td>分值</td><td>评估方法</td><td>评分标准</td><td>得分</td><td>备注</td></tr><tr><td>相关 资料</td><td>有检测结果登记表（电子、纸质均可）、标本交接登记（10分）</td><td>10</td><td>现场观 察，查阅 相关资料</td><td>无标本交接登记扣5分；无检测结果 记结果登记与其他检测结果</td><td></td><td></td></tr><tr><td>（10分）</td><td></td><td>150</td><td></td><td>登记未分开扣3分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td></td><td></td></tr></table></body></html> # 专家总体意见： 一、亮点 二、问题与不足 三、建议 专家签字： 注：1.对第三方检测机构 HPV 检测的质量控制评估参照本评估表进行；2.如本地未采用 HPV 检测方法进行宫颈癌初筛，则无需对该部分进行评估。# 评估表4.细胞学检查 得分 <html><body><table><tr><td>评估内容</td><td colspan=\"2\">评估标准</td><td></td><td>分值评估方法</td><td>评分标准</td><td>得分</td><td>备注</td></tr><tr><td rowspan=\"3\">人员 要求 （10分）</td><td colspan=\"2\">宫颈细胞学阅片人员中至少有1名经过培训且考核合格的检验 技师或细胞病理医师（2分)</td><td rowspan=\"3\">10</td><td rowspan=\"3\">现场观 察，访谈 医务人员</td><td>无经过培训考核合格的检验技师或细 胞病理医师，扣2 分； 科室内只有1名细胞阅片人员，扣２ 分；</td><td></td><td rowspan=\"3\"></td></tr><tr><td colspan=\"2\" rowspan=\"2\">宫颈细胞学阅片人员应具有一年以上宫颈细胞学阅片工作经验， 需经培训考核合格后上岗。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "（6分）</td><td>阅片人员阅片时间不足1年，扣2分； 阅片人员未经过正规培训，扣2分；</td></tr><tr><td>经过正规培训但考核不合格，扣2分； 无检验技师或细胞病理医师，扣2分;</td></tr><tr><td rowspan=\"3\">检查 环境 （10分）</td><td colspan=\"2\">筛查时每人每日阅片量不多于100张（2分） 有照明和通风设备（2分）</td><td rowspan=\"3\">10</td><td rowspan=\"3\">现场观察</td><td>阅片量>100/日，扣2分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "照明和通风设备不合理酌情扣分;</td><td></td><td rowspan=\"3\"></td></tr><tr><td colspan=\"2\" rowspan=\"2\">阅片、制片环境分开（4分）</td><td rowspan=\"2\">阅片、制片环境未分开，扣4分；</td><td></td></tr><tr><td>环境不合理酌情扣分，扣完为止;</td></tr><tr><td rowspan=\"2\"></td><td colspan=\"2\">有专门的细胞学涂片保存柜（4分） 细胞学制片、设备试剂齐全（95%酒精、苏木素、0.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "1%HCL、稀碳</td><td rowspan=\"2\">5</td><td rowspan=\"2\"></td><td rowspan=\"2\"></td><td>无专门的细胞学涂片保存柜，扣4分。</td><td rowspan=\"2\"></td></tr><tr><td>酸锂溶液、桔黄、EA50、无水乙醇、封片剂（如二甲苯）、中性 树胶、计时器等）（5分）</td><td></td><td>物品每少一项扣0.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "5分，扣完为止;</td></tr><tr><td rowspan=\"3\">设备 (物)</td><td>巴氏涂片</td><td>显微镜，性能良好（5分）</td><td rowspan=\"3\">5</td><td rowspan=\"3\">现场观察</td><td>性能较差，酌情扣分。</td><td rowspan=\"3\"></td><td>此项</td></tr><tr><td>液基细胞学</td><td>振荡器（膜式机不需要）；膜式机/离心式 机/离心沉降机；显微镜等；性能良好（5</td><td>设备少一项，扣2分，共5分，扣完 为止;；</td><td>分如 取 均 都 有</td></tr><tr><td>分）</td><td></td><td>性能较差，酌情扣分;</td><td>分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "平</td></tr></table></body></html> <html><body><table><tr><td>评估内容</td><td>评估标准</td><td>分值</td><td>评估方法</td><td>评分标准</td><td>得分备注</td><td></td></tr><tr><td rowspan=\"5\">检告 (30分)</td><td>涂片是否封片（5分）</td><td>5</td><td rowspan=\"7\">现杨观察人</td><td>全部没有封片，扣5分； ≤50%以下封片，扣2分； >50%封片，扣1分；</td><td></td><td rowspan=\"6\"></td></tr><tr><td></td><td></td><td>染色方法不符合要求，酌情扣分，</td><td></td></tr><tr><td>现场考核制片人员，描述或观察细胞学标本的染色流程</td><td>15</td><td>扫有为是不规范、不全面扣1.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "5分， 扣完为止;</td><td></td></tr><tr><td>以 TBS分类报告的形式报告结果（5分） 1周内完成制片，报告及时反馈（2周内）（5分）</td><td>10</td><td>未使用TBS 分类报告，扣5分; 反馈时间超过1个月，扣5分； 反馈时间2周-1个月，扣3分。</td><td></td></tr><tr><td>有质控制度（8分）</td><td>8</td><td>无质控制度，扣8分； 有质控制度，但制度制定不合理，</td><td></td></tr><tr><td rowspan=\"2\">质量 控制 （40分）</td><td rowspan=\"2\">开展室内质控，有质控记录/报告（16分)</td><td rowspan=\"2\">16 现场观察询 问，查阅相 关资料</td><td>扣4分； 无室内质控，扣16分; 有室内质控，但无室内质控记录/</td><td></td><td rowspan=\"6\"></td></tr><tr><td>接受上级细胞学检查质控或室间质评，有质控记录/报告</td><td>报告，扣8分； 有室内质控记录/包括，记录不合理 或规范扣4分 无上级细胞学检查质控或室间质 评，扣16分；（以下２项不再评分）</td><td></td></tr><tr><td rowspan=\"2\">资料</td><td>（16分） 有细胞学登记表、个案表格、随访/阳性表格、标本交接登</td><td>16</td><td rowspan=\"2\">现场观察询</td><td>有上级细胞学检查质控或室间质 评，但无质控记录/报告，扣8分； 有上级细胞学检查质控记录/报告， 但记录不合理或不规范，扣4分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td></td><td rowspan=\"2\"></td></tr><tr><td>记等（8分） 细胞学涂片编号清晰，阳性涂片永久保存，阴性涂片保存至</td><td></td><td>每缺一项登记扣1分，每份表册记 录不完整扣0.5分，扣完为止; 编号不清晰扣1分;</td><td></td></tr><tr><td>信息 (10分)</td><td>一个筛查周期结束，方便查找（2分）</td><td>10</td><td>问，查阅相 关资料</td><td>未按要求保存扣1分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td></td><td></td></tr></table></body></html> <html><body><table><tr><td>评估内容</td><td>评估标准</td><td>分值</td><td>评估方法 现场随机抽</td><td>评分标准 90%-95%扣2分；85%-89%扣3分；</td><td>得分</td><td>备注</td></tr><tr><td rowspan=\"3\">相关 指标 （30分）</td><td>标本满意率≥95%（10分）</td><td>10</td><td rowspan=\"3\">取10张阳 性涂片和 20张阴性 涂片，进行 复核。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "复核</td><td>80-84%扣5分；小于80%扣10分； （标本满意率_ ） 阳性符合率80%-84%扣2分；</td><td></td><td rowspan=\"3\"></td></tr><tr><td>阳性涂片复查符合率≥85%（判读相差两个级别以下）（10 分）</td><td>者查看标本 满意情况，</td><td>75%-79%扣5分；小于75%扣10分； （阳性涂片复查符合率_</td><td></td></tr><tr><td>阴性涂片复查的符合率≥95%（10分）</td><td>20 并对同一张 涂片判读， 相差两个级 别以上为结 果不符合。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "(请注明实 际结果) 试卷考核 1-2名，20</td><td>阴性符合率90%-94%扣5分；小于 90%扣10分。（阴性涂片复查的符合率_</td><td></td></tr><tr><td>理论 知识 （10分）</td><td>理论考试合格（10分）</td><td>10</td><td>分之内 百分制考 核，基本得 分为所有参 加考核人员</td><td>考试平均分≥90分=10分，80-89 分=9分，70-79 分=8分，60-69分 =6 分，<60 分=0分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "（实际分值—）</td><td></td><td></td></tr><tr><td>得分</td><td></td><td></td><td>的平均分</td><td></td><td></td><td></td></tr></table></body></html> # 专家总体意见： 一、亮点 二、问题与不足 三、建议 注：1.第三方检测机构细胞学检查质量控制参照本评估表进行；2.如本地只采用细胞学检查方法进行宫颈癌初筛，该部分得分 $^ * 2$ 为最终得分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "# 评估表5.阴道镜检查 评估地点： 评估时间： 得分 <html><body><table><tr><td>评估内容</td><td colspan=\"2\">评估标准 有专人负责（1分）</td><td>分值</td><td>评估方法</td><td>评分标准</td><td>得分 备注</td></tr><tr><td rowspan=\"5\">人员 要求 （10分）</td><td colspan=\"2\">近3年参加过上级培训（2分）</td><td rowspan=\"5\">10 8</td><td rowspan=\"5\">员 图像不清晰，扣3分; 放大倍数不符合要求，扣2分；</td><td>无专人负责，扣1分； 未参加过上级机构培训，扣2分; 无护士协助，扣1分； 从事阴道镜专业技术工作的实践经</td><td rowspan=\"5\">执业 前未 接受 过阴 道镜 专业 术 扣5</td></tr><tr><td>医护配比合理(1:1或2:1）（1分） 1.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "具有1年以上从事阴道镜专业技术工作的实践经验；或执</td><td>现场观察， 10 访谈医务人</td><td>验不足1年和执业前未接受过阴道 镜专业技术培训，两项条件均不满</td></tr><tr><td colspan=\"2\">业前接受省级以上（含省级）至少3个月的阴道镜专项技术 培训 2.每年诊治子官颈细胞学异常的新病例不少于 150 例</td><td>足扣5分； 每年评价新细胞学异常病例数不足 接比例[年工作量不低于，1505例） 50-99人，扣3分；100-150人，扣 2分；</td></tr><tr><td colspan=\"2\">每人每日工作量小于30例 (1分) 能够配备满足业务需要的工作用房（2分）</td><td>每日工作量大于30人，根据情况酌 情扣分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "诊室面积不合理，扣2分;</td></tr><tr><td colspan=\"2\">环境整洁，物品摆放整洁、合理有序（4分) 有良好的通风、消毒、照明、冷暖条件（2分)</td><td>环境杂乱，扣2分; 物品摆放杂乱无序，扣2分; 通风、消毒、照明、冷暖条件较差，</td></tr><tr><td>设备 物品</td><td>检查室有保护隐私的措施（2分）</td><td>处于正常功能的阴道镜，图像清晰、色调 柔和、不失真；放大倍数一般为 5-20倍;</td><td>现场观察</td><td>酌情扣分； 无隐私保护，扣2分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "色彩失真，扣3分；</td><td></td></tr></table></body></html> <html><body><table><tr><td>评估内容</td><td colspan=\"2\">评估标准</td><td>分值</td><td>评估方法</td><td>评分标准</td><td>得分备注</td></tr><tr><td rowspan=\"4\">设备 物品 （15分）</td><td>常用 物品 （3分）</td><td>大棉球或棉块、止血材料（纱布或带绳棉 塞）、长镊子、活检钳、颈管刮匙、子宫 颈固定钩、装有10%中性甲醛溶液的标本瓶</td><td rowspan=\"4\">3 40</td><td rowspan=\"4\">现场观察 现场观察阴</td><td>缺一项扣0.",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "5分，扣完为止;</td><td></td></tr><tr><td>常用试剂</td><td>5%醋酸，5%复方碘溶液（4分） 4</td><td>试剂配备不正确，扣2分； 未标有配制时间，扣1分; 试剂不在要求的保存期内，扣1分。无检查指征，扣5分；</td></tr><tr><td colspan=\"2\">符合阴道镜检查指征（5分）；</td><td>道镜医生对 无医患沟通，扣3分； 妇女进行阴 醋酸试验操作不规范，涂醋酸和观 道镜检查的 察时间小于60秒，扣7分;</td></tr><tr><td colspan=\"2\">阴道镜检查操作流程符合规范，检查内容全面（15分）</td><td>其他各环节检查及操作流程不规 范，酌情扣分,共15分，扣完为止； 来进行充分定位活检，函情扣分，</td></tr><tr><td rowspan=\"8\">（40分） 检查结果 和图文报</td><td colspan=\"2\"></td><td rowspan=\"8\">行口头描 述，并进行 模拟操作</td><td rowspan=\"8\">全过程。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "如 果评估现场 没有受检 无活检指征，扣15分； 者让家</td><td></td></tr><tr><td rowspan=\"2\">宫颈活检：符合宫颈活检指征，活检方法和操作规范（15分）</td><td rowspan=\"2\">员对检查过 程和内容进 无ECC 指征，扣5分;</td></tr><tr><td></td></tr><tr><td rowspan=\"2\">ECC:符合ECC 指征，操作规范（5分） 检查图像识别判断准确（15分）</td><td rowspan=\"6\"></td><td>ECC操作不规范，酌情扣分，共5 分，扣完为止。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td rowspan=\"2\"></td></tr><tr><td>20%的报告图像识别、结果判断不准 确，扣15分；</td></tr><tr><td>处理建议适当（10分）</td><td>随机调阅 10-20份阴 10分；</td><td>50%的报告下一步建议不正确，扣</td></tr><tr><td>注意事项及复诊安排有交待（5分）</td><td>道镜于报 告的规范性</td><td>50%得报告注意事项及复诊安排无</td></tr><tr><td>报告规范（有阴道镜检查指征，有转化区类型和拟诊；所有 图像要求至少保存3-4张图，包括生理盐水下、醋酸下、醋</td><td>报告不规范，酌情扣分，扣完为止; 未按要求留存图像，扣5分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td></td></tr><tr><td>酸下可疑病灶部位放大等）（10分）</td><td></td><td></td></tr></table></body></html> <html><body><table><tr><td>评估内容</td><td>评估标准</td><td>分值</td><td>评估方法</td><td>评分标准</td><td>得分</td><td>备注</td></tr><tr><td rowspan=\"2\">信息 登记 （5分）</td><td>有阴道镜检查登记表/册（2分）</td><td>5</td><td>现场观察</td><td>无阴道镜检查登记表，扣2分; 筛查项目阴道镜检查登记表和门 诊检查登记表未分开，扣1分； 无可疑/阳性病例随访登记表，扣3</td><td></td><td></td></tr><tr><td>有可疑/阳性病例随访登记表/册 (3分)</td><td>10</td><td>分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "专家随机调 阅10~ 20 份阴道镜检 查报告，对</td><td>75%-79%扣2分；70%-74%扣5分； 小于70%扣10分；</td><td></td><td></td></tr><tr><td>相关 指标 （20分）</td><td>阴道镜拟诊符合率≥80%（10分） 阴道镜拟诊高级别病变与病理结果符合率≥60%（10分）</td><td>10</td><td>拟诊结果进 行判定。现场观察</td><td>（阴道镜拟诊符合率 小于60%扣10分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "（阴道镜检查诊断高度病变与病 理结果符合率 _）</td><td></td><td></td></tr><tr><td>理论 知识 （10分）</td><td>理论考试合格（10分）</td><td>10</td><td>试卷考核1-2 名，20分钟之 内完成答题， 核，百御考 为所有参加考 核人员的平均</td><td>考试平均分≥90分=10分，80-89 分分分6079分=8分，60-69分 （实际分值</td><td></td><td></td></tr><tr><td>得分</td><td></td><td>150</td><td>分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td></td><td></td><td></td></tr></table></body></html> # 专家总体意见： 一、亮点 二、问题与不足 三、建议 # 评估表 6.组织病理检查 评估地点： 评估时间： 得分 <html><body><table><tr><td>评估内容</td><td>评估标准</td><td>分值</td><td>评估方法</td><td>评分标准</td><td>得分</td><td>备注</td></tr><tr><td rowspan=\"2\">人员 要求 （10分）</td><td>在岗人员获得病理医生执业证书资质，且人员数量≥2人（5 分）</td><td rowspan=\"2\">10</td><td rowspan=\"2\">现场观察, 访谈医务 人员。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td>每有１人未获资质扣２分，如均无 资质扣5分；</td><td rowspan=\"2\"></td><td rowspan=\"2\"></td></tr><tr><td>接受地市级以上宫颈组织病理学专项培训（5分)</td><td>每有1人未接受过专业培训扣2</td></tr><tr><td rowspan=\"3\">检查 环境 （5分）</td><td>有良好的照明和通风设备（1分）</td><td rowspan=\"2\">5</td><td rowspan=\"2\">现场观察</td><td>分，如均未参加专项培训扣5 分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "照明、通风设备不合理扣1分；</td><td rowspan=\"2\"></td><td rowspan=\"2\"></td></tr><tr><td>阅片、制片环境分开（2分）</td><td>阅片和制片环境未分开扣2分； 洁污和交叉感染等根据现场酌情</td></tr><tr><td rowspan=\"2\">检查</td><td>洁污分开，符合预防交叉感染要求（2分） 病历资料保存完整（文字、玻片、蜡块）（5分）</td><td rowspan=\"2\">15</td><td rowspan=\"2\">现场观察</td><td>扣分。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "资料不完整扣5分；</td><td rowspan=\"2\"></td><td rowspan=\"2\"></td></tr><tr><td>病理学的染色试剂及设备符合使用要求（苏木素、伊红、计 时器、染色机等）（5分）</td><td>染色方法不符合要求扣5分，各种 试剂少一项扣2分，扣完为止；</td></tr><tr><td rowspan=\"2\">设备 （15分） 基本 技能</td><td>病理学检查设备功能良好（脱水机（手工脱水），包埋机、 切片机、展片机、干燥仪（干燥箱）、显微镜、蜡块柜、切 片柜等）（5分）</td><td rowspan=\"2\"></td><td rowspan=\"2\"></td><td>设备每少一项扣2分，扣完为止； 设备每有一项不合格扣2分，扣完</td><td></td><td rowspan=\"2\"></td></tr><tr><td>现场考核或操作合格（8分）</td><td>为止。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "现场考察 分；</td><td>以现场阅片结果为依据，酌情扣</td><td></td></tr><tr><td rowspan=\"4\">（20分） 制度 流程 （20分）</td><td>病理切片检查结果符合率≥95%（8分）</td><td rowspan=\"2\">20</td><td rowspan=\"2\">现场随机抽 取20份切 片进行复 核。</td><td rowspan=\"2\">90%-94%扣2分；85%-89%扣4分； 小于85%扣8分;</td><td rowspan=\"2\"></td><td rowspan=\"2\"></td></tr><tr><td></td></tr><tr><td>开展免疫组化染色项目（4分）</td><td rowspan=\"3\">20</td><td rowspan=\"3\">现场考察 现场观察, 查阅相关 资料。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td>（病理切片结果符合率----%) 未开展扣4份。</td><td rowspan=\"3\"></td><td rowspan=\"3\"></td></tr><tr><td>必要的工作制度（质量检查、标本处理、预防感染）（4分）</td><td>每缺一项扣2分，扣完为止; 一项工作流程不合理扣2分，扣完</td></tr><tr><td>操作流程、技术规范（4分） 标本按规定处理（2分）</td><td>为止； 未按规定处理扣2分；</td></tr></table></body></html> # 专家总体意见： <html><body><table><tr><td>评估内容</td><td>评估标准</td><td>分值</td><td>评估方法</td><td>评分标准</td><td>得分备注</td><td></td></tr><tr><td rowspan=\"3\">质量 控制 （20分）</td><td>有质控制度（4分）</td><td rowspan=\"3\">20</td><td rowspan=\"3\">现场观察 询问，查阅 相关资料。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "</td><td>无质控制度，扣4分； 有质控制度，但制度制定不合理， 扣2分；</td><td></td><td rowspan=\"3\"></td></tr><tr><td>开展室内质控，有质控记录/报告（8分）</td><td>无室内质控，扣8分; 有室内质控，但无室内质控记录/ 报告，扣5分； 有室内质控记录/包括，记录不合</td></tr><tr><td>开展室间质评，有质评记录/报告（8分）</td><td>理或规范扣3分; 无室间质评，扣8分； 有室间质评，但无室间质评记录/ 报告，扣5分； 有室间质评记录/报告，但记录不</td></tr><tr><td rowspan=\"2\">信息 资料 （20分）</td><td>病理登记表、标本交接登记、结果报告反馈记录（10分)</td><td rowspan=\"2\">20</td><td rowspan=\"2\">现场观察， 查阅相关扣完为止; 资料。",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "试卷考核1-2 名，20分钟</td><td>合理或不规范，扣3分。要求项目独立的登记表，每缺一项 扣5分；每项登记不规范扣3分，</td><td></td><td rowspan=\"2\"></td></tr><tr><td>病理学切片编号清晰，方便查找，保存时间符合要求（10分)</td><td>编号不清晰扣5分; 查找不方便扣5分; 考试平均分≥90分=10分，80-89</td></tr><tr><td>理论 知识 （10分）</td><td>理论考试合格（10分）</td><td>10</td><td>之内完成答 题，以百分制 考核，基本得 分为所有参 加考核人员 的平均分。</td><td>分=9分，70-79分=8分，60-69分 =6 分，<60分=0分。（实际分值_</td><td></td><td></td></tr><tr><td>得分</td><td></td><td>120</td><td></td><td></td><td></td><td></td></tr></table></body></html> 一、亮点二、问题与不足三、建议",
    "source": "宫颈癌筛查质量评估手册",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛查质量评估手册/宫颈癌筛查质量评估手册.md"
  },
  {
    "text": "![](images/2b689efbd1046009e88fb324a8da52a595ba6c794de667d5de507aa0d37ad8dc.jpg) # 宫颈癌筛检与世贸中心健康计划 # 什么是宫颈癌筛检？宫颈癌筛检可在您出现疾病症状之前检查您是否有宫颈癌迹象。它不会筛检卵巢、子宫、阴道或外阴癌。两种筛检测试均可帮助预防宫颈癌或及早发现它： 巴氏测试（或巴氏涂片检查）检查子宫颈的癌前病变、细胞病变，如果未加以适当治疗，它们可能导致宫颈癌。",
    "source": "宫颈癌筛检与世贸中心健康计划",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛检与世贸中心健康计划/宫颈癌筛检与世贸中心健康计划.md"
  },
  {
    "text": "HPV 测试检查会导致这些细胞病变的病毒（人乳头瘤病毒）。筛检利于及早治疗，并可延缓甚至阻止癌症恶化。# 宫颈癌筛检的潜在风险是什么？异常筛检测试结果也可能引起轻微的心理效应，例如短时间加剧焦虑、痛苦及对健康的担忧。如果您有与这些筛检测试或诊断程序相关的疑虑或其他问题，请告知您的医生。在多数情况下，宫颈癌筛检的益处大于与筛检有关的风险。# 通过世贸中心健康计划我能够接受哪些宫颈癌筛检测试？每个临床卓越中心 (CCE) 和全国性医疗服务提供者网络(NPN) 均已制定为其会员执行宫颈癌筛检的流程。",
    "source": "宫颈癌筛检与世贸中心健康计划",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛检与世贸中心健康计划/宫颈癌筛检与世贸中心健康计划.md"
  },
  {
    "text": "您应联系您的 CCE 或 NPN 讨论您的资格以及宫颈癌筛检的可用选项。通过巴氏涂片检查或 HPV 测试进行筛检存在某些风险。如果测试结果异常，将需要接受更频繁的测试和侵入性诊断程序，例如阴道镜检查和宫颈活检。这些诊断程序会造成阴道出血、疼痛、感染和漏诊（由于不适当采样）。通过巴氏涂片检查或 HPV 测试进行筛检存在某些风险。如果测试结果异常，将需要接受更频繁的测试和侵入性诊断程序，例如阴道镜检查和宫颈活检。",
    "source": "宫颈癌筛检与世贸中心健康计划",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛检与世贸中心健康计划/宫颈癌筛检与世贸中心健康计划.md"
  },
  {
    "text": "这些诊断程序会造成阴道出血、疼痛、感染和漏诊（由于不适当采样）。# 世贸中心健康技术遵循哪些宫颈癌筛检指导方针？世贸中心健康计划遵守美国预防服务特别小组 (USPSTF)制定的循证筛检指导方针。USPSTF 是一个独立团体，汇集全国的预防及循证医学专家。如果您的年龄在 21 岁到 65 岁之间，您应每 3 年接受一次巴氏涂片检查。如果您的年龄在 30 岁到 65 岁之间，您应每 5 年接受一次结合HPV 测试的巴氏涂片检查。",
    "source": "宫颈癌筛检与世贸中心健康计划",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛检与世贸中心健康计划/宫颈癌筛检与世贸中心健康计划.md"
  },
  {
    "text": "如果您面临较高的宫颈癌风险（例如有家族病史或以往有癌症诊断），您可能需要更早或接受更多次的筛检。# 了解更多信息。请致电 1-888-982-4748 或访问 www.cdc.gov/wtc世贸中心 | 五角大楼 | 宾夕法尼亚州尚克斯维尔 # 未参加世贸中心健康计划的私人医生可以为我提供筛检服务吗？可以，在多数情况下，与会员建立长期关系的私人医生为其提供筛检服务可能更合适。但是，如果您选择私人医生为您提供服务，您必须通过自己的基本保险为这些服务付费或自行付费。",
    "source": "宫颈癌筛检与世贸中心健康计划",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛检与世贸中心健康计划/宫颈癌筛检与世贸中心健康计划.md"
  },
  {
    "text": "世贸中心健康计划只承保通过计划提供的筛检的费用。# 如果我的检测结果为阴性，将发生什么情况？正常检测结果意味着不存在异常细胞。但是，巴氏涂片检查的准确率无法达到 $100 \\%$ 。您应在 3 年内回来接受下一次筛检测试。多数时候，宫颈癌发展缓慢，跟进巴氏涂片检查应能够及时发现任何病变并加以治疗。# 如果我的宫颈癌检测结果为阳性，将发生什么情况？巴氏涂片检查表明存在异常病变时，需要接受进一步检测或跟进检查。",
    "source": "宫颈癌筛检与世贸中心健康计划",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛检与世贸中心健康计划/宫颈癌筛检与世贸中心健康计划.md"
  },
  {
    "text": "下一步取决于巴氏涂片检查的结果、巴氏涂片检查的既往史，以及您可能有的宫颈癌的风险因素。如果您的检测结果为阳性，医生将向您说明将来可能进行的检测和治疗。如果巴氏涂片检查表明存在癌症或癌前可疑病变，世贸中心健康计划将通过世贸中心健康计划中已登记的核准医疗服务提供者，根据国家综合癌症网络 (NCCN) 的建议，承保跟进检查和相关诊断测试。如果巴氏涂片检查表明存在列于世贸中心相关健康状况列表上的浸润性宫颈癌或其他癌症，那么您的病况可能符合世贸中心可确认癌症的要求，世贸中心健康计划将通过世贸中心健康计划中已登记的核准医疗服务提供者，承保有医疗需要的所有癌症治疗。如果巴氏涂片检查表明存在良性病况或世贸中心健康计划不承保的病况，但这些病况需要进行治疗，因为世贸中心健康计划无法提供承保服务，您的 CCE 或 NPN 医疗服务提供者将把您转给您的主治医师进行跟进治疗，并很有可能由您的健康保险提供承保服务。# 了解更多信息。请致电 1-888-982-4748 或访问 www.cdc.gov/wtc世贸中心 | 五角大楼 | 宾夕法尼亚州尚克斯维尔",
    "source": "宫颈癌筛检与世贸中心健康计划",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌筛检与世贸中心健康计划/宫颈癌筛检与世贸中心健康计划.md"
  },
  {
    "text": "# 宫颈癌诊疗指南 （2022 年版） # 一、概述 子宫颈癌是常见的妇科恶性肿瘤之一, 发病率在我国女性恶性肿瘤中居第二位, 位于乳腺癌之后。2018 年全球新发子宫颈癌病例超过56.9 万例，死亡病例超过 31.1 万例。其中 $8 5 \\%$ 的病例发生于发展中国家。我国 2015 年约有新发病例 11.1 万，死亡病例3.4 万。我国子宫颈癌死亡分布情况总体上农村略高于城市，中西部地区约为东部地区的两倍。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "我国子宫颈癌患者中位发病年龄是51 岁，但主要好发于 2 个年龄段，以 $4 0 \\sim 5 0$ 岁为最多， $6 0 \\sim 7 0$ 岁又有一高峰出现，20 岁以前少见。然而值得关注的是近年来子宫颈癌的平均发病年龄在逐渐降低，有年轻化趋势。因此，十分有必要在全国范围内规范宫颈癌的诊断与治疗。另一方面，宫颈癌的发生可通过对癌前病变的检查和处理得以有效控制。西方国家的经验显示，宫颈癌的发生率在密切筛查的人群中减少了$70 \\% { \\sim } 9 0 \\%$ 。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "2020 年 11 月 17 日，WHO 启动了“加速消除宫颈癌”的全球战略 。本指南适用于宫颈鳞癌、腺癌及腺鳞癌，占所有宫颈癌的 $90 \\%$ 以上。部分特殊病理类型，如小细胞癌、透明细胞癌、肉瘤等发病率低，目前国际国内尚未达成共识，故本指南不适合用于这些少见病理类型的宫颈癌。本指南借鉴了国际上公认的宫颈癌诊疗指南，如美国国家综合癌症网络（national comprehensive cancernetwork，NCCN）指南、国际妇产科联盟（international federationof gynecology and obstetrics，FIGO）指南等，并结合我国以往指南进行修订。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "在临床实践中，宫颈癌注重规范化综合治疗理念，同时也注重个体化治疗，需结合医院的设备、技术条件以及患者的病情进行治疗。对于病情复杂的宫颈癌患者，本指南未涵盖的，建议参加临床试验。# 二、病因学 目前已经明确高危型人乳头瘤病毒（human papilloma virus，HPV）持续感染是宫颈癌及癌前病变发生的必要因素，即宫颈发生癌变的过程中，HPV 感染是最为关键的环节。在妇女一生中，感染高危型HPV 的概率达 $70 \\%$ 以上，但只有不到 $10 \\%$ 的妇女发展成宫颈癌或宫颈上皮内瘤变（cervical intraepithelial neoplasia，CIN），主要原因是 $80 \\%$ 的妇女的 HPV 感染为一过性。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "除持续性高危型HPV 感染的作用外，还需要其他内源性和外源性因子的共同参与和作用，才能造成宫颈癌的发生。所以可以将引发子宫颈癌的危险因素分为两类：一是生物学因素，即高危型 HPV 持续感染；二是外源性的行为性危险因素。# （一）HPV 感染。目前已发现和鉴定出 200 多个亚型的 HPV，大约有 54 种可以感染生殖道黏膜。依据各型HPV 与子宫颈癌发生的危险性不同分为高危型和低危型。高危型（如 HPV16、18、31、33、35、39、45、51、52、56、58、59、68 型）与子宫颈癌的发生相关，尤其是HPV16 型和 18 型和子宫颈癌关系最为密切。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "低危型 HPV（如 6、11、42、43、44 型）感染则可能引起生殖器及肛周湿疣。目前人乳头瘤病毒疫苗已在国内上市，可以按照适宜的年龄进行推广接种，以预防宫颈癌前病变及宫颈癌。# （二）行为性危险因素。1.由于 HPV 主要是通过性传播，所以一些可能增加HPV 感染的因素如初次性生活开始年龄小、多个性伴侣或性伴侣有多个性伙伴、性卫生不良或者有性传播疾病病史会增加 HPV 感染风险，从而增加宫颈癌的发生风险。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "2.月经及孕产因素：早婚、早育，多孕多产、经期、产褥期卫生不良。3.吸烟。4.口服避孕药。5.自身免疫性疾病或者长期免疫抑制（如肾移植患者需要长期口服免疫抑制药物）。6.营养状况不良，营养失调：如 $\\beta$ 胡萝卜素、叶酸、维生素A、 维生素C 缺乏、微量元素的失衡等。# 三、临床表现 # （一）症状。宫颈癌前病变和宫颈癌早期可以没有任何症状，随着病变严重程度的增加，会出现接触性阴道出血，异常白带如血性白带、白带增多, 不规则阴道出血或绝经后阴道出血。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "晚期宫颈癌还可出现阴道大量出血，可合并有水样甚至米汤样白带，另外可能出现由于肿瘤侵犯其他器官所导致的相应症状，如侵犯膀胱可出现血尿，侵犯直肠可出现血便，肿瘤侵透膀胱、直肠可出现瘘，侵犯宫旁压迫输尿管导致肾盂积水可能出现腰疼，肺转移可能导致咳嗽、咯血等相关症状；肿瘤合并感染可出现发热症状；也可有肾功能衰竭及恶病质情况。# （二）体征。宫颈早期浸润癌（ⅠA1 期和ⅠA2 期）可能没有任何相关异常体征，宫颈浸润癌（ⅠB1 期以上）通过妇科检查可发现宫颈肿物，大体上可分为菜花型、结节型、溃疡型以及颈管型，颈管型有时候表现为宫颈表面光滑，仅宫颈管明显增粗，质地变硬。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "如果阴道受侵可发现阴道穹窿或阴道壁肿瘤。宫旁受累患者妇科检查三合诊可发现宫旁增厚，如ⅢB 期患者肿瘤一直延伸到盆壁；晚期患者可能在腹股沟或锁骨上区域扪及肿大淋巴结。# 四、诊断检查 # （一）宫颈/阴道细胞学涂片检查及HPV 检测。宫颈/阴道细胞学涂片检查及 HPV 检测是现阶段发现早期宫颈癌及癌前病变（CIN）的初筛手段，特别是对临床体征不明显的早期病变的诊断。取材应在宫颈上皮的移行带处，即新旧鳞-柱上皮交界间的区域。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "目前主要采用宫颈液基薄层细胞学检查（thin-prep cytology test，TCT）。HPV 检测可以作为 TCT 的有效补充，二者联合有利于提高筛查效率。对于 HPV16 及 18 型阳性的患者建议直接转诊阴道镜，进行组织学活检。# （二）阴道镜检查。阴道镜检查对发现子宫颈癌前病变、早期子宫颈癌、确定病变部位有重要作用，可提高活检的阳性率。在不具备阴道镜的医疗单位，也可以应用 $3 \\%$ 或 $5 \\%$ 醋酸后或碘溶液涂抹宫颈后肉眼观察，在有醋白上皮或碘不着色处取活检，送病理检查。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "阴道镜活检的同时应注意宫颈管刮术的重要性，特别是当阴道镜检查发现鳞状上皮内病变自转化区延伸至宫颈管内、细胞学筛查提示有非典型腺细胞及阴道镜下未见鳞-柱转化区等情况时。只有专业的阴道镜医师才能决定可以省略宫颈管刮术，否则所有接受阴道镜活检的患者均要做颈管刮术。# （三）妇科检查。妇科检查是临床分期最重要手段，临床分期需要 2 名副高以上职称妇科医生决定，分期一旦确定, 治疗后不能改变分期。# 1.视诊 应在充足照明条件下进行，直接观察外阴和通过阴道窥器观察阴道及宫颈。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "除一般观察外应注意癌浸润范围，宫颈肿瘤的位置、范围、形状、体积及与周围组织的关系。# 2.触诊 肿瘤的质地、浸润范围及其与周围的关系等必须通过触诊来确定。有些黏膜下及颈管内浸润，触诊比视诊更准确。三合诊检查可了解阴道旁、宫颈旁及子宫旁有无浸润，肿瘤与盆壁关系，子宫骶骨韧带、子宫直肠陷凹、直肠本身及周围情况等。# （四）病理诊断。阴道镜或直视下的宫颈组织学活检病理检查是最终确诊的金标准。对于少见或疑难病理类型（如腺癌或小细胞癌等），应行免疫组化检查协助鉴别和诊断。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "对于多次咬取活检仍不能确诊者，需进一步采取较深部组织时可用切取法。当宫颈表面活检阴性、阴道细胞学涂片检查阳性或影像检查不能排除宫颈管癌时，可行宫颈锥形切除送病理检查。由于宫颈活检组织较小，无法完全确定宫颈病变的浸润深度和范围，故对于ⅠA1 期和ⅠA2 期的宫颈早期浸润癌的确诊，必须通过宫颈锥切术的术后病理才能最终确诊宫颈病变范围是否为早期浸润癌。# （五）影像学检查。由于解剖部位表浅，绝大多数子宫颈癌经妇科检查及细胞病理学检查即可被确诊。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "在子宫颈癌诊断中影像学检查的价值主要是对肿瘤转移、侵犯范围和程度的了解（包括评价肿瘤局部侵犯的范围，淋巴结转移及远处器官转移等），以指导临床决策并用于疗效评价。用于子宫颈癌的影像检查方法包括： # 1.腹盆腔超声 主要用于宫颈局部病变的观察，同时可以观察盆腔及腹膜后区淋巴结转移情况，以及腹盆腔其他脏器的转移情况，另外可发现浅表淋巴结的转移情况。由于分辨率的限制，目前对于宫颈局部病变以及全身转移情况的评估主要还是依靠核磁和 CT 检查。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "# 2.盆腔 MRI 无辐射，多序列、多参数成像，具有优异的软组织分辨力，是子宫颈癌最佳影像学检查方法，有助于病变的检出和大小、位置的判断，尤其对活检为 CIN3 患者可用于除外内生性病变；明确病变侵犯范围，提供治疗前分期的重要依据，可显示病变侵犯宫颈基质的深度，判断病变局限于宫颈、侵犯宫旁或是否侵犯盆壁，能够显示阴道内病变的范围，但有时对病变突入阴道腔内贴邻阴道壁与直接侵犯阴道壁难以鉴别；能够提示膀胱、直肠壁的侵犯，但需结合镜检。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "同时检出盆腔、腹膜后区及腹股沟区的淋巴结转移。对于非手术治疗的患者，可用于放疗靶区勾画、治疗中疗效监测、治疗末疗效评估及治疗后随诊。# 3.腹盆腔 CT： CT 软组织分辨力低，平扫病变与正常子宫颈密度相近，尤其对局限于宫颈的早期子宫颈癌观察效果差；增强 CT 扫描对比度优于平扫，但仍有近1/2 的病变呈等密度而难以明确范围。CT 的优势主要在于显示中晚期病变方面，评价宫颈病变与周围结构（如膀胱、直肠等）的关系，淋巴结转移情况，以及大范围扫描腹盆腔其他器官是否存在转移。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "对于有核磁禁忌证的患者可选择 CT检查。# 4.胸部射线摄影及胸部CT 检查 主要目的是为了排除肺转移和纵隔淋巴结转移，胸片只能除外明显肺转移，无法评估纵隔淋巴结，所以有条件的医院还是应该行胸部CT 检查。# 5.核医学影像检查 不推荐使用正电子发射计算机体层成像（positron emissiontomography-computed tomography，PET-CT）评价宫颈癌的局部浸润情况，但对于下列情况，推荐有条件者使用 PET-CT：（1）FIGO分期为ⅠB1 期及以上的初诊患者疗前分期（包括ⅠB1 期有保留生育功能需求的患者）；（2）因其他原因行单纯子宫切除术意外发现宫颈癌拟全身评估者；（3）拟行放射治疗需影像辅助勾画靶区；（4）存在高危因素的患者治疗结束 $3 \\sim 6$ 个月后随访监测；（5）随访过程中可疑出现复发转移的患者，包括出现临床症状或相关肿瘤标志物升高。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "核素骨扫描仅用于怀疑有骨转移的患者。# 6.腔镜检查 膀胱镜、直肠镜：临床上怀疑膀胱或直肠受侵的患者应对其进行相应腔镜检查。没有条件的单位应转上级医院诊治。# （六）肿瘤标志物检查。肿瘤标志物异常升高可以协助诊断、疗效评价、病情监测和治疗后的随访监测，尤其在随访监测中具有重要作用。鳞癌相关抗原是宫颈鳞状细胞癌的重要标志物，血清鳞癌相关抗原水平超过 $1 .5 \\mathrm { n g / m l }$ 被视为异常。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "因宫颈癌以鳞状细胞癌最为常见，所以鳞癌相关抗原是子宫颈癌诊治过程中最常被检测的血清学肿瘤标志物。宫颈腺癌可以有癌胚抗原、糖类抗原（carbohydrate antigen，CA）125 或 CA19-9 的升高。# 五、子宫颈癌的分类和分期 # （一）子宫颈癌的组织学分类。子宫颈癌主要包括宫颈鳞状细胞癌、腺癌、腺鳞癌及其他少见类型。其中鳞状细胞癌最常见，约占 $80 \\%$ ，腺癌占 $1 5 \\% \\sim 2 0 \\%$ 。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "随着子宫颈癌普查工作的开展，宫颈鳞状细胞癌的发生率及死亡率均呈下降趋势，但腺癌的发生率近 30 年来却呈上升趋势。各种病理类型中鳞癌的预后最好，宫颈腺癌和腺鳞癌的预后相对较差，这种差别在晚期患者中更为明显。目前宫颈恶性肿瘤病理类型主要参照世界卫生组织公布的病理分型（WHO，2014）（表 1）。表 1 宫颈肿瘤组织学分类及编码（WHO，2014） <html><body><table><tr><td colspan=\"2\">肿瘤组织学分类</td><td>编码</td></tr><tr><td colspan=\"2\">上皮肿瘤</td><td></td></tr><tr><td>鳞癌和前驱病变</td><td></td><td></td></tr><tr><td></td><td>鳞状上皮内病变</td><td></td></tr><tr><td></td><td>低级别鳞状上皮内病变</td><td>8077/0</td></tr><tr><td></td><td>高级别鳞状上皮内病变</td><td>8077/2</td></tr><tr><td></td><td>鳞状细胞癌，非特殊型（NOS）</td><td>8070/3</td></tr><tr><td></td><td>角化型癌</td><td>8071/3</td></tr><tr><td></td><td>非角化型癌</td><td>8072/3</td></tr><tr><td></td><td>乳头状鳞癌</td><td>8052/3</td></tr><tr><td></td><td>基底样癌</td><td>8083/3</td></tr><tr><td></td><td>湿疣性癌</td><td>8051/3</td></tr><tr><td></td><td>疣状癌</td><td>8051/3</td></tr><tr><td></td><td>鳞状-移行细胞癌</td><td>8120/3</td></tr><tr><td></td><td>淋巴上皮瘤样癌</td><td>8082/3</td></tr><tr><td colspan=\"2\">良性鳞状上皮病变</td><td></td></tr><tr><td></td><td>鳞状化生</td><td></td></tr><tr><td></td><td>尖锐湿疣</td><td></td></tr><tr><td></td><td>鳞状上皮乳头状瘤</td><td>8052/0</td></tr></table></body></html> <html><body><table><tr><td colspan=\"2\">移行细胞化生</td></tr><tr><td colspan=\"2\">腺癌和前驱病变</td></tr><tr><td></td><td>原位腺癌 8140/2</td></tr><tr><td></td><td>腺癌 8140/3</td></tr><tr><td></td><td>子宫颈腺癌，普通型 8140/3</td></tr><tr><td></td><td>黏液性癌，非特殊型（NOS） 8480/3 8482/3</td></tr><tr><td></td><td>胃型 肠型 8144/3</td></tr><tr><td></td><td>印戒细胞型 8490/3</td></tr><tr><td></td><td>绒毛管状腺癌 8263/3</td></tr><tr><td></td><td>子宫内膜样癌 8380/3</td></tr><tr><td></td><td>透明细胞癌 8310/3</td></tr><tr><td></td><td>浆液性癌 8441/3 中肾管癌 9110/3</td></tr><tr><td></td><td>混合性腺癌-神经内分泌癌 8574/3</td></tr><tr><td colspan=\"2\">良性腺上皮肿瘤和瘤样病变</td></tr><tr><td></td><td>子宫颈息肉</td></tr><tr><td></td><td>苗勒上皮乳头状瘤</td></tr><tr><td></td><td>纳氏囊肿 隧道样腺丛</td></tr><tr><td></td><td>微腺体增生</td></tr><tr><td></td><td colspan=\"2\">小叶状子宫颈腺体增生</td></tr></table></body></html> <html><body><table><tr><td></td><td colspan=\"2\">弥漫性层状子宫颈管腺体增生</td></tr><tr><td></td><td>中肾管残余和增生</td><td></td></tr><tr><td></td><td>阿-斯反应</td><td></td></tr><tr><td></td><td>子宫颈管内膜异位</td><td></td></tr><tr><td></td><td>子宫内膜异位</td><td></td></tr><tr><td></td><td>输卵管子宫内膜样化生</td><td></td></tr><tr><td></td><td>异位前列腺组织</td><td></td></tr><tr><td colspan=\"2\">其他上皮肿瘤</td><td></td></tr><tr><td>腺鳞癌</td><td></td><td>8560/3</td></tr><tr><td></td><td>毛玻璃细胞癌 腺样基底细胞癌</td><td>8015/3 8098/3</td></tr><tr><td></td><td>腺样囊性癌</td><td>8200/3</td></tr><tr><td>未分化癌</td><td></td><td>8020/3</td></tr><tr><td colspan=\"2\">神经内分泌肿瘤</td><td></td></tr><tr><td colspan=\"2\"></td><td></td></tr><tr><td></td><td>低级别神经内分泌肿瘤 类癌 非典型类癌</td><td>8240/3 8249/3</td></tr><tr><td></td><td>高级别神经内分泌癌</td><td>小细胞神经内分泌癌（小细胞癌)</td><td>8041/3</td></tr><tr><td></td><td>大细胞神经内分泌癌</td><td></td><td>8013/3</td></tr><tr><td colspan=\"4\">间叶肿瘤和瘤样病变</td></tr><tr><td colspan=\"4\">良性</td></tr></table></body></html> <html><body><table><tr><td></td><td>平滑肌瘤</td><td>8890/0</td></tr><tr><td></td><td>横纹肌瘤</td><td>8905/0</td></tr><tr><td>其他</td><td></td><td></td></tr><tr><td colspan=\"2\">恶性</td><td></td></tr><tr><td></td><td>平滑肌肉瘤</td><td>8890/3</td></tr><tr><td></td><td>横纹肌肉瘤</td><td>8910/3</td></tr><tr><td></td><td>腺泡状软组织肉瘤</td><td>9581/3</td></tr><tr><td></td><td>血管肉瘤</td><td>9120/3 9540/3</td></tr><tr><td></td><td colspan=\"2\">恶性外周神经鞘瘤</td></tr><tr><td></td><td>其他肉瘤</td><td></td></tr><tr><td></td><td>脂肪肉瘤 未分化宫颈肉瘤</td><td>8850/3</td></tr><tr><td></td><td>尤因肉瘤</td><td>8805/3 9364/3</td></tr><tr><td>瘤样病变</td><td></td><td></td></tr><tr><td></td><td>手术后梭形细胞结节</td><td></td></tr><tr><td></td><td>淋巴瘤样病变</td><td></td></tr><tr><td colspan=\"3\">混合性上皮-间叶肿瘤</td></tr><tr><td></td><td>腺肌瘤</td><td>8932/0</td></tr><tr><td></td><td>腺肉瘤</td><td>8933/3</td></tr><tr><td>癌肉瘤 黑色素肿瘤</td><td></td><td>8980/3</td></tr><tr><td colspan=\"3\"></td></tr><tr><td>蓝痣</td><td></td><td>8780/0</td></tr></table></body></html> <html><body><table><tr><td>恶性黑色素瘤</td><td>8720/3</td></tr><tr><td colspan=\"2\">生殖细胞肿瘤</td></tr><tr><td>卵黄囊瘤</td><td></td></tr><tr><td colspan=\"2\">淋巴和髓系肿瘤</td></tr><tr><td>淋巴瘤</td><td></td></tr><tr><td>髓系肿瘤</td><td></td></tr><tr><td colspan=\"2\">继发性肿瘤</td></tr></table></body></html> # （二）子宫颈癌的分期。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "目前采用的是FIGO 2018年会议修改的宫颈癌临床分期标准。由妇科检查确定临床分期（表 2）。本版分期标准相对于上一版进行了比较大的改动，首先是在ⅠA 期诊断中，不再考虑水平间质浸润宽度，新版标准仅根据间质浸润深度来区分ⅠA1 期和ⅠA2期，主要是考虑宽度可能会受人为因素的影响。其次是细化了ⅠB期的亚分期，由原来的 2 个亚分期增加到 3 个亚分期，这样更有利于对患者术后辅助治疗选择和预后判断。最后一个重要的变化就是将淋巴结转移纳入分期系统，将淋巴结转移定义为ⅢC 期，而且增加了淋巴结转移的证据标注（r 代表影像学发现淋巴结转移，p 代表病理学证实）。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "表 2 国际妇产科联盟宫颈癌临床分期标准（FIGO 2018） <html><body><table><tr><td>分期</td><td>描述</td></tr><tr><td>一</td><td>肿瘤严格局限于宫颈（扩展至宫体将被忽略)</td></tr><tr><td>IA</td><td>仅能在显微镜下诊断的浸润癌，所测量的最大浸润深度≤5.0mm</td></tr></table></body></html> <html><body><table><tr><td></td><td>的浸润癌</td></tr><tr><td>I A1</td><td>所测量间质浸润深度<3.",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "0mm</td></tr><tr><td>I A2 IB</td><td>所测量间质浸润深度≥3.0mm而≤5.0mm 所测量的最大浸润深度>5.0mm 的浸润癌(病变范围超过 I A期),</td></tr><tr><td>I B1</td><td>病变局限于宫颈。间质浸润深度>5.0mm 而最大径线≤2.0cm 的浸润癌</td></tr><tr><td>I B2</td><td>最大径线>2.",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "0cm而≤4.0cm的浸润癌</td></tr><tr><td>I B3</td><td>最大径线>4.0cm 的浸润癌</td></tr><tr><td>Ⅱ</td><td>宫颈肿瘤侵犯超出子宫，但未达盆壁且未达阴道下1/3</td></tr><tr><td>II A</td><td>肿瘤侵犯限于阴道上2/3，无宫旁浸润。</td></tr><tr><td>II A1 II A2</td><td>最大径线≤4cm 的浸润癌 最大径线>4.",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "0cm 的浸润癌</td></tr><tr><td>IIB IⅢ</td><td>有宫旁浸润，但未扩展至盆壁 肿瘤扩展到骨盆壁和/或累及阴道下1/3 和/或导致肾孟积水或肾</td></tr><tr><td></td><td>无功能者和/或侵犯盆腔和/或腹主动脉旁淋巴结</td></tr><tr><td>IⅢIA</td><td>肿瘤累及阴道下1/3，没有扩展到骨盆壁</td></tr><tr><td>IⅢIB IIIC</td><td>肿瘤扩展到骨盆壁和/或引起肾孟积水或肾无功能 侵犯盆腔和/或腹主动脉旁淋巴结（包括微转移)，无论肿瘤大小</td></tr><tr><td></td><td>和范围（需标注r或p，r表示影像诊断，p表示病理诊断）</td></tr><tr><td>IIIC1</td><td>仅有盆腔淋巴结转移</td></tr><tr><td>IIIC2</td><td>腹主动脉旁淋巴结转移</td></tr><tr><td>IV</td><td>肿瘤侵犯膀胱或直肠黏膜（病理证实）或肿瘤播散超出真骨盆。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "</td></tr></table></body></html> <html><body><table><tr><td></td><td>泡状水肿不能分为IV期</td></tr><tr><td>IVA</td><td>肿瘤侵犯膀胱或直肠黏膜</td></tr><tr><td>IVB</td><td>肿瘤播散至远处器官</td></tr></table></body></html> # 六、治疗 # （一）子宫颈癌的治疗方式。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "1.宫颈镜下浸润癌（微小浸润癌） 即ⅠA 期，由于ⅠA 期肿瘤的判定依据显微镜下测量，咬取活检标本不能包含全部病变，无法进行病变范围的测量，故正确诊断需行锥切活检，准确地诊断ⅠA 期宫颈癌需对切缘阴性的锥切标本进行细致的病理检查。ⅠA1 期无生育要求者可行筋膜外全子宫切除术（I型子宫切除术）。如患者有生育要求，可行宫颈锥切术，切缘阴性则定期随访。因ⅠA1 期淋巴结转移率 $< 1 \\%$ ，目前认为ⅠA1 期无需行淋巴结切除术。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "如淋巴脉管间隙受侵可行宫颈锥切术（切缘阴性）或改良根治性子宫切除术并实施盆腔淋巴结切除术。ⅠA2 期宫颈癌淋巴结转移率约为 $3 \\% { \\sim } 5 \\%$ ，可行次广泛子宫切除术（Ⅱ型改良根治性子宫切除术）加盆腔淋巴结切除术。要求保留生育功能者，可选择宫颈锥切术（切缘阴性）或根治性宫颈切除术及盆腔淋巴结切除术（对于有生育要求的患者建议施根治性宫颈切除术）。# 2.宫颈浸润癌 （1）ⅠB1、IIB2、ⅡA1 期：采用手术或放疗，预后均良好。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "手术方式为Ⅲ型根治性子宫切除术和盆腔淋巴结切除术±腹主动脉淋巴结取样术。术后辅助治疗参见放射治疗。要求保留生育功能者，如宫颈肿瘤直径不超过 2cm，可选择根治性宫颈切除术加盆腔淋巴结切除术 $\\boldsymbol { \\cdot } \\pm$ 腹主动脉淋巴结取样术。（2）ⅠB3、ⅡA2 期：可选择的治疗方法有： $\\textcircled{1}$ 同步放化疗；$\\textcircled{2}$ 根治性子宫切除及盆腔淋巴清扫、腹主动脉淋巴结取样、术后个体化辅助治疗； $\\textcircled{3}$ 新辅助化疗后手术； $\\textcircled{4}$ 同步放化疗后辅助子宫切除术。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "以上方法首选同步放化疗。FIGO 指南（2018 年）推荐的局部晚期宫颈癌的治疗还包括另外一种选择即新辅助化疗后行根治性子宫切除术及淋巴结切除术。目前对于新辅助化疗后再手术对于宫颈癌患者预后的影响还存在争议，故一般推荐在临床试验中或者无放疗条件的区域，对于放疗相对不敏感的病理类型（如腺癌）尤其适合。ⅠB 期总的5 年生存率约 $8 0 \\% { \\sim } 9 0 \\%$ ，其中宫颈肿瘤直径大于4cm，有淋巴结转移、宫旁受侵和/或切缘阳性等高危因素者 5 年生存率仅 $4 0 \\% { \\sim } 7 0 \\%$ 。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "对部分早期初治宫颈癌患者选择治疗方法时，应考虑到有高危因素的患者可能选择放化疗更为有利。目前认为局部晚期患者的标准治疗仍是同步放化疗。（3） $\\mathrm { I I } \\mathrm { B } { \\sim } \\mathrm { I V } \\mathrm { A }$ 期：同步放化疗（具体方案见放射治疗及增敏化疗）（4）ⅣB 期：以系统治疗为主，支持治疗相辅助，部分患者可联合局部手术或个体化放疗。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "# （二）外科治疗。手术治疗主要应用于早期宫颈癌，即 $\\mathrm { ~ I ~ A ~ } \\tilde { } \\tilde { } \\mathrm { ~ I ~ I ~ A ~ }$ 期。手术包括子宫切除与淋巴结切除两部分。不同的分期所需要切除的范围有所不同。为了更好的描述手术切除范围有多位学者尝试提出了多种宫颈癌手术的分型系统，其中 Piver 分型和 Q-M 分型是被国内外大多数学者所接受和采用的宫颈癌手术分型系统。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "1.Piver 手术分型系统 1974 年提出的Piver 5 型子宫切除手术分类系统至今仍广泛应用。Ⅰ型：筋膜外子宫切除术。［适用于ⅠA1 期不伴有淋巴血管间隙受侵（lymph-vascular space invasion，LVSI）的患者］ Ⅱ型：改良根治性子宫切除术，切除范围还包括 1/2 骶、主韧带和上1/3 阴道。（适用于ⅠA1 伴有 LVSI 及ⅠA2 期患者） Ⅲ型：根治性子宫切除术，切除范围包括毗邻盆壁切除主韧带、从骶骨附着处切除骶韧带及切除上1/2 阴道。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "（为标准的宫颈癌根治手术，适用于ⅠB1、ⅠB2，选择性ⅠB3/ⅡA1 期患者） Ⅳ型：扩大根治性子宫切除术。（适用于部分复发患者） V 型：盆腔脏器廓清术。（适用于部分ⅣA 期及复发患者） # 2.Q-M 手术分型 为了更加准确描述手术范围和更好的个体化手术方案，2008年法国专家Querleu 和Morrow 在参考和咨询了世界各国的解剖学和宫颈癌手术医生的意见后，综合完成了宫颈癌根治术的新分型，这种基于三维解剖结构的分型也称Q-M 分型。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "2015 年，美国NCCN指南建议采用Q-M 分型 。Q-M 分型包含子宫的手术分型及淋巴结清扫分级两部分。其中手术分型仅与宫旁切除范围有关，宫旁切除范围以固定解剖结构为分界。A 型（子宫颈旁最少切除型）子宫颈旁组织切除至输尿管内侧，但在子宫颈外侧宫骶韧带及膀胱子宫韧带基本不切除，阴道切除<1cm,不切除阴道旁组织。（适用于ⅠA1 期不伴有LVSI 的患者） B 型（切除子宫颈旁组织达输尿管）子宫颈旁组织切除达输尿管隧道水平，部分切除宫骶及膀胱子宫韧带，不切除子宫颈旁组织中子宫深静脉下方的骶神经丛，阴道切除至少1cm（适用于ⅠA1伴有 LVSI 及ⅠA2 期患者） B1 如上描述B2 如上描述并宫旁淋巴结切除 C 型（切除子宫颈旁组织至与髂内血管系统交界处）切除膀胱子宫韧带在膀胱水平，切除距肿瘤或子宫颈下缘 $1 .",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "5 \\sim 2 \\mathrm { c m }$ 的阴道及与之相关的阴道旁组织（适用于ⅠB1、ⅠB2，选择性ⅠB3/ⅡA1期患者） C1 保留自主神经 C2 不保留自主神经 D 型（外侧扩大切除）切除子宫颈旁组织达盆壁，血管达髂内血管系统之上，暴露坐骨神经根完全游离（适用于部分ⅣA 期及复发患者） D1 切除子宫颈旁组织达盆壁D2 如上描述，并切除下腹下血管及附属筋膜或肌肉组织（盆 腔内扩大切除） 淋巴结清扫分级: 腹膜后淋巴结切除的范围，以动脉为解剖标志分为4 级。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "闭孔淋巴结默认为常规切除。1 级：切除髂内外动脉周围淋巴结，与 2 级分界标志为髂内、外动脉分叉处；2 级：切除髂总动脉周围淋巴结，与 3 级分界标志为腹主动脉分叉处；3 级：切除腹主动脉旁淋巴结至肠系膜下动脉水平；4 级：淋巴结切除至腹主动脉左肾静脉下水平。由于根治性子宫切除术对盆腔自主神经的损伤导致患者术后发生膀胱功能异常、结直肠蠕动功能异常以及性功能异常，保留神经的根治性子宫切除术（nerve-sparing radical hysterectomy，NSRH）不断得到研究和推广，NSRH 手术属于 Q-M 分型的 C1 型根治，NSRH 可通过开腹、腹腔镜及机器人腹腔镜途径完成。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "筋膜外子宫切除术（Ⅰ型或 A 型）可采取经阴道或开腹或微创（腹腔镜及机器人腹腔镜）途径入路。目前有前瞻性随机对照试验表明，微创根治性子宫切除术与开腹根治性子宫切除术相比，无病生存率和总体生存率较低。宫颈癌手术中淋巴结切除范围涉及盆腔淋巴结及腹主动脉淋巴结。ⅠA1（伴 LVSI）至ⅡA 期均应行盆腔淋巴结切除术 $\\pm$ 腹主动脉旁淋巴结取样术。研究显示，Ⅰ期和Ⅱ期宫颈癌患者术后盆腔淋巴结转移率分别为 $0 { \\sim } 1 6 .",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "0 \\%$ 和 $2 4 .5 \\% { \\sim } 3 1 .0 \\%$ ，因此，根据前哨淋巴结转移状况进行选择性淋巴结切除可降低宫颈癌患者术后并发症的发生率。前哨淋巴结检测应用的示踪剂有生物染料、放射性同位素和荧光染料，可通过肉眼识别、核素探测或红外线探测。系统性淋巴结切除术及前哨淋巴结定位切除均可通过开腹、腹腔镜及机器人腹腔镜途径完成。$\\mathrm { \\Delta I \\sim I I A }$ 期宫颈鳞癌卵巢转移率低于 $1 \\%$ ，对要求保留卵巢功能的未绝经患者术中可以保留外观正常的卵巢。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "目前认为宫颈腺癌发生隐匿性卵巢转移的概率较高，故保留卵巢应慎重。术中可将所保留的卵巢进行移位（如腹腔内或腹膜后结肠旁沟高位处），以避免术后盆腔放疗对卵巢功能的损伤。近年来对一些渴望生育的早期、无淋巴结转移的年轻宫颈癌患者施行保留生育功能的手术。ⅠA1 期无 LVSI 可行切缘阴性的宫颈锥切术，如病变范围广可行宫颈切除术；ⅠA1 伴 LVSI 及ⅠA2期患者可行切缘阴性（阴性切缘宽度最好达3mm）的宫颈锥切术/宫颈切除术 $+$ 经腹或腹腔镜下盆腔淋巴结切除术 $\\pm$ 腹主动脉旁淋巴结取样术，或实施经腹、经阴道或腹腔镜下根治性宫颈切除术 $+$ 盆腔淋巴结切除术 $\\pm$ 腹主动脉旁淋巴结取样术；ⅠB1 期（ $< 2 \\mathrm { c m }$ ）采用根治性宫颈切除术 $+$ 盆腔淋巴结切除术±腹主动脉旁淋巴结取样术。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "对于 $\\mathrm { ~ I ~ A 2 \\sim \\mathrm { ~ I ~ B 1 ~ } }$ 期伴 LVSI 及ⅠB2 期的患者是否可行保留生育功能的手术目前尚无统一结论，需慎重考虑。宫颈癌患者术后需根据复发危险因素选择辅助治疗，以降低复发率，改善预后，详见放射治疗原则部分。# （三）放射治疗。对于不具备放疗资质的医疗机构应及时转诊需要放疗的患者到有条件的医疗单位进行治疗；对未装备腔内后装近距离放疗设备的医疗单位，应建议需要腔内后装近距离放疗的宫颈癌患者在行外照射前到有相应设别的单位会诊咨询，做好双向转诊工作，以避免放疗中断。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "适用于各期宫颈癌。放疗包括体外照射和近距离放疗及二者联合应用。研究表明同步放化疗较单纯放疗提高了疗效，降低了复发风险。早期宫颈癌患者手术后早期子宫颈癌患者手术后病理学检查发现高危因素（手术切缘不净、宫旁受侵、淋巴结转移等）或中危因素（术中/后如发现肿瘤大、深部间质受侵和/或脉管间隙受侵）时需补充术后辅助放疗。# 1.放疗的原则 恶性肿瘤的放疗原则与其他治疗手段一样，要最大限度地杀灭癌细胞，尽最大可能保护正常组织和重要器官，即尽量提高治疗效果，降低并发症。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "因此，适当的治疗工具、适宜的照射范围、足够的照射剂量、均匀的剂量分布、合理的照射体积、个别对待是放疗的基本要求。放疗完成的期限是获得最佳疗效的必备因素。放疗时间超过9周比少于7 周的患者有更高的盆腔控制失败率，推荐 56 天内完成所有的外照射和近距离放疗。行根治性放疗时，对肿瘤区域给予根治剂量照射，由于照射范围较大，照射剂量也高，因此，在治疗中要重点关注肿瘤附近的正常组织和器官，特别是一些对放射线敏感的组织和器官的防护。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "姑息性放疗的目的是为了减轻症状，减少患者痛苦，但不一定能延长患者的生存时间。根治性治疗与姑息性治疗是相对的，在治疗过程中可根据肿瘤及患者情况而互相转换。若放疗联合手术综合治疗时，要根据肿瘤情况及患者条件决定是否术后放疗。术前放疗是计划性的，其目的是通过术前放疗，降低癌细胞活力或减少种植和扩散的机率；缩小肿瘤范围，提高手术切除率；杀伤亚临床病灶，降低局部复发率。术后放疗是根据手术后病理检查结果决定，具有不良预后影响因素：如存有手术切缘不净、宫旁受侵、淋巴结转移任一高危因素，术后需辅助放化疗。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "术中/后如发现肿瘤大、深部间质受侵和/或脉管间隙受侵等中危因素，根据 2015 年 NCCN 指南的 Sedlis 标准（表 3），术后需辅助盆腔放疗或放化疗。如淋巴结转移、切缘阳性、宫旁浸润、深间质浸润、宫颈局部肿瘤体积大以及脉管瘤栓等，可行术后放疗，术后辅助放疗减少局部复发，提高疗效，但手术和放疗两种治疗并用也增加了治疗并发症。表3 宫颈癌合并中危因素者术后盆腔放疗指征 <html><body><table><tr><td>LVSI</td><td>间质浸润深度</td><td>肿瘤直径（临床查体）</td></tr><tr><td>+</td><td>外 1/3</td><td>任何大小</td></tr><tr><td>+</td><td>中1/3</td><td>≥2cm</td></tr><tr><td></td><td>内 1/3</td><td>≥5cm</td></tr><tr><td></td><td>中1/3及外 1/3</td><td>≥4cm</td></tr></table></body></html> # 2.",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "体外照射 （1）常规放疗：即在模拟机或 CT 模拟机下定位下的放疗。靶区：一般应当包括子宫、宫颈、宫旁和上1/2 阴道，盆腔淋巴引流区如髂内、闭孔、髂外、髂总淋巴结。ⅢA 期患者包括全部阴道。必要时包括腹股沟区。采用四野箱式照射或等中心前后对穿照射。应用高能 $6 \\sim 1 2 \\mathrm { M V X }$ 射线。界限：上界：腹主分叉（一般在L3 下缘到L5 上缘之间）；下界：闭孔下缘（ⅢA 期患者除外），其端点与设野最宽处的连线约通过股骨内1/3；外界：在真骨盆外 $1 .",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "5 \\sim 2 .0 \\mathrm { c m }$ ；前界：耻骨联合前缘（据不同肿瘤而定）；后界：全部骶骨在照射野内（据不同肿瘤而定）。应用多叶光栅或不规则挡铅屏蔽保护正常组织。剂量：采用常规分割照射，每次 $1 .8 \\sim 2 .0 \\mathrm { G y }$ ，每周 5 次。总剂量 $4 5 \\sim 5 0 \\mathrm { G y }$ ， $5 \\sim 6$ 周。（2）三维适形放疗及调强适形放疗：以 CT 或 MRI 为基础的计划设计和适形遮挡技术是目前外放射治疗的标准治疗方法。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "对于不能手术的宫颈癌患者，正电子发射体层成像（positron emissiontomography，PET）检查有助于确定淋巴结转移的范围，也有助于术后患者是否还有残留阳性淋巴结的诊断。根据妇科检查以及影像学情况确定肿瘤靶区（gross target volume，GTV），以宫颈癌直接扩散和淋巴结转移途径确定临床靶区（clinical target volume，CTV）。外照射的治疗靶区需要包括子宫体、宫颈、宫旁、阴道（下界距离肿瘤至少 3 cm）和相应的淋巴引流区。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "如手术或影像学检查未发现阳性淋巴结，照射范围需包括髂外淋巴结、髂内淋巴结、闭孔淋巴结和骶前淋巴结引流区。如淋巴结转移的风险较大（如肿瘤体积≥4cm 或ⅡB 期以上或真骨盆内有可疑/确定淋巴结转移），照射范围还要包括髂总淋巴结区。如已发生髂总或腹主动脉旁淋巴结转移，则需进行盆腔延伸野及腹主动脉旁淋巴结照射，上界应达肾血管水平（或根据受累淋巴结的范围调整上界更高水平）。如病变已侵犯阴道下1/3，双侧腹股沟淋巴结也应包括在照射范围内。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "以 CTV 外放一定距离（ $0 .5 { \\sim } 1 .5 \\mathrm { c m } )$ 形成计划靶区（planningtarget volume，PTV）。放疗剂量： $4 5 { \\sim } 5 0 \\mathrm { G y } / 1 .8 { \\sim } 2 \\mathrm { G y } / 5 { \\sim } 6$ 周，同时评估危及器官，如直肠、乙状结肠、膀胱、小肠、骨骼等照射范围内危及器官。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "对于不能切除的实体肿瘤或体积局限的肉眼病灶或转移淋巴结，可以采用调强适形放疗技术对病灶进行加量放疗，追加剂量一般为 $1 0 { \\sim } 2 0 \\mathrm { G y } .$ 。# 3.近距离照射 将密封的放射源直接放入人体的天然管腔内（如子宫腔、阴道等）为腔内照射。放射源直接放入肿瘤组织间进行照射为组织间照射，二者同属于近距离照射。宫颈癌的腔内放疗有其自然的有利条件，宫颈、宫体及阴道对放射线耐受量高、放射源距肿瘤最近、以较小的照射体积可取得较大的放疗效果。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "（1）体内照射的放射源：见表 4。表 4 常用近距离放射源 <html><body><table><tr><td>放射源</td><td>镭-226</td><td>钴-60</td><td>艳-137</td><td>铱-192</td></tr><tr><td>放射比度（Ci／cm²）</td><td>2.1 最高3.8</td><td>1900</td><td>27.5</td><td>9000</td></tr><tr><td>半衰期</td><td>1590年</td><td>5.",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "3年</td><td>33年</td><td>74天</td></tr></table></body></html> （2）传统的腔内照射法：斯德哥尔摩法、巴黎法、曼彻斯特法和北京法等，多使用的是镭、铯放射源，目前已较少使用。（3）后装腔内放疗及剂量计算：后装腔内放疗是先将空载的放射容器置于体腔内病变部位，然后在有防护屏蔽的条件下远距离地将放射源通过管道传输到容器内进行治疗。腔内放疗是宫颈癌根治性放疗中的重要治疗手段。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "采用宫腔管联合阴道施源器的腔内治疗方法最常用。根据患者及肿瘤的解剖特点选择不同的阴道施源器与宫腔管联合使用。当联合外放射治疗时，近距离放疗通常在放疗后期进行，这时肿瘤体积已明显缩小，使得施源器放置的部位能够达到近距离治疗的理想剂量几何形状分布。后装腔内治疗机根据其对 A 点放射剂量率的高低可分为 3 类：低剂量率（ $( 0 .6 6 7 { \\sim } 3 .3 3 \\mathrm { c G y / \\ m i n } )$ 、中剂量率（3.",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "33${ \\sim } 2 0 \\mathrm { c G y } / \\operatorname* { m i n } )$ 、高剂量率（在20cGy／min 以上）。行根治性调强适形放疗时建议每周行锥形束CT 验证，第 3 周外照射放疗结束时行影像学评估确定是否需要修改放疗计划。一般情况下每周 $1 \\sim 2$ 次，每周 A 点剂量在 $5 { \\sim } 1 0 \\mathrm { G y }$ ，A 点总剂量在 $2 0 { \\sim } 4 5 \\mathrm { G y }$ ，体外加腔疗总剂量不低于75Gy[2Gy 分次放射等效剂量（equivalent dose in 2Gy/f，EQD2）]，整个疗程体外加腔内放疗剂量因临床分期、肿瘤大小的不同而异，一般总剂量在$7 5 { \\sim } 9 0 \\mathrm { G y }$ 。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "直肠、膀胱 ICRU 参考点剂量限制在 A 点处方剂量的$6 0 \\% \\sim 7 0 \\%$ 以下，最高不能超过 $80 \\%$ ，超量者可考虑减少驻留点或降低处方剂量。NCCN 指南中对A 点的剂量推荐，是以传统的、经广泛验证的低剂量率和分割的近距离治疗为基础。在这个剂量系统里，体外照射采用每天 $1 .8 { \\sim } 2 \\mathrm { G y }$ ，近距离放疗采用以低剂量率为 $4 0 { \\sim } 7 0 ~ \\mathrm { c G y / h }$ 时 A 点剂量。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "如果使用高剂量率进行近距离放疗，则需通过线性二次模型将 A 点高剂量率的剂量转换为具有相同生物学效应的低剂量率剂量，计算公式： $\\scriptstyle \\mathrm { E Q D 2 = D \\times \\hbar ( \\ d + \\alpha / \\beta ) }$ $/ ( 2 + \\alpha / \\beta ) ,$ ，D 为实际物理总剂量， $\\textrm { d }$ 为单次剂量，肿瘤组织 $\\alpha / \\beta { = } 1 0$ Gy，正常组织评估其晚反应时 $\\alpha / \\beta { = } 3 \\mathrm { G y } \\iota$ （直肠、膀胱、乙状结肠）。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "联合使用外放射治疗时，近距离放疗的剂量分割方案有多种选择，最常用的高剂量率近距离放疗是进行 4 次或 5 次宫腔和阴道施源器的置入，每次 A 点剂量为 6 或 7 Gy，A 点总剂量达到 28Gy/4次或 $3 0 \\mathrm { G y } / 5$ 次，转化为低剂量率等效生物学剂量为 A 点 $4 0 \\mathrm { G y }$ 。为了提高治疗效果，减少放疗并发症的危害，建议有条件医疗机构对腔内后装放疗采用图像引导的三维近距离放疗技术。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "但由于没有考虑到肿瘤的三维形状及肿瘤与正常组织结构的相互关系，A 点和 ICRU 直肠、膀胱参考点有很大局限性。已有证据表明，图像引导的近距离放疗可以提高患者的生存率并减少治疗副反应。MRI 是最佳的残留肿瘤评估的影像方法，最好在近距离治疗前行 MRI 检查。没有 MRI 设备时也可以使用 CT，但 CT对病灶范围的确定及靶区的勾画都远不如 MRI 准确。近距离放疗的剂量目标以 EQD2 计算，小肿瘤和消退迅速的肿瘤可以适当减少近距离放疗的剂量。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "三维后装建议采用欧洲近距离放疗学组和欧洲放射肿瘤学会推荐的三维后装治疗的 GTV、CTV 概念，应用MRI 图像勾画靶区，以T2WI 序列所示的肿瘤范围为GTV。将CTV按照肿瘤负荷和复发的危险程度分3 类：高危CTV（high risk CTV，HR-CTV）包括宫颈和肉眼可见的肿瘤侵犯的范围；中危 CTV（intermediate risk CTV，IR-CTV）表示明显的显微镜下肿瘤区，推荐包括外照射开始前的肿瘤范围；低危 CTV 指可能的显微镜下播散区，一般用手术或外照射处理。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "建议以 D90、D100 评估 GTV、HR-CTV 和 IR-CTV 的剂量，以 $\\mathrm { V } _ { 1 5 0 } , \\mathrm { V } _ { 2 0 0 }$ 评估高剂量体积；以$\\mathrm { D } _ { 1 \\mathrm { c m } 3 \\setminus \\mathrm { ~ D } _ { 2 \\mathrm { c m } 3 } }$ 评估危及器官受量。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "A 点剂量仍需报告，作为评价靶区剂量的参考。HR-CTV 剂量达到 $8 0 \\mathrm { G y }$ ，对于肿瘤体积大或退缩不佳病灶，剂量应该 ${ \\geq } 8 7 ~ \\mathrm { G y }$ 。根据已公布的指南，正常组织的限定剂量为：直肠 $2 \\mathrm { c m } ^ { 3 } { \\le } 6 5 \\sim 7 5 \\mathrm { G y }$ ；乙状结肠 $2 \\mathrm { c m } ^ { 3 } { \\le } 7 0 { \\sim } 7 5 \\ \\mathrm { G y }$ ；膀胱 $2 \\mathrm { c m } ^ { 3 } { \\le } 8 0 { \\sim } 9 0 \\mathrm { G y }$ 。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "如果达不到这些参数要求，应该考虑增加组织间插植技术来提高剂量。4.腔内照射与体外照射的组合 除极少数早期宫颈癌只行腔内照射外，均需腔内及体外联合照射，在宫颈癌的靶区内组成剂量分布较均匀的有效治疗。总的放疗时间尽量限制在8 周内完成。# 5.放疗并发症 由于放射源种类、放射方法、照射面积、照射部位、单位剂量、总剂量、总的分割次数及总治疗时间等因素的不同，以及患者对放射线敏感性的差异，放射治疗并发症的发生概率及严重程度也各不相同。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "从事放射治疗的工作者一方面要了解放射治疗并发症，另一方面要熟悉腹、盆腔器官对放射线的耐受剂量，以减少放射治疗的并发症。（1）近期并发症：包括治疗中及治疗后不久发生的并发症，如感染、阴道炎、外阴炎、皮肤干湿性反应、骨髓抑制、胃肠反应、直肠反应、膀胱反应和机械损伤等。（2）远期并发症：常见的有放射性直肠炎、放射性膀胱炎、皮肤及皮下组织的改变、生殖器官的改变、放射性小肠炎等。最常见的是放射性直肠炎，多发生在放疗后 $1 \\mathord { \\sim } 1 .",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "5$ 年。主要表现为：大便次数增多、黏液便、便血，严重者可出现直肠阴道瘘，其次常见的是放射性膀胱炎，多数在 1 年半左右，主要表现为尿频、尿痛、尿血、排尿不畅，严重者可出现膀胱阴道瘘。6.危及器官的耐受剂量 宫颈癌放射治疗的危及器官包括膀胱、直肠、结肠、骨髓、皮肤、小肠、输尿管等，一般用 $\\mathrm { T D } _ { 5 / 5 }$ 表示最小放射耐受量，表示在治疗后5 年内，严重并发症发生率不超过 $5 \\%$ 。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "表 5 为各个危险器官的 $\\mathrm { T D } _ { 5 / 5 }$ 。表 5 正常组织的 $\\mathrm { T D } _ { 5 / 5 }$ （Gy） <html><body><table><tr><td>器官</td><td>损伤 TD5/5</td><td>照射面积或长度</td></tr><tr><td>皮肤</td><td>溃疡、严重纤维化55</td><td>100cm2</td></tr><tr><td>小肠</td><td>溃疡、穿孔、出血50</td><td>100cm2</td></tr><tr><td>结肠</td><td>溃疡、狭窄 45</td><td>100cm2</td></tr><tr><td>直肠</td><td>溃疡、狭窄 60</td><td>100cm²</td></tr><tr><td>肾脏</td><td>急、慢性肾炎 20</td><td>全肾</td></tr></table></body></html> <html><body><table><tr><td>膀胱</td><td>挛缩</td><td>60</td><td>整个膀胱</td></tr><tr><td>输尿管</td><td>狭窄</td><td>75</td><td>5～10cm</td></tr><tr><td>卵巢</td><td>永久不育</td><td>2～3</td><td>整个卵巢</td></tr><tr><td>子宫</td><td>坏死、穿孔</td><td>>100</td><td>整个子宫</td></tr><tr><td>阴道</td><td>溃疡、瘘管</td><td>90</td><td>全部</td></tr><tr><td>成人骨骼</td><td>坏死、骨折、硬化60</td><td></td><td>整块骨或10cm2</td></tr><tr><td>脊髓</td><td>梗死、坏死</td><td>45</td><td>10cm</td></tr><tr><td>成人肌肉</td><td>纤维化</td><td>60</td><td>整块肌肉</td></tr><tr><td>骨髓</td><td>再生不良</td><td>2</td><td>全身骨髓</td></tr><tr><td></td><td></td><td>30</td><td>局部骨髓</td></tr><tr><td>淋巴结及萎缩、硬化 淋巴管</td><td></td><td>50</td><td>整个淋巴结</td></tr><tr><td>胎儿</td><td>死亡</td><td>2</td><td>整个胎儿</td></tr><tr><td>外周神经</td><td>神经炎</td><td>60</td><td>10cm2</td></tr></table></body></html> # （四）化学治疗。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "化疗在宫颈癌治疗中的作用越来引起重视，主要应于用放疗时单药或联合化疗进行放疗增敏，即同步放化疗。另外，还有术前的新辅助化疗以及晚期远处转移、复发患者的姑息治疗等。治 疗宫颈癌的有效药有顺铂、紫杉醇、5-氟尿嘧啶、异环磷酰胺、吉西他滨、拓扑替康等。# 1.同步放化疗 在放疗的同时进行的化疗，也称为增敏化疗。目前 NCCN 治疗指南推荐的在放疗期间进行含铂类方案的增敏化疗，首选顺铂周疗： $3 0 \\sim 4 0 \\mathrm { m g } / \\mathrm { m } ^ { 2 }$ ，每周 1 次。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "顺铂毒性不耐受可用卡铂替换。临床研究中还有顺铂联合方案的同步化疗方案：顺铂 $5 0 \\sim$ $7 0 \\mathrm { m g } / \\mathrm { m } ^ { 2 }$ ，紫杉醇 $1 3 5 \\sim 1 7 5 \\mathrm { m g } / \\mathrm { m } ^ { 2 }$ ，放疗第 1 和 29 天。顺铂 $+$ 紫杉醇周疗：顺铂 $2 5 \\sim 3 0 \\mathrm { m g } / \\mathrm { m } ^ { 2 }$ ，紫杉醇 $6 0 \\sim 8 0 \\mathrm { m g } / \\mathrm { m } ^ { 2 }$ ，放疗第 1、8、15、22、29 和 36 天。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "需根据患者放化疗的不良反应进行剂量调整，总体原则是不影响放疗正常进行。# 2.新辅助化疗 新辅助化疗是指患者在手术前行 2～3 个疗程的化疗，目的在于：缩小肿瘤体积，消灭微转移灶和亚临床病灶，使原来不能手术的患者获得手术机会。一些非随机研究结果显示，新辅助化疗减少了术中播散及术后转移的概率。目前，主要用于局部肿瘤大的早期患者。新辅助化疗方案常以铂类为基础的联合方案，如顺铂 $+$ 紫杉醇方案、PVB 方案（顺铂 $+$ 长春新碱 $+$ 博来霉素）、BIP 方案（顺铂 $+$ 博来霉素 $+$ 异环磷酰胺 $+$ 美司钠）等。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "给药途径包括静脉全身化疗或动脉插管介入化疗。目前最常用的为紫杉醇 $+$ 顺铂。# 3.系统性化疗 主要用于既不能手术也不能放疗的复发或转移性宫颈癌患者。2020 年NCCN 子宫颈癌治疗指南推荐的用于复发或转移癌的一线化疗方案有：顺铂联合紫杉醇、顺铂联合紫杉醇及贝伐珠单抗、紫杉醇联合拓朴替康及贝伐珠单抗为一类推荐方案，卡铂联合紫杉醇及贝伐珠单抗作为接受过顺铂治疗的患者首选，除此之外顺铂联合拓扑替康、拓扑替康联合紫杉醇也是备选方案。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "可供选择的一线单药化疗药物有：卡铂、顺铂和紫杉醇。2018 年起NCCN 指南在一线治疗失败后的宫颈癌二线治疗中，首先推荐帕博利珠单抗用于PD-L1 阳性或微卫星高度不稳定/错配修复功能缺陷肿瘤，研究显示其单药在二线治疗的客观缓解率为$14 .3 \\%$ ，完全缓解率为 $2 .6 \\%$ ，且有 $91 \\%$ 的患者缓解时间超过半年。2021 年 Keynote-826（NCT03635567）的结果发现在一线治疗的PD-L1 阳性宫颈癌患者中，与化疗 $\\dot { \\bf { \\varepsilon } } \\pm { \\bf { \\varepsilon } }$ 贝伐珠单抗相比，帕博利珠单抗联合化疗 $\\pm$ 贝伐珠单抗将患者死亡风险降低了 $36 \\%$ ，显著延长总生存时间和无进展生存时间，基于此FDA 批准了帕博利珠单抗$+$ 化疗 $\\pm$ 贝伐珠单抗在 PD-L1 阳性[综合阳性评分（combinedpositive score，CPS） $\\geqslant 1 ]$ 的复发或转移性宫颈癌的一线治疗。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "二线化疗药物有：贝伐单抗、多西紫杉醇、白蛋白结合型紫杉醇、吉西他滨、表阿霉素、5－氟尿嘧啶、异环磷腺胺、伊立替康、丝裂霉素、培美曲塞、拓扑替康、长春新碱等。目前多项免疫检查点抑制剂联合靶向药物、化疗或放疗研究正在临床试验过程中，联合使用这类药物仍然需要更多的临床研究数据支持 。鼓励复发性、持续性宫颈癌参加临床试验。# 五、随访 对于新发宫颈癌患者应建立完整病案和相关资料档案，治疗后定期随访监测。具体内容如下： 治疗结束最初2 年内每3 个月1 次、第3～5 年每6 个月1 次、然后每年随诊1 次。",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "Ⅱ期以上患者治疗后 $3 \\sim 6$ 个月复查时应全身MRI 或 CT 检查评估盆腔肿瘤控制情况，必要时行PET-CT 检查。宫颈或阴道细胞学检查，根据临床症状提示行必要的实验室检查及其他影像学检查。连续随诊5 年后根据患者情况继续随诊。放疗后规律阴道冲洗，必要时使用阴道扩张器，尽早恢复性生活，均有利于减少阴道粘连。附件1：缩略语附件 2：宫颈癌诊断与治疗流程 # 附件1 # 缩略语 CA：（carcinoma antigen）癌抗原125 CEA：（carcinoembryonic antigen）癌胚抗原 CIN：（cervical intraepithelial neoplasia）宫颈上皮内瘤变 CTV：（clinical target volume）临床靶区 FIGO：（International Federation of Gynecology and Obstetrics）国际妇产科联合会 HR-CTV：（high risk clinical target volume）高危临床靶区（近距离放疗专用） LVSI：（Lymph-vascular space invasion）淋巴血管间隙受侵 NCCN：（ National Comprehensive Cancer Network）美国国立综合癌症网络 NSRH： （Nerve-sparing radical hysterectomy）保留神经的根治性子宫切除术 PTV：（planning target volume）计划靶区 SCC：（squamous cancinoma- associated antigen）鳞癌相关抗原 附件2 # 子宫颈癌诊断与治疗流程 ![](images/0c6e7f23e591e71771444e56b73ebff09077a52a7c1ef2da2da61cfa6704c0b4.jpg) 附件3 # 宫颈癌诊疗指南（2022 年版）编写审定专家组 （按姓氏笔画排序） 组长：马丁 成员：华克勤、向阳、刘从容、刘爱军、李斌、吴小华、吴令英、张福泉、陈雁、林仲秋、周琦、郎锦义、娄阁、姚书忠、袁光文、黄曼妮、董梅",
    "source": "宫颈癌诊疗指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌诊疗指南/宫颈癌诊疗指南.md"
  },
  {
    "text": "# 微小RNA与宫颈癌 熊焱强，王 玎，李志英\\*(三峡大学仁和医院妇产科，宜昌 443002) 摘 要：微小RNA (microRNA, miRNA) 在宫颈癌的发生、侵袭、转移和复发等过程中扮演重要角色，与其预后密切相关。它能在组织、血清和血浆等标本中稳定存在，可通过调控靶基因从而促进宫颈癌细胞凋亡，并能改变宫颈癌细胞对药物和射线的敏感性，这使得 miRNA 有望成为一种与宫颈癌诊疗密切相关的新型分子标志物。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "就miRNA 在宫颈癌的早期分子诊断、治疗以及预后判断等方面的最新研究进展作一综述。关键词：微小RNA ；宫颈癌；诊断；治疗；预后中图分类号 ：Q522 ；R737.33 文献标志码：A # MicroRNA and cervical cancer XIONG Yan-Qiang, WANG Ding, LI Zhi-Ying\\* (Department of Gynaecology and Obstetrics, Ren-he Hospital, China Three Gorges University, Yichang 443002, China) Abstract: microRNA (miRNA) plays an important role in the occurrence, invasion, metastasis and recurrence of cervical cancer, which is closely related to the prognosis of cervical cancer.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "MiRNAs can not only exist stably in tissue, serum and plasma, but also promote cervical cancer cell apoptosis and change drug and radiation sensitivity of cervical cancer cell line through regulating target genes.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Since miRNA is closely related to cervical cancer diagnosis and treatment, it is expected to be a new kind of molecular marker.This article reviews the latest research progress in molecular diagnosis, treatment and prognosis of miRNAs in the early stage of cervical cancer.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Key words: miRNA; cervical cancer; diagnosis; treatment; prognosis 宫颈癌是最常见的妇科恶性肿瘤，全球每年共有 527 600 人被诊断为宫颈癌，其中 265 700 人死亡，在女性恶性肿瘤中发病率排第 2 位，死亡率排第 4位 [1-2]。尽管已经明确了 HPV 感染为宫颈癌的主要病因，但由于缺乏有效的临床早期诊断和治疗的肿瘤分子标志物，大多数宫颈癌患者确诊时已是中晚期，故而导致疗效不佳，死亡率仍然居高不下。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "MicroRNA (miRNA) 是一类长度约为 $1 8 { \\sim } 2 2 ~ \\mathrm { n t }$ 的非编码小 RNA，是生物体内重要的转录后调控子。MiRNA 与宫颈癌细胞增殖、凋亡、侵袭、转移和血管生成等过程密切相关 [3]。此外，miRNA 在各类标本中能够稳定存在，且其表达水平对宫颈癌的治疗和预后具有重要意义。本文介绍了 miRNA 在宫颈癌的早期诊断、治疗及预后判断的研究现状。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "# 1 MiRNA的生物学特性及其检测方法 # 1.1 MiRNA 1993 年 Lee 等 [4] 利用定位克隆法在秀丽新小杆线虫中克隆了调控胚胎发育的 lin-4 基因，发现该基因不编码蛋白质，却含有与 lin-14 mRNA 3'UTR区互补的反义序列，这是 miRNA 的首次发现。目前在人类细胞中已经发现了 1 000 多种 miRNA ( 其中约 400 多种已被证实 )，其数量只占蛋白质编码基因的 $1 \\%$ ，调节约 $30 \\%$ 的基因的表达 [5]。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "目前众多学者认为，miRNA 主要通过促进 mRNA 的降解和抑制蛋白质翻译两种作用机制介导转录后基因调控。此外，还可以将结合的 mRNA 运输至 P-body胞浆复合体，在其中完成脱腺苷酸化过程，然后再由核酸酶对靶 mRNA 进行酶切降解。miRNA 具有组织特异性、时序表达特异性和高度保守性，在细胞增殖、细胞死亡和肿瘤形成等生物过程中起着重要的作用 [6]。# 1.2 MiRNA的检测方法 MiRNA 的相对分子质量小，且在组织、血液等样本中的表达水平低，使得对检测方法的灵敏度和准确度要求较高。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "目前检测 miRNA 的方法主要有 RNA 印迹 (Northern blotting)、RT-PCR、RT-qPCR、基 因 芯 片 和 Solexa 测 序 等 技 术。其 中 Northernblotting 检测的灵敏度高，被认为是研究 miRNA 表达水平最可靠的技术。但其操作复杂、样本量需求大、灵敏度较低，不适用于大量临床样本的检测[7]。RT-PCR 方法是检测 miRNA 表达的常用方法，可分为茎环法 (stem-loop RT-PCR) 和 polyA 加尾法，其中茎环法特异性较高。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "而 RT-qPCR 可以很精确地定量分析 miRNA，是目前检测 miRNA 最常用的方法，但需要选择合适的内参，以消除样品间miRNA含量的差异，内参的稳定性决定了检测结果的可靠性 [8]。基因芯片检测具有通量大、检测速度快和灵敏度高等优点，主要用于 miRNA 表达谱的检测。但 miRNA 芯片只能分析己知 miRNA 的表达水平，无法分析未知的 miRNA，且准确性和重复性较差，一般多用于初筛，其结果常需要进行 RT-qPCR 验证 [9]。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "# 2 组织miRNA与宫颈癌 # 2.1 宫颈脱落细胞miRNA在宫颈癌筛查中的价值 宫颈癌是目前唯一被 WHO 确定可以通过筛查降低浸润性癌发生率的恶性肿瘤，HPV 分型检测是目前使用最广泛的筛查手段，但 HPV 筛查具有特异性差和阳性预测值低等局限性 [10]。MiRNA 在宫颈癌组织与正常组织之间以及不同病理类型宫颈癌组织之间的表达谱都存在着差异性，且 miRNA 在组织样本中极其稳定，不易降解，使其可以作为宫颈癌早期筛查及诊断的标记物。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Tian 等 [11] 运用 RT-qPCR 检测了 1 021 位 HPV 阳性的女性的宫颈脱落细胞，发现了 miR-34a、miR-92a、miR-93、miR-218、miR-375 和 miR-424 等 6 种表达特异的 miRNA。在高级宫颈上皮内瘤变 (CIN) 的宫颈脱落细胞中，miR-424、miR-375、miR-34a 和 miR-218 的表达水平均低于低级 CIN 和正常细胞 $( P < 0 .",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "0 5 )$ 。其中miR-424 和 miR-375 检测宫颈癌的灵敏度分别为$7 6 .0 \\%$ 和 $74 .9 \\%$ ，明显高于巴氏试验的 $6 3 .8 \\%$ ( $P <$ 0.05)，且两者的 NPV ( 阴性预测值 ) 分别为 $8 5 .7 \\%$ 、$8 5 .4 \\%$ ，均高于巴氏试验的 $7 9 .3 \\%$ 。MiR-424、miR-375 和 miR-218 三者联合检测能进一步提高 miRNA的检测性能，其效果较单一 miRNA 检测和巴氏试验更好。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Malta 等 [12] 对 73 名女性的宫颈脱落细胞中的 let-7c 进行了检测，发现在 CIN 患者的宫颈脱落细胞中 let-7c 的表达明显低于正常人，此外，let-$7 c$ 在宫颈癌组织中的表达量也是显著降低的 [13]，因此，宫颈脱落细胞中 let-7c 的低表达也可以作为宫颈癌筛查的指标之一。这些研究都预示着宫颈脱落细胞中的一些 miRNA 可以作为宫颈癌筛查新的标记物，甚至有可能取代传统检测手段。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "# 2.2 组织miRNA在宫颈癌治疗中的价值 针对宫颈癌的治疗，临床上以手术治疗为主，并辅以放化疗。提高放化疗疗效一方面可通过新药研发，另一方面也可通过提高肿瘤细胞对药物和射线的敏感性来实现。研究发现 [14-16]，miRNAs 可以提高宫颈癌细胞对化疗药物和射线的敏感性，从而促进宫颈癌细胞的凋亡。如 Lin 等 [14] 研究发现，转染 miR-224 后 SiHa 细胞中 miR-224 表达量明显增加，使得其对紫杉醇的敏感性增强，其 IC50 值明显低于对照组。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Huang 等 [15] 报道称，上调 miR-15a 和 miR-16 能显著增强化疗药物喜树碱 (CPT) 引起的 HeLa 细胞的自噬和凋亡。其机制是：miR-$1 5 \\mathrm { a } / 1 6$ 是强有力的细胞自噬的诱导物，可以作用于mTORC2 复合物中的 Rictor ；超表达 $\\operatorname* { m i R } \\substack { - 1 5 \\mathrm { a } / 1 6 }$ 消耗了内源性 Rictor，从而减弱 mTORC1 和 $\\mathsf { p } 7 0 \\mathsf { S } 6 \\mathsf { K }$ 的磷酸化程度，抑制宫颈癌 HeLa 细胞的增殖和细胞周期 $\\mathrm { G } _ { 1 } / \\mathrm { S }$ 转换。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "总的来说， $\\operatorname* { m i R } \\substack { - 1 5 \\mathrm { a } / 1 6 }$ 能通过诱导自噬而抑制宫颈癌细胞的增殖并增强 CPT 化疗的效果。Wang 等 [16] 研究发现，上调 miR-218 可降低宫颈癌细胞的抗辐射性 $( \\mathrm { R } ^ { 2 } { = } 0 .6 5 1 6$ , $P < 0 .0 0 1$ )。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "在体外实验中发现，提高 miR-218 的表达量能提高HeLa、SiHa、C33A 和 CaSki 等宫颈癌细胞系的辐射敏感度。他们还在动物实验中证实，miR-218 超表达联合辐射能极强地诱导宫颈癌细胞凋亡，从而抑制肿瘤的生长。提示 miR-218 可以作为宫颈癌放疗敏感性的预测指标，也可以作为宫颈癌联合治疗的一个新靶点。MiRNAs 也能够通过调控靶基因从而促进宫颈癌细胞凋亡，抑制肿瘤的发生发展。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Zhao 等[17] 发现，与相邻的正常组织相比，宫颈癌组织中miR-491-5p的表达显著下调，增加宫颈癌细胞中 miR-491-5p的表达量能显著抑制其增殖、迁移和入侵，诱导细胞凋亡，并能抑制接种 HeLa 细胞的模型小鼠体内肿瘤的生长。通过双荧光素酶报告基因分析显示，miR-491-5p 的目标基因是人类端粒酶逆转录酶(hTERT)，且 miR-491-5p 参与了 PI3K/AKT 信号通路的调控。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Song 等 [18] 发现，宫颈癌组织及宫颈癌细胞系中miR-133a 的表达水平明显下调，而恢复miR-133a 的表达水平能抑制宫颈癌细胞的增殖、迁移和入侵，促进细胞体外凋亡并抑制其体内浸润，其机制与 miR-133a 抑制 EGFR 的表达和激活蛋白激酶 ERK 信号通路有关。Zhao 等 [19] 发现，miR-20a 在宫颈癌患者中的表达水平明显高于正常对照组，miR-20a 的异常表达与淋巴结转移、组织学分级、肿瘤直径等有关。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "通过慢病毒成功建立了稳定的anti-miR-20a 宫颈癌细胞系，在体外和体内抑制miR-20a 的表达均可以通过调节细胞周期来促进宫颈癌细胞的凋亡，并减少肿瘤转移。通过荧光素酶实验和 Western blot 实验发现，敲除 miR-20a 后，TIMP2 和 ATG7 的表达升高，因此推测 miR-20a 通过抑制 ATG7 和 TIMP2 而促进宫颈癌细胞的增殖、迁移和入侵。Sun 等 [20] 发现，miR-182 高表达能够抑制宫颈癌细胞增殖并促进其凋亡，其机制可能是miR-182 抑制了 DNA 甲基转移酶 3 (DNMT3a) 的表达，从而诱导宫颈癌细胞凋亡。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "综上可知，miRNAs 可以通过抑制不同靶基因从而调控宫颈癌细胞的增殖、凋亡及对药物的敏感性，这使得其可以作为宫颈癌治疗的新靶点。# 2.3 组织miRNA对宫颈癌预后的评估 决定肿瘤预后的因素众多，准确的判断预后对于宫颈癌临床治疗具有重要的指导价值。目前认为与宫颈癌预后相关的因素主要有：年龄、病理类型、FIGO 分期、淋巴结转移以及治疗手段的选择等。近期研究[21-23]发现，miRNAs表达水平与FIGO分期、淋巴结转移、肿瘤分化程度等密切相关，可以作为宫颈癌预后判断指标，而且也是宫颈癌的独立预后因素。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Wang 等 [21] 分析了 114 例宫颈癌患者肿瘤组织中 miRNA 的表达情况，发现在宫颈癌组织中miR-145 表达显著下调。结合临床数据发现，miR-145 表达水平与 FIGO 分期、淋巴结转移、肿瘤分化程度等有关。Kaplan-Meier 生存曲线显示，miR-145 低表达的宫颈癌患者总体生存期短于高表达者，其 5 年生存率约为高表达者的 $50 \\%$ ；分析多变量 Cox 回归模型显示，miR-145 是宫颈癌独立预后因素。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Shen 等 [22] 应用 RT-qPCR 检测了 126 例宫颈癌患者肿瘤组织和相邻正常组织 miR-224 表达水平，发现宫颈癌组织中的 miR-224 表达显著上调，而且miR-224 的表达水平与宫颈癌 FIGO 分期、淋巴结转移、肿瘤分化程度、血管侵犯以及 HPV 感染有关。Kaplan-meier 分析表明，宫颈癌患者中 miR-224 高表达者总生存期明显短于低表达者 $( P < 0 .",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "0 0 1 )$ 。Cox 回归分析发现，miR-224 是宫颈癌的独立预后因素。另一项研究 [23] 分析了 30 例宫颈癌患者肿瘤组织和正常组织中 miR-21-3p 和 miR-21-5p 的表达水平，发现在 HPV 阳性的宫颈癌样本中 miR-21 的表达量明显高于对照组 $( P { < } 0 .0 5 )$ 。通过多变量分析发现，miR-21 的表达与临床病理相关，包括肿瘤浸润深度和淋巴结转移等因素。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "miR-21 表达上调预示着预后不良，其可以作为宫颈癌患者临床结局独立的预测标记物。因此，在术后对患者癌组织中特异性的 miRNAs 进行检测可以预测其临床结局，对miRNAs 预测较差的患者术后进行辅助治疗、增加复查频率有可能改善其临床结局并延长生存期。# 3 循环miRNA与宫颈癌 循环 miRNA (circulating microRNAs, c-miRNAs)是指存在于细胞分泌的膜包裹颗粒 ( 包括外泌体和微囊泡 ) 内的非编码小 RNA，分泌后的 c-miRNAs既能与蛋白质结合也能够游离存在，可以作为信号分子在细胞间交换表观遗传信息 [24]。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "循环 miRNA主要存在于血清、胞外体和单核细胞中，其多与蛋白质构成复合物从而保持稳定，在 $- 8 0 ^ { \\circ } \\mathrm { C }$ 长期保存的患者血清、血浆等样本中依旧能够稳定存在 [25]。循环 miRNA 作为疾病诊断、进展和治疗的新的临床生物标志物，可以用来识别恶性肿瘤分化程度，预测生存期和对治疗的反应[26]。# 3.1 循环miRNA在宫颈癌早期诊断中的应用 Jia 等 [27] 通过 Solexa 测序发现了 12 个在宫颈癌患者血清中表达量显著上调的 miRNAs，并应用 RT-qPCR 技术确定了其中 5 个 (miR-21、miR-29、miR-25、miR-200 和 miR-486-5) 可作为宫颈癌生物标志物。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "它们的接受者操作特性曲线下面积(AUC) 如 下 ：miR-21 为 0.819，miR-29a 为 0.819，miR-25 为 0.726，miR-200a 为 0.658，miR-486-5p为0.685，其中miR-21 的特异性和敏感性均为最高。而上述 5 种 miRNAs 联合检测的 AUC 值为 0.908，明显高于鳞状细胞癌抗原 (SCC) 的 0.655 和 CA125的0.570。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "5 种miRNAs 联合检测宫颈癌的特异性和灵敏度为 $8 8 .6 \\%$ 和 $8 1 .0 \\%$ ，阳性和阴性预测值分别为 0.90 和 0.78。作者认为以血清中 miRNAs 作为诊断宫颈癌的依据较 SCC 和 CA125 更具优势，且 5种血清 miRNAs 联合检测比单个 miRNA 检测更为可靠。Zhang 等 [28] 运用 RT-qPCR 技术分析了 184例宫颈癌患者、186 例 CIN 患者及 193 例正常对照血清中 444 种 miRNAs，发现 66 种 miRNAs 的表达存在差异，其中 miR-16-2\\*、miR-195、miR-2861及 miR-497 在宫颈癌患者血清中的表达量较正常对照组有明显差异，4 种 miRNAs 联合检测宫颈癌的AUC 为 0.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "894。作者认为这些 miRNAs 可以作为宫颈癌的非侵入性的诊断标记物。综上可知，循环miRNAs 可以作为宫颈癌早期无创诊断的肿瘤标记物，甚至有望取代传统的非特异性的SCC 和CA125等血清标记物，但需要更大的临床样本来验证。另外，降低 miRNA 检测费用也是其临床推广应用的又一大关键因素。# 3.2 循环miRNA与宫颈癌预后 Tang 等 [29] 通过 RT-qPCR 检测了 112 例宫颈癌和 50 例子宫肌瘤患者血清和宫颈组织中 miR-218的表达情况。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "发现宫颈癌组织和血清中 miR-218 的表达显著低于对照组 $( P < 0 .0 0 1 )$ )。结合临床资料显示，血清 miR-218 的表达下降与高级别的临床分期、病理类型和淋巴节转移相关，但与年龄、绝经情况、妊娠和分娩、肿瘤大小以及家族肿瘤病史等因素无关。miR-218 表达量的减少与宫颈癌侵袭性密切相关，也意味着更差的预后。Ma 等 [30] 使用 RT-qPCR检测了 60 例宫颈癌患者和 60 例健康正常人血清中 miR-205 的表达情况。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "发现宫颈癌患者血清中miR-205 表达水平显著高于健康人 $( P < 0 .0 1 )$ ，血清miR-205 的高表达与肿瘤低分化 $( P = 0 .0 0 9 _ { , } ^ { }$ )、淋巴结转移 $P = 0 .0 1 5 ^ { \\cdot }$ )、肿瘤分期 $( P = 0 .0 0 1 \\$ ) 等密切相关。此外，Kaplan-meier 生存分析表明，miR-205高表达的宫颈癌患者的 5 年生存率为 $1 6 .",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "6 7 \\%$ ，明显低于 miR-205 低表达者的 $5 3 .3 3 \\%$ ，通过多变量Cox 回归分析发现，miR-205 可以作为宫颈癌一个独立的预后指标。这些研究都表明，某些特异的循环 miRNA 可以作为宫颈癌独立的预后指标，对宫颈癌患者的治疗方案的选择及治疗后随访都具有重要作用。# 4 总结与展望 miRNA 几乎参与了宫颈癌发生发展的全过程，在宫颈癌的诊断、预后及治疗中都具有重要的作用。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "循环 miRNA 作为一种新的生物学标志物具有创伤小、可重复、易获取的优点，可用于宫颈癌早期诊断，预测放化疗疗效及动态监测治疗效果，并可作为治疗靶标。但宫颈癌相关特异性 miRNA 表达谱的筛选、样本处理和检测手段的标准化以及内参基因的选择等仍是今后研究中需要解决的关键问题。虽然相关研究尚处于起步阶段，但随着检测方法的成熟和研究的深入，miRNA 未来会在宫颈癌的诊断、个体化治疗和预后评估等方面拥有广阔的应用前景。",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "# [参 考 文 献] [1] Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012.Int J Cancer, 2015, 136: 359-86 [2] Torre LA, Bray F, Siegel RL, et al.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Global cancer statistics, 2012.CA Can J Clin, 2015, 65: 87-108 [3] González-Quintana V, Palma-Berré L, Campos-Parra AD, et al.MicroRNAs are involved in cervical cancer development, progression, clinical outcome and improvement treatment response.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Oncol Rep, 2016, 35: 3-12 [4] Lee RC, Feinbaum RL, Ambros V.The C.elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.Cell, 1993, 75: 843- 54 [5] Lee I, Ajay SS, Yook JI, et al.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "New class of microRNA targets containing simultaneous $5 ^ { \\prime }$ -UTR and $3 ^ { \\prime }$ -UTR interacttion sites.Genome Res, 2009, 19: 1175-83 [6] Bartel DP.MicroRNAs: genomics, biogenesis, mechanism, and function.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Cell, 2004, 116: 281-97 [7] Pall GS, Hamilton AJ.Improved northern blot method for enhanced detection of small RNA.Nat Protoc, 2008, 3: 1077-84 [8] Xiang M, Zeng Y, Yang R, et al.U6 is not a suitable endogenous control for the quantification of circulating microRNAs.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Biochen Biophys Res Commun, 2014, 454: 210-4 [9] Liu CG, Calin GA, Meloon B, et al.An oligonucleotide microchip for genome- wide microRNA profiling in human and mouse tissues.Proe Natl Acad Sci USA, 2004, 101: 9740-4 [10] Forouzanfar MH, Foreman KJ, Delossantos AM, et al.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.Lancet, 2011, 378: 1461- 84 [11] Tian QF, Li Y, Wang FF, et al.MicroRNA detection in cervical exfoliated cells as atriage for human papillomaviruspositive women.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "J Natl Cancer Ins, 2014, 106: 241-8 [12] Malta M, Ribeiro J, Monteiro P, et al.Let- $.7 c$ is a candidate biomarker for cervical intraepithelial lesions: a pilot study.Mol Diagn Ther, 2015, 19: 191-6 [13] Huang L, Lin JX, Yu YH, et al.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix.PLoS One, 2012, 7: e33762 [14] L i n F, Wa n g P, S h e n Y, e t a l .",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "U p r e g u l a t i o n o f microRNA-224 sensitizes human cervical cells SiHa to paclitaxel.Eur J Gynaecol Oncol, 2015, 36: 432-6 [15] Huang N, Wu J, Qiu W, et al.MiR-15a and miR-16 induce autophagy and enhance chemosensitivity of Camptothecin.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Cancer Biol Ther, 2015, 16: 941-8 [16] Wang Y, Han XY, Qiu HF, et al.MicroRNA-218 enhances the radiosensitivity of human cervical cancer via promoting radiation induced apoptosis.Int J Med Sci, 2014, 11: 691-6 [17] Zhao Q, Zhai YX, Liu HQ, et al.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "MicroRNA-491-5p suppresses cervical cancer cell growth by targeting hTERT.Oncol Rep, 2015, 34: 979-86 [18] Song X, Shi B, Huang K, et al.miR-133a inhibits cervical cancer growth by targeting EGFR.Oncol Rep, 2015, 34:1573-80 [19] Zhao S, Yao D, Chen J, et al.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "MiR-20a promotes cervical cancer proliferation and metastasis in vitro and in vivo.PLoS One, 2015, 10: e0120905 [20] Sun J, Ji J, Huo G, et al.miR-182 induces cervical cancer cell apoptosis through inhibiting the expression of DNMT3a.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Int J Clin Exp Pathol, 2015, 8: 4755-63 [21] Wang Q, Qin J, Chen A, et al.Downregulation of microRNA-145 is associated with aggressive progression and poor prognosis in human cervical cancer.Tumour Biol, 2015, 36: 3703-8 [22] Shen SN, Wang LF, Jia YF, et al.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer.Diagn Pathol, 2013, 8: 69-75 [23] Han Y, Xu GX, Lu H, et al.Dysregulation of miRNA-21 and their potential as biomarkers for the diagnosis of cervical cancer.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Int J Clin Exp Pathol, 2015, 8: 7131-9 [24] Wang K.Export of microRNAs and microRNA-protective protein by mam-malian cells.Nucleic Acids Res, 2010, 38: 7248-59 [25] Köberle V, Thomas P, Christian S, et al.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers.PLoS One, 2013, 8: e75184-94 [26] Silva SS, Lopes C, Teixeira AL, et al.Forensic miRNA: Potential biomarker for body fluids.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Forensic Sci Int Genet, 2015, 14: 1-10 [27] Jia W, Wu Y, Zhang Q, et al.Expression profile of circulating microRNAs as a promising fingerprint for cervical cancer diagnosis and monitoring.Mol Clin Oncol, 2015, 3: 51-8 [28] Zhang Y, Zhang D, Wang F, et al.",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "Serum miRNAs panel (miR$1 6 - 2 ^ { * }$ , miR-195, miR-2861, miR-497) as novel noninvasive biomarkers for detection of cervical cancer.Sci Rep, 2015, 5: 17942-50 [29] Tang BB, Liu SY, Zhan Y, et al.microRNA-218 expression and its association with the clinic opathological characteristics of patients with cervical cancer.Exp Ther Med, 2015, 10: 269-74 [30] Ma QH, Wan GP, Wang SX, et al.Serum microRNA-205 as a novel biomarker for cervical cancer patients.Cancer Cell International, 2014, 14: 81-7",
    "source": "微小RNA与宫颈癌",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/微小RNA与宫颈癌/微小RNA与宫颈癌.md"
  },
  {
    "text": "# 相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨H 石新兰 黄利鸣 黎家华 徐 弘三峡大学医学院病理教研室 \"湖北省宜昌市 HHIGGI# 摘要 目的!检测宫颈上皮内瘤!;<=\"和浸润性宫颈鳞癌相关癌基因蛋白表达状态#探讨宫颈鳞状上皮恶性转化及鳞癌演进机制\\$方法!采用 \"D 法检测 FG 例正常宫颈#HI 例 ;<=#IX 例浸润癌 D;=V%6MI%6FN%JK%DK% $\\mathrm { n m } 2 3$ %4R-A4%JR;(3#/5\\$&%SJTU 蛋白表达状态\\$ 结果!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": ";<=!级 JK%DK 表达下调甚至缺失#D;=V%6MI%6FN 阳性表达率明显高于 ;<=\"%\\$级#D;=V%6MI%6FN 和 JKPDK 同时 F 种与同时 I 种以上异常表达率显著高于 ;<=%%\\$级&浸润癌$\\mathrm { n m } 2 3$ %4R-A4%JR;(3#/5\\$& 阳性表达率明显降低#SJTU 阳性表达率明显升高\\$ 结论!相关癌基因蛋白表达异常与宫颈鳞状上皮恶性转化及鳞癌演进密切相关&同时检测 D;=V%6MI%6FN 和 JKPDK 表达状态有助于准确判断 ;<= 恶变潜能\\$ 关键词 癌基因蛋白 宫颈上皮内瘤 宫颈鳞癌中图分类号!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "KYIYCII 文献标识码!L 文章编号!NGGGRXNYZ!FGGH\"GX’GHIXRGI # !\"# \\$%&’#(()\\*+ \\*, -#./012 3+4\\*&’\\*01)+( /+2 0\"1 5’\\*6’1(()\\*+ \\*, 7#’8)9:.;<=:>\\*=( 7:’9)+\\*>: \"#\\$ %\\$&’(& )\\*(&+ ,\\$-\\$&+ ,\\$ .\\$(#\\*( /0 (’ !\"#\\$%&’\"(& )\\* +,&-).",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": ")/01 &-\" 2\"345,.65-)).)\\* 7-%\"\" 8)%/\"9 :(4;\"%94&01 <45-,(/1 =>?\"4 ?@(0’:40 A@B140)81C 12 3/0/40 5/’(0/3 2&426520/\\$&7 /865/77\\$2& \\$& 4/59\\$4(’ \\$&05(/6\\$0#/’\\$\\*- &/2& 6’(7( :;<=>(&3 \\$&9(7\\$9/ 7?\\*(-2\\*7 4(54\\$&2-(@ (&3 02 70\\*3A 0#/ 652+5/77\\$2& 2B 4/59\\$4(’ 7?",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "\\*(-2\\*7 4(54\\$& &2-(C D10\"\\*2(C <--\\*&2#\\$7024#/-\\$4(’ \"D -/0#23 E(7 \\*7/3 02 3/0/40 5/’(0/3 2&426520/\\$&7 /865/77\\$2& \\$& FG 4(7/7 2B &25-(’ 4/59\\$4(’ 0\\$77\\*/@ HI ;<=7 (&3 I!\\$&9(7\\$9/ 4/59\\$4(’ 7?\\*-2\\*7 4(54\\$&2-(C -1(=.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "0(C <& ;<=!@ 0#/ /865/77\\$2& 2B JK!DK E(7 ’2E 25 ’277@ 0#/ 627\\$0\\$9/ 5(0/ 2B D;=L!6MI!6FN E(7 7\\$+&\\$B\\$4(&0& ’A #\\$+#/5@ 0#/ 6/54/&0(+/ 0#(0 FO I 25 H 0A6/7 2B D;=L!6MI!6FN (&3 JKPDK /865/77/3 (Q&25-(’’A E(7 7\\$+&\\$B\\$4(&0’A #\\$+#/5 0#(& 0#(0 \\$& ;<=\"!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "#C 1#/ 627\\$0\\$9/ 5(0/ 2B &-FI!4R-A4 (&3 JR;(3#/5\\$& E(7 7\\$+& &\\$B\\$4(&0’A ’2E/5 \\$& \\$&9(7\\$9/ 4/59\\$4(’ 7?\\*-2\\*7 4(54\\$&2-( E#\\$4# 0#/ 627\\$0\\$9/ 5(0/ 2B SJTU E(7 #\\$+#/5 0#(& 0#(0 \\$& ;<=7C 7\\*+4.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "=(()\\*+(C K/’(0/3 2&426520/\\$&7 (Q&25-(’ /865/77\\$2& (5/ \\$-6250(&0 3\\*5\\$&+ 4/59\\$& 4(’ /6\\$0#\\$\\*- -(’\\$+&(&0 05(&7B25-(0\\$2& (&3 0#/ 0\\*-25 652+5/77\\$2&C <0 -(A Q/ \\*7/B\\*’ 02 /70\\$-(0/ \\$07 -(’\\$+& &(&0 05(&7B25-(0\\$2& 6277\\$Q\\$’\\$0A 02 3/0/40 D;=V!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "6MI!6FN (&3 JKPDK /865/77\\$2& \\$& 4/59\\$4(’ 3A76’(7\\$( /6\\$0#/’\\$\\*-C E1F G\\*’2( W&426520/\\$&7 ;/59\\$4(’ \\$&05(/6\\$0#/’\\$(’ &/26’(7( ;/59\\$4(’ 7?\\*(-2\\*7 4(54\\$&2-( [<= 可演进为浸润癌%特别是 ;<=!级%演变为浸润癌的潜能远高于 ;<=\"!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "\\$级%与宫颈鳞癌的发生密切相关& 准确判断 ;<= 级别%正确评估 ;<= 发展为浸润癌的潜能%有利于降低宫颈鳞癌发病率&本研究采用免疫组化方法检测 ;<= 至浸润癌各时期相关癌基因蛋白表达状态% 试图寻找引起宫颈上皮细胞恶性转化和宫颈鳞癌浸润进展的关键基因%探讨关键基因的生物学特征及临床意义& # \\* 材料与方法 # ,-, 标本来源 收集三峡大学医学院附属医院病理科近 ,.年宫颈活检标本 ,.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": ", 例\" 其中!正常宫颈 /.例!各级#\\$% 0\\* 例!浸润癌 \\*!例\" 均为治疗前的活检标本或首选治疗为手术的术后标本!经 $10 \\%$ 甲醛固定!石蜡包埋!病理检查确诊并依据 234 分类方法进行组织分类\" 浸润癌按 ,556 年 7\\$84 标准分期\" # ,9/ 方法和试剂 采用 :& 法检测癌基因蛋白表达状态\" 免疫组化染色过程严格按照 :& 试剂盒说明书进行\" ;’<显色!苏木素复染\" $\\mathrm { P C N A } \\ \\mathrm { , p 5 3 } \\ \\mathrm { , p 2 1 } \\ \\mathrm { , E R } \\ \\mathrm { , P R } \\ \\mathrm { , n m } 2 3 \\$ #AB@CA#=D#EFGHIJ?",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "#K=87 等单抗及 :& 试剂盒购自福州迈新生物技术公司\" # L9\\* 结果判断 以核或膜或浆出现明显的棕黄色颗粒为阳性细胞\" 随机抽取 6 个高倍视野!计数阳性细胞数目!以阳性细胞数 $5 5 \\%$ 为阳性表达标准\" # ,90 统计学分析 采用 $\\chi ^ { 2 }$ 检验\" # ) 结果 # /9, 相关癌基因蛋白的表达部位 &#%’ $\\mathrm { \\nabla .p } 5 3$ 为核表达\\$=>#&>#AD@CA 在正常鳞状上皮为核表达!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "在不典型增生上皮和癌组织!为核或浆表达\\$ $_ { \\mathrm { p 2 1 , n m } 2 3 }$ #K=87 为 浆 表 达 \\$=D#EFGHIJ?为膜表达!见图 ,\" # /9/ 宫颈组织相关癌基因蛋白的阳性表达率见表 ,\" 正常鳞状上皮少量基底细胞表达 &#%’\\$#\\$% 和癌组织阳性细胞数目明显增多!&#%’阳性表达率逐渐升高!原位癌#浸润癌%N!期阳性表达率达 $100 \\%$ \"(6\\* 阳性表达率随 #\\$% 级别的升高而升高!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "#\\$% !级和浸润癌阳性表达率明显高于正常宫颈和 #\\$%\"#&级组织\" (/, 阳性表达率在正常宫颈和 #\\$%%#&级都很低!!级则明显升高\" =>#&> 核表达率从 #\\$%%级N浸润癌逐级降低!#\\$% !级及浸润癌明显低于正常宫颈组织\" 正常宫颈组织全部表达 $\\mathrm { n m } 2 3$ 蛋白!$\\mathrm { n m } 2 3$ 阳性率随着浸润癌分期的升高而逐渐降低\" =D#EFGHIJ?",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "阳性表达率也随着浸润癌分期的升高而逐渐降低!并明显低于 #\\$%%N!级\" 浸润癌!尤其是 $\\mathbb { I } \\sim \\mathbb { N }$ 期浸润癌!K=87 阳性表达率明显高于正常宫颈和 #\\$%%#&级组织!$P { < } 0 .0 5$ \" ![](images/add1074cd5cfbb634a0ae1057c5de5effa28b241a6dac20e5c181968b1d0be80.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "jpg) 图, $\\mathrm { p } 5 3$ 蛋白在浸润性鳞癌中的表达状态 $ { \\mathrm { S P } } \\times 2 0 0$ # /9\\* 各级 #\\$% 组织相关癌基因蛋白R受体同时 / 种及以上异常表达情况 见表 /\" 表 \\* 相关癌基因蛋白在宫颈组织中的阳性表达 $\\%$ <html><body><table><tr><td>病理分类</td><td>例数</td><td>PCNA</td><td>p53</td><td>p21</td><td>ER</td><td>PR</td><td>nm23</td><td>C-myc</td><td>E-Cadherin</td><td>VEGF</td></tr><tr><td>正常宫颈</td><td>19</td><td>26.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "3</td><td>31.5</td><td>15.7</td><td>68.2</td><td>57.1</td><td>100</td><td>84.2</td><td>40.0</td><td>8.3</td></tr><tr><td>CIN I</td><td>12</td><td>41.6</td><td>16.6</td><td>16.6</td><td>42.9</td><td>14.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "3</td><td>87.5</td><td>91.6</td><td>92.3</td><td>12.5</td></tr><tr><td>CIN II</td><td>12</td><td>41.6</td><td>33.3</td><td>16.6</td><td>42.9</td><td>15.4</td><td>85.7</td><td>91.6</td><td>91.7</td><td>14.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "2</td></tr><tr><td>CIN II</td><td>18</td><td>62.5</td><td>64.7</td><td>66.6</td><td>0</td><td>0</td><td>89.4</td><td>94.1</td><td>88.2</td><td>40.0</td></tr><tr><td>浸润癌I</td><td>8</td><td>100</td><td>40.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "0</td><td>50.0</td><td>0</td><td>8.3</td><td>57.1</td><td>66.6</td><td>66.6</td><td>20.0</td></tr><tr><td>浸润癌IⅡ</td><td>8</td><td>100</td><td>50.0</td><td>33.3</td><td>0</td><td>8.3</td><td>40.0</td><td>33.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "3</td><td>50.0</td><td>66.6</td></tr><tr><td>浸润癌ⅡⅢ</td><td>10</td><td>100</td><td>40.0</td><td>40.0</td><td>0</td><td>10.0</td><td>30.0</td><td>30.0</td><td>40.0</td><td>60.0</td></tr><tr><td>浸润癌IV</td><td>12</td><td>66.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "0</td><td>50.0</td><td>33.3</td><td>0</td><td>16.6</td><td>33.3</td><td>33.3</td><td>41.6</td><td>60.0</td></tr></table></body></html> &#%’%细胞核增殖抗原\\$/0%雌激素受体\\$’0%孕激素受体\\$1/23%血管内皮生长因子 表 !\"#\\$%!&’(!&)\\* 及 +,-\", 在 .",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "/\\$ 组织同时出现) 种及以上异常表达 $\\%$ <html><body><table><tr><td>病理分类</td><td>例数</td><td>2种异常表达</td><td>3 种或4种异常表达</td></tr><tr><td>正常宫颈</td><td>20</td><td>40.0</td><td>0</td></tr><tr><td>CIN I</td><td>13</td><td>46.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "1</td><td>0</td></tr><tr><td>CIN II</td><td>12</td><td>50.0</td><td>0</td></tr><tr><td>CIN II</td><td>18</td><td>100</td><td>80.0</td></tr></table></body></html> # ( 讨论 #\\$% 是宫颈鳞癌的癌前病变!有恶变潜能\" 不同级别的 #\\$% 恶变潜能不同\" #\\$%!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "级发展为浸润癌的潜能远高于 #\\$%\"##级\" 因此!#\\$% 的级别决定其治疗方案!准确判断 #\\$% 的级别非常重要\" &#%’#()\\*#(+, 等癌基因蛋白异常表达可诱导细胞恶性转化!\"#\\$!级和宫颈癌 %\"\\$& 指数显著高于正常宫颈和 \"#\\$\"\"#级# %\"\\$& 指数有助于评估 \"#\\$ 细胞增殖活性\" 区别 \"#\\$!级和 \"#\\$\"\"\\$级 ’()!\\$\\*+, -& 等’.)报道从低级别 \"#\\$ 到浸润癌 $\\mathrm { N } -$ ,\\*0 表达率不断增加!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "魏欣净等’1)报道宫颈炎组织无2.( 表达#而不典型增生\"原位癌和浸润癌阳性表达率逐渐升高# $\\mathrm { p } 2 1$ 蛋白在宫颈肿瘤发展中起重要作用!\"#\\$!级和宫颈癌组织 $\\mathrm { p } 5 3$ 蛋白阳性表达率也明显高于正常宫颈组织’4)!本研究显示 \"#\\$!级和浸润癌 %\"\\$&\"231 和 2.( 蛋白阳性表达率明显高于正常宫颈和 \"#\\$%\"\\$级!另外#雌\"孕激素水平降低有助于宫颈鳞癌的发生’3)#绝大多数 \"#\\$ 和浸润性鳞癌不表达 $\\mathrm { E R } ^ { [ 6 , 7 ] }$ !",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "由于正常宫颈组织和 \"#\\$\"\"\\$级也可表达 %\"\\$&\"231 和 $\\mathrm { p } 2 1$ 蛋白# 出现 569%6 丢失#因此#凭单一指标结果不能准确判断 \"#\\$ 恶变潜能!本研究发现 \"#\\$!级中 $\\mathrm { P C N A } \\operatorname { s p } 5 3$ 和 2.( 蛋白及 569%6 表达同时出现 .种异常的百分率为$100 \\%$ #明显高于正常宫颈组织\\$同时出现 1 种及以上异常的百分率为 $8 0 .",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "0 \\%$ # 而正常宫颈组织和 \"#\\$\"\"\\$级无一例同时出现 1 种及以上异常的情况!因此# 对于 \"#\\$ 患者# 可同时检测 %\"\\$&\"231 和 2.(蛋白及 569%6 表达状态#若同时出现 1 种及以上异常表达#则具有高度恶变潜能#应及时手术治疗!恶性肿瘤的演进机制还不明确!可能多种癌基因蛋白异常表达在宫颈鳞癌的演进中起重要作用!=>> \"- 等’!)报道 \"#\\$!级和宫颈鳞癌 $\\mathrm { n m } 2 3$ 蛋白阳性表达率明显降低#而 \"#\\$\"\"\\$级与正常宫颈组织全部为 $\\mathrm { n m } 2 3$ 蛋白中到强表达# $\\mathrm { n m } 2 3$ 蛋白低表达可能与宫颈鳞癌的演进密切相关!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "而细胞周期调节蛋白 A/@BA 在宫颈鳞癌的表达状态及生物学意义还有待于进一步研究!C,>??\\* -D 等’E)报道宫颈鳞癌 $\\mathrm { c - }$ @BA 蛋白阳性率随着 F#GH 分期的升高而升高#但随着病理学分级的升高而降低#并且 A/@BA 阳性患者 3 年生存率与 A/@BA 阴性患者无明显差异!罗营等’(:)报道正常宫颈组织和 \"#\\$ $\\mathbf { \\boldsymbol { c } }$ /@BA 蛋白阳性表达率都很高#浸润癌则明显降低!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "5/\"\\*IJ>,+?表达下调使癌细胞连接松散#有利于癌细胞向深部浸润!本文显示浸润癌\" $\\mathbf { I } \\sim \\mathbf { I } \\mathbf { V }$ 期 $\\mathrm { n m } 2 3$ \"A/@BA\"5/\"\\*IJ>,+?阳性表达率均明显低于正常宫颈和 \"#\\$ 组织# 但$\\mathrm { n m } 2 3 \\mathrm { \\ : .c - m y c }$ 和 5/\"\\*IJ>,+?",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "的表达状态之间未见明显相关性!可见# $\\mathrm { n m } 2 3$ \"A/@BA\"5/\"\\*IJ>,+?蛋白异常表达与宫颈鳞癌浸润进展密切相关# 但宫颈鳞癌的演进机制是多途径多方面的!本研究表明 \"#\\$!级和浸润癌# 尤其是浸润癌$\\mathbb { I } \\sim \\mathbb { N }$ 期 L5GF 阳性表达率明显高于正常宫颈和\"#\\$%\"\\$级组织!L5GF 在肿瘤血管形成中起重要作用’(()!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "L5GF 参与宫颈鳞癌血管形成#为其快速生长提供条件!# 参考文献 !\"#\\$ %& ’\\$() %& \\*+# ,& \\$- ./0 123/45\\$2.-46\\$ .7-464-8 4( 7\\$2647./ 4(!-2.\\$94-+\\$/4./ (\\$39/.:4..(; 7\\$2647./ 7.274(3<.=>?@ A+4( B\\$; > CD()/E& !FFFG !!HCIJK LMLNLMO H P.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "42 QR& P.42 BS& >.8.92.T.:+ 1,& \\$- ./@ 2.: .(; 7U<87 3(73!923-\\$4(: ;#24() -#<32 923)2\\$::43( 4( -+\\$ #-\\$24(\\$ 7\\$264V =>?@ W#!<324G !FFXG XIYOJK OXLNOXX L 魏欣净&王美清@子宫颈不典型增生\"鳞癌 9H!\"9OL 蛋白表达的临 床意义=>?@中华病理学杂志&HZZZ&HFCHJK!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "H[N!HM I 李新英&糜若然&焦书竹&等@9OL 蛋白在宫颈鳞状上皮内瘤变与宫 颈癌中的过度表达与 \\1] 的关系 =>?@ 中华病理学杂志&!FFM&H[ C[JKL[ZNL[!O 张 蓉&王淑玉&许培箴 @I[ 例宫颈癌的临床病理特点分析=>?@中国 临床医学&HZZZ&MC!JKOINOO [ ^.(.4 BG Q+43_.‘.WG \"4( aG \\$- ./@ b<<#(3+4:-37+\\$<47.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "/ ;\\$-\\$7!-43( 35 :\\$V :-\\$234; 2\\$7\\$9-32:G 787/4(:G .(; 787/4(U;\\$9\\$(;\\$(- T4(.:!\\$: 4( -+\\$ (32<./ .(; (\\$39/.:-47 :c#.<3#: \\$94-+\\$/4.35 -+\\$ #-\\$24(\\$ 7\\$264V=>?@ A.(7\\$2G !FFXG XHYFJK !MZFN!M!F M P3(3).",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "T4 \\G ’#d44 QG ^3(4:+4 bG \\$- ./@ D:-23)\\$( 2\\$7\\$9-32 /37./4_.!-43( 4( (32<./ .(; (\\$39/.:-47 \\$94-+\\$/4#< 35 -+\\$ #-\\$24(\\$ 7\\$264V=>?@ A.(7\\$2G !FFZG [[Y!HJK H[HZNH[HM X a\\$\\$ AQG ,.; >@ (<HLU\\!923-\\$4( 4<<#(32\\$.",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "7-464-8 4( 4(-2.\\$9!4-+\\$/4./ (\\$39/.:4..(; 4(6.:46\\$ :c#.<3#: 7\\$// 7.274(3<.35 -+\\$ #!-\\$24(\\$ 7\\$264V =>?@ 1.-+3/ b(-G !FFXG IXY!ZJK XZ[NX!!F S2\\$((.QBG \\*\\$5\\$24(3 aAG 14(-3 ,RG \\$- ./@ 7U<87 923-\\$4( \\$V92\\$:!",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": ":43( 4: (3- .( 4(;\\$9\\$(;\\$(- 923)(3:-47 92\\$;47-32 4( 7\\$2647./ :c#.!<3#: 7\\$// 7.274(3<.=>?@ S2._ > B\\$; S43/ e\\$:G HZZHG LOYIJK IHON ILZ !Z 罗 营G糜若然G岳天孚@7U<87 蛋白在宫颈癌组织中的表达水平 与临床指标的关系=>?@中国肿瘤临床G!FFFGH[YHJK!!ON!![ !!R/4-./3T ]W@ ]D,’:G 2\\$7\\$9-32: .(; .()43)(\\$:4: =>?@ Q\\$<4( A.(7\\$2 S43/G !FFFG FYHJK H!!NHHZ %\"##\\$%#&%’( 收稿& %杨红欣校对&",
    "source": "相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨/相关癌基因蛋白表达与宫颈鳞癌演进机制的探讨.md"
  },
  {
    "text": "# 自助宫颈筛查： 筛查的自主权掌握在您手中。几乎所有宫颈癌都是由HPV引起的。但好消息是宫颈癌几乎是完全可以预防的。# 什么是人乳头瘤病毒（HPV）？HPV是一种通过性接触传播的常见病毒。这包括亲密接触、口交、阴道性交和肛交。大多数人在一生中的某个时候都会感染HPV并完全不自知。通常没有任何症状。大多数HPV感染不会引起任何问题，并且会在2年内被身体清除。但有时，某些HPV类型不会自行清除，并可能导致子宫颈细胞异常。",
    "source": "自助宫颈筛查",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/自助宫颈筛查/自助宫颈筛查.md"
  },
  {
    "text": "随着时间的推移，这些异常细胞可能会变成癌细胞。# 为什么宫颈筛查很重要？导致宫颈癌的细胞变化可能在您不知不觉的情况下发生。筛查可有助于： 发现您是否存在产生异常细胞的风险。及早发现和治疗异常细胞有助于预防癌症。在早期发现癌症，在这个时期会有较多的治疗选项。![](images/1248679b316d6ad7842893fc7ff39ba8ee689c8cf385b0e3b531f008f42f14f5.",
    "source": "自助宫颈筛查",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/自助宫颈筛查/自助宫颈筛查.md"
  },
  {
    "text": "jpg) 在健康方面发挥主动作用。自主宫颈筛查使您可以在您感到安全和舒适的任何地方自己进行宫颈癌。自主宫颈筛查涉及HPV检测。HPV检测可查找导致宫颈癌的病毒。它可以检出那些有更高几率发生由HPV引起的异常细胞变化的人。# 哪些人应该接受自助宫颈筛查？任何有宫颈的人，包括女性和TTGD人士（即双灵人、跨性别人士和多元性别人士），若年龄在25至69岁之间，都应该接受期宫颈癌筛查。如果您的抹片检查结果一直是正常的，您可以在69岁时停止宫颈筛查。",
    "source": "自助宫颈筛查",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/自助宫颈筛查/自助宫颈筛查.md"
  },
  {
    "text": "如果您过去接受过癌前细胞治疗，请咨询医护人员。如果有以下情况，您应该定期筛查： 您已接种HPV疫苗。您曾经与任何性别的其他人发生过性接触；以及/或 您已绝经。如果出现以下情况，请勿进行自助宫颈筛查： 冈 您有症状，例如两次月经期间出血。冈 您怀孕了或使用子宫托。请向医护人员咨询，讨论宫颈筛查方案以及进行筛查的时间。冈 您已切除子宫颈（例如，做过全子宫切除术）。请咨询医护人员，了解这种情况下是否仍需要进行宫颈筛查。",
    "source": "自助宫颈筛查",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/自助宫颈筛查/自助宫颈筛查.md"
  },
  {
    "text": "# 我为什么应该考虑自助宫颈筛查？自助宫颈筛查检测HPV，这种病毒会导致子宫颈细胞发生改变，从而导致宫颈癌。• 您不需要去见医护人员或进行窥镜检查（骨盆）。您可以在家中自行进行，或者如果您愿意，也可以在医护人员办公室进行。• 这项检查既简单又无痛：您可以使用Q-tip小棉签从阴道收集样本。• 这是免费的。• HPV检测非常准确。因为它非常准确，所以，如果您的检测结果显示您没有HPV，那么，您可以等5年再进行下一次筛查。",
    "source": "自助宫颈筛查",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/自助宫颈筛查/自助宫颈筛查.md"
  },
  {
    "text": "# 我能正确操作吗？会痛吗？检测很简单，应该不会痛。您可以通过在阴道内转动棉签来采集样本；不必插入很深。如果您按照试剂盒中的说明进行操作，就可以正确完成操作。您采集的样本与医护人员采集的样本同样准确。# 如何解读筛查结果？• 如果未发现HPV：未来5年内您无需再次筛查。您的子宫颈上不太可能有异常细胞。• 如果发现HPV：您可能需要进行抹片检查或阴道镜检查（一种更仔细地观察宫颈的检查），具体取决于您的结果。",
    "source": "自助宫颈筛查",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/自助宫颈筛查/自助宫颈筛查.md"
  },
  {
    "text": "这个结果并不意味着您已患上或将会患上癌症。但这确实意味着需要更多地去见医护人员。<html><body><table><tr><td colspan=\"2\">宫颈癌如何形成： 并非所有HPV感染都会导致癌症。若会导致宫颈癌，通常也需要15到20年的时间。大多数感染都会自行消失而不会引起任何问题。</td></tr><tr><td>HPV检测：查找HPV感染</td><td>抹片检查：查找异常细胞变化和/或HPV</td></tr><tr><td>·自助宫颈筛查使用HPV检测来查找阴道中的HPV。",
    "source": "自助宫颈筛查",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/自助宫颈筛查/自助宫颈筛查.md"
  },
  {
    "text": "·HPV检测不需要宫颈采样。</td><td>·在抹片检查中，医护人员会从您的宫颈采集细胞。·检查其中是否有任何细胞改变和/或HPV。要检测的项目取决 于您的年龄和健康史。</td></tr></table></body></html> # 我应该接种HPV疫苗吗？一般来说，任何年满9岁的人都应该接种这种疫苗。这种疫苗可非常有效地预防导致大多数宫颈癌的HPV类型。要了解更多信息，请访问immunizebc.",
    "source": "自助宫颈筛查",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/自助宫颈筛查/自助宫颈筛查.md"
  },
  {
    "text": "ca/hpv。# 如何进行筛查 1.得到自我筛查试剂盒。如果您符合资格，请在线 (screeningbc.ca/cervix) 或通过电话 (1-877-702-6566) 索取试剂盒。筛查试剂盒将用普通、无标记的包装通过邮寄方式寄送给您。2.完成检测。严格遵行试剂盒里的说明即可。这项检测是无痛的且非常容易进行。您还可以要求医护人员向您解释或演示如何采集样本，或者他们也可以为您采集。3.回邮试剂盒进行检测。",
    "source": "自助宫颈筛查",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/自助宫颈筛查/自助宫颈筛查.md"
  },
  {
    "text": "在采集样本的当天，将完整的试剂盒投递到最近的邮政信箱。我们将会在您回邮试剂盒之后的4至6个星期将检测结果寄给您。您还可以在线查看检测结果：healthgateway.gov.bc.ca。如果您不想做自助筛查或有任何症状，请与医护人员预约时间进行抹片检查。请访问screeningbc.ca/cervix，查找您附近的诊所。# 联系我们 需要考虑的方面 o 如果您在性交后、两次月经之间或绝经后出现出血；阴道分泌物增多；盆腔疼痛或性交疼痛，请不要进行自助筛查。",
    "source": "自助宫颈筛查",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/自助宫颈筛查/自助宫颈筛查.md"
  },
  {
    "text": "与医护人员谈谈。即使您的筛查结果正常，也应该好好检查一下这些症状，这一点非常重要。o HPV结果可能会引起一定程度的焦虑。这个结果并不意味着您已患上或将会患上宫颈癌。大多数人都会自行消除HPV感染，而且，并不是每个感染HPV的人都会患上癌症。o 筛查可能会导致不必要的压力、治疗，或对未来怀孕产生潜在的长期影响（早产或低出生体重）。o 没有哪项筛查检测是完美的。即使您有癌前细胞或宫颈癌，您的结果也可能表明未发现HPV。",
    "source": "自助宫颈筛查",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/自助宫颈筛查/自助宫颈筛查.md"
  },
  {
    "text": "或者，即使您的宫颈细胞正常，也可能会显示有HPV。BC Cancer Cervix Screening 801-686 West Broadway Vancouver, BC V5Z 1G1 电话：1-877-702-6566 电子邮件： screening@bccancer.bc.ca 网站： www.screeningbc.ca/cervix 我们将根据《个人信息保护法》及《信息自由和隐私权保护法》（若适用）收集您的个人信息，并予以保护，以防未经授权的使用和披露。这些信息仅可根据以上法律的规定来使用和披露、用于质量保证管理、向有关医护人员披露或当法律要求时披露。对于BC省癌症中心（BC Cancer）的信息收集，如果您有任何问题，可向癌症筛查部营运总监提出。（地址：801 – 686 WestBroadway, Vancouver BC V5Z 1G1，网站：www.screeningbc.ca，或电邮：screening@bccancer.bc.ca）",
    "source": "自助宫颈筛查",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/自助宫颈筛查/自助宫颈筛查.md"
  }
]